stilbenes and Neoplasms

stilbenes has been researched along with Neoplasms* in 449 studies

Reviews

225 review(s) available for stilbenes and Neoplasms

ArticleYear
Recent Trends in Tubulin-Binding Combretastatin A-4 Analogs for Anticancer Drug Development.
    Current medicinal chemistry, 2022, Volume: 29, Issue:21

    Although significant progress over several decades has been evidenced in cancer therapy, there remains a need for the development of novel and effective therapeutic strategies to treat several relapsed and intractable cancers. In this regard, tubulin protein has become one of the efficient and major targets for anticancer drug discovery. Considering the antimitotic ability, several tubulin inhibitors have been developed to act against various cancers. Among various tubulin inhibitors available, combretastatin-A4 (CA-4), a naturally occurring lead molecule, offers exceptional cytotoxicity (including the drugresistant cell lines) and antivascular effects. Although CA-4 offers exceptional therapeutic efficacy, several new advancements have been proposed, in terms of structural modification via A and B rings, as well as cis-olefinic bridging, which provide highly efficient analogs with improved tubulin-binding efficiency to meet the anticancer drug development requirements. This review systematically emphasizes the recent trends and latest developments in the anticancer drug design and discovery using CA-4 analogs as the tubulin inhibiting agents by highlighting their structure-activity relationships (SAR) and resultant pharmacological efficacies.

    Topics: Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Neoplasms; Stilbenes; Structure-Activity Relationship; Tubulin; Tubulin Modulators

2022
Resveratrol as a modulatory of apoptosis and autophagy in cancer therapy.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2022, Volume: 24, Issue:7

    Cancer is one of the leading causes of death, with a heavy socio-economical burden for countries. Despite the great advances that have been made in the treatment of cancer, chemotherapy is still the most common method of treatment. However, many side effects, including hepatotoxicity, renal toxicity, and cardiotoxicity, limit the efficacy of conventional chemotherapy. Over recent years, natural products have attracted attention as therapeutic agents against various diseases, such as cancer. Resveratrol (RES), a natural polyphenol occurring in grapes, nuts, wine, and berries, exhibited potential for preventing and treating various cancer types. RES also ameliorates chemotherapy-induced detrimental effects. Furthermore, RES could modulate apoptosis and autophagy as the main forms of cancer cell deaths by targeting various signaling pathways and up/downregulation of apoptotic and autophagic genes. This review will summarize the anti-cancer effects of RES and focus on the fundamental mechanisms and targets for modulating apoptosis and autophagy by RES.

    Topics: Apoptosis; Autophagy; Humans; Neoplasms; Resveratrol; Signal Transduction; Stilbenes

2022
The science of resveratrol, formulation, pharmacokinetic barriers and its chemotherapeutic potential.
    International journal of pharmaceutics, 2022, Apr-25, Volume: 618

    Chemopreventive properties of resveratrol has been studied for decades. Despite its potential for chemotherapeutic advancement, the compound has pharmaceutical limitations, such as, the drug has a poor pharmacokinetic profile and low bioavailability. Studies have comforting results that that the nano-formulations may aid the future resveratrol drug development. Resveratrol can also be encapsulated as co-drug with an anticipation of gaining improved targeting and pharmacokinetic parameters, as well as achieving desired therapeutic plasma levels. It has been envisaged that the nanoformulations can also address the issue of drug accumulation, which may lead to hepatotoxicity. Nanoformulations can bring a major improvement in the bioavailability of resveratrol but still the formulation still suffers with pharmacokinetics issues clinically. This review encompasses the pharmacokinetics barriers associated with resveratrol and a possible suggestion to overcome those barriers for improving absorbance, reducing toxicity andimproving the drug releaseand encapsulation efficiency. The article also suggest that co-administration of resveratrol with chemotherapeutic drugsmust be tested in vivo on a wide range of cancers to avoid accidental proliferation exacerbation. The review's focusses on the resveratrol formulation and make suggestions for improvements in order to overcome the pharmacokinetic and toxicity issues.

    Topics: Biological Availability; Humans; Neoplasms; Pharmaceutical Preparations; Resveratrol; Stilbenes

2022
Applications of resveratrol in the treatment of gastrointestinal cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, Volume: 153

    Natural product compounds have lately attracted interest in the scientific community as a possible treatment for gastrointestinal (GI) cancer, due to their anti-inflammatory and anticancer properties. There are many preclinical, clinical, and epidemiological studies, suggesting that the consumption of polyphenol compounds, which are abundant in vegetables, grains, fruits, and pulses, may help to prevent various illnesses and disorders from developing, including several GI cancers. The development of GI malignancies follows a well-known path, in which normal gastrointestinal cells acquire abnormalities in their genetic composition, causing the cells to continuously proliferate, and metastasize to other sites, especially the brain and liver. Natural compounds with the ability to affect oncogenic pathways might be possible treatments for GI malignancies, and could easily be tested in clinical trials. Resveratrol is a non-flavonoid polyphenol and a natural stilbene, acting as a phytoestrogen with anti-cancer, cardioprotective, anti-oxidant, and anti-inflammatory properties. Resveratrol has been shown to overcome resistance mechanisms in cancer cells, and when combined with conventional anticancer drugs, could sensitize cancer cells to chemotherapy. Several new resveratrol analogs and nanostructured delivery vehicles with improved anti-GI cancer efficacy, absorption, and pharmacokinetic profiles have already been developed. This present review focuses on the in vitro and in vivo effects of resveratrol on GI cancers, as well as the underlying molecular mechanisms of action.

    Topics: Antioxidants; Gastrointestinal Neoplasms; Humans; Neoplasms; Polyphenols; Resveratrol; Stilbenes

2022
Recent advances in combretastatin A-4 codrugs for cancer therapy.
    European journal of medicinal chemistry, 2022, Nov-05, Volume: 241

    CA4 is a potent microtubule polymerization inhibitor and vascular disrupting agent. However, the in vivo efficiency of CA4 is limited owing to its poor pharmacokinetics resulting from its high lipophilicity and low water solubility. To improve the water solubility, CA4 phosphate (CA4P) has been developed and shows potent antivascular and antitumor effects. CA4P had been evaluated as a vascular disrupting agent in previousc linical trials. However, it had been discontinued due to the lack of a meaningful improvement in progression-free survival and unfavorable partial response data. Codrug is a drug design approach to chemically bind two or more drugs to improve therapeutic efficiency or decrease adverse effects. This review describes the progress made over the last twenty years in developing CA4-based codrugs to improve the therapeutic profile and achieve targeted delivery to cancer tissues. It also discusses the existing problems and the developmental prospects of CA4 codrugs.

    Topics: Antineoplastic Agents, Phytogenic; Drug Design; Humans; Neoplasms; Organophosphates; Stilbenes; Water

2022
Mechanism of Resveratrol-Induced Programmed Cell Death and New Drug Discovery against Cancer: A Review.
    International journal of molecular sciences, 2022, Nov-08, Volume: 23, Issue:22

    Resveratrol (3,5,4'-trihydroxy-

    Topics: Antineoplastic Agents; Apoptosis; Drug Discovery; Humans; Neoplasms; Resveratrol; Stilbenes

2022
Resveratrol and other Stilbenes: Effects on Dysregulated Gene Expression in Cancers and Novel Delivery Systems.
    Anti-cancer agents in medicinal chemistry, 2021, Volume: 21, Issue:5

    Trans-resveratrol (RESV), pterostilbene, trans-piceid and trans-viniferins are bioactive stilbenes present in grapes and other plants. Several groups applied biotechnology to introduce their synthesis in plant crops. Biochemical interaction with enzymes, regulation of non-coding RNAs, and activation of signaling pathways and transcription factors are among the main effects described in literature. However, solubility in ethanol, short half-life, metabolism by gut bacteria, make the concentration responsible for the effects observed in cultured cells difficult to achieve. Derivatives obtained by synthesis, trans-resveratrol analogs and methoxylated stilbenes show to be more stable and allow the synthesis of bioactive compounds with higher bioavailability. However, changes in chemical structure may require testing for toxicity. Thus, the delivery of RESV and its natural analogs incorporated into liposomes or nanoparticles, is the best choice to ensure stability during administration and appropriate absorption. The application of RESV and its derivatives with anti-inflammatory and anticancer activity is presented with description of novel clinical trials.

    Topics: Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Molecular Structure; Nanoparticles; Neoplasms; Resveratrol; Stilbenes

2021
Development of novel derivatives of stilbene and macrocyclic compounds as potent of anti-microtubule factors.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021, Volume: 133

    Microtubules (composed of α- and β-tubulin heterodimers) ubiquitous cellular polymers are important components of the cytoskeleton and play diverse roles within the cell, such as maintenance of cell structure, protein trafficking or chromosomal segregation during cell division. The polymers of tubulin play a pivotal role in mitosis and are regarded as an excellent target for chemotherapeutic agents to treat cancer. This review presents a brief overview of the synthesis and mechanism of action of new compounds targeting the dynamic of microtubule - tubulin polymerization/depolymerization. It is divided into the following parts: section I concerns targeting microtubules- tubulin-binding drugs derivatives of stilbene. In section II there are presented photoswitchable inhibitors of microtubule dynamics. Section III concerns using macrocyclic compounds as tubulin inhibitors. In this review, the authors focused primarily on reports produced inthe last five years and the latest strategies in this field.

    Topics: Antineoplastic Agents; Macrocyclic Compounds; Microtubules; Molecular Targeted Therapy; Neoplasms; Stilbenes; Tubulin Modulators

2021
Natural Product-Based Hybrids as Potential Candidates for the Treatment of Cancer: Focus on Curcumin and Resveratrol.
    Molecules (Basel, Switzerland), 2021, Jul-31, Volume: 26, Issue:15

    One of the main current strategies for cancer treatment is represented by combination chemotherapy. More recently, this strategy shifted to the "hybrid strategy", namely the designing of a new molecular entity containing two or more biologically active molecules and having superior features compared with the individual components. Moreover, the term "hybrid" has further extended to innovative drug delivery systems based on biocompatible nanomaterials and able to deliver one or more drugs to specific tissues or cells. At the same time, there is an increased interest in plant-derived polyphenols used as antitumoral drugs. The present review reports the most recent and intriguing research advances in the development of hybrids based on the polyphenols curcumin and resveratrol, which are known to act as multifunctional agents. We focused on two issues that are particularly interesting for the innovative chemical strategy involved in their development. On one hand, the pharmacophoric groups of these compounds have been used for the synthesis of new hybrid molecules. On the other hand, these polyphenols have been introduced into hybrid nanomaterials based on gold nanoparticles, which have many potential applications for both drug delivery and theranostics in chemotherapy.

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Products; Curcumin; Drug Delivery Systems; Gold; Humans; Metal Nanoparticles; Neoplasms; Resveratrol; Stilbenes

2021
Piceatannol: A natural stilbene for the prevention and treatment of cancer.
    Pharmacological research, 2020, Volume: 153

    The World Health Organization (WHO) has documented that cancer is the second foremost reason for death worldwide. Various factors are responsible for cancer, for instance, exposure to different physical, chemical and biological carcinogens, infections, hereditary, poor dietary habits and lifestyle etc. Cancer is a preventable disease if detected at an early stage; however, most of the cases of cancer are diagnosed at an incurable advanced or metastatic stage. According to WHO about 70 % of deaths due to cancer occur in countries with low- or middle-income. The major problems associated with the conventional therapies are cancer recurrence, development of chemoresistance, affordability, late-stage diagnosis, adverse side effects and inaccessible treatment. Thus, there is an urgent need to find alternative treatment modalities, which have easy accessibility and are affordable with minimum side effects. In this article, we reviewed the natural stilbene known as "Piceatannol" for its anticancer properties. Numerous preclinical studies have reported the potential of Piceatannol to prevent or impede the growth of various cancers originating from different organs such as brain, breast, cervical, colon, liver, lung, prostate, skin, etc. The current review primarily emphasises on the insights of Piceatannol source, chemistry, and the molecular mechanisms involved in the regression of the tumor. This review supports Piceatannol as a potential anticancer and chemopreventive agent and suggests that it can be effectively employed as a capable anti-cancer drug.

    Topics: Antineoplastic Agents, Phytogenic; Humans; Molecular Structure; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Stilbenes

2020
Azobenzene Photoswitch for Isomerization-Dependent Cancer Therapy via Azo-Combretastatin A4 and Phototrexate.
    Photochemistry and photobiology, 2020, Volume: 96, Issue:6

    The adverse effects of chemotherapeutic drugs to healthy organs/cells greatly limit their clinical efficacy and patient compliance. The unique behavior of azobenzene photoswitch offers a remarkable tool to address the side effects of chemotherapeutic drugs. The azobenzene moiety has been integrated within some chemotherapeutic drugs to realize photo-triggered activation of drug cytotoxicity. However, the clinical translation of these agents has been facing a few barriers. In this short review, we present our viewpoints on potential solutions to address the following challenges associated with azobenzene-based photoswitchable chemotherapeutic drugs, including poor tissue penetration of light, hypoxia-induced drug degradation in solid tumor and the autonomous cis-trans relaxation.

    Topics: Antineoplastic Agents; Azo Compounds; Humans; Isomerism; Neoplasms; Stilbenes

2020
Piceatannol mediated regulation of deregulated signaling pathways in different cancers: Tumbling of the ninepins of molecular oncology.
    Cellular and molecular biology (Noisy-le-Grand, France), 2020, Sep-30, Volume: 66, Issue:6

    With the recent technological advancements, a new golden era of natural products drug discovery has dawned. Increasingly it is being realized that structural modularity of many pharmacologically active products derived natural sources allows a building-block approach which can be exploited for analysis of regulation of deregulated oncogenic protein networks in different cancers. Piceatannol has been shown to effectively modulate JAK/STAT, Wnt/β-catenin, mTOR pathway in different cancers. In addition, certain hints have emerged which shed light on the regulation of microRNAs by piceatannol in some cancers. Regulation of deregulated oncogenic pathways by Piceatannol is gradually capturing attention and might be helpful in the multi-targeting of deregulated oncogenic networks in cancers.

    Topics: Animals; beta Catenin; Humans; Janus Kinases; Medical Oncology; Neoplasms; Signal Transduction; STAT Transcription Factors; Stilbenes; Wnt Proteins

2020
Overview of Cellular Mechanisms and Signaling Pathways of Piceatannol.
    Current stem cell research & therapy, 2020, Volume: 15, Issue:1

    Stilbenoids are a group of naturally occurring phenolic compounds found in various plant species. They share a common backbone structure known as stilbene. However, differences in the nature and position of substituents have made it possible to produce many derivatives. Piceatannol [PT], a hydroxylated derivative from resveratrol, exerts various biological activities ranging from cancer prevention, cardio- protection, neuro-protection, anti-diabetic, depigmentation and so on. Although positive results were obtained in most cell culture and animal studies, the relevant cellular and molecular mechanisms of cytokines and signaling pathway about their biological effects still unclear. Thus, in the current review, we focus on the latest findings of PT on cellular biology in order to better understand the underlying therapeutic mechanisms of PT among various diseases.

    Topics: Animals; Cardiovascular Diseases; Cell Cycle; Fabaceae; Humans; Neoplasms; Neuroprotection; Phytotherapy; Protein Kinase Inhibitors; Resveratrol; Signal Transduction; Stilbenes

2020
Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage ("SEE") Signal to Facilitate the Elimination of "Cold, Non-Responsive" Low PD-L1-Expressing Tumors by PD-L1 Blockade.
    International journal of molecular sciences, 2019, Nov-27, Volume: 20, Issue:23

    Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Humans; Neoplasms; Resveratrol; Stilbenes

2019
Pterostilbene: Mechanisms of its action as oncostatic agent in cell models and in vivo studies.
    Pharmacological research, 2019, Volume: 145

    Pterostilbene, a natural dimethylated analog of resveratrol, exerts pleiotropic anticancer effects against a variety of cancer types. Due to the better lipophilic and oral absorption, higher cellular uptake and a longer half-life than resveratrol, pterostilbene may have a good prospect in the future clinic application. In this review, we summarize the previous in vitro and in vivo studies about the anticancer actions of pterostilbene on malignances, and we also evaluate the evidence related to the effects of pterostilbene on blocking normal cell carcinogenesis. Special focus is placed on the oncostatic effects of pterostilbene, including inhibition of tumor growth, metastasis, angiogenesis and cancer stem cells, activation of apoptosis, and enhancement of immunotherapy. We then clarify the emerging investigations about pterostilbene and chemotherapy and radiotherapy. Taken together, the information complied herein may serve as a comprehensive reference for the anticancer mechanisms of pterostilbene and may advance it as a future adjuvant therapeutic agent for cancer.

    Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Combined Modality Therapy; Humans; Immunotherapy; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Stilbenes

2019
Stilbene Compounds Inhibit Tumor Growth by the Induction of Cellular Senescence and the Inhibition of Telomerase Activity.
    International journal of molecular sciences, 2019, Jun-02, Volume: 20, Issue:11

    Topics: Animals; Antineoplastic Agents; Cellular Senescence; Humans; Neoplasms; Resveratrol; Stilbenes; Telomerase

2019
Effect of resveratrol and pterostilbene on aging and longevity.
    BioFactors (Oxford, England), 2018, Volume: 44, Issue:1

    Over the past years, several studies have found that foods rich in polyphenols protect against age-related disease, such as atherosclerosis, cardiovascular disease, cancer, arthritis, cataracts, osteoporosis, type 2 diabetes (T2D), hypertension and Alzheimer's disease. Resveratrol and pterostilbene, the polyphenol found in grape and blueberries, have beneficial effects as anti-aging compounds through modulating the hallmarks of aging, including oxidative damage, inflammation, telomere attrition and cell senescence. In this review, we discuss the relationship between resveratrol and pterostilbene and possible aging biomarker, including oxidative stress, inflammation, and high-calorie diets. Moreover, we also discuss the positive effect of resveratrol and pterostilbene on lifespan, aged-related disease, and health maintenance. Furthermore, we summarize a variety of important mechanisms modulated by resveratrol and pterostilbene possibly involved in attenuating age-associated disorders. Overall, we describe resveratrol and pterostilbene potential for prevention or treatment of several age-related diseases by modulating age-related mechanisms. © 2017 BioFactors, 44(1):69-82, 2018.

    Topics: AMP-Activated Protein Kinases; Animals; Antioxidants; Cardiovascular Diseases; Cataract; Cellular Senescence; Humans; Inflammation; Longevity; Neoplasms; Neurodegenerative Diseases; NF-E2-Related Factor 2; Osteoporosis; Oxidative Stress; Resveratrol; Sirtuin 1; Stilbenes; Telomere Homeostasis

2018
Chemoprevention by resveratrol and pterostilbene: Targeting on epigenetic regulation.
    BioFactors (Oxford, England), 2018, Volume: 44, Issue:1

    Epigenetic mechanisms are essential in regulating normal cellular functions and play an important role during the disease developmental stages. However, aberrant epigenetic mechanisms may lead to pathological consequences such as cancer, neurological disorders, bone and skeletal diseases, cardiovascular dysfunction, and metabolic syndrome. The molecular mechanisms of epigenetic modification include DNA methylation, histone modification (acetylation, methylation and phosphorylation), and microRNAs (miRNAs). Unlike genetic modifications, epigenetic states of genes are reversible and can be altered by certain intrinsic and extrinsic factors. In the past few decades, accumulated evidence shows that dietary phytochemicals with chemopreventive effects are also potent epigenetic regulators. Resveratrol and pterostilbene are stilbenoids, which have been reported to have anti-cancer, anti-inflammatory, anti-lipid, and anti-diabetic properties. Stilbenoids are also reported to improve cardiovascular disease. By altering DNA methylation and histone modification or by modulating miRNA expression, resveratrol, and pterostilbene become potent epigenetic modifiers. In this review, we summarize these studies and underlying mechanisms of resveratrol and pterostilbene and their influence on epigenetic mechanisms. © 2017 BioFactors, 44(1):26-35, 2018.

    Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Bone Diseases; Cardiovascular Diseases; Chemoprevention; DNA Methylation; Epigenesis, Genetic; Histones; Humans; MicroRNAs; Neoplasms; Neurodegenerative Diseases; Protein Processing, Post-Translational; Resveratrol; Stilbenes

2018
Apoptotic and Nonapoptotic Activities of Pterostilbene against Cancer.
    International journal of molecular sciences, 2018, Jan-18, Volume: 19, Issue:1

    Cancer is a major cause of death. The outcomes of current therapeutic strategies against cancer often ironically lead to even increased mortality due to the subsequent drug resistance and to metastatic recurrence. Alternative medicines are thus urgently needed. Cumulative evidence has pointed out that pterostilbene (

    Topics: Antineoplastic Agents; Apoptosis; Complementary Therapies; Endoplasmic Reticulum Stress; Humans; MicroRNAs; Neoplasm Metastasis; Neoplasms; Neoplastic Cells, Circulating; Stilbenes

2018
Recent Advances in Development of Polyphenols as Anticancer Agents.
    Mini reviews in medicinal chemistry, 2018, Volume: 18, Issue:15

    Still now, for many forms of the disseminated cancers there is no curative therapy available. The discovery of novel active chemotherapeutic agents is largely essential to overcome this problem. Natural compounds polyphenols are mainly characterized by a huge structural variance; they can render them intrinsic dietary components due to their common occurrence in plants. Now-a-days, polyphenols (secondary metabolites) are characterized by a vast spectrum of physiological significance. From the past twenty years in the world of scientific research, polyphenols play an important role in a wide range of physiological processess. This review focuses on the development of polyphenols as antitumor agent in recent research studies.

    Topics: Antineoplastic Agents; Humans; Kidney; Liver; Neoplasms; Plants; Polyphenols; Stilbenes; Tea; Wine

2018
Regulation of Cell Signaling Pathways and miRNAs by Resveratrol in Different Cancers.
    International journal of molecular sciences, 2018, Feb-26, Volume: 19, Issue:3

    Genomic and proteomic studies have helped improve our understanding of the underlying mechanism(s) of cancer development and progression. Mutations, overexpressed oncogenes, inactivated/downregulated tumor suppressors, loss of apoptosis, and dysregulated signal transduction cascades are some of the well-studied areas of research. Resveratrol has gained considerable attention in the last two decades because of its pleiotropic anticancer activities. In this review, we have summarized the regulation of WNT, SHH (sonic hedgehog)/GLI (glioma-associated oncogene homolog), TGFβ1 (transforming growth factor beta 1)/SMAD, NOTCH, TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), STAT (signal transducer and activator of transcription), and microRNAs by resveratrol in different cancers. The importance of these signaling pathways in cancer progression, along with their modulation by resveratrol, is discussed. Further, we also evaluate the mechanisms and implications of the downregulation of oncogenic miRNAs and the upregulation of tumor suppressor miRNAs by resveratrol, both of which also define its ability to inhibit tumor growth and metastasis. It is envisioned that designing effective clinical trials will be helpful for the identification of resveratrol responders and non-responders and the elucidation of how this phytochemical can be combined with current therapeutic options to improve their clinical efficacy and reduce off-target effects.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; MicroRNAs; Neoplasms; Receptors, Notch; Resveratrol; Signal Transduction; Smad Proteins; STAT Transcription Factors; Stilbenes; TNF-Related Apoptosis-Inducing Ligand; Transforming Growth Factor beta1; Treatment Outcome; Wnt Signaling Pathway; Zinc Finger Protein GLI1

2018
Bioactivities of Phenolics by Focusing on Suppression of Chronic Diseases: A Review.
    International journal of molecular sciences, 2018, May-25, Volume: 19, Issue:6

    Phenolics, which are secondary metabolites of plants, exhibit remarkable bioactivities. In this contribution, we have focused on their protective effect against chronic diseases rather than their antioxidant activities, which have been widely discussed in the literature. A large body of epidemiological studies has proven the bioactivities of phenolics in both standard compounds and natural extracts: namely, anticancer, anti-inflammatory, and antibacterial activities as well as reducing diabetes, cardiovascular disease, and neurodegenerative disease. Phenolics also display anti-analgesic, anti-allergic, and anti-Alzheimer's properties. Thus, this review provides crucial information for better understanding the bioactivities of phenolics in foods and fills a gap in the existing collective and overall knowledge in the field.

    Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Bacterial Infections; Chalcones; Coumaric Acids; Edible Grain; Flavonoids; Fruit; Humans; Hydroxybenzoates; Inflammation; Neoplasms; Stilbenes; Vegetables

2018
Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights.
    International journal of molecular sciences, 2018, Jun-20, Volume: 19, Issue:6

    Inflammation is the principal response invoked by the body to address injuries. Despite inflammation constituting a crucial component of tissue repair, it is well known that unchecked or chronic inflammation becomes deleterious, leading to progressive tissue damage. Studies over the past years focused on foods rich in polyphenols with anti-inflammatory and immunomodulatory properties, since inflammation was recognized to play a central role in several diseases. In this review, we discuss the beneficial effects of resveratrol, the most widely investigated polyphenol, on cancer and neurodegenerative, respiratory, metabolic, and cardiovascular diseases. We highlight how resveratrol, despite its unfavorable pharmacokinetics, can modulate the inflammatory pathways underlying those diseases, and we identify future opportunities for the evaluation of its clinical feasibility.

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Inflammation; Mice; Neoplasms; Obesity; Rats; Respiratory Tract Diseases; Resveratrol; Stilbenes

2018
Prevention from radiation damage by natural products.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2018, Aug-01, Volume: 47

    Radiotherapy is a mainstay of cancer treatment since decades. Ionizing radiation (IR) is used for destruction of cancer cells and shrinkage of tumors. However, the increase of radioresistance in cancer cells and radiation toxicity to normal tissues are severe concerns. The exposure to radiation generates intracellular reactive oxygen species (ROS), which leads to DNA damage by lipid peroxidation, removal of thiol groups from cellular and membrane proteins, strand breaks and base alterations.. Plants have to deal with radiation-induced damage (UV-light of sun, other natural radiation sources). Therefore, it is worth speculating that radioprotective mechanisms have evolved during evolution of life. We hypothesize that natural products from plants may also protect from radiation damage caused as adverse side effects of cancer radiotherapy.. The basis of this systematic review, we searched the relevant literature in the PubMed database.. Flavonoids, such as genistein, epigallocatechin-3-gallate, epicatechin, apigenin and silibinin mainly act as antioxidant, free radical scavenging and anti-inflammatory compounds, thus, providing cytoprotection in addition to downregulation of several pro-inflammatory cytokines. Comparable effects have been found in phenylpropanoids, especially caffeic acid phenylethylester, curcumin, thymol and zingerone. Besides, resveratrol and quercetin are the most important cytoprotective polyphenols. Their radioprotective effects are mediated by a wide range of mechanisms mainly leading to direct or indirect reduction of cellular stress. Ascorbic acid is broadly used as antioxidant, but it has also shown activity in reducing cellular damage after irradiation mainly due to its antioxidant capabilities. The metal ion chelator, gallic acid, represents another natural product attenuating cellular damage caused by radiation.. Some secondary metabolites from plants reveal radioprotective features against cellular damage caused by irradiation. These results warrant further analysis to develop phytochemicals as radioprotectors for clinical use.

    Topics: Antioxidants; Ascorbic Acid; Curcumin; DNA Damage; Flavonoids; Humans; Lipid Peroxidation; Neoplasms; Phytochemicals; Plants; Polyphenols; Radiation Injuries; Radiation-Protective Agents; Radiotherapy; Reactive Oxygen Species; Resveratrol; Stilbenes

2018
Natural products and their derivatives as cyclooxygenase-2 inhibitors.
    Future medicinal chemistry, 2018, Volume: 10, Issue:20

    From ancient times, natural products have been continuously used as therapeutic agents in the treatment of various ailments. Many drugs from the natural origin are available in the market as potent medicines. Over expression of cyclooxygenase-2 (COX-2) enzyme is associated with various physical disorders like various types of inflammations associated with cardiovascular diseases or malignancies. The COX-2 inhibitory activity of many active constituents derived from plants is well established in the literature. These include coumarins, alkaloids, flavonoids, cinnamates, stilbenes and xanthines. In the present review, an attempt has been made to summarize applications of compounds since 2000 obtained from natural sources as COX-2 inhibitors. A brief synthetic methodology to access these natural product derivatives has been highlighted along with the Structure Activity Relationship (SAR).

    Topics: Alkaloids; Biological Products; Cardiovascular Diseases; Cinnamates; Coumarins; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Discovery; Flavonoids; Humans; Molecular Structure; Neoplasms; Stilbenes; Structure-Activity Relationship

2018
Schweinfurthins: Lipid Modulators with Promising Anticancer Activity.
    Lipids, 2018, Volume: 53, Issue:8

    The schweinfurthin family of compounds displays exciting potent and differential cytotoxicity against human cancer cell lines. Currently, the effect of schweinfurthins on tumor development and progression is being explored in animal models of cancer with promising results. The first schweinfurthin family member, vedelianin, was isolated in 1992, followed by other schweinfurthins in 1998. This opened up the door for the synthesis of additional analogs. At present, the focus of research lies on delineating the mechanism of schweinfurthin action and identifying the nature of sensitivity. It appears that many of the intracellular effects of schweinfurthins are due to, or impacted by, the effect of schweinfurthins on lipid metabolism, synthesis, and homeostasis. These effects include impaired trafficking from the trans-golgi network, disruption of lipid rafts, changes in oxysterol-binding protein activity, and interference with the isoprenoid biosynthesis pathway (IBP). Cancer cells are known to rely heavily on fatty acid, lipid, and sterol synthesis for growth and proliferation. Therefore, compounds that target these needs, such as schweinfurthins, display promise as novel therapeutics. This timely review will take an in-depth look at the history of schweinfurthins, their synthesis, where the research presently stands, and the questions that remain.

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Lipid Metabolism; Lipids; Molecular Structure; Neoplasms; Stilbenes

2018
[Emerging Actions of Pterostilebene on Cancer Research].
    Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2018, Dec-20, Volume: 21, Issue:12

    Pterostilbene (3,5-dimethoxy-4'-hydroxystilbene) is a polyphenolic compound primarily found in blueberries, grapes, and a tree wood, pterocarpus marsupium. Studies demonstrate that pterostilbene inhibits a variety of cancers, such as lung, breast, stomach, colon, etc. The anti-cancer activities are related to the regulation of several hallmarks of cancer. Moreover, pterostilbene exhibits much greater bioavailability and bioactivity than resveratrol which warrants further investigation in the anti-cancer functions and mechanisms.
.. 【中文题目:紫檀芪抗肿瘤作用机制研究进展】 【中文摘要:紫檀芪(3,5-二甲氧基-4’-羟基二苯乙烯)是一种主要存在于蓝莓、葡萄和花榈木中的多酚类化合物。已有的研究发现紫檀芪具有抗肺癌、乳腺癌、胃癌、结肠癌等多种肿瘤的抗癌作用。其作用机制涉及调控影响多种肿瘤生物学特性。此外,紫檀芪具有比白藜芦醇更高的生物利用度和生物活性,其抗肿瘤作用和机制值得深入探讨和研究。
】 【中文关键词:紫檀芪;肿瘤;凋亡;增殖;侵袭】.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Plant Extracts; Stilbenes

2018
Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy.
    Current pharmaceutical design, 2018, Volume: 24, Issue:36

    The growing incidence of cancer, the toxic side-effects associated with conventional chemotherapeutic agents and the development of multidrug resistance (MDR) drive the search for novel and more effective drugs with multi-target activity and selectivity towards cancer cells. Stilbenes are a group of naturally occurring phenolic compounds of plant origin derived from the phenylpropanoid pathway that may exist as cis- or trans-isomers. Although the trans-isomer is the more common and stable configuration, resveratrol being a representative compound, cis-stilbenes are potent cytotoxic agents that bind to and inhibit tubulin polymerization, destabilizing microtubules. This review summarizes the chemistry and biological evaluation of cytotoxic stilbenes and their synthetic derivatives as promising antimitotic leads for cancer therapy, focusing on the most potent compounds, the combretastatins. Combretastatins isolated from the South African bushwillow Combretum caffrum are among the most potent antimitotic and vascular disrupting agents (VDAs) of natural origin. Preclinical studies have demonstrated their potent antitumor effects in a wide variety of tumors, both in vitro and in vivo, being currently under evaluation in phase 2 and phase 3 clinical trials for several types of solid tumors. Topics covered herein include synthetic medicinal chemistry, modes of action, structure-activity relationships (SAR), preclinical and clinical studies as VDAs in cancer therapy, either as single agents or in combination with cytotoxic anticancer drugs, antiangiogenic agents, or radiation therapy, and development of appropriate formulations based on nanocarriers (e.g., liposomes, nanoemulsions, polymeric, lipid and ceramic nanoparticles, carbon nanotubes) for improved bioavailability and targeted delivery of combretastatins to the tumor vasculature.

    Topics: Animals; Antimitotic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Drug Delivery Systems; Drug Development; Humans; Nanostructures; Neoplasms; Stilbenes; Structure-Activity Relationship

2018
Small Molecules as SIRT Modulators.
    Mini reviews in medicinal chemistry, 2018, Volume: 18, Issue:13

    Sirtuins are a family of NAD+-dependent deacetylases (class III histone deacetylases). Seven mammalian sirtuins, SIRT1-7, are identified, as the functions and locations differ greatly. SIRT1 and SIRT2 locate in nucleus and cytoplasm, while SIRT3-5 in mitochondria. Sirtuins are not only involved in many important biological processes such as apoptosis, cellular senescence, endocrine signaling, glucose homeostasis, aging, and longevity, it can also control circadian clocks and mitochondrial biogenesis. Small molecules that can modulate the sirtuins activity have been shown to have potentials for treating many human diseases such as type II diabetes, cancer, rheumatoid arthritis, cardiovascular and other age-relating diseases. Some polyphenolic natural products such as Resveratrol, Fisetin, and Quercetin have demonstrated health benefits due to their SIRT1 activation effects. Some structurally diverse synthetic compounds, such as SRT1720, SRT1460, Selisistat (EX 527), and AGK2 were used as small molecular SIRT modulators (IC50 = 0.04-100 μM) to treat ischemic stroke, myocardial infarction, neurodegenerative diseases, cancer, aging, and obesity. In order to get better understanding of how the small molecules interact with the sirtuin, the small molecules that having SIRT inhibitory or activation effect, found by HTS or other modern medicinal chemistry techniques, are reviewed in this article.

    Topics: Humans; Imidazoles; Naphthalenes; Neoplasms; Neurodegenerative Diseases; Polyphenols; Pyrimidinones; Resveratrol; Sirtuins; Small Molecule Libraries; Stilbenes; Triterpenes

2018
Resveratrol as an anti-cancer agent: A review.
    Critical reviews in food science and nutrition, 2018, Jun-13, Volume: 58, Issue:9

    Owing to their antimicrobial, antioxidant, and anti-inflammatory activity, grapes (Vitis vinifera L.) are the archetypal paradigms of fruits used not only for nutritional purposes, but also for exclusive therapeutics. Grapes are a prominent and promising source of phytochemicals, especially resveratrol, a phytoalexin antioxidant found in red grapes which has both chemopreventive and therapeutic effects against various ailments. Resveratrol's role in reducing different human cancers, including breast, cervical, uterine, blood, kidney, liver, eye, bladder, thyroid, esophageal, prostate, brain, lung, skin, gastric, colon, head and neck, bone, ovarian, and cervical, has been reviewed. This review covers the literature that deals with the anti-cancer mechanism of resveratrol with special reference to antioxidant potential. Furthermore, this article summarizes the literature pertaining to resveratrol as an anti-cancer agent.

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Cell Line, Tumor; Disease Models, Animal; Fruit; Humans; Neoplasms; Phytoalexins; Phytochemicals; Resveratrol; Sesquiterpenes; Stilbenes; Vitis

2018
Polyphenol nanoformulations for cancer therapy: experimental evidence and clinical perspective.
    International journal of nanomedicine, 2017, Volume: 12

    Cancer is defined as the abnormal cell growth that can cause life-threatening malignancies with high financial costs for patients as well as the health care system. Natural polyphenols have long been used for the prevention and treatment of several disorders due to their antioxidant, anti-inflammatory, cytotoxic, antineoplastic, and immunomodulatory effects discussed in the literature; thus, these phytochemicals are potentially able to act as chemopreventive and chemotherapeutic agents in different types of cancer. One of the problems regarding the use of polyphenolic compounds is their low bioavailability. Different types of formulations have been designed for the improvement of bioavailability of these compounds, nanonization being one of the most notable approaches among them. This study aimed to review current data on the nanoformulations of natural polyphenols as chemopreventive and chemotherapeutic agents and to discuss their molecular anticancer mechanisms of action. Nanoformulations of natural polyphenols as bioactive agents, including resveratrol, curcumin, quercetin, epigallocatechin-3-gallate, chrysin, baicalein, luteolin, honokiol, silibinin, and coumarin derivatives, in a dose-dependent manner, result in better efficacy for the prevention and treatment of cancer. The impact of nanoformulation methods for these natural agents on tumor cells has gained wider attention due to improvement in targeted therapy and bioavailability, as well as enhancement of stability. Today, several nanoformulations are designed for delivery of polyphenolic compounds, including nanosuspensions, solid lipid nanoparticles, liposomes, gold nanoparticles, and polymeric nanoparticles, which have resulted in better antineoplastic activity, higher intracellular concentration of polyphenols, slow and sustained release of the drugs, and improvement of proapoptotic activity against tumor cells. To conclude, natural polyphenols demonstrate remarkable anticancer potential in pharmacotherapy; however, the obstacles in terms of their bioavailability in and toxicity to normal cells, as well as targeted drug delivery to malignant cells, can be overcome using nanoformulation-based technologies, which optimize the bioefficacy of these natural drugs.

    Topics: Antineoplastic Agents; Antioxidants; Biological Availability; Catechin; Curcumin; Drug Delivery Systems; Humans; Nanocomposites; Nanoparticles; Neoplasms; Polyphenols; Quercetin; Resveratrol; Stilbenes

2017
Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases.
    Advances in biological regulation, 2017, Volume: 65

    Natural products or nutraceuticals promote anti-aging, anti-cancer and other health-enhancing effects. A key target of the effects of natural products may be the regulation of the PI3K/PTEN/Akt/mTORC1/GSK-3 pathway. This review will focus on the effects of curcumin (CUR), berberine (BBR) and resveratrol (RES), on the PI3K/PTEN/Akt/mTORC1/GSK-3 pathway, with a special focus on GSK-3. These natural products may regulate the pathway by multiple mechanisms including: reactive oxygen species (ROS), cytokine receptors, mirco-RNAs (miRs) and many others. CUR is present the root of turmeric (Curcuma longa). CUR is used in the treatment of many disorders, especially in those involving inflammatory processes which may contribute to abnormal proliferation and promote cancer growth. BBR is also isolated from various plants (Berberis coptis and others) and is used in traditional medicine to treat multiple diseases/conditions including: diabetes, hyperlipidemia, cancer and bacterial infections. RES is present in red grapes, other fruits and berries such as blueberries and raspberries. RES may have some anti-diabetic and anti-cancer effects. Understanding the effects of these natural products on the PI3K/PTEN/Akt/mTORC1/GSK-3 pathway may enhance their usage as anti-proliferative agent which may be beneficial for many health problems.

    Topics: Berberine; Cardiovascular Diseases; Curcumin; Gene Expression Regulation; Glycogen Synthase Kinase 3; Humans; Inflammation; Mechanistic Target of Rapamycin Complex 1; Neoplasms; Neurodegenerative Diseases; Osteoarthritis; Phosphatidylinositol 3-Kinases; Protective Agents; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Resveratrol; Signal Transduction; Stilbenes

2017
Cancer Chemoprevention by Resveratrol: The p53 Tumor Suppressor Protein as a Promising Molecular Target.
    Molecules (Basel, Switzerland), 2017, Jun-18, Volume: 22, Issue:6

    Increasing epidemiological and experimental evidence has demonstrated an inverse relationship between the consumption of plant foods and the incidence of chronic diseases, including cancer. Microcomponents that are naturally present in such foods, especially polyphenols, are responsible for the benefits to human health. Resveratrol is a diet-derived cancer chemopreventive agent with high therapeutic potential, as demonstrated by different authors. The aim of this review is to collect and present recent evidence from the literature regarding resveratrol and its effects on cancer prevention, molecular signaling (especially regarding the involvement of p53 protein), and therapeutic perspectives with an emphasis on clinical trial results to date.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Biomarkers, Tumor; Chemoprevention; Clinical Trials as Topic; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Outcome Assessment, Health Care; Resveratrol; Signal Transduction; Stilbenes; Tumor Suppressor Protein p53

2017
Childhood cancer chemotherapy-induced bone damage: pathobiology and protective effects of resveratrol and other nutraceuticals.
    Annals of the New York Academy of Sciences, 2017, Volume: 1403, Issue:1

    Intensive cancer chemotherapy causes significant bone loss, for which the mechanisms remain unclear and effective treatments are lacking. This is a significant issue particularly for childhood cancers, as the most common ones have a >75% cure rate following chemotherapy; there is an increasing population of survivors who live with chronic bone defects. Studies suggest that these defects are the result of reduced bone from increased marrow fat formation and increased bone resorption following chemotherapy. These changes probably result from altered expression/activation of regulatory molecules or pathways regulating skeletal cell formation and activity. Treatment with methotrexate, an antimetabolite commonly used in childhood oncology, has been shown to increase levels of proinflammatory/pro-osteoclastogenic cytokines (e.g., enhanced NF-κB activation), leading to increased osteoclast formation and bone resorption, as well as to attenuate Wnt signaling, leading to both decreased bone and increased marrow fat formation. In recent years, understanding the mechanisms of action and potential health benefits of selected nutraceuticals, including resveratrol, genistein, icariin, and inflammatory fatty acids, has led to preclinical studies that, in some cases, indicate efficacy in reducing chemotherapy-induced bone defects. We summarize the supporting evidence.

    Topics: Antimetabolites, Antineoplastic; Bone Resorption; Cell Differentiation; Child; Dietary Supplements; Humans; Methotrexate; Neoplasms; Protective Agents; Resveratrol; Stilbenes

2017
Nanoparticle formulations to enhance tumor targeting of poorly soluble polyphenols with potential anticancer properties.
    Seminars in cancer biology, 2017, Volume: 46

    Polyphenols have been extensively studied for their relevant anticancer activity. Quite often however their instability, extensive metabolization, low bioavailability and poor solubility limit their application in cancer prevention and therapy. Formulation in nanoparticles has been widely proposed as a means to overcome these limits, maximize localization and specific activity at tumor site. The present review is intended as an update of literature regarding nanoparticulate carriers aimed to deliver polyphenols to the cancer site. Three molecules were chosen, all of which were hydrophobic and poorly soluble, representative of different polyphenol classes: quercetin (QT) among the flavonoid group, curcumin (CUR) as representative of curcuminoids, and resveratrol (RSV) among the stilbenes. In particular, nanoparticulate systems suitable for poorly soluble drugs will be described and attention will be paid to characteristics designed to improve tumor targeting, specific delivery and interaction with tumor cells.

    Topics: Biological Availability; Curcumin; Drug Compounding; Humans; Nanoparticles; Neoplasms; Polyphenols; Quercetin; Resveratrol; Stilbenes

2017
Significance of Resveratrol in Clinical Management of Chronic Diseases.
    Molecules (Basel, Switzerland), 2017, Aug-18, Volume: 22, Issue:8

    Resveratrol could be beneficial to health and provides protection against a wide array of pathologies and age-associated problems, as evident from preclinical studies. However, a comparison of animal and human studies reveals that this dietary polyphenol cannot protect against metabolic diseases and their associated complications. The clinical outcomes are affected by many factors such as sample size. This article not only presents a comprehensive review of the current advances concerning the dose, the extent of absorption, interaction and toxicity of resveratrol in human studies, but also describes its therapeutic effects against several chronic diseases such as diabetes mellitus, obesity, cardiovascular diseases, cancer and aging and the related diseases.

    Topics: Aging; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Neoplasms; Obesity; Polyphenols; Resveratrol; Stilbenes

2017
Gnetin-C and other resveratrol oligomers with cancer chemopreventive potential.
    Annals of the New York Academy of Sciences, 2017, Volume: 1403, Issue:1

    Resveratrol has been extensively studied to investigate its biological effects, including its chemopreventive potential against cancer. Over the past decade, various resveratrol oligomers, both naturally occurring and synthetic, have been described. These resveratrol oligomers result from the polymerization of two or more resveratrol units to form dimers, trimers, tetramers, or even more complex derivatives. Some oligomers appear to have antitumor activities that are similar or superior to monomeric resveratrol. In this review, we discuss resveratrol oligomers with anticancer potential, with emphasis on well-characterized compounds, such as the dimer gnetin-C and other oligomers from Gnetum gnemon, whose safety, pharmacokinetic, and biological activities have been studied in humans.

    Topics: Benzofurans; Chemoprevention; Humans; Neoplasms; Stilbenes

2017
Therapeutic Implications of Autophagy Inducers in Immunological Disorders, Infection, and Cancer.
    International journal of molecular sciences, 2017, Sep-12, Volume: 18, Issue:9

    Autophagy is an essential catabolic program that forms part of the stress response and enables cells to break down their own intracellular components within lysosomes for recycling. Accumulating evidence suggests that autophagy plays vital roles in determining pathological outcomes of immune responses and tumorigenesis. Autophagy regulates innate and adaptive immunity affecting the pathologies of infectious, inflammatory, and autoimmune diseases. In cancer, autophagy appears to play distinct roles depending on the context of the malignancy by either promoting or suppressing key determinants of cancer cell survival. This review covers recent developments in the understanding of autophagy and discusses potential therapeutic interventions that may alter the outcomes of certain diseases.

    Topics: Adaptive Immunity; Animals; Autoimmune Diseases; Autophagy; Benzylisoquinolines; Cholecalciferol; Humans; Immune System Diseases; Immunity, Innate; Indoles; Infections; Isoquinolines; Lysosomes; Maprotiline; Metformin; Neoplasms; Phenols; Pyrroles; Resveratrol; Sirolimus; Spermidine; Stilbenes; Tetrahydroisoquinolines; Trehalose

2017
Biological Mechanisms by Which Antiproliferative Actions of Resveratrol Are Minimized.
    Nutrients, 2017, Sep-21, Volume: 9, Issue:10

    Preclinical and clinical studies have offered evidence for protective effects of various polyphenol-rich foods against cardiovascular diseases, neurodegenerative diseases, and cancers. Resveratrol is among the most widely studied polyphenols. However, the preventive and treatment effectiveness of resveratrol in cancer remain controversial because of certain limitations in existing studies. For example, studies of the activity of resveratrol against cancer cell lines in vitro have often been conducted at concentrations in the low μM to mM range, whereas dietary resveratrol or resveratrol-containing wine rarely achieve nM concentrations in the clinic. While the mechanisms underlying the failure of resveratrol to inhibit cancer growth in the intact organism are not fully understood, the interference by thyroid hormones with the anticancer activity of resveratrol have been well documented in both in vitro and xenograft studies. Thus, endogenous thyroid hormones may explain the failure of anticancer actions of resveratrol in intact animals, or in the clinic. In this review, mechanisms involved in resveratrol-induced antiproliferation and effects of thyroid hormones on these mechanisms are discussed.

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Transformation, Neoplastic; Humans; Neoplasms; Resveratrol; Signal Transduction; Stilbenes; Thyroid Hormones; Treatment Failure

2017
Resveratrol and cancer treatment: updates.
    Annals of the New York Academy of Sciences, 2017, Volume: 1403, Issue:1

    Cancer, a growing health problem worldwide, affects millions of people every year. The overall survival rates of most cancers have been prolonged owing to the efforts of clinicians and scientists. However, some tumors develop resistance to chemoradiotherapeutic agents, and the cancer research community continues to search for effective sensitizers. Resveratrol, a natural polyphenolic phytoalexin, has shown promising effects in inhibiting proliferation and cancer progression in several tumor models. However, its molecular mechanisms and applications in chemotherapy and radiotherapy have yet to be fully determined. In this concise review, we highlight the role and related molecular mechanisms of resveratrol in cancer treatment. In particular, we focus on the role of resveratrol in the tumor microenvironment and the sensitization of cancer cells for chemotherapy and radiotherapy. Resveratrol shows promising efficacies in cancer treatment and may be applied in clinical therapy, but it requires further clinical study.

    Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Neoplasms; Resveratrol; Signal Transduction; Stilbenes

2017
A comprehensive review of the health perspectives of resveratrol.
    Food & function, 2017, Dec-13, Volume: 8, Issue:12

    Many natural products present in our diet, including flavonoids, can prevent the progression of cancer and other diseases. Resveratrol, a natural polyphenol present in various fruits and vegetables, plays an important role as a therapeutic and chemopreventive agent used in the treatment of various illnesses. It exhibits effects against different types of cancer through different pathways. It additionally exerts antidiabetic, anti-inflammatory, and anti-oxidant effects in a variety of cell types. Furthermore, the cardiovascular protective capacities of resveratrol are associated with multiple molecular targets and may lead to the development of novel therapeutic strategies for atherosclerosis, ischemia/reperfusion, metabolic syndrome, and heart failure. Accordingly, this article presents an overview of recent developments in the use of resveratrol for the prevention and treatment of different diseases along with various mechanisms. In addition, the present review summarizes the most recent literature pertaining to resveratrol as a chemotherapeutic agent against multiple diseases and provides an assessment of the potential of this natural compound as a complementary or alternative medicine.

    Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Resveratrol; Stilbenes

2017
The Role of Resveratrol in Cancer Therapy.
    International journal of molecular sciences, 2017, Dec-01, Volume: 18, Issue:12

    Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Neoplasms; Resveratrol; Stilbenes

2017
Regulation of signal transduction cascades by Pterostilbenes in different cancers: Is it a death knell for oncogenic pathways.
    Cellular and molecular biology (Noisy-le-Grand, France), 2017, Dec-15, Volume: 63, Issue:12

    Interdisciplinary research has revolutionized the field of medicine and we have witnessed exponential increase in the high-impact research in past few decades. However, the road to this burgeoning research field is obstacle-ridden because of intratumor heterogeneity, loss of apoptosis and dysregulation of spatio-temporally controlled signaling pathways. Ground-breaking findings obtained through genetic, genomic and proteomic studies have considerably improved our concepts related to the complexity of protein network and excitingly, discovery of miRNAs has added another layer of intricacy to quantitatively regulated gene networks. In this review, we chronicle the milestone achievements and discuss how Pterostilbenes effectively regulated different cellular pathways. We have provided detailed mechanistic insights related to regulation of JAK-STAT signaling, Notch pathway, Wnt mediated intracellular signaling by pterostilbene. Underlying mechanisms about regulation of PI3K/AKT and MAPK pathways by pterostilbene in different cancers.  Regulation of Metastasis-associated protein 1 (MTA1) proteins and Human telomerase reverse transcriptase (hTERT) in cancer cells by pterostilbene. Pterostilbene has also been reported to modulate the expression of various oncogenic and tumor suppressor microRNAs in cancer cells. Better and sharper comprehension of the concepts associated with the modes of action of pterostilbene in different cancers will be useful in identification of cancers which can be efficiently targeted by pterostilbene.

    Topics: Apoptosis; Humans; Janus Kinases; MicroRNAs; Neoplasms; Receptors, Notch; Signal Transduction; STAT Transcription Factors; Stilbenes; Wnt Proteins

2017
Metabolomics of cancer cell cultures to assess the effects of dietary phytochemicals.
    Critical reviews in food science and nutrition, 2017, May-03, Volume: 57, Issue:7

    Cancer is a multi-factorial disease and is a major cause of morbidity and mortality worldwide. Dietary phytochemicals have been used for the treatment of cancer throughout history due to their safety, low toxicity, and general availability. Several studies have been performed to elucidate the effects of dietary phytochemicals on cancer metabolism, and many molecular targets of phytochemicals have been discovered. In spite of remarkable progress, their effects on cancer metabolism have not yet been fully clarified. Recent developments in metabolomics allowed to probe much further the metabolism of cancer, highlighting altered metabolic pathways and offering a new powerful tool to investigate cancer disease. In this review, we discuss the main metabolic alterations of cancer cells and the potentiality of phytochemicals as promising modulators of cancer metabolism. We will focus on the application of nuclear magnetic resonance-based metabolomics on breast and hepatocellular cancer cell lines to evaluate the impact of curcumin and resveratrol on cancer metabolome with the aim to demonstrate the premise of this approach to provide useful information for a better understanding of impact of diet components on cancer disease.

    Topics: Cell Line, Tumor; Curcumin; Humans; Magnetic Resonance Spectroscopy; Metabolome; Metabolomics; Neoplasms; Phytochemicals; Resveratrol; Stilbenes

2017
Review of Cytotoxic CA4 Analogues that Do Not Target Microtubules: Implications for CA4 Development.
    Mini reviews in medicinal chemistry, 2017, Volume: 17, Issue:16

    One of the most studied anti-cancer compounds of the last several decades is the microtubule targeting agent and cis-stilbene, combretastatin A4 (CA4). Despite promising results at the pre-clinical level, future clinical use of CA4 as a monotherapy is in question due to metabolic vulnerability and conformational instability.. Thus, medicinal chemists have focused on synthesizing derivatives with improved pharmokinetic profile. One common strategy has been the incorporation of the ethylene linker into a ring system, thus preventing the isomerization of CA4 into the virtually inactive trans-isomer. Although many structurally stable and potent analogues of CA4 have been designed and synthesized, several analogues have been discovered to possess anti-proliferative properties seemingly independent of microtubule targeting. The presence of such analogues suggests that CA4 may also possess nonmicrotubule targets, which reveals the necessity for future structure activity relationship studies and optimization of any non-microtubule targeting. Furthermore, analogues of CA4 not inhibiting microtubule polymerization can no longer be assumed to be inactive.. Future clinical development of the CA4 pharmacophore requires that attention should be paid to abnormal CA4 analogues, which appear to retain cytotoxicity independent of canonical microtubule inhibition.

    Topics: Animals; Antineoplastic Agents; Drug Discovery; Humans; Microtubules; Molecular Targeted Therapy; Neoplasms; Stilbenes

2017
Patent Survey of Resveratrol, Taxol, Podophyllotoxin, Withanolides and Their Derivatives Used in Anticancer Therapy.
    Recent patents on biotechnology, 2017, Volume: 11, Issue:2

    Resveratrol, taxol, podophyllotoxin, withanolides and their derivatives find applications in anti-cancer therapy. They are plant-derived compounds whose chemical structures and synthesis limit their natural availability and restrict a large-scale industrial production. Hence, their production by various biotechnological approaches may hold promise for a continuous and reliable mode of supply.. We review process and product patents in this regard.. Accordingly, we provide a general outline to search the freely accessible WIPO, EPO, USPTO and Cambia databases with several keywords and patent codes. We have tabulated both granted and filed patents from the said databases.. We retrieved ~40 patents from these databases. Novel biotechnological processes for production of these anticancer compounds include Agrobacterium rhizogenes-mediated hairy root culture, suspension culture, cell culture with elicitors, use of recombinant microorganisms, and bioreactors among others. The results are indicative of being both database-specific as well as queryspecific. A ten-year search window yielded 33 patents. The utility of the search strategy is discussed in the light of biotechnological developments in the field. Those who examine patent literature using similar search strategies may complement their knowledge obtained from perusal of mainstream journal resources.

    Topics: Humans; Neoplasms; Paclitaxel; Patents as Topic; Podophyllotoxin; Resveratrol; Stilbenes; Withanolides

2017
Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer.
    Seminars in cancer biology, 2017, Volume: 46

    In the recent years, polyphenols have gained significant attention in scientific community owing to their potential anticancer effects against a wide range of human malignancies. Epidemiological, clinical and preclinical studies have supported that daily intake of polyphenol-rich dietary fruits have a strong co-relationship in the prevention of different types of cancer. In addition to direct antioxidant mechanisms, they also regulate several therapeutically important oncogenic signaling and transcription factors. However, after the discovery of microRNA (miRNA), numerous studies have identified that polyphenols, including epigallocatechin-3-gallate, genistein, resveratrol and curcumin exert their anticancer effects by regulating different miRNAs which are implicated in all the stages of cancer. MiRNAs are short, non-coding endogenous RNA, which silence the gene functions by targeting messenger RNA (mRNA) through degradation or translation repression. However, cancer associated miRNAs has emerged only in recent years to support its applications in cancer therapy. Preclinical experiments have suggested that deregulation of single miRNA is sufficient for neoplastic transformation of cells. Indeed, the widespread deregulation of several miRNA profiles of tumor and healthy tissue samples revealed the involvement of many types of miRNA in the development of numerous cancers. Hence, targeting the miRNAs using polyphenols will be a novel and promising strategy in anticancer chemotherapy. Herein, we have critically reviewed the potential applications of polyphenols on various human miRNAs, especially which are involved in oncogenic and tumor suppressor pathways.

    Topics: Catechin; Curcumin; Gene Expression Regulation, Neoplastic; Genistein; Humans; MicroRNAs; Neoplasms; Polyphenols; Resveratrol; Signal Transduction; Stilbenes

2017
Cancer chemoprevention - selected molecular mechanisms.
    Postepy higieny i medycyny doswiadczalnej (Online), 2017, Mar-02, Volume: 71, Issue:0

    The effect of diet on cancer formation and prevention of carcinogenesis has attracted considerable attention for years and is the subject of several studies. Some components of the daily diet, such as resveratrol, curcumin, genistein, gingerol, can significantly reduce the risk of cancer or affect the rate of tumor progression. Cancer chemoprevention assumes the use of natural or synthetic biologically active substances in order to prevent, inhibit or reverse the progression of cancer. There are many biologically active compounds in several natural products, i.e. garlic, ginger, soy, curcuma, tomatoes, cruciferous plants or green tea. Their chemopreventive activity is based on the inhibition of processes underlying carcinogenesis (inflammation, transformation and proliferation), but also affects the final phase of carcinogenesis - angiogenesis and metastasis. Despite the relatively low toxicity of chemopreventive agents, their molecular targets often coincide with the objectives of the currently used cancer therapies. The widespread use of chemopreventive agents may contribute to reduction of the rate of cancer incidence, and increase the effectiveness of conventional cancer therapies. In the present study, selected molecular mechanisms of the chemopreventive activity have been discussed, especially their involvement in the regulation of signal transduction, cell cycle regulation, apoptosis, metastasis and angiogenesis. The role of chemopreventive agents in the inflammatory process, the metabolism of xenobiotics and multidrug resistance has been also characterized.

    Topics: Anticarcinogenic Agents; Apoptosis; Catechols; Chemoprevention; Curcumin; Fatty Alcohols; Humans; Neoplasms; Neovascularization, Pathologic; Resveratrol; Signal Transduction; Stilbenes

2017
Implications of Resveratrol on Glucose Uptake and Metabolism.
    Molecules (Basel, Switzerland), 2017, Mar-07, Volume: 22, Issue:3

    Resveratrol-a polyphenol of natural origin-has been the object of massive research in the past decade because of its potential use in cancer therapy. However, resveratrol has shown an extensive range of cellular targets and effects, which hinders the use of the molecule for medical applications including cancer and type 2 diabetes. Here, we review the latest advances in understanding how resveratrol modulates glucose uptake, regulates cellular metabolism, and how this may be useful to improve current therapies. We discuss challenges and findings regarding the inhibition of glucose uptake by resveratrol and other polyphenols of similar chemical structure. We review alternatives that can be exploited to improve cancer therapies, including the use of other polyphenols, or the combination of resveratrol with other molecules and their impact on glucose homeostasis in cancer and diabetes.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Biological Transport; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Drug Synergism; Glucose; Homeostasis; Humans; Neoplasms; Polyphenols; Resveratrol; Signal Transduction; Stilbenes

2017
Mediterranean Way of Drinking and Longevity.
    Critical reviews in food science and nutrition, 2016, Volume: 56, Issue:4

    The relation between alcohol consumption and mortality is a J-shaped curve in most of the many studies published on this topic. The Copenhagen Prospective Population Studies demonstrated in the year 2000 that wine intake may have a beneficial effect on all cause mortality that is additive to that of alcohol. Wine contains various poliphenolic substances which may be beneficial for health and in particular flavonols (such as myricetin and quercetin), catechin and epicatechin, proanthocyanidins, anthocyanins, various phenolic acids and the stilbene resveratrol. In particular, resveratrol seems to play a positive effect on longevity because it increases the expression level of Sirt1, besides its antioxidant, anti-inflammatory and anticarcinogenic properties. Moderate wine drinking is part of the Mediterranean diet, together with abundant and variable plant foods, high consumption of cereals, olive oil as the main (added) fat and a low intake of (red) meat. This healthy diet pattern involves a "Mediterranean way of drinking," that is a regular, moderate wine consumption mainly with food (up to two glasses a day for men and one glass for women). Moderate wine drinking increases longevity, reduces the risk of cardiovascular diseases and does not appreciably influence the overall risk of cancer.

    Topics: Alcohol Drinking; Cardiovascular Diseases; Diet, Mediterranean; Female; Flavonols; Humans; Liver Cirrhosis; Longevity; Male; Mediterranean Region; Neoplasms; Phenols; Resveratrol; Risk Factors; Sex Factors; Sirtuins; Stilbenes; Wine

2016
Natural Products as a Vital Source for the Discovery of Cancer Chemotherapeutic and Chemopreventive Agents.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2016, Volume: 25 Suppl 2

    Throughout history, natural products have played a dominant role in the treatment of human ailments. For example, the legendary discovery of penicillin transformed global existence. Presently, natural products comprise a large portion of current-day pharmaceutical agents, most notably in the area of cancer therapy. Examples include Taxol, vinblastine, and camptothecin. These structurally unique agents function by novel mechanisms of action; isolation from natural sources is the only plausible method that could have led to their discovery. In addition to terrestrial plants as sources for starting materials, the marine environment (e.g., ecteinascidin 743, halichondrin B, and dolastatins), microbes (e.g., bleomycin, doxorubicin, and staurosporin), and slime molds (e.g., epothilone B) have yielded remarkable cancer chemotherapeutic agents. Irrespective of these advances, cancer remains a leading cause of death worldwide. Undoubtedly, the prevention of human cancer is highly preferable to treatment. Cancer chemoprevention, the use of vaccines or pharmaceutical agents to inhibit, retard, or reverse the process of carcinogenesis, is another important approach for easing this formidable public health burden. Similar to cancer chemotherapeutic agents, natural products play an important role in this field. There are many examples, including dietary phytochemicals such as sulforaphane and phenethyl isothiocyanate (cruciferous vegetables) and resveratrol (grapes and grape products). Overall, natural product research is a powerful approach for discovering biologically active compounds with unique structures and mechanisms of action. Given the unfathomable diversity of nature, it is reasonable to suggest that chemical leads can be generated that are capable of interacting with most or possibly all therapeutic targets.

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Products; Cancer Vaccines; Chemoprevention; Cytarabine; Dietary Supplements; Humans; Neoplasms; Phytochemicals; Resveratrol; Stilbenes

2016
A Comprehensive Review on the Chemotherapeutic Potential of Piceatannol for Cancer Treatment, with Mechanistic Insights.
    Journal of agricultural and food chemistry, 2016, Feb-03, Volume: 64, Issue:4

    Cancer is a diverse class of diseases characterized by uncontrolled cell growth that constitutes the greatest cause of mortality and morbidity worldwide. Despite steady progress, the treatment modalities of cancer are still insufficient. Several new concepts have emerged for therapeutic intervention in malignant diseases with the goal of identifying specific targets and overcoming resistance against current cytotoxic therapies. Many studies have reported the remarkable and significant properties of dietary plant polyphenols such as curcumin, resveratrol, flavopiridol, indirubin, magnolol, piceatannol, parthenolide, epigallocatechin gallate, and cucurbitacin as anticancer agents known for their pleiotropic effects on cancer, immune cells, and inflammation. Piceatannol, an analogue and metabolite of resveratrol, is a natural stilbene commonly found in grape skins and wine. Compared to resveratrol, this molecule exhibits superior bioactivities as an inhibitor of COX-1/2 and the CSN-associated kinase. Piceatannol is thought to be a potent natural compound with many therapeutic effects, such as the prevention of hypercholesterolemia, arrhythmia, atherosclerosis, angiogenesis, and cardiovascular diseases. It also demonstrates vasorelaxation, antioxidant, and anticancer activities. This comprehensive review summarizes the current data regarding the mechanisms of action of piceatannol, its chemopreventive properties, and its possible therapeutic potential against various types of human cancer.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Humans; Neoplasms; Resveratrol; Stilbenes

2016
Role of Natural Stilbenes in the Prevention of Cancer.
    Oxidative medicine and cellular longevity, 2016, Volume: 2016

    Natural stilbenes are an important group of nonflavonoid phytochemicals of polyphenolic structure characterized by the presence of a 1,2-diphenylethylene nucleus. Stilbenes have an extraordinary potential for the prevention and treatment of different diseases, including cancer, due to their antioxidant, cell death activation, and anti-inflammatory properties which associate with low toxicity under in vivo conditions. This review aims to discuss various approaches related to their mechanisms of action, pharmacological activities in animal models and humans, and potential chemoprevention in clinical studies. The biological activity of natural stilbenes is still incompletely understood. Furthermore, after administration to animals or humans, these molecules are rapidly metabolized. Thus pharmacokinetics and/or activities of the natural structures and their metabolites may be very different. Novel drug formulations have been postulated in order to improve stability and bioavailability, to minimize side effects, and to facilitate interaction with their domains in target proteins. These pharmacological improvements should lead stilbenes to become effective candidates as anticancer drugs.

    Topics: Animals; Chemoprevention; Clinical Trials as Topic; Humans; Neoplasms; Resveratrol; Stilbenes; Structure-Activity Relationship

2016
Resveratrol and the mitochondria: From triggering the intrinsic apoptotic pathway to inducing mitochondrial biogenesis, a mechanistic view.
    Biochimica et biophysica acta, 2016, Volume: 1860, Issue:4

    Mitochondria, the power plants of the cell, are known as a cross-road of different cellular signaling pathways. These cytoplasmic double-membraned organelles play a pivotal role in energy metabolism and regulate calcium flux in the cells. It is well known that mitochondrial dysfunction is associated with different diseases such as neurodegeneration and cancer. A growing body of literature has shown that polyphenolic compounds exert direct effects on mitochondrial ultra-structure and function. Resveratrol is known as one of the most common bioactive constituents of red wine, which improves mitochondrial functions under in vitro and in vivo conditions.. This paper aims to review the molecular pathways underlying the beneficial effects of resveratrol on mitochondrial structure and functions. In addition, we discuss the chemistry and main sources of resveratrol.. Resveratrol represents the promising effects on mitochondria in different experimental models. However, there are several reports on the detrimental effects elicited by resveratrol on mitochondria.. An understanding of the chemistry and source of resveratrol, its bioavailability and the promising effects on mitochondria brings a new hope to therapy of mitochondrial dysfunction-related diseases.

    Topics: Animals; Apoptosis; Humans; Mitochondria; Neoplasms; Neurodegenerative Diseases; Resveratrol; Stilbenes

2016
Combination chemoprevention with grape antioxidants.
    Molecular nutrition & food research, 2016, Volume: 60, Issue:6

    Antioxidant ingredients present in grape have been extensively investigated for their cancer chemopreventive effects. However, much of the work has been done on individual ingredients, especially focusing on resveratrol and quercetin. Phytochemically, whole grape represents a combination of numerous phytonutrients. Limited research has been done on the possible synergistic/additive/antagonistic interactions among the grape constituents. Among these phytochemical constituents of grapes, resveratrol, quercetin, kaempferol, catechin, epicatechin, and anthocyanins (cyanidin and malvidin) constitute more than 70% of the grape polyphenols. Therefore, these have been relatively well studied for their chemopreventive effects against a variety of cancers. While a wealth of information is available individually on cancer chemopreventive/anti-proliferative effects of resveratrol and quercetin, limited information is available regarding the other major constituents of grape. Studies have also suggested that multiple grape antioxidants, when used in combination, alone or with other agents/drugs show synergistic or additive anti-proliferative response. Based on strong rationale emanating from published studies, it seems probable that a combination of multiple grape ingredients alone or together with other agents could impart 'additive synergism' against cancer.

    Topics: Animals; Anthocyanins; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Catechin; Cell Line, Tumor; Chemoprevention; Disease Models, Animal; Humans; Kaempferols; Neoplasms; Plant Extracts; Polyphenols; Quercetin; Resveratrol; Stilbenes; Vitis

2016
Prevention and treatment of cancers by immune modulating nutrients.
    Molecular nutrition & food research, 2016, Volume: 60, Issue:6

    Epidemiological and laboratory data support the protective effects of bioactive nutrients in our diets for various diseases. Along with various factors, such as genetic history, alcohol, smoking, exercise, and dietary choices play a vital role in affecting an individual's immune responses toward a transforming cell, by either preventing or accelerating a neoplastic transformation. Ample evidence suggests that dietary nutrients control the inflammatory and protumorigenic responses in immune cells. Immunoprevention is usually associated with the modulation of immune responses that help in resolving the inflammation, thus improving clinical outcome. Various metabolic pathway-related nutrients, including glutamine, arginine, vitamins, minerals, and long-chain fatty acids, are important components of immunonutrient mixes. Epidemiological studies related to these substances have reported different results, with no or minimal effects. However, several studies suggest that these nutrients may have immune-modulating effects that may lower cancer risk. Preclinical studies submit that most of these components may provide beneficial effects. The present review discusses the available data, the immune-modulating functions of these nutrients, and how these substances could be used to study immune modulation in a neoplastic environment. Further research will help to determine whether the mechanistic signaling pathways in immune cells altered by nutrients can be exploited for cancer prevention and treatment.

    Topics: Animals; Arginine; Catechin; Cell Line, Tumor; Diet; Disease Models, Animal; Fatty Acids, Unsaturated; Glutamine; Humans; Isothiocyanates; Lignans; Meta-Analysis as Topic; Micronutrients; Neoplasms; Observational Studies as Topic; Phytochemicals; Polyphenols; Randomized Controlled Trials as Topic; Stilbenes

2016
Impact of nanotechnology on the delivery of natural products for cancer prevention and therapy.
    Molecular nutrition & food research, 2016, Volume: 60, Issue:6

    Chemoprevention of human cancer by dietary products is a practical approach of cancer control, especially when chemoprevention is involved during the early stages of the carcinogenesis process. Research over the last few decades has clearly demonstrated the efficacy of dietary products for chemoprevention in cell culture and preclinical animal model systems. However, these in vitro and in vivo effects have not been able to be translated to bedside for clinical use. Among many reasons, inefficient systemic delivery and bioavailability of promising chemopreventive agents are considered to significantly contribute to such a disconnection. Since its advent in the field of cancer, nanotechnology has provided researchers with expertise to explore new avenues for diagnosis, prevention, and therapy of the disease. In a similar trait, we introduced a novel concept in which nanotechnology was utilized for enhancing the outcome of chemoprevention (Cancer Res. 2009; 69:1712-1716). This idea, which we termed as 'nanochemoprevention', was exploited by several laboratories and has now become an advancing field in chemoprevention research. This review summarizes some of these applications of nanotechnology in medicine, particularly focused on controlled and sustained release of bioactive compounds with emphasis on current and future utilization of nanochemoprevention for prevention and therapy of cancer.

    Topics: Animals; Anticarcinogenic Agents; Biological Products; Catechin; Cell Line, Tumor; Chemoprevention; Curcumin; Disease Models, Animal; Humans; Nanoparticles; Nanotechnology; Neoplasms; Resveratrol; Stilbenes

2016
Targeting cancer stem-like cells using dietary-derived agents - Where are we now?
    Molecular nutrition & food research, 2016, Volume: 60, Issue:6

    Diet has been linked to an overwhelming proportion of cancers. Current chemotherapy and targeted therapies are limited by toxicity and the development of resistance against these treatments results in cancer recurrence or progression. In vitro evidence indicates that a number of dietary-derived agents have activity against a highly tumorigenic, chemoradiotherapy resistant population of cells within a tumour. This population is associated with cancer recurrence and is therefore clinically significant. Targeting this subpopulation, termed cancer stem-like cells with dietary-derived agents provides a potentially low toxicity strategy to enhance current treatment regimens. In addition, dietary-derived compounds also provide a novel approach to cancer prevention strategies. This review focusses on selected diet-derived agents that have been shown to specifically target cancer stem-like cells using in vivo models, or in clinical trials. Furthermore, the potential limitations of these studies are discussed, and areas of research that need to be addressed to allow successful translation of dietary-derived agents to the clinical arena are highlighted.

    Topics: Animals; Anticarcinogenic Agents; Catechin; Cell Line, Tumor; Curcumin; Diet; Disease Models, Animal; Flavonoids; Humans; Isothiocyanates; Neoplasms; Neoplastic Stem Cells; Randomized Controlled Trials as Topic; Resveratrol; Stilbenes; Sulfoxides; Vitamin A

2016
Nutritional immunology: function of natural killer cells and their modulation by resveratrol for cancer prevention and treatment.
    Nutrition journal, 2016, 05-04, Volume: 15, Issue:1

    Natural killer (NK) cells as part of the innate immune system represent the first line of defence against (virus-) infected and malignantly transformed cells. The emerging field of nutritional immunology focuses on compounds featuring immune-modulating activities in particular on NK cells, which e.g. can be exploited for cancer prevention and treatment. The plant-based nutrition resveratrol is a ternary hydroxylated stilbene, which is present in many foods and beverages, respectively. In humans it comprises a large variety of distinct biological activities. Interestingly, resveratrol strongly modulates the immune response including the activity of NK cells. This review will give an overview on NK cell functions and summarize the resveratrol-mediated modulation thereof.

    Topics: Antineoplastic Agents, Phytogenic; Diet; Humans; Killer Cells, Natural; Neoplasms; Nutritional Physiological Phenomena; Plants, Edible; Resveratrol; Stilbenes

2016
The Use of Stilbene Scaffold in Medicinal Chemistry and Multi- Target Drug Design.
    Current medicinal chemistry, 2016, Volume: 23, Issue:23

    The stilbene scaffold is a basic element for a number of biologically active natural and synthetic compounds, and it is considered as a privileged structure. Stilbenes exemplified by resveratrol, combretastatin A-4 and pterostilbene are of significant interest for drug research and development because of their potential in therapeutic and preventive application. Resveratrol, present in grapes and other food products, plays a role in the prevention of several human pathological processes and has been suggested as an anticancer agent. Moreover, recent evidence has revealed its potential effect on the aging process, diabetes and neurological dysfunction. Combretastatin A-4, from the bark of South African bush willow Combretum caffrum, also shows significant antitumor activity. Pterostilbene is closely related to resveratrol, sharing the same unique therapeutic potential as anti-inflammatory, antineoplastic and antioxidant agent. Therefore, research and development of stilbene-based medicinal chemistry have become rapidly evolving and increasingly active topics covering almost the whole range of therapeutic fields. In the present review, we provide an overview of the role of stilbenes in medicinal chemistry. In this context, we highlight the chemical methodologies adopted for the synthesis of stilbene derivatives, and outline the successful design of novel stilbene based hybrids in the field of cancer, Alzheimer's and other relevant diseases. This information may be useful in further design of stilbene-based molecules as new leads for the development of novel agents with clinical potential or as effective chemical probes to dissect biological processes.

    Topics: Alzheimer Disease; Antineoplastic Agents, Phytogenic; Bibenzyls; Chemistry, Pharmaceutical; Drug Design; Humans; Neoplasms; Resveratrol; Stilbenes; Structure-Activity Relationship

2016
Roles of Dietary Phytoestrogens on the Regulation of Epithelial-Mesenchymal Transition in Diverse Cancer Metastasis.
    Toxins, 2016, 05-24, Volume: 8, Issue:6

    Epithelial-mesenchymal transition (EMT) plays a key role in tumor progression. The cells undergoing EMT upregulate the expression of cell motility-related proteins and show enhanced migration and invasion. The hallmarks of EMT in cancer cells include changed cell morphology and increased metastatic capabilities in cell migration and invasion. Therefore, prevention of EMT is an important tool for the inhibition of tumor metastasis. A novel preventive therapy is needed, such as treatment of natural dietary substances that are nontoxic to normal human cells, but effective in inhibiting cancer cells. Phytoestrogens, such as genistein, resveratrol, kaempferol and 3,3'-diindolylmethane (DIM), can be raised as possible candidates. They are plant-derived dietary estrogens, which are found in tea, vegetables and fruits, and are known to have various biological efficacies, including chemopreventive activity against cancers. Specifically, these phytoestrogens may induce not only anti-proliferation, apoptosis and cell cycle arrest, but also anti-metastasis by inhibiting the EMT process in various cancer cells. There have been several signaling pathways found to be associated with the induction of the EMT process in cancer cells. Phytoestrogens were demonstrated to have chemopreventive effects on cancer metastasis by inhibiting EMT-associated pathways, such as Notch-1 and TGF-beta signaling. As a result, phytoestrogens can inhibit or reverse the EMT process by upregulating the expression of epithelial phenotypes, including E-cadherin, and downregulating the expression of mesenchymal phenotypes, including N-cadherin, Snail, Slug, and vimentin. In this review, we focused on the important roles of phytoestrogens in inhibiting EMT in many types of cancer and suggested phytoestrogens as prominent alternative compounds to chemotherapy.

    Topics: Anticarcinogenic Agents; Antineoplastic Agents; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Genistein; Humans; Indoles; Kaempferols; Neoplasm Metastasis; Neoplasms; Phytoestrogens; Resveratrol; Stilbenes

2016
Challenges in Analyzing the Biological Effects of Resveratrol.
    Nutrients, 2016, Jun-09, Volume: 8, Issue:6

    The suggested health effects (e.g., disease prevention) of dietary bioactive compounds such as resveratrol are challenging to prove in comparison to man-made drugs developed for therapeutic purposes. Dietary bioactive compounds have multiple cellular targets and therefore have a variety of biological effects. Extrapolating the biological effects of dietary compounds from in vitro and in vivo animal experiments to humans may lead to over- or under-estimation of the effect and role of these compounds. The present paper will discuss a few of these challenges and suggest directions for future research. Questions we address include: (1) Is the combinatorial effect of resveratrol and other compounds real? (2) What are the real and relevant doses of resveratrol after administration? and (3) Is it possible to estimate the preventive effect of resveratrol by clinical trials using standard experimental designs? The examples concerning resveratrol taken from the scientific literature are mainly from 2010 and later. The challenges pointed out in this review are similar to most naturally occurring bioactive compounds.

    Topics: Alzheimer Disease; Animals; Antioxidants; Biological Availability; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Humans; Metabolic Diseases; Neoplasms; Phytochemicals; Randomized Controlled Trials as Topic; Resveratrol; Stilbenes

2016
Polyphenol compounds and PKC signaling.
    Biochimica et biophysica acta, 2016, Volume: 1860, Issue:10

    Naturally occurring polyphenols found in food sources provide huge health benefits. Several polyphenolic compounds are implicated in the prevention of disease states, such as cancer. One of the mechanisms by which polyphenols exert their biological actions is by interfering in the protein kinase C (PKC) signaling pathways. PKC belongs to a superfamily of serine-threonine kinase and are primarily involved in phosphorylation of target proteins controlling activation and inhibition of many cellular processes directly or indirectly.. Despite the availability of substantial literature data on polyphenols' regulation of PKC, no comprehensive review article is currently available on this subject. This article reviews PKC-polyphenol interactions and its relevance to various disease states. In particular, salient features of polyphenols, PKC, interactions of naturally occurring polyphenols with PKC, and future perspective of research on this subject are discussed.. Some polyphenols exert their antioxidant properties by regulating the transcription of the antioxidant enzyme genes through PKC signaling. Regulation of PKC by polyphenols is isoform dependent. The activation or inhibition of PKC by polyphenols has been found to be dependent on the presence of membrane, Ca(2+) ion, cofactors, cell and tissue types etc. Two polyphenols, curcumin and resveratrol are in clinical trials for the treatment of colon cancer.. The fact that 74% of the cancer drugs are derived from natural sources, naturally occurring polyphenols or its simple analogs with improved bioavailability may have the potential to be cancer drugs in the future.

    Topics: Curcumin; Humans; Neoplasms; Polyphenols; Protein Kinase C; Resveratrol; Signal Transduction; Stilbenes

2016
Bio-/Chemosensors and Imaging with Aggregation-Induced Emission Luminogens.
    Chemical record (New York, N.Y.), 2016, Volume: 16, Issue:4

    Aggregation-induced emission (AIE) luminogens show abnormal fluorescent behavior; they are non-emissive in solution, but they become strongly emissive after aggregation. Sensing and imaging are the major applications of AIE luminogens. By properly manipulating the aggregation and deaggregation of AIE molecules, various bio-/chemosensors have been developed. Moreover, AIE molecules with targeting groups have been devised for imaging of organelles and cancer cells. In this account, we report our recent work on the application of AIE luminogens for the construction of bio-/chemosensors and imaging.

    Topics: Animals; Biosensing Techniques; DNA, Single-Stranded; Fluorescent Dyes; G-Quadruplexes; Humans; Indoles; Luminescence; Metals; Molecular Imaging; Neoplasms; Organelles; Organosilicon Compounds; Proteins; Stilbenes

2016
Promising therapeutic potential of pterostilbene and its mechanistic insight based on preclinical evidence.
    European journal of pharmacology, 2016, Oct-15, Volume: 789

    Pterostilbene (PS) is a well-recognized antioxidant that primarily exists in blueberries, grapevines and heartwood of red sandalwood. Interest in this compound has been renewed in recent years, and studies have found that PS possesses an array of pharmacological properties, including chemopreventive, antiinflammatory, antidiabetic, antidyslipidemic, antiatherosclerotic and neuroprotective effects. However, the greater in vivo bioavailability of PS, as compared to resveratrol, is an added advantage for its efficacy. This review provides a summary regarding the sources, pharmacokinetic aspects and pharmacodynamics of PS, with a focus on the molecular mechanisms underlying its protective effects against cancer, brain injuries and heart disease. Studies regarding the safety profile of PS have also been included. Based on the presently available evidence, we conclude that PS represents an active phytonutrient and a potential drug with pleiotropic health applications.

    Topics: Animals; Cardiovascular Diseases; Central Nervous System Diseases; Humans; Neoplasms; Safety; Stilbenes

2016
Role of angiogenic factors of herbal origin in regulation of molecular pathways that control tumor angiogenesis.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:11

    The formation of blood capillaries to sustain development and growth of new tissues is referred to as angiogenesis. Angiogenesis is pivotal in both carcinogenesis and metastasis since capillaries are the sole source of supplying nutrients and oxygen to the proliferating tumor cells; therefore, this dependency of tumor growth on angiogenesis challenges researchers to halt tumor growth by targeting angiogenesis with the help of either synthetic or natural inhibitors. Many synthetic inhibitors of angiogenesis have not only come into force but also resulted in some severe adverse effects. Natural compounds may effectively fit into this condition and possibly decrease the time of treatment. In the recent past, literature is replete with evidences advocating the usefulness of natural compounds that target multiple biochemical pathways. The additional advantage of natural compounds is that their active principles interact with one another and work synergistically to give more meaningful and reliable effects than individual principle. Hence, if we are somehow able to combine more than two natural compounds, then it may be possible to enhance their potential by many folds, which shall prove to be very effective in combating tumor angiogenesis. This review shall discuss the concept of angiogenesis, molecular pathways, and angiogenic inhibitors and their specific targets and potential of natural compounds to greatly enhance the current knowledge of angiogenesis-inhibiting factors.

    Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Artemisinins; Catechin; Cell Proliferation; Curcumin; Humans; Neoplasms; Neovascularization, Pathologic; Plant Extracts; Resveratrol; Stilbenes; Triterpenes

2016
Anticancer Efficacy of Polyphenols and Their Combinations.
    Nutrients, 2016, Sep-09, Volume: 8, Issue:9

    Polyphenols, found abundantly in plants, display many anticarcinogenic properties including their inhibitory effects on cancer cell proliferation, tumor growth, angiogenesis, metastasis, and inflammation as well as inducing apoptosis. In addition, they can modulate immune system response and protect normal cells against free radicals damage. Most investigations on anticancer mechanisms of polyphenols were conducted with individual compounds. However, several studies, including ours, have indicated that anti-cancer efficacy and scope of action can be further enhanced by combining them synergistically with chemically similar or different compounds. While most studies investigated the anti-cancer effects of combinations of two or three compounds, we used more comprehensive mixtures of specific polyphenols and mixtures of polyphenols with vitamins, amino acids and other micronutrients. The mixture containing quercetin, curcumin, green tea, cruciferex, and resveratrol (PB) demonstrated significant inhibition of the growth of Fanconi anemia head and neck squamous cell carcinoma and dose-dependent inhibition of cell proliferation, matrix metalloproteinase (MMP)-2 and -9 secretion, cell migration and invasion through Matrigel. PB was found effective in inhibition of fibrosarcoma HT-1080 and melanoma A2058 cell proliferation, MMP-2 and -9 expression, invasion through Matrigel and inducing apoptosis, important parameters for cancer prevention. A combination of polyphenols (quercetin and green tea extract) with vitamin C, amino acids and other micronutrients (EPQ) demonstrated significant suppression of ovarian cancer ES-2 xenograft tumor growth and suppression of ovarian tumor growth and lung metastasis from IP injection of ovarian cancer A-2780 cells. The EPQ mixture without quercetin (NM) also has shown potent anticancer activity in vivo and in vitro in a few dozen cancer cell lines by inhibiting tumor growth and metastasis, MMP-2 and -9 secretion, invasion, angiogenesis, and cell growth as well as induction of apoptosis. The presence of vitamin C, amino acids and other micronutrients could enhance inhibitory effect of epigallocatechin gallate (EGCG) on secretion of MMPs. In addition, enrichment of NM with quercetin (EPQ mix) enhanced anticancer activity of NM in vivo. In conclusion, polyphenols, especially in combination with other polyphenols or micronutrients, have been shown to be effective against multiple targets in cancer development and progression, and s

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Biological Availability; Catechin; Cell Line, Tumor; Cell Proliferation; Curcumin; Disease Models, Animal; Humans; Micronutrients; Neoplasms; Plant Extracts; Polyphenols; Quercetin; Resveratrol; Stilbenes; Tea

2016
Synergistic Anticancer Effect of Tocotrienol Combined with Chemotherapeutic Agents or Dietary Components: A Review.
    International journal of molecular sciences, 2016, Sep-22, Volume: 17, Issue:10

    Tocotrienol (T3), unsaturated vitamin E, is gaining a lot of attention owing to its potent anticancer effect, since its efficacy is much greater than that of tocopherol (Toc). Various factors are known to be involved in such antitumor action, including cell cycle arrest, apoptosis induction, antiangiogenesis, anti-metastasis, nuclear factor-κB suppression, and telomerase inhibition. Owing to a difference in the affinity of T3 and Toc for the α-tocopherol transfer protein, the bioavailability of orally ingested T3 is lower than that of Toc. Furthermore, cellular uptake of T3 is interrupted by coadministration of α-Toc in vitro and in vivo. Based on this, several studies are in progress to screen for molecules that can synergize with T3 in order to augment its potency. Combinations of T3 with chemotherapeutic drugs (e.g., statins, celecoxib, and gefitinib) or dietary components (e.g., polyphenols, sesamin, and ferulic acid) exhibit synergistic actions on cancer cell growth and signaling pathways. In this review, we summarize the current status of synergistic effects of T3 and an array of agents on cancer cells, and discuss their molecular mechanisms of action. These combination strategies would encourage further investigation and application in cancer prevention and therapy.

    Topics: Antineoplastic Agents; Catechin; Coumaric Acids; Dietary Supplements; Dioxoles; Drug Synergism; Drug Therapy, Combination; Humans; Lignans; Neoplasms; Resveratrol; Stilbenes; Tocotrienols

2016
Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status.
    Pharmacological reports : PR, 2016, Volume: 68, Issue:6

    For the first time combretastatins were isolated from African willow tree Combretum Caffrum. Subsequent studies have shown the impact of combretastatin A4 phosphate, a water-soluble prodrug, on endothelial cells in tumor vascular system. The same effect was not observed in the vascular system. This selectivity is associated with combretastatins mechanism of action: binding to colchicine domain of microtubules, which affects the cytoskeleton functionality of immature endothelial cells. At the same time, combretastatins directly induce cell death via apoptosis and/or mitotic catastrophe pathways. The combination of both elements makes combretastatin an anticancer compound of high efficiency. The cis-configuration is crucial for its biological activity. To date, many derivatives were synthesized. The attempts to resolve spontaneous isomerization to less active trans-stilbene derivative are still in progress. This issue seems to be overcome by incorporation of the ethene bridge with heterocyclic moiety in combretastatins structure. This modification retains the cis-configuration and prevents isomerization. Nevertheless, combretastatin A4 phosphate disodium is still the most potent compound of this group. The combination therapy, which is the most effective treatment, includes combretastatin A4 phosphate (CA4P) and conventional chemotherapeutics and/or radiotherapy. CA4P is relatively well tolerated giving adverse events of moderate severity, which includes: nausea, vomiting, headache, and tumor pain. The aforementioned effects subside on the day of drug administration or on the following day.

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Humans; Nausea; Neoplasms; Stilbenes; Structure-Activity Relationship

2016
Unraveling the Anticancer Effect of Curcumin and Resveratrol.
    Nutrients, 2016, Nov-10, Volume: 8, Issue:11

    Resveratrol and curcumin are natural products with important therapeutic properties useful to treat several human diseases, including cancer. In the last years, the number of studies describing the effect of both polyphenols against cancer has increased; however, the mechanism of action in all of those cases is not completely comprehended. The unspecific effect and the ability to interfere in assays by both polyphenols make this challenge even more difficult. Herein, we analyzed the anticancer activity of resveratrol and curcumin reported in the literature in the last 11 years, in order to unravel the molecular mechanism of action of both compounds. Molecular targets and cellular pathways will be described. Furthermore, we also discussed the ability of these natural products act as chemopreventive and its use in association with other anticancer drugs.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Curcumin; Humans; Neoplasms; Resveratrol; Stilbenes

2016
The paradoxical pro- and antiangiogenic actions of resveratrol: therapeutic applications in cancer and diabetes.
    Annals of the New York Academy of Sciences, 2016, Volume: 1386, Issue:1

    Resveratrol, a polyphenol found in grapes, peanuts, and red wine, plays different roles in diseases such as cancer and diabetes. Existing information indicates that resveratrol provides cardioprotection, as evidenced by superior postischemic ventricular recovery, reduced myocardial infarct size, and decreased number of apoptotic cardiomyocytes associated with resveratrol treatment in animal models. Cardiovascular benefits are experienced in humans with routine but not acute consumption of red wine. In this concise review, the paradoxical pro- and antiangiogenic effects of resveratrol are described, and different roles for resveratrol in the formation of new blood vessels are explained through different mechanisms. It is hypothesized that the effects of resveratrol on different cell types are not only dependent on its concentration but also on the physical and chemical conditions surrounding cells. The findings discussed herein shed light on potential therapeutic proapoptotic and antiangiogenic applications of low-dose resveratrol treatment in the prevention and treatment of different diseases.

    Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Neoplasms; Resveratrol; Stilbenes

2016
Anti-metastatic potential of resveratrol and its metabolites by the inhibition of epithelial-mesenchymal transition, migration, and invasion of malignant cancer cells.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2016, Dec-15, Volume: 23, Issue:14

    Increased epithelial-mesenchymal transition (EMT) and cell migration and invasion abilities of cancer cells play important roles in the metastatic process of cancer. Resveratrol is a stilbenoid, a type of natural polyphenol found in the skin of grapes, berries, and peanuts. A number of experiments have examined resveratrol's ability to target diverse pathways associated with carcinogenesis and cancer progression.. This article aims to present updated overview of the knowledge that resveratrol and its metabolites or analogs have the potential to inhibit metastasis of cancer via affecting many signaling pathways related with EMT, cancer migration, and invasion in diverse organs of the body.. This article starts with a short introduction describing diverse beneficial effects of resveratrol including cancer prevention and the aim of the present study. To address the effects of resveratrol on cancer metastasis, mechanisms of EMT, migration, invasion, and their relevance with cancer metastasis, anti-metastatic effects of resveratrol through EMT-related signaling pathways and inhibitory effects of resveratrol on migration and invasion are highlighted. In addition, anti-metastatic potential of resveratrol metabolites and analogs is addressed.. Resveratrol was demonstrated to turn back the EMT process induced by diverse signaling pathways in several cellular and animal cancer models. In addition, resveratrol can exert chemopreventive efficacies on migration and invasion of cancer cells by inhibiting the related pathways and target molecules. Although these findings display the anti-metastatic potential of resveratrol, more patient-oriented clinical studies demonstrating the marked efficacies of resveratrol in humans are still needed.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Movement; Epithelial-Mesenchymal Transition; Fruit; Humans; Neoplasm Invasiveness; Neoplasms; Phytotherapy; Plant Extracts; Resveratrol; Stilbenes

2016
Antagonistic role of natural compounds in mTOR-mediated metabolic reprogramming.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt A

    Cells reprogram their metabolism very early during carcinogenesis; this event is critical for the establishment of other cancer hallmarks. Many oncogenes and tumor suppressor genes control metabolism by interplaying with the existing nutrient-sensing intracellular pathways. Mammalian target of rapamycin, mTOR, is emerging as a collector and sorter of a metabolic network controlling upstream and downstream modulation of these same genes. Natural compounds represent a source of anti-cancer molecules with chemopreventive and therapeutic properties. This review describes selected pathways and genes orchestrating the metabolic reprogramming and discusses the potential of natural compounds to target oncogenic metabolic aberrations.

    Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Transformation, Neoplastic; Cellular Reprogramming; Curcumin; Humans; Neoplasms; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quercetin; Resveratrol; Signal Transduction; Stilbenes; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53

2015
Resveratrol and cancer: Challenges for clinical translation.
    Biochimica et biophysica acta, 2015, Volume: 1852, Issue:6

    Significant work has been done towards identifying the health-beneficial effects of the grape antioxidant resveratrol in a variety of bioassay- and disease- models, with much research being focused on its possible application to cancer management. Despite the large number of preclinical studies dealing with different aspects of the biological effects of resveratrol, its translation to clinics is far from reality due to a variety of challenges. In this review, we discuss the issues and questions associated with resveratrol becoming an effective in vivo anticancer drug, from basic metabolic issues to the problems faced by incomplete understanding of the mechanism(s) of action in the body. We also explore efforts taken by researchers, both public and private, to contend with some of these issues. By examining the published data and previous clinical trials, we have attempted to identify the problems and issues that hinder the clinical translation of resveratrol for cancer management. This article is part of a Special Issue entitled: Resveratrol: Challenges in translating pre-clinical findings to improved patient outcomes.

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Resveratrol; Stilbenes; Translational Research, Biomedical

2015
Common pathways in health benefit properties of RSV in cardiovascular diseases, cancers and degenerative pathologies.
    Current pharmaceutical biotechnology, 2015, Volume: 16, Issue:3

    Lots of epidemiological studies have put forward the beneficial effects of dietary polyphenols consumption in the prevention of diseases related to aging i.e vascular pathologies, neurodegeneration, cancers and associated inflammatory processes. Among polyphenols, resveratrol (trans-3,4',5- trihydroxystilbene, RSV), a naturally occurring stilbene widely distributed in foodstuffs such as grapes and wine, has been the most studied. Researches performed since the last decades in vitro, in animal models and in (pre)clinical studies have pointed out its pleiotropic health benefits by acting on multiple signaling pathways which go beyond its originally described direct antioxidant activity. However, its low bioavailability upon oral ingestion and lack of specificity may hamper the translation of the encouraging experimental data into human health benefits. Herein we provide an overview on the capacity of RSV to regulate oxidative stress-induced signaling and to modulate key components of signal transduction pathways which are commonly altered in cardiovascular, neurodegenerative and cancer pathologies. We also have attempted to provide a comprehensive outlook on RSV metabolism and biological activity of its main metabolites and discussed about the new strategies developed to circumvent its poor bioavailability and to improve its therapeutic efficacy, including synthesis of new derivatives and new formulations for its cell delivery.

    Topics: Animals; Antioxidants; Cardiovascular Diseases; Humans; Neoplasms; Neurodegenerative Diseases; Polyphenols; Resveratrol; Signal Transduction; Stilbenes; Wine

2015
A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer.
    Phytotherapy research : PTR, 2015, Volume: 29, Issue:6

    Cancer remains a major health problem worldwide. Among many other factors, two regulatory defects that are present in most cancer cells are constitutive activation of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway and the induction of indoleamine 2, 3-dioxygenase (IDO), an enzyme that catalyzes tryptophan degradation, through JAK/STAT signaling. Cytokine signaling activates STAT proteins in regulating cell proliferation, differentiation, and survival through modulation of target genes. Many phytochemicals can inhibit both JAK/STAT signaling and IDO expression in antigen-presenting cells by targeting different pathways. Some of the promising phytochemicals that are discussed in this review include resveratrol, cucurbitacin, curcumin, (-)-epigallocatechin gallate, and others. It is now evident that phytochemicals play key roles in inhibition of tumor proliferation and development and provide novel means for therapeutic targeting of cancer.

    Topics: Animals; Catechin; Cell Proliferation; Cucurbitacins; Curcumin; Disease Models, Animal; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Janus Kinases; Neoplasms; Phytochemicals; Resveratrol; Signal Transduction; STAT Transcription Factors; Stilbenes

2015
In vitro and in vivo antitumoral effects of combinations of polyphenols, or polyphenols and anticancer drugs: perspectives on cancer treatment.
    International journal of molecular sciences, 2015, Apr-24, Volume: 16, Issue:5

    Carcinogenesis is a multistep process triggered by genetic alterations that activate different signal transduction pathways and cause the progressive transformation of a normal cell into a cancer cell. Polyphenols, compounds ubiquitously expressed in plants, have anti-inflammatory, antimicrobial, antiviral, anticancer, and immunomodulatory properties, all of which are beneficial to human health. Due to their ability to modulate the activity of multiple targets involved in carcinogenesis through direct interaction or modulation of gene expression, polyphenols can be employed to inhibit the growth of cancer cells. However, the main problem related to the use of polyphenols as anticancer agents is their poor bioavailability, which might hinder the in vivo effects of the single compound. In fact, polyphenols have a poor absorption and biodistribution, but also a fast metabolism and excretion in the human body. The poor bioavailability of a polyphenol will affect the effective dose delivered to cancer cells. One way to counteract this drawback could be combination treatment with different polyphenols or with polyphenols and other anti-cancer drugs, which can lead to more effective antitumor effects than treatment using only one of the compounds. This report reviews current knowledge on the anticancer effects of combinations of polyphenols or polyphenols and anticancer drugs, with a focus on their ability to modulate multiple signaling transduction pathways involved in cancer.

    Topics: Acids; Animals; Anthocyanins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinogenesis; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Flavones; Flavonoids; Humans; Isoflavones; Lignans; Mice; Nanotechnology; Neoplasms; Phenols; Phosphorylation; Polyphenols; Rats; Signal Transduction; Stilbenes

2015
Resveratrol nanoformulation for cancer prevention and therapy.
    Annals of the New York Academy of Sciences, 2015, Volume: 1348, Issue:1

    Chemoprevention of human cancer(s) is a viable option for cancer control, especially when chemopreventive intervention is involved during the early stages of the carcinogenesis process. Naturally occurring bioactive food components, such as dietary polyphenols, have shown good antioxidant activity and other beneficial activities. In addition, compounds belonging to the polyphenolic chemical class may play promising roles in cancer prevention. Among them, the phytoalexin resveratrol has demonstrated antiproliferative effects, as well as the ability to inhibit initiation and promotion of induced cancer progression in a wide variety of tumor models. However, resveratrol, like other natural polyphenols, is an extremely photosensitive compound with low chemical stability and limited bioavailibility, which limit the therapeutic application of its beneficial effects. In this context, the development of innovative formulation strategies able to overcome physicochemical and pharmacokinetic limitations of this compound could be beneficial. This may be achieved via nanotechnology approaches utilizing suitable carriers that allow slow, sustained, and controlled release of the encapsulated agent. This review focuses on the recent developments of novel nanoformulations used to deliver sustained levels of resveratrol.

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Humans; Nanocapsules; Neoplasms; Resveratrol; Stilbenes

2015
Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation.
    Annals of the New York Academy of Sciences, 2015, Volume: 1348, Issue:1

    The mechanistic target of rapamycin complex 1 (mTORC1) signaling pathway is hyperactivated in a variety of cancers and tumor syndromes. Therefore, mTORC1 inhibitors are being actively investigated for treatment of neoplasms. The concern with the monotherapy use of mTORC1 inhibitors, such as rapamycin, is that they cause upregulation of autophagy, a cell survival mechanism, and suppress the negative feedback loop to the oncogene Akt. In turn, Akt promotes cell survival, causing the therapy to be partially effective, but relapse occurs upon cessation of treatment. In this review, we describe the current literature on resveratrol as well as our work, which uses rapamycin in combination with resveratrol. We found that this combination treatment efficiently blocked upregulation of autophagy and restored inhibition of Akt in different cancer and tumor models. Interestingly, the combination of rapamycin and resveratrol selectively promoted apoptosis of cells with mTOR pathway hyperactivation. Moreover, this combination prevented tumor growth and lung metastasis when tested in mouse models. Finally, mass spectrometry-based identification of cellular targets of resveratrol provided mechanistic insight into the mode of action of resveratrol. The addition of resveratrol to rapamycin treatment may be a promising option for selective and targeted therapy for diseases with mTORC1 hyperactivation.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Humans; Molecular Targeted Therapy; Neoplasms; Resveratrol; Signal Transduction; Stilbenes; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2015
Assessing the aftermath of an alcohol-fueled weekend: Alcohol-induced DNA damage and faulty repairs may raise the risk of certain cancers, but resveratrol could provide some relief.
    Cancer cytopathology, 2015, Volume: 123, Issue:9

    Topics: Alcohol-Related Disorders; Anticarcinogenic Agents; Binge Drinking; DNA Damage; Female; Humans; Male; Neoplasms; Prognosis; Resveratrol; Risk Assessment; Stilbenes; Treatment Outcome

2015
Enhancing Activity of Anticancer Drugs in Multidrug Resistant Tumors by Modulating P-Glycoprotein through Dietary Nutraceuticals.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:16

    Multidrug resistance is a principal mechanism by which tumors become resistant to structurally and functionally unrelated anticancer drugs. Resistance to chemotherapy has been correlated with overexpression of p-glycoprotein (p-gp), a member of the ATP-binding cassette (ABC) superfamily of membrane transporters. P-gp mediates resistance to a broad-spectrum of anticancer drugs including doxorubicin, taxol, and vinca alkaloids by actively expelling the drugs from cells. Use of specific inhibitors/blocker of p-gp in combination with clinically important anticancer drugs has emerged as a new paradigm for overcoming multidrug resistance. The aim of this paper is to review p-gp regulation by dietary nutraceuticals and to correlate this dietary nutraceutical induced-modulation of p-gp with activity of anticancer drugs.

    Topics: Abietanes; Alkaloids; Allyl Compounds; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Benzodioxoles; beta Carotene; Biflavonoids; Capsaicin; Catechin; Catechols; Curcumin; Dietary Supplements; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Fatty Alcohols; Furocoumarins; Humans; Indoles; Limonins; Neoplasms; Phytotherapy; Piperidines; Polyunsaturated Alkamides; Proanthocyanidins; Quercetin; Resveratrol; Stilbenes; Sulfides; Tea; Triterpenes; Xanthophylls

2015
Natural polyphenols based new therapeutic avenues for advanced biomedical applications.
    Drug metabolism reviews, 2015, Volume: 47, Issue:4

    Polyphenols are naturally occurring, synthetic or semisynthetic organic compounds that offer a vast array of advanced biomedical applications. The mostly researched polyphenolic compounds are resveratrol and flavanols, notably (-)-epicatechin. The ongoing research on clinically important resveratrol and flavanols has revealed their potentials as extremely efficient drug agents that can be leveraged for new therapeutic designs for combating stroke related injuries, cancer and renal failures. Here, we have highlighted recent developments in this area with an emphasis on the biomedical applications of polyphenols. Also, a perspective on the future research directions has been discussed. We believe that this review would facilitate further research and development of polyphenols as a therapeutic avenue in medical science.

    Topics: Aging; Animals; Anti-Infective Agents; Antioxidants; Catechin; Food Hypersensitivity; Humans; Models, Biological; Neoplasms; Polyphenols; Renal Insufficiency; Resveratrol; Stilbenes; Stroke

2015
Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans.
    Molecular nutrition & food research, 2014, Volume: 58, Issue:1

    Several recently published clinical trials have extended our knowledge on the use of resveratrol (RVT) to treat several human pathological and metabolic disorders. Herein, we present insights into the metabolism, biological effects, and toxicity of RVT in humans. Recent data show that RVT exhibits antioxidant and anti-inflammatory activities. It can also improve glucose and lipid metabolism, it acts on cardiovascular parameters, and can modify some pathways involved in carcinogenesis. However, these effects are mostly tiny and the results are sometimes controversial as they depend on the protocols (i.e. dose, form of administration, patients' characteristics, adjuvant therapy, etc.). Toxicological data confirm that RVT is well tolerated. Any adverse effects (mainly concerning the abdomen), at doses of ≥0.5 g/day for long periods, remain moderate and reversible. Nevertheless, the efficacy and safety of RVT need to be further investigated.

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Glucose; Humans; Lipid Metabolism; Neoplasms; Resveratrol; Stilbenes

2014
Resveratrol: from basic studies to bedside.
    Cancer treatment and research, 2014, Volume: 159

    Plants produce a remarkable amount of low molecular mass natural products endowed with a large array of pivotal biological activities. Among these molecules, resveratrol (3,5,4'-trihydroxystilbene) has been identified as an important modulator of cell phenotype with a complex and pleiotropic mode of action. Extensive literature regarding its activity, mainly employing cellular models, suggests that this polyphenol controls cell proliferation, induces differentiation, and activates apoptosis and autophagy. The compound also modulates angiogenesis and inflammation. Similarly, studies on implanted cancers and chemical-induced tumors confirm the potential chemotherapeutical interest of the compound. Likewise, several reports clearly demonstrated, in animal models, that the compound might positively affect the development and evolution of chronic diseases including type 2 diabetes, obesity, coronary heart disease, metabolic syndrome, and neurogenerative pathologies. Finally, a number of investigations stated that the toxicity of the molecule is scarce. Despite these promising observations, few clinical trials have yet been performed to evaluate the effectiveness of the molecule both in prevention and treatment of human chronic disease. Preliminary findings therefore suggest the need for more extensive clinical investigations.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Biomedical Research; Cellular Senescence; Clinical Trials as Topic; Humans; Neoplasms; Resveratrol; Stilbenes

2014
Resveratrol in peanuts.
    Critical reviews in food science and nutrition, 2014, Volume: 54, Issue:6

    Peanuts are important dietary food source of resveratrol with potent antioxidant properties implicated in reducing risk of cancer, cardiovascular and Alzheimer's disease, and delaying aging. Resveratrol is a naturally occurring stilbene phytoalexin phenolic compound produced in response to a variety of biotic and abiotic stresses. This paper is a review of trans-resveratrol and related stilbenes from peanuts--their chemical structures, mechanisms for their biosynthesis, and concentrations in comparison with other major food sources. It will also discuss trans-resveratrol's absorption, bioavailability, and major health benefits; processes to enhance their biosynthesis in peanuts by biotic and abiotic stresses; process optimization for enhanced levels in peanuts and their potential food applications; and methods used for its extraction and analysis.

    Topics: Alzheimer Disease; Antioxidants; Arachis; Biological Availability; Cardiovascular Diseases; Diet; Humans; Neoplasms; Resveratrol; Stilbenes

2014
Resveratrol and cancer: focus on in vivo evidence.
    Endocrine-related cancer, 2014, Volume: 21, Issue:3

    Resveratrol is a naturally occurring polyphenol that provides a number of anti-aging health benefits including improved metabolism, cardioprotection, and cancer prevention. Much of the work on resveratrol and cancer comes from in vitro studies looking at resveratrol actions on cancer cells and pathways. There are, however, comparatively fewer studies that have investigated resveratrol treatment and cancer outcomes in vivo, perhaps limited by its poor bioavailability when taken orally. Although research in cell culture has shown promising and positive effects of resveratrol, evidence from rodents and humans is inconsistent. This review highlights the in vivo effects of resveratrol treatment on breast, colorectal, liver, pancreatic, and prostate cancers. Resveratrol supplementation in animal models of cancer has shown positive, neutral as well as negative outcomes depending on resveratrol route of administration, dose, tumor model, species, and other factors. Within a specific cancer type, there is variability between studies with respect to strain, age, and sex of animal used, timing and method of resveratrol supplementation, and dose of resveratrol used to study cancer endpoints. Together, the data suggest that many factors need to be considered before resveratrol can be used for human cancer prevention or therapy.

    Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Resveratrol; Stilbenes

2014
Could resveratrol be a useful drug for the treatment of malignant hemopathies?
    Recent patents on anti-cancer drug discovery, 2014, Volume: 9, Issue:3

    Resveratrol is a poly-phenol with many beneficial effects: not only as an antioxidant, anti-inflammatory, and antiatherogenic agent, as well as a platelet aggregation inhibitor, but also as an antiproliferative and proapoptotic factor in various types of cancers. There are reviews about the mechanisms responsible for its effects in leukemia and lymphomas, emphasizing the chemosensitizing role of resveratrol, which allows overcoming the multidrug resistance of cancers. The action of resveratrol occurs preferentially on leukemic cells, and not on the normal ones. In addition, it is one of the few drugs that act on leukemic stem cells. If experimental results are promising, its application in humans encounters some difficulties. The paper presents the causes of its low bioavailability, as well as recent patents that allow improvement of its bioavailability, development of new extraction procedures, obtaining new formulae, and associating resveratrol with other drugs in order to increase its effects. These patents allow optimizing its effects in order to obtain an adjuvant agent for treatment of oncohematological disorders.

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Drug Therapy, Combination; Hematologic Neoplasms; Humans; Neoplasms; Patents as Topic; Resveratrol; Stilbenes

2014
AMPK at the nexus of energetics and aging.
    Cell metabolism, 2014, Jul-01, Volume: 20, Issue:1

    When energy supply is low, organisms respond by slowing aging and increasing resistance to diverse age-related pathologies. Targeting the mechanisms underpinning this response may therefore treat multiple disorders through a single intervention. Here, we discuss AMP-activated protein kinase (AMPK) as an integrator and mediator of several pathways and processes linking energetics to longevity. Activated by low energy, AMPK is both prolongevity and druggable, but its role in some pathologies may not be beneficial. As such, activating AMPK may modulate multiple longevity pathways to promote healthy aging, but unlocking its full potential may require selective targeting toward substrates involved in longevity assurance.

    Topics: Aging; AMP-Activated Protein Kinases; Animals; Aspirin; Energy Metabolism; Humans; Metabolic Diseases; Metformin; Mitochondria; Neoplasms; Resveratrol; Stilbenes

2014
Resveratrol oligomers for the prevention and treatment of cancers.
    Oxidative medicine and cellular longevity, 2014, Volume: 2014

    Resveratrol (3,4',5-trihydroxystilbene) is a naturally derived phytoalexin stilbene isolated from grapes and other plants, playing an important role in human health and is well known for its extensive bioactivities, such as antioxidation, anti-inflammatory, anticancer. In addition to resveratrol, scientists also pay attention to resveratrol oligomers, derivatives of resveratrol, which are characterized by the polymerization of two to eight, or even more resveratrol units, and are the largest group of oligomeric stilbenes. Resveratrol oligomers have multiple beneficial properties, of which some are superior in activity, stability, and selectivity compared with resveratrol. The complicated structures and diverse biological activities are of significant interest for drug research and development and may provide promising prospects as cancer preventive and therapeutical agents. This review presents an overview on preventive or anticancer properties of resveratrol oligomers.

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Humans; Neoplasms; Polymers; Resveratrol; Stilbenes

2014
From French Paradox to cancer treatment: anti-cancer activities and mechanisms of resveratrol.
    Anti-cancer agents in medicinal chemistry, 2014, Volume: 14, Issue:6

    Resveratrol (3, 5, 4'-trihydroxy-trans-stilbene, RVT), a stilbenoid, polyphenol phytochemical present in berries, grape, peanuts and wine. It has been suggested as a major contributor to "French Paradox" that reduces the mortality from coronary heart disease (CHD) by consuming RVT in red wine even in some of French population with a high-fat intake. With extensive research, it has been found that RVT is a versatile and pleiotropic agent, it not only possesses cardiovascular-protective benefits by its powerful antioxidant capacity, anti-inflammatory, regulating metabolism and anti-aging effects, but also has strong anti-tumor activities through inhibiting tumor cell proliferation, inducing cell apoptosis, promoting tumor cell differentiation, preventing tumor invasion and metastasis, and further moderating the host immune system to kill tumor cells. This review will focus on RVT's anti-tumor activity and tumor prevention potential including: the anti-tumor spectrum in vitro and in vivo; molecular targets and signal pathways involving RVT anti-tumor mechanisms; evidences from clinical trial for its bioavailability, dosage, toxicity and benefit in humans; and its prospective including its analog, deviations, and combinative chemotherapy.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Proliferation; France; Humans; Neoplasms; Resveratrol; Signal Transduction; Stilbenes; Wine

2014
Targeting cancer with nano-bullets: curcumin, EGCG, resveratrol and quercetin on flying carpets.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:9

    It is becoming progressively more understandable that different phytochemicals isolated from edible plants interfere with specific stages of carcinogenesis. Cancer cells have evolved hallmark mechanisms to escape from death. Concordant with this approach, there is a disruption of spatiotemproal behaviour of signaling cascades in cancer cells, which can escape from apoptosis because of downregulation of tumor suppressor genes and over- expression of oncogenes. Genomic instability, intra-tumor heterogeneity, cellular plasticity and metastasizing potential of cancer cells all are related to molecular alterations. Data obtained through in vitro studies has convincingly revealed that curcumin, EGCG, resveratrol and quercetin are promising anticancer agents. Their efficacy has been tested in tumor xenografted mice and considerable experimental findings have stimulated researchers to further improve the bioavailability of these nutraceuticals. We partition this review into different sections with emphasis on how bioavailability of curcumin, EGCG, resveratrol and quercetin has improved using different nanotechnology approaches.

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Antioxidants; Apoptosis; Catechin; Cell Proliferation; Cell Transformation, Neoplastic; Curcumin; Drug Carriers; Humans; Lactic Acid; Mice; Nanoparticles; Neoplasms; Phytochemicals; Polyglycolic Acid; Polyhydroxyethyl Methacrylate; Polylactic Acid-Polyglycolic Acid Copolymer; Quercetin; Resveratrol; Silicon Dioxide; Stilbenes; Xenograft Model Antitumor Assays

2014
The role of phytochemicals as micronutrients in health and disease.
    Current opinion in clinical nutrition and metabolic care, 2014, Volume: 17, Issue:6

    Intake of dietary phytochemicals has frequently been associated with health benefits. Noninfectious diseases including cardiovascular disease (CVD), cancer and diabetes are major causes of death, whereas dementia cases are also increasing to 'epidemic' proportion. This review will focus on recent progress on mechanisms underlying the potential role of dietary phytochemicals in CVD, diabetes, cancer and dementia, with consideration of the latest clinical data.. The association of tea (Camellia sinensis), particularly catechins, with reported mechanistic effects for CVD, diabetes, cancer and cognition contributes to our understanding of the suggested benefits of tea consumption on health from limited and inconclusive clinical trial and epidemiological data. Resveratrol, which occurs in grapes (Vitis vinifera) and wine, and curcumin, a component of turmeric (Curcuma longa), are also emerging as potentially relevant to health, particularly for CVD and dementia, with some promising data also concluded for curcumin in cancer. Other phytochemicals mechanistically relevant for health include anthocyanins, isoflavones and glucosinolates, which are also discussed.. Evidence for the role of phytochemicals in health and disease is growing, but associations between phytochemicals and disease need to be more firmly understood and established from more robust clinical data using preparations that have been phytochemically characterized.

    Topics: Cardiovascular Diseases; Catechin; Clinical Trials as Topic; Curcuma; Curcumin; Dementia; Diabetes Mellitus; Humans; Micronutrients; Neoplasms; Phytochemicals; Plant Extracts; Resveratrol; Stilbenes; Tea; Vitis; Wine

2014
Regulation of microRNAs by natural agents: new strategies in cancer therapies.
    BioMed research international, 2014, Volume: 2014

    MicroRNAs (miRNAs) are short noncoding RNA which regulate gene expression by messenger RNA (mRNA) degradation or translation repression. The plethora of published reports in recent years demonstrated that they play fundamental roles in many biological processes, such as carcinogenesis, angiogenesis, programmed cell death, cell proliferation, invasion, migration, and differentiation by acting as tumour suppressor or oncogene, and aberrations in their expressions have been linked to onset and progression of various cancers. Furthermore, each miRNA is capable of regulating the expression of many genes, allowing them to simultaneously regulate multiple cellular signalling pathways. Hence, miRNAs have the potential to be used as biomarkers for cancer diagnosis and prognosis as well as therapeutic targets. Recent studies have shown that natural agents such as curcumin, resveratrol, genistein, epigallocatechin-3-gallate, indole-3-carbinol, and 3,3'-diindolylmethane exert their antiproliferative and/or proapoptotic effects through the regulation of one or more miRNAs. Therefore, this review will look at the regulation of miRNAs by natural agents as a means to potentially enhance the efficacy of conventional chemotherapy through combinatorial therapies. It is hoped that this would provide new strategies in cancer therapies to improve overall response and survival outcome in cancer patients.

    Topics: Antineoplastic Agents; Biological Products; Biomarkers, Tumor; Catechin; Curcumin; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasms; Resveratrol; RNA Stability; Stilbenes

2014
Resveratrol-mediated reversal of tumor multi-drug resistance.
    Current drug metabolism, 2014, Volume: 15, Issue:7

    Multi-drug resistance (MDR) to cancer chemotherapy is a major obstacle to the effective treatment of tumors. Resveratrol, a natural product, may inhibit efflux transporters, such as P-glycoprotein (P-gp), multi-drug resistance-associated protein (MRP) and breast cancer resistance protein (BCRP), and could become a potential multi-drug-resistant regulator. But it remains unclear how resveratrol exerts its reversal effect. In this review, we attempt to reveal the interactions between resveratrol and ABC transporter proteins, and summarize the research profile of resveratrol's reversal mechanisms, thus to provide pivotal information on the development and application of multi-drug resistance reversal agents.

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplasms; Resveratrol; Stilbenes

2014
Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease.
    Archives of toxicology, 2014, Volume: 88, Issue:12

    Resveratrol, a natural compound endowed with multiple health-promoting effects, has received much attention given its potential for the treatment of cardiovascular, inflammatory, neurodegenerative, metabolic and age-related diseases. However, the translational potential of resveratrol has been limited by its specificity, poor bioavailability and uncertain toxicity. In recent years, there has been an accumulation of evidence demonstrating that resveratrol modulates sphingolipid metabolism. Moreover, resveratrol forms higher order oligomers that exhibit better selectivity and potency in modulating sphingolipid metabolism. This review evaluates the evidence supporting the modulation of sphingolipid metabolism and signaling as a mechanism of action underlying the therapeutic efficacy of resveratrol and oligomers in diseases, such as cancer.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Binding Sites; Cardiovascular Diseases; Drug Discovery; Humans; Molecular Docking Simulation; Molecular Structure; Neoplasms; Neurodegenerative Diseases; Resveratrol; Signal Transduction; Sphingolipids; Stilbenes

2014
Regulation of autophagy by polyphenolic compounds as a potential therapeutic strategy for cancer.
    Cell death & disease, 2014, Nov-06, Volume: 5

    Autophagy, a lysosomal degradation pathway for cellular constituents and organelles, is an adaptive and essential process required for cellular homeostasis. Although autophagy functions as a survival mechanism in response to cellular stressors such as nutrient or growth factor deprivation, it can also lead to a non-apoptotic form of programmed cell death (PCD) called autophagy-induced cell death or autophagy-associated cell death (type II PCD). Current evidence suggests that cell death through autophagy can be induced as an alternative to apoptosis (type I PCD), with therapeutic purpose in cancer cells that are resistant to apoptosis. Thus, modulating autophagy is of great interest in cancer research and therapy. Natural polyphenolic compounds that are present in our diet, such as rottlerin, genistein, quercetin, curcumin, and resveratrol, can trigger type II PCD via various mechanisms through the canonical (Beclin-1 dependent) and non-canonical (Beclin-1 independent) routes of autophagy. The capacity of these compounds to provide a means of cancer cell death that enhances the effects of standard therapies should be taken into consideration for designing novel therapeutic strategies. This review focuses on the autophagy- and cell death-inducing effects of these polyphenolic compounds in cancer.

    Topics: Acetophenones; Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzopyrans; Cell Line, Tumor; Curcumin; Gene Expression Regulation, Neoplastic; Genistein; Humans; Membrane Proteins; Neoplasms; Polyphenols; Quercetin; Resveratrol; Signal Transduction; Stilbenes

2014
Effects of dietary phytophenols on the expression of microRNAs involved in mammalian cell homeostasis.
    Journal of the science of food and agriculture, 2013, Volume: 93, Issue:13

    Besides synthesizing nutritive substances (proteins, fats and carbohydrates) for energy and growth, plants produce numerous non-energetic so-called secondary metabolites (mainly polyphenols) that allow them to protect themselves against infections and other types of hostile environments. Interestingly, these polyphenols often provide cells with valuable bioactive properties for the maintenance of their functions and homeostasis (signaling, gene regulation, protection against acquired or infectious diseases, etc.) both in humans and animals. Namely, from a nutritional point of view, and based on epidemiological data, it is now well accepted that the regular consumption of green vegetables, fruits and fibers has protective effects against the onset of cancer as well as of inflammatory, neurodegenerative, metabolic and cardiovascular diseases, and consequently increases the overall longevity. In particular, grapevine plants produce large amounts of a wide variety of polyphenols. The most prominent of those-resveratrol-has been shown to impair or delay cardiovascular alterations, cancer, inflammation, aging, etc. Until recently, the molecular bases of the pleiotropic effects of resveratrol remained largely unclear despite numerous studies on a variety of signaling pathways and the transcriptional networks that they control. However, it has been recently proposed that the protective properties of resveratrol may arise from its modulation of small non-coding regulatory RNAs, namely microRNAs. The aim of this review is to present up-to-date data on the control of microRNA expression by dietary phytophenols in different types of human cells, and their impact on cell differentiation, cancer development and the regulation of the inflammatory response.

    Topics: Animals; Antioxidants; Cardiovascular Diseases; Cell Differentiation; Cell Physiological Phenomena; Diet; Dietary Fiber; Fruit; Gene Expression; Homeostasis; Humans; Inflammation; MicroRNAs; Neoplasms; Phenols; Plants; Polyphenols; Resveratrol; Signal Transduction; Stilbenes; Vegetables

2013
ABCG2: recent discovery of potent and highly selective inhibitors.
    Future medicinal chemistry, 2013, Volume: 5, Issue:9

    ABCG2 impacts oral availability, tissue distribution and excretion of its substrates, including anticancer and anti-infectious drugs. Highly expressed at physiological barriers, its secretion level significantly controls drug distribution. Furthermore, its increased content into many types of cancer may lead to cell chemoresistance. Owing to the clinical relevance of ABCG2 in the multidrug resistance phenomenon, ABCG2 constitutes an appealing therapeutic target to increase drug distribution. Development of ABCG2 inhibitors can be used in combination with anticancer drugs to block the drug secretion from cancer cells. Very recently, an alternative use of ABCG2 inhibitors in enhancing the bioavailability of ABCG2 substrates has emerged. Hence, it is important to investigate ABCG2 inhibitors with high selectivity, high potency and safety. New inhibitors discovered during the last 5 years will be presented and discussed.

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Chalcones; Chromones; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; Quinolines; Stilbenes

2013
Tubulin-interactive stilbene derivatives as anticancer agents.
    Cellular & molecular biology letters, 2013, Volume: 18, Issue:3

    Microtubules are dynamic polymers that occur in eukaryotic cells and play important roles in cell division, motility, transport and signaling. They form during the process of polymerization of α- and β-tubulin dimers. Tubulin is a significant and heavily researched molecular target for anticancer drugs. Combretastatins are natural cis-stilbenes that exhibit cytotoxic properties in cultured cancer cells in vitro. Combretastatin A-4 (3'-hydroxy-3,4,4',5-tetramethoxy-cis-stilbene; CA-4) is a potent cytotoxic cis-stilbene that binds to β-tubulin at the colchicine-binding site and inhibits tubulin polymerization. The prodrug CA-4 phosphate is currently in clinical trials as a chemotherapeutic agent for cancer treatment. Numerous series of stilbene analogs have been studied in search of potent cytotoxic agents with the requisite tubulin-interactive properties. Microtubule-interfering agents include numerous CA-4 and transresveratrol analogs and other synthetic stilbene derivatives. Importantly, these agents are active in both tumor cells and immature endothelial cells of tumor blood vessels, where they inhibit the process of angiogenesis. Recently, computer-aided virtual screening was used to select potent tubulin-interactive compounds. This review covers the role of stilbene derivatives as a class of antitumor agents that act by targeting microtubule assembly dynamics. Additionally, we present the results of molecular modeling of their binding to specific sites on the α- and β-tubulin heterodimer. This has enabled the elucidation of the mechanism of stilbene cytotoxicity and is useful in the design of novel agents with improved anti-mitotic activity. Tubulin-interactive agents are believed to have the potential to play a significant role in the fight against cancer.

    Topics: Antineoplastic Agents, Phytogenic; Binding, Competitive; Cell Survival; Clinical Trials as Topic; Humans; Models, Molecular; Molecular Structure; Neoplasms; Stilbenes; Tubulin

2013
Regulating miRNA by natural agents as a new strategy for cancer treatment.
    Current drug targets, 2013, Volume: 14, Issue:10

    MicroRNAs (miRNAs) are small single-strand non-coding endogenous RNAs that regulate gene expression by multiple mechanisms. Recent evidence suggests that miRNAs are critically involved in the pathogenesis, evolution, and progression of cancer. The miRNAs are also crucial for the regulation of cancer stem cells (CSCs). In addition, miRNAs are known to control the processes of Epithelial-to-Mesenchymal Transition (EMT) of cancer cells. This evidence suggests that miRNAs could serve as targets in cancer treatment, and as such manipulating miRNAs could be useful for the killing CSCs or reversal of EMT phenotype of cancer cells. Hence, targeting miRNAs, which are deregulated in cancer, could be a promising strategy for cancer therapy. Recently, the regulation of miRNAs by natural, nontoxic chemopreventive agents including curcumin, resveratrol, isoflavones, (-)-epigallocatechin-3-gallate (EGCG), lycopene, 3,3'- diindolylmethane (DIM), and indole-3-carbinol (I3C) has been described. Therefore, natural agents could inhibit cancer progression, increase drug sensitivity, reverse EMT, and prevent metastasis though modulation of miRNAs, which will provide a newer therapeutic approach for cancer treatment especially when combined with conventional therapeutics.

    Topics: Animals; Antineoplastic Agents; Carotenoids; Catechin; Curcumin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Lycopene; MicroRNAs; Molecular Targeted Therapy; Neoplasms; Neoplastic Stem Cells; Resveratrol; Stilbenes

2013
What is new for resveratrol? Is a new set of recommendations necessary?
    Annals of the New York Academy of Sciences, 2013, Volume: 1290

    Numerous scientific papers have suggested health-promoting effects of resveratrol, including claims in the prevention of diseases such as coronary heart disease, diabetes, and cancer. Therefore, it was proposed that the scientific community needed to express recommendations on the human use of resveratrol. Such recommendations were formulated after the first international resveratrol conference in Denmark, Resveratrol2010. The working group stated that the evidence was "not sufficiently strong to justify recommendation for the chronic administration of resveratrol to human beings, beyond the dose which can be obtained from dietary sources." It was a disappointing conclusion relative to the positive claims about the therapeutic potential of resveratrol made by the media. However, since 2010, results from the first clinical trials on resveratrol have been made available. Because of these emerging results, it is necessary to formulate updated versions of the recommendations.

    Topics: Animals; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Neoplasms; Practice Guidelines as Topic; Resveratrol; Stilbenes

2013
Resveratrol in the management of human cancer: how strong is the clinical evidence?
    Annals of the New York Academy of Sciences, 2013, Volume: 1290

    Among the plethora of biochemical mechanisms engaged by resveratrol in preclinical systems, its anticarcinogenic effects represent some of the most convincing and intriguing. As outlined in this review, there is considerable interest in developing resveratrol for cancer prevention and treatment. The plasma pharmacokinetics of resveratrol in humans are now reasonably well defined, and studies have shown that repeated daily doses up to 1 g are safe and well tolerated, although gastrointestinal toxicity is observed at higher intakes. However, care is needed regarding underlying conditions in specific patient groups, and there is potential for drug interactions at doses greater than 1 gram. Little is known regarding the pharmacodynamic effects of resveratrol in humans, but the observation that it modulates components of the insulin-like growth factor system in the plasma of volunteers is encouraging. While the knowledge base that helps determine whether resveratrol may be useful in cancer management has increased substantially in recent years, important questions remain.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Disease Management; Dose-Response Relationship, Drug; Humans; Neoplasms; Resveratrol; Stilbenes

2013
Resveratrol analogs: promising chemopreventive agents.
    Annals of the New York Academy of Sciences, 2013, Volume: 1290

    Although resveratrol can modulate multiple stages of carcinogenesis, by most common standards it is not a good drug candidate. Resveratrol lacks potency, high efficacy, and target specificity; it is rapidly metabolized and serum concentrations are low. Using resveratrol as a scaffold, we produced over 100 derivatives, some of which have target specificity in the nanomolar range. Aromatase inhibition was enhanced over 6000-fold by using 1,3-thiazole as the central ring of resveratrol. Optimizing the substitution pattern of the two phenyl rings and the central heterocyclic linker led to selective QR1 induction with a CD value of 87 nM. Several derivatives have been selected for evaluation of synergistic effects. Preliminary results with pairs of compounds are promising and further experiments, in a constant multidrug manner, will allow us to create polygonograms for larger combinations of derivatives. The objective is to develop a highly efficacious cocktail of derivatives based on the structure of resveratrol.

    Topics: Animals; Antineoplastic Agents; Chemoprevention; Humans; Neoplasms; Resveratrol; Stilbenes; Structure-Activity Relationship

2013
Importance of lipid microdomains, rafts, in absorption, delivery, and biological effects of resveratrol.
    Annals of the New York Academy of Sciences, 2013, Volume: 1290

    The preventive effects of the phytoalexin trans-resveratrol toward cancer have been largely described at the cellular and molecular levels in both in vivo and in vitro models; however, its primary targets are still poorly identified. In this review, we show the crucial role of cell membrane microdomains, that is, lipid rafts, not solely in the initiation of the early biochemical events triggered by resveratrol leading to cancer cell death, but also in resveratrol absorption and distribution. Resveratrol accumulates in lipid rafts and is then taken up by cells through raft-dependent endocytosis. These events allow early activation of kinase pathways and redistribution of cell death receptors within lipid microdomains, events ultimately leading to apoptotic cell death.

    Topics: Absorption; Animals; Apoptosis; Drug Delivery Systems; Humans; Lipid Metabolism; Membrane Microdomains; Neoplasms; Resveratrol; Stilbenes; Treatment Outcome

2013
Resveratrol-based combinatorial strategies for cancer management.
    Annals of the New York Academy of Sciences, 2013, Volume: 1290

    In recent years combination chemoprevention has been increasingly appreciated and investigated as a viable and effective strategy for cancer management. A plethora of evidence suggests that a combination of agents may afford synergistic (or additive) advantage for cancer management by multiple means, such as by (1) enhancing the bio-availability of chemopreventive agents, (2) modifying different molecular targets, and (3) lowering the effective dose of agent/drug to be used for cancer management. Resveratrol has been shown to afford chemopreventive and therapeutic effects against certain cancers. Recent studies are suggesting that resveratrol may be very useful when given in combination with other agents. The two major advantages of using resveratrol in combination with other agents are synergistically or additively enhancing the efficacy against cancer and limiting the toxicity and side effects of existing therapies. However, concerted and multidisciplinary efforts are needed to identify the most optimal combinatorial strategies.

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combinatorial Chemistry Techniques; Disease Management; Humans; Neoplasms; Resveratrol; Stilbenes

2013
Grape phytochemicals and associated health benefits.
    Critical reviews in food science and nutrition, 2013, Volume: 53, Issue:11

    The phytochemicals present in fruits and vegetables may play an important role in deceasing chronic disease risk. Grapes, one of the most popular and widely cultivated and consumed fruits in the world, are rich in phytochemicals. Epidemiological evidence has linked the consumption of grapes with reduced risk of chronic diseases, including certain types of cancer and cardiovascular disease. In vitro and in vivo studies have shown that grapes have strong antioxidant activity, inhibiting cancer cell proliferation and suppressing platelet aggregation, while also lowering cholesterol. Grapes contain a variety of phytochemicals, like phenolic acids, stilbenes, anthocyanins, and proanthocyanidins, all of which are strong antioxidants. The phytochemical composition of grapes, however, varies greatly among different varieties. While extensive research exists, a literature review of the health benefits of grapes and their phytochemicals has not been compiled to summarize this work. The aim of this paper is to critically review the most recent literature regarding the concentrations, biological activities, and mechanisms of grape phytochemicals.

    Topics: Antioxidants; Cardiovascular Diseases; Flavonoids; Fruit; Health Promotion; Humans; Hydroxybenzoates; Neoplasms; Phenols; Phytochemicals; Plant Extracts; Platelet Aggregation Inhibitors; Stilbenes; Vitis; Wine

2013
Toxicological and pharmacological concerns on oxidative stress and related diseases.
    Toxicology and applied pharmacology, 2013, Dec-15, Volume: 273, Issue:3

    Although reactive oxygen species (ROS) such as superoxide, hydrogen peroxide and hydroxyl radical are generated as the natural byproduct of normal oxygen metabolism, they can create oxidative damage via interaction with bio-molecules. The role of oxidative stress as a remarkable upstream part is frequently reported in the signaling cascade of inflammation as well as chemo attractant production. Even though hydrogen peroxide can control cell signaling and stimulate cell proliferation at low levels, in higher concentrations it can initiate apoptosis and in very high levels may create necrosis. So far, the role of ROS in cellular damage and death is well documented with implicating in a broad range of degenerative alterations e.g. carcinogenesis, aging and other oxidative stress related diseases (OSRDs). Reversely, it is cleared that antioxidants are potentially able to suppress (at least in part) the immune system and to enhance the normal cellular protective responses to tissue damage. In this review, we aimed to provide insights on diverse OSRDs, which are correlated with the concept of oxidative stress as well as its cellular effects that can be inhibited by antioxidants. Resveratrol, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, statins, nebivolol and carvedilol, pentaerythritol tetranitrate, mitochondria-targeted antioxidants, and plant-derived drugs (alone or combined) are the potential medicines that can be used to control OSRD.

    Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Benzopyrans; Carbazoles; Carvedilol; Diabetes Mellitus; Disease Models, Animal; Ethanolamines; Humans; Hydrogen Peroxide; Inflammatory Bowel Diseases; Nebivolol; Neoplasms; Neurodegenerative Diseases; Osteoporosis; Oxidative Stress; Propanolamines; Reactive Oxygen Species; Resveratrol; Stilbenes; Vascular Diseases

2013
Synergistic effect of resveratrol and radiotherapy in control of cancers.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:11

    Cancers will continue to be a threat to health unless they can be controlled by combinations of treatment modalities. In this review, evaluate the role of resveratrol (RSV) as a radiosensitizing agent was evaluated and underlying mechanisms holistically explored in different cancer models focusing on therapeutic possibilities. The ability of RSV to modify the effect of radiation exposure in normal and cancer cells has indeed been shown quite convincingly, the combination of RSV and IR exhibiting synergistic effects on different cancer cells. This is relevant since controlled exposure to IR is one of the most frequently applied treatments in cancer patients. However, radiotherapy (XRT) treatment regimes are very often not effective in clinical practice as observed in patients with glioma, prostate cancer (PCa), melanoma, for example, largely due to tumour radioresistant properties. Sensitization of IR-induced apoptosis by natural products such as RSV is likely to be relevant in cancer control and treatment. However, all cancers do not respond to RSV+IR in a similar manner. Therefore, for those such as the radioresistant PCa or melanoma cells, the RSV+IR regime has to be very carefully chosen in order to achieve effective and desirable outcomes with minimum toxicity to normal cells. They are reports that the highest concentration of 100 ?M RSV and highest dose of 5 Gy IR are sufficient to kill cells by induction of apoptosis, indicating that RSV is effective in radiosensitizing otherwise radioresistant cells. In general, it has been shown in different cancer cells that RSV+XRT effectively act by enhancing expression of anti-proliferative and pro-apoptotic molecules, and inhibiting pro-proliferative and anti-apoptotic molecules, leading to induction of apoptosis through various pathways, and cell death. If RSV+XRT can suppress the signature of cancer stemness, enhance the radiosensitivity by either targeting the mitochondrial functionality or modulating the tumour necrosis factor-mediated or Fas-FasL-mediated pathways of apoptosis in different cancers, particularly in vivo, its therapeutic use in the control of cancers holds promise in the near future.

    Topics: Animals; Apoptosis; Cell Proliferation; Chemoradiotherapy; Humans; Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Resveratrol; Stilbenes

2013
Targeting mTOR: evaluating the therapeutic potential of resveratrol for cancer treatment.
    Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:7

    Resveratrol (3,4',5-trihydroxystilbene; RSV), a natural polyphenol found in a variety of daily food including grapes and red wine, has long been suspected to have multifaceted health beneficial properties, including anti-inflammation, anti-oxidant, and anticancer activities. Over the past few years, numerous studies have suggested that suppressing the activity of mammalian target of rapamycin (mTOR), a critical regulator of cell metabolism, growth, and proliferation, may provide a key mechanism underlying the anticarcinogenic properties of resveratrol. It has been found that resveratrol targets multiple components of the phosphatidylinositol 3- kinase(PI3K)/Akt and mTOR signaling pathways, including PI3K, Akt, PTEN, and DEPTOR, suggesting that this natural compound and its derivatives may offer a promising new cancer treatment. In the current review, we discuss recent findings on the molecular mechanisms regulating mTOR signaling and the therapeutic potential of resveratrol for cancer treatment by targeting mTOR.

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Antioxidants; Humans; Molecular Targeted Therapy; Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Resveratrol; Signal Transduction; Stilbenes; TOR Serine-Threonine Kinases

2013
Resveratrol and cancer treatment: is hormesis a yet unsolved matter?
    Current pharmaceutical design, 2013, Volume: 19, Issue:30

    Plants produce many low molecular mass natural compounds endowed with biological activity. Among them, resveratrol (3,5,4'-trihydroxystilbene) has been demonstrated to be able to affect a plethora of pivotal cellular molecular processes, including transduction pathways and gene expression. These activities result, in turn, in several different cell phenotypes. Particularly, frequent effects of resveratrol treatment appear to be the reduction of growth and the activation of programmed cell death. Accordingly, a number of trials are currently under development to evaluate the possibility of using resveratrol in cancer therapy, both as single agent or in association with other anticancer compounds. However, some reports suggest that, at low concentrations, not only resveratrol does not inhibit the proliferation and/or the survival of cells but, conversely, it induces proliferation and/or protects cells against toxic agents. On the basis of these biphasic effects, it has been proposed that resveratrol belongs to the so-called hormetic compounds. Hormesis is an expression employed by toxicologists to describe a U-shaped (or J-shaped) dose response characterized by a beneficial effect at low doses and a toxic (or inhibitory) activity at high dose. In this review, we will reappraise data that might suggest or disprove that resveratrol is endowed with clear hormetic properties.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Hormesis; Humans; Neoplasms; Resveratrol; Stilbenes

2013
Phytochemicals resveratrol and sulforaphane as potential agents for enhancing the anti-tumor activities of conventional cancer therapies.
    Current pharmaceutical biotechnology, 2012, Volume: 13, Issue:1

    Even though conventional cancer therapies, comprising surgery and chemo- and radiotherapy, play an important role in the treatment of most solid tumours, successful therapeutic outcome is often limited due to high toxicity and related side-effects, as well as the development of multi-drug resistances. Therefore, there is need for new therapeutic strategies not only to obtain higher treatment efficacy, but also for the reduction of toxicity and adverse effects. Emerging evidence suggests that natural compounds with distinct anticarcinogenic activity may be considered as potential agents for enhancing the therapeutic effects of common cancer treatments. By using the examples of resveratrol and sulforaphane this review will summarize the findings of recent investigations focusing this topic so far and the current knowledge of the molecular mechanisms by which these selected phytochemicals may potentiate the anti-tumor effects of different cancer therapies.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Isothiocyanates; Neoplasms; Resveratrol; Stilbenes; Sulfoxides; Thiocyanates

2012
Pterostilbene and cancer: current review.
    The Journal of surgical research, 2012, Volume: 173, Issue:2

    Pterostilbene (trans-3,5-dimethoxy-4-hydroxystilbene) is an antioxidant that is primarily found in blueberries. Studies suggest that pterostilbene exhibits the hallmark characteristics of an effective anticancer agent based on its antineoplastic properties in several common malignancies. In vitro models have shown that pterostilbene inhibits cancer growth through alteration of the cell cycle, induction of apoptosis, and inhibition of metastasis. In vivo, pterostilbene inhibits tumorigenesis and metastasis with negligible toxicity. Pterostilbene has also been shown to be effective as an inducer of antioxidant capacity in multiple cancer cell lines that may facilitate its function as an anticarcinogenic compound. Additionally, preliminary studies show that pterostilbene exhibits much greater bioavailability compared with other stilbene compounds; however the exact pharmacologic mechanism of pterostilbene and its effects in humans are still under investigation. In this review, we present a comprehensive summary of the antineoplastic mechanisms of pterostilbene based on the results of preclinical studies and highlight recent advances in the study of this dietary compound.

    Topics: Animals; Blueberry Plants; Drug Evaluation, Preclinical; Humans; Neoplasms; Phytotherapy; Plant Extracts; Stilbenes

2012
Resveratrol in human cancer chemoprevention--choosing the 'right' dose.
    Molecular nutrition & food research, 2012, Volume: 56, Issue:1

    There is now robust preclinical evidence to suggest that resveratrol possesses cancer chemopreventive properties. A series of clinical pilot studies has provided insights into its pharmacokinetics, and data on its human antineoplastic pharmacodynamics start to emerge. It is likely that resveratrol will be developed further in the clinic as a putative cancer chemopreventive agent. The question that remains unresolved is: What is the most suitable dose of resveratrol for effective cancer preventive intervention? Mechanistic studies in cells in vitro have almost invariably used concentrations of resveratrol in the 10(-5) to 10(-4)  M range, which is much higher than those which can be achieved in the human biophase after consumption of doses up to 1 g. Many of the preclinical efficacy studies in rodent models of carcinogenesis have employed doses which are dramatically above those which can be ingested with the diet. New experimental paradigms need to be used to obtain information on pharmacological changes elicited by resveratrol when present at very low concentrations or when administered at dietary-relevant doses.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Neoplasms; Resveratrol; Stilbenes

2012
Old wine in a new bottle: the Warburg effect and anticancer mechanisms of resveratrol.
    Current pharmaceutical design, 2012, Volume: 18, Issue:12

    Resveratrol found in fruits, vegetables and beverages such as red wine, has been extensively evaluated for its anticardiovascular disease and cancer preventive effects. Even though studies have demonstrated its anti-tumor effects, there is still no clear explanation for cancer cell selective mechanisms of action of resveratrol. Initial investigations were focused on its anti-oxidant and cytoprotective mechanism of action, yet, a large number of studies have demonstrated that resveratrol can behave either as anti-oxidant or pro-oxidant depending on the selective microenvironment. What makes resveratrol a protective agent in normal cells and a radical generator possessing cytotoxic activity against cancer cells is a widely debated topic. There must be certain conditions found in tumors that allow resveratrol to become a pro-oxidant that clearly differs from that found in normal cells. Results of studies from our group have established that many different dietary agents can mobilize intracellular copper ions and in the process, generate reactive oxygen species through Fenton type reactions leading to oxidative DNA breakage and consequently, cell death. More significantly, we demonstrated that such pro-oxidant-induced DNA damage and apoptotic activity are enhanced in low pH environments; characteristically observed in tumors due to preferential dependence on glycolysis or the "Warburg effect". This review discusses the recent advancements in understanding the pro-oxidant anti-cancer behavior of resveratrol as a dietary chemopreventive agent, explained in the light of the Warburg effect.

    Topics: Animals; Copper; Glycolysis; Humans; Hydrogen-Ion Concentration; Neoplasms; Reactive Oxygen Species; Resveratrol; Stilbenes

2012
Regulation of cell death and survival by resveratrol: implications for cancer therapy.
    Anti-cancer agents in medicinal chemistry, 2012, Oct-01, Volume: 12, Issue:8

    Apoptosis is a critical regulatory mechanism to control tissue homeostasis. Accordingly, too little apoptosis can contribute to cancer. Natural compounds, e.g. polyphenols such as resveratrol, have emerged as promising agents for cancer chemoprevention and therapy, since they interfere with various major signaling cascades that are aberrantly regulated in cancers. For example, resveratrol can antagonize signaling events that prevent apoptosis or support cancer proliferation. Further elucidation of the signaling events that are regulated by resveratrol is anticipated to path the way for the transfer of resveratrol and its derivatives into clinical application for chemoprevention or treatment of human cancers.

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Biological Products; Cell Death; Cell Proliferation; Cell Survival; Humans; Neoplasms; Resveratrol; Stilbenes

2012
Resveratrol in cancer: cellular and mitochondrial consequences of proton transport inhibition.
    Current pharmaceutical design, 2012, Volume: 18, Issue:10

    Transformed cells suffer several changes leading to the increase of protective mechanisms and show a metabolic profile in accordance with higher proliferative capacity. In these mechanisms, changes in mitochondrial activity cause a higher glycolytic metabolism in detriment of oxidative phosphorylation. In these changes, H⁺-ATPase regulation seems to be importantly involved. During the last years, polyphenols and specially the stilbene resveratrol and related members of its family have been studied because they are able to affect tumour cell growth and cancer progression. Among the different effects induced by resveratrol, inhibition of H⁺-ATPase seems to be one important mechanism in its effect on cancer progression. Further, an ectopic H⁺-ATPase located in the outer surface of plasma membrane has been recently involved in cancer progression and angiogenesis. In this article we review the latest findings about resveratrol inhibition of H⁺-ATPase and its importance in tumour cell growth and cancer progression.

    Topics: Antineoplastic Agents; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Proton-Translocating ATPases; Resveratrol; Stilbenes

2012
Resveratrol: potential as anticancer agent.
    Journal of dietary supplements, 2012, Volume: 9, Issue:1

    Cancer is one of the leading causes of deaths in the world. Current chemotherapeutic agents are associated with serious side effects in patients therefore researchers are trying to find an alternative agent that is effective against cancer as well as less toxic. Resveratrol (3,5,4'-trihydroxystilbene), commonly found in red wine and grape skins, is a phytoalexin agent that was originally extracted from the roots of Polygonum cuspidatum. Resveratrol is believed to work as a chemopreventive agent by producing its effect on cell apoptosis, antiproliferation, and anti-inflammation.. To determine whether resveratrol is effective as an anticancer agent.. A systematic review was performed by searching various databases for primary, secondary, and tertiary references. Databases included PubMed, EBSCO, Cochrane, AccessPharmacy, and StatRef by using key terms of "resveratrol," "cancer," and "anticancer." Review search looked at both animal and human studies limited within 10 years.. The major mechanisms of actions through which resveratrol works include proapoptotic, antiproliferation, and anti-inflammation. Numerous in vitro and in vivo studies have supported these mechanisms thus warranting further research in human studies for resveratrol's anticancer effects. Pharmacokinetic human studies suggest good tolerability in healthy subjects, although they have low absorptive characteristics.. Resveratrol appears to have anticancer effects. Additionally, these studies indicate that resveratrol's chemoprevention effect is dose and duration dependent. It has synergistic effect with anticancer drugs in vitro. Further human studies need to be done.

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Fallopia japonica; Humans; Neoplasms; Outcome Assessment, Health Care; Phytotherapy; Plant Extracts; Resveratrol; Stilbenes; Vitis; Wine

2012
[Metabolic homeostasis as the cornerstone of aging].
    Medecine sciences : M/S, 2012, Volume: 28, Issue:3

    During the last decade, studies aimed at investigating genes and molecular pathways involved in aging have been very fruitful and led to the identification of several mechanisms responsible for aging. Overall, those results put forward the capacity of cells and organisms to sense and respond to stress, as a critical factor for a healthy and long life. Those molecular pathways are tightly linked with the overall metabolism of an organism. Indeed, environmental stresses trigger a plethora of defense mechanisms which are energy demanding while still the organism has to allocate energy for the maintenance of basic functions. So all along our life, we have to adapt to different stresses while optimizing energy use. This review aims at highlighting data from the literature that support the crucial role of metabolism as a modulator of aging and age-associated disease, as illustrated by the beneficial effect of dietary restriction on longevity and cancer development.

    Topics: Aging; Animals; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Caloric Restriction; Cell Transformation, Neoplastic; Drosophila melanogaster; Energy Metabolism; Homeostasis; Humans; Insulin; Insulin-Like Growth Factor I; Longevity; Membrane Transport Proteins; Mice; Models, Biological; Neoplasms; Protein Kinases; Resveratrol; Signal Transduction; Stilbenes; TOR Serine-Threonine Kinases

2012
The anticancer effects of resveratrol: modulation of transcription factors.
    Nutrition and cancer, 2012, Volume: 64, Issue:4

    Resveratrol (3, 4', 5-trihydroxystilbene), a naturally occurring phytoalexin readily available in the diet, is reported to possess both chemopreventive and chemotherapeutic activities in several cancers. However, despite the identification of numerous molecular targets, the underlying mechanisms involved in the anticancer activities of resveratrol are not completely understood. Resveratrol is postulated to function as a potential signaling pathway modulator and, as such, is demonstrated to affect a multitude of signal transduction pathways associated with tumorigenesis and/or carcinogenesis; it is likely that this collective activity, rather than just a single effect, may play an important role in the anticancer properties of resveratrol. Since transcription factors control the expression of many genes, the elucidation of molecular targets of resveratrol involved in transcriptional regulation is necessary to better understand how this dietary phytochemical affects chemopreventive and chemotherapeutic processes. As a result, investigators have increasingly searched for and examined possible targets of resveratrol. In this review, we summarize the current knowledge on molecular targets, specifically transcription factors, that contribute to the observed anticancer effects of resveratrol related to 1) inhibition of carcinogenic activation and induction of carcinogen detoxification, 2) induction of growth arrest and apoptosis, and 3) suppression of proinflammatory signaling pathways related to cancer progression.

    Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Humans; Neoplasms; NF-E2-Related Factor 2; Receptors, Aryl Hydrocarbon; Resveratrol; Signal Transduction; Stilbenes; Transcription Factors

2012
Control of MicroRNA expression as a new way for resveratrol to deliver its beneficial effects.
    Journal of agricultural and food chemistry, 2012, Sep-12, Volume: 60, Issue:36

    Grapes produce large amounts of polyphenols. Many of them accumulate in the skin, pulp, and seeds and are consequently found in wine. The health benefits of a moderate consumption of wine have been attributed at least in part to grape's polyphenols. Among them, resveratrol (3,5,4'-trihydroxystilbene) is a phytoalexin that stimulates plant cell defenses against infections and also plays protective roles in humans, where it delays cardiovascular alterations and exerts anticancer and anti-inflammatory effects. Despite numerous studies, the molecular mechanisms of resveratrol action are only partially understood. Given its pleiotropic effects, it was previously suggested that resveratrol protective properties may arise from its modulation of the expression of microRNAs. Therefore, this review will focus on the effects of resveratrol on microRNA populations in humans and human cell lines, especially emphasizing the microRNAs that have been implicated in resveratrol effects on inflammation, cancer, metabolism, and muscle differentiation.

    Topics: Animals; Gene Expression Regulation; Humans; MicroRNAs; Neoplasms; Plant Extracts; Resveratrol; Stilbenes; Vitis

2012
[Resveratrol--phytophenol with wide activity].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2012, Volume: 32, Issue:188

    Resveratrol (3,5,4'-trihydroxystilbene) is a natural phytophenol. It is found in many plants, but the highest concentration was detected in different grape-derived products, especially in red wine. The substance is also an active ingredient of some over-the-counter diet supplements. High resveratrol popularity is a consequence of wide biological properties. Numbers of epidemiological and experimental studies have proved a complex chemiopreventive activity of resveratrol against various cardio-vascular disorders and cancer. Furthermore, the compound possesses anti-inflammatory activity and positively regulates glucose level and metabolism of adipose tissue. Diet rich in resveratrol promotes longevity and attenuates neurodegenerative diseases.

    Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents; Atherosclerosis; Cardiovascular Diseases; Chemoprevention; Glucose; Humans; Longevity; Neoplasms; Neurodegenerative Diseases; Resveratrol; Stilbenes

2012
Glucan–resveratrol–vitamin C combination offers protection against toxic agents.
    Toxins, 2012, Nov-09, Volume: 4, Issue:11

    Biological immunomodulators are routinely evaluated as a natural source of molecules with profound effects on the immune system. They belong to a group of physiologically active compounds, collectively termed biological response modifiers. Most of the studies were focused on immune system stimulation. Recently, they have become the focus of studies seeking molecules that are able to overcome negative effects of various immunotoxins. This paper concentrates on the effects of a glucan/resveratrol/vitamin C combination on immunosuppressive effects of mercury and perfluorinated hydrocarbons. Effects described in this review have strong clinical potential, as environmental contaminants have adverse effects on all aspects of the immune system and represent a serious threat to the health of both humans and animals.

    Topics: Animals; Ascorbic Acid; Drug Combinations; Environmental Pollutants; Glucans; Humans; Immune System; Immunity, Cellular; Immunity, Humoral; Neoplasms; Protective Agents; Resveratrol; Stilbenes; Thimerosal

2012
Energy restriction: stepping stones towards cancer therapy.
    Future oncology (London, England), 2012, Volume: 8, Issue:12

    Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Energy Metabolism; Enzyme Inhibitors; Hexokinase; Humans; Molecular Targeted Therapy; Neoplasms; Protein Kinases; Resveratrol; Stilbenes; Thiazolidinediones

2012
Developments of combretastatin A-4 derivatives as anticancer agents.
    Current medicinal chemistry, 2011, Volume: 18, Issue:4

    Tubulin protein is one of several members of a small family of globular proteins. It offers a potential target for anticancer drug design and development. Combretastatin A-4 (CA-4) is a potent anticancer and antiangiogenesis natural substance isolated from Combretum caffrum. Modifications on the CA-4 structure have led to a great number of novel CA-4 derivatives as potent tubulin inhibitors and high cytotoxic anticancer agents is becoming an interesting field, leading to a breakthrough in the treatment of cancer. In this review, the recent developments of novel CA-4 derivatives via the modifications on the A- and B-ring and the double bond as anticancer agents are discussed.

    Topics: Antineoplastic Agents; Combretum; Humans; Neoplasms; Stilbenes; Tubulin; Tubulin Modulators

2011
Resveratrol and cellular mechanisms of cancer prevention.
    Annals of the New York Academy of Sciences, 2011, Volume: 1215

    The use of novel and improved chemopreventive and chemotherapeutic agents for the prevention and treatment of cancer is on the rise. Natural products have always afforded a rich source of such agents. Epidemiological evidence suggests that a higher flavonoid intake is associated with low cancer risk. Accumulating data clearly indicate that the induction of apoptosis is an important component in the chemoprevention of cancer by naturally occurring dietary agents. Resveratrol, a naturally occurring polyphenol, demonstrates pleiotropic health benefits, including antioxidant, anti-inflammatory, antiaging, cardioprotective, and neuroprotective activities. Because of these properties and their wide distribution throughout the plant kingdom, resveratrol is envisioned as a potential chemopreventive/curative agent. Currently, a number of preclinical findings from our lab and elsewhere suggest resveratrol to be a promising natural weapon in the war against cancer. Remarkable progress in elucidating the molecular mechanisms underlying the anticancer properties of resveratrol has been achieved. Here, we focus on some of the myriad pathways that resveratrol targets to exert its chemopreventive role and advocate that resveratrol holds tremendous potential as an efficient anticancer drug of the future.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Resveratrol; Signal Transduction; Stilbenes

2011
Chemoprevention in experimental animals.
    Annals of the New York Academy of Sciences, 2011, Volume: 1215

    The potential cancer-preventive effects of resveratrol, evident from the data obtained by various studies, are summarized in this review. Resveratrol (trans-3,5,4'-trihydroxystilbene), a naturally occurring polyphenolic compound, was first isolated in 1940 as a constituent of the roots of white Hellebore (Veratrum grandiflorum O. Loes), and is now found to be present in various plants including grapes, berries, peanuts, and red wine. This review first briefly describes the current evidence on the link between resveratrol and cancer occurrence, based on epidemiological studies. Subsequently, investigations with resveratrol in animal models of colon carcinogenesis are presented, followed by a comprehensive compilation of resveratrol on cancer. In the second part, the article focuses on results from investigations on cancer-preventive mechanisms of resveratrol. Biological activities including antioxidant effects, modulation of carcinogen metabolism, anti-inflammatory potential, antioxidant properties, antiproliferative mechanisms by induction of apoptosis, and cell differentiation are discussed. Some novel information on its modulating effects on cell signaling pathway, metabolism studies, bioavailability, and cancer-preventive efficacy is also provided. Based on these findings, resveratrol may be used as a promising candidate for cancer chemoprevention.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Chemoprevention; Clinical Trials as Topic; Disease Models, Animal; Humans; Neoplasms; Resveratrol; Stilbenes

2011
Chemopreventive effects of resveratrol and resveratrol derivatives.
    Annals of the New York Academy of Sciences, 2011, Volume: 1215

    Resveratrol is considered to have a number of beneficial effects. Recently, our group modified the molecule and synthesized a number of compounds with different biochemical effects. Polymethoxy and polyhydroxy derivatives of resveratrol were shown to inhibit tumor cell growth in various cell lines and inflammation pathways (cyclooxygenases activity), in part more effectively than resveratrol itself. One lead compound (hexahydroxystilbene, M8) turned out to be the most effective inhibitor of tumor cell growth and of cyclooxygenase 2 activity. M8 was then studied in two different human melanoma mouse models. This novel resveratrol analog was able to inhibit melanoma tumors in a primary tumor model alone and in combination with dacarbacine, an anticancer compound that is used for melanoma treatment. We also tested the development of lymph node metastasis in a second melanoma model and again M8 successfully inhibited the tumor as well as the size and weight of lymph node metastasis. Hydroxylated resveratrol analogs therefore represent a novel class of anticancer compounds and promising candidates for in vivo studies.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Chemoprevention; Humans; Neoplasms; Resveratrol; Stilbenes; Structure-Activity Relationship

2011
The phenomenon of resveratrol: redefining the virtues of promiscuity.
    Annals of the New York Academy of Sciences, 2011, Volume: 1215

    Cancer chemoprevention entails the ingestion of dietary or pharmaceutical agents that can prevent, delay, or reverse the process of carcinogenesis. With support provided by the National Cancer Institute, we have been actively engaged in the systematic discovery and characterization of natural chemopreventive agents. The typical approach involves identifying active crude substances such as extracts derived from terrestrial plants or marine organisms, utilizing in vitro bioassay systems, followed by the isolation of pure active components. As part of this project, an extract obtained from a nonedible Peruvian legume, Cassia quinquangulata Rich. (Leguminosae), was evaluated and found to be active as an inhibitor of cyclooxygenase. The active component was identified as resveratrol. Surprisingly broad spectrum activity was observed, indicative of potential to inhibit carcinogenesis at the stages of initiation, promotion, and progression. This discovery has led to many additional research efforts. There are now around 3,500 papers concerning some aspect of resveratrol action, yet the molecule is unusually promiscuous and specific mechanisms remain elusive. Considering the structural simplicity of this stilbene, the intensity of interest is phenomenal.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cassia; Drug Delivery Systems; Humans; Neoplasms; Phytotherapy; Plant Extracts; Resveratrol; Stilbenes

2011
Resveratrol in cancer management: where are we and where we go from here?
    Annals of the New York Academy of Sciences, 2011, Volume: 1215

    Resveratrol has been shown to afford protection against several diseases. A plethora of studies have suggested that resveratrol imparts cancer chemopreventive and therapeutic responses. However, an important issue with the future development of resveratrol for disease management is its low bioavailability due to its rapid metabolism in mammals. Therefore, efforts are needed to enhance its bioavailability in humans. In this direction, some possible scenarios include enhancing the bioavailability of resveratrol by novel mechanism-based combinations with agents that can inhibit the in vivo metabolism of resveratrol, nanoparticle-mediated delivery, use of naturally occurring or synthetic analogues of resveratrol, and use of conjugated metabolites of resveratrol, though these need to be carefully evaluated as they may need to be deconjugated from resveratrol at the target organ to elicit a biological response. Thus, concerted and multidisciplinary efforts are needed to take resveratrol to the next level, that is, from the "bench-to-bedside."

    Topics: Animals; Chemoprevention; Disease Management; Humans; Neoplasms; Resveratrol; Stilbenes

2011
Chemosensitization of tumors by resveratrol.
    Annals of the New York Academy of Sciences, 2011, Volume: 1215

    Because tumors develop resistance to chemotherapeutic agents, the cancer research community continues to search for effective chemosensitizers. One promising possibility is to use dietary agents that sensitize tumors to the chemotherapeutics. In this review, we discuss that the use of resveratrol can sensitize tumor cells to chemotherapeutic agents. The tumors shown to be sensitized by resveratrol include lung carcinoma, acute myeloid leukemia, promyelocytic leukemia, multiple myeloma, prostate cancer, oral epidermoid carcinoma, and pancreatic cancer. The chemotherapeutic agents include vincristine, adriamycin, paclitaxel, doxorubicin, cisplatin, gefitinib, 5-fluorouracil, velcade, and gemcitabine. The chemosensitization of tumor cells by resveratrol appears to be mediated through its ability to modulate multiple cell-signaling molecules, including drug transporters, cell survival proteins, cell proliferative proteins, and members of the NF-κB and STAT3 signaling pathways. Interestingly, this nutraceutical has also been reported to suppress apoptosis induced by paclitaxel, vincristine, and daunorubicin in some tumor cells. The potential mechanisms underlying this dual effect are discussed. Overall, studies suggest that resveratrol can be used to sensitize tumors to standard cancer chemotherapeutics.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Resistance, Neoplasm; Fruit; Humans; Neoplasms; Resveratrol; Stilbenes; Vegetables

2011
Targeting cell signaling and apoptotic pathways by dietary agents: role in the prevention and treatment of cancer.
    Nutrition and cancer, 2011, Volume: 63, Issue:2

    Cancer is one of the leading causes of death in the United States and around the world. Most modern drug-targeted therapies, besides being enormously expensive, are associated with serious side effects and morbidity. Still, the search continues for an ideal treatment that has minimal side effects and is cost-effective. Indeed, the design and development of chemopreventive agents that act on specific and/or multiple molecular and cellular targets is gaining support as a rational approach to prevent and treat cancer. We present evidence on numerous dietary agents identified from fruits and vegetables that act on multiple signal transduction and apoptotic cascades in various tumor cells and animal models. Some of the most interesting and well documented are turmeric (curcumin), resveratrol, silymarin, EGCG, and genistein. This review will provide an insight on the cellular and molecular mechanism(s) by which dietary agents modulate multiple signaling and apoptotic pathways in tumor cells and elucidate the role of these agents in both prevention and treatment of cancer.

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Catechin; Clinical Trials as Topic; Curcuma; Curcumin; Diet; Disease Models, Animal; Fruit; Genistein; Humans; Neoplasms; Resveratrol; Signal Transduction; Silymarin; Stilbenes; United States; Vegetables

2011
Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds.
    The Journal of nutritional biochemistry, 2011, Volume: 22, Issue:9

    The emergence of cancer stem cell theory has profound implications for cancer chemoprevention and therapy. Cancer stem cells give rise to the tumor bulk through continuous self-renewal and differentiation. Understanding the mechanisms that regulate self-renewal is of greatest importance for discovery of anticancer drugs targeting cancer stem cells. Naturally occurring dietary compounds have received increasing attention in cancer chemoprevention. The anticancer effects of many dietary components have been reported for both in vitro and in vivo studies. Recently, a number of studies have found that several dietary compounds can directly or indirectly affect cancer stem cell self-renewal pathways. Herein we review the current knowledge of most common natural dietary compounds for their impact on self-renewal pathways and potential effect against cancer stem cells. Three pathways (Wnt/β-catenin, Hedgehog and Notch) are summarized for their functions in self-renewal of cancer stem cells. The dietary compounds, including curcumin, sulforaphane, soy isoflavone, epigallocatechin-3-gallate, resveratrol, lycopene, piperine and vitamin D(3), are discussed for their direct or indirect effect on these self-renewal pathways. Curcumin and piperine have been demonstrated to target breast cancer stem cells. Sulforaphane has been reported to inhibit pancreatic tumor-initiating cells and breast cancer stem cells. These studies provide a basis for preclinical and clinical evaluation of dietary compounds for chemoprevention of cancer stem cells. This may enable us to discover more preventive strategies for cancer management by reducing cancer resistance and recurrence and improving patient survival.

    Topics: Alkaloids; Animals; Anticarcinogenic Agents; Benzodioxoles; beta Catenin; Carotenoids; Catechin; Cell Differentiation; Cell Proliferation; Cholecalciferol; Curcumin; Diet; Humans; Isoflavones; Isothiocyanates; Lycopene; Neoplasms; Neoplastic Stem Cells; Piperidines; Polyunsaturated Alkamides; Resveratrol; Signal Transduction; Stilbenes; Sulfoxides; Thiocyanates; Wnt Proteins

2011
Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4.
    Current medicinal chemistry, 2011, Volume: 18, Issue:20

    Tumor blood vessels are an important emerging target for anti-cancer therapy. The antimitotic agent combretastatin A-4 (CA-4), a cis-stilbene natural product isolated from the South African tree Combretum caffrum Kuntze, is the lead compound of a new class of anti-cancer drugs that target tumor vasculature. CA-4 inhibits tubulin polymerization by interacting at the colchicine binding site on tubulin. This alters the morphology of endothelial cells and causes vascular shutdown and regression of tumor vasculature. Some tubulin-binding vascular-disrupting agents (VDAs) are currently in clinical trials for cancer therapy. As a consequence of the potential favorable applications of these compounds, several analogs projected to induce rapid and selective vascular shutdown in tumors have been synthesized during the last few years. Many of these molecules have already been tested for their effects on tubulin polymerization as well as for their antiproliferative activity and other biological properties, and possible mechanisms of action have been investigated. The aim of the present review is to offer an overview of most recently developed combretastatin derivatives, focusing on biological effects exerted by these compounds. The published data about new analogs are presented and compared, and a detailed investigation of structure-activity relationships is described.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Combretum; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes; Structure-Activity Relationship

2011
Epigenetic diet: impact on the epigenome and cancer.
    Epigenomics, 2011, Volume: 3, Issue:4

    A number of bioactive dietary components are of particular interest in the field of epigenetics. Many of these compounds display anticancer properties and may play a role in cancer prevention. Numerous studies suggest that a number of nutritional compounds have epigenetic targets in cancer cells. Importantly, emerging evidence strongly suggests that consumption of dietary agents can alter normal epigenetic states as well as reverse abnormal gene activation or silencing. Epigenetic modifications induced by bioactive dietary compounds are thought to be beneficial. Substantial evidence is mounting proclaiming that commonly consumed bioactive dietary factors act to modify the epigenome and may be incorporated into an 'epigenetic diet'. Bioactive nutritional components of an epigenetic diet may be incorporated into one's regular dietary regimen and used therapeutically for medicinal or chemopreventive purposes. This article will primarily focus on dietary factors that have been demonstrated to influence the epigenome and that may be used in conjunction with other cancer prevention and chemotherapeutic therapies.

    Topics: Anticarcinogenic Agents; Catechin; Curcumin; Diet; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Epigenesis, Genetic; Epigenomics; Genistein; Histones; Humans; Isothiocyanates; MicroRNAs; Neoplasms; Polyphenols; Resveratrol; Stilbenes; Tea

2011
Interaction of phenothiazines, stilbenes and flavonoids with multidrug resistance-associated transporters, P-glycoprotein and MRP1.
    Acta biochimica Polonica, 2011, Volume: 58, Issue:4

    Multidrug resistance (MDR) of cancer cells poses a serious obstacle to successful chemotherapy. The overexpression of multispecific ATP-binding cassette transporters appears to be the main mechanism of MDR. A search for MDR-reversing agents able to sensitize resistant cells to chemotherapy is ongoing in the hope of their possible clinical use. Studies of MDR modulators, although they have not produced clinically beneficial effects yet, may greatly enrich our knowledge about MDR transporters, their specificity and mechanism of action, especially substrate and/or inhibitor recognition. In the present review, interactions of three groups of modulators: phenothiazines, flavonoids and stilbenes with both P-glycoprotein and MRP1 are discussed. Each group of compounds is likely to interact with the MDR transporters by a different mechanism. Phenothiazines probably interact with drug binding sites, but they also could indirectly affect the transporter's activity by perturbing lipid bilayers. Flavonoids mainly interact with ABC proteins within their nucleotide-binding domains, though the more hydrophobic flavonoids may bind to regions within transmembrane domains. The possible mechanism of MDR reversal by stilbenes may result from their direct interaction with the transporter (possibly within substrate recognition sites) but some indirect effects such as stilbene-induced changes in gene expression pattern and in apoptotic pathways should also be considered. Literature data as well as some of our recent results are discussed. Special emphasis is put on cases when the interactions of a given compound with both P-glycoprotein and MRP1 have been studied simultaneously.

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Binding Sites; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flavonoids; Humans; Hydrophobic and Hydrophilic Interactions; Lipid Bilayers; Multidrug Resistance-Associated Proteins; Neoplasms; Phenothiazines; Protein Interaction Domains and Motifs; Stilbenes; Structure-Activity Relationship; Substrate Specificity

2011
NAD(+) -dependent histone deacetylases (sirtuins) as novel therapeutic targets.
    Medicinal research reviews, 2010, Volume: 30, Issue:6

    Histone deacetylases (HDACs) are enzymes that cleave off acetyl groups from acetyl-lysine residues in histones and various nonhistone proteins. Four different classes of HDACs have been identified in humans so far. Although classes I, II, and IV are zinc-dependent amidohydrolases, class III HDACs depend on nicotinamide adenine dinucleotide (NAD(+)) for their catalytic activity. According to their homology to Sir2p, a yeast histone deacetylase, the class III is also termed sirtuins. Seven members have been described in humans so far. As sirtuins are involved in many physiological and pathological processes, their activity has been associated with the pathogenesis of cancer, HIV, metabolic, or neurological diseases. Herein, we present an overview over sirtuins including their biology, targets, inhibitors, and activators and their potential as new therapeutic agents.

    Topics: Animals; Epigenesis, Genetic; HIV Infections; Humans; Inhibitory Concentration 50; Models, Chemical; NAD; Neoplasms; Niacinamide; Protein Binding; Resveratrol; Signal Transduction; Silent Information Regulator Proteins, Saccharomyces cerevisiae; Sirtuin 2; Sirtuins; Stilbenes

2010
Biochemical effects of SIRT1 activators.
    Biochimica et biophysica acta, 2010, Volume: 1804, Issue:8

    SIRT1 is the closest mammalian homologue of enzymes that extend life in lower organisms. Its role in mammals is incompletely understood, but includes modulation of at least 34 distinct targets through its nicotinamide adenine dinucleotide (NAD(+))-dependent deacetylase activity. Recent experiments using small molecule activators and genetically engineered mice have provided new insight into the role of this enzyme in mammalian biology and helped to highlight some of the potentially relevant targets. The most widely employed activator is resveratrol, a small polyphenol that improves insulin sensitivity and vascular function, boosts endurance, inhibits tumor formation, and ameliorates the early mortality associated with obesity in mice. Many of these effects are consistent with modulation of SIRT1 targets, such as PGC1alpha and NFkappaB, however, resveratrol can also activate AMPK, inhibit cyclooxygenases, and influence a variety of other enzymes. A novel activator, SRT1720, as well as various methods to manipulate NAD(+) metabolism, are emerging as alternative methods to increase SIRT1 activity, and in many cases recapitulate effects of resveratrol. At present, further studies are needed to more directly test the role of SIRT1 in mediating beneficial effects of resveratrol, to evaluate other strategies for SIRT1 activation, and to confirm the specific targets of SIRT1 that are relevant in vivo. These efforts are especially important in light of the fact that SIRT1 activators are entering clinical trials in humans, and "nutraceutical" formulations containing resveratrol are already widely available.

    Topics: Animals; Cardiotonic Agents; Energy Metabolism; Enzyme Activation; Heterocyclic Compounds, 4 or More Rings; Humans; Insulin Resistance; Learning; Longevity; Memory; Mice; Models, Biological; NAD; Neoplasms; Niacinamide; O-Acetyl-ADP-Ribose; Resveratrol; Silent Information Regulator Proteins, Saccharomyces cerevisiae; Sirtuin 1; Stilbenes

2010
Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers.
    Future oncology (London, England), 2010, Volume: 6, Issue:1

    Experiments on estrogen metabolism, formation of DNA adducts, mutagenicity, cell transformation and carcinogenicity have led to and supported the hypothesis that the reaction of specific estrogen metabolites, mostly the electrophilic catechol estrogen-3,4-quinones, with DNA can generate the critical mutations to initiate breast and other human cancers. Analysis of depurinating estrogen-DNA adducts in urine demonstrates that women at high risk of, or with breast cancer, have high levels of the adducts, indicating a critical role for adduct formation in breast cancer initiation. Men with prostate cancer or non-Hodgkin lymphoma also have high levels of estrogen-DNA adducts. This knowledge of the first step in cancer initiation suggests the use of specific antioxidants that can block formation of the adducts by chemical and biochemical mechanisms. Two antioxidants, N-acetylcysteine and resveratrol, are prime candidates to prevent breast and other human cancers because in various M in vitro and in vivo experiments, they reduce the formation of estrogen-DNA adducts.

    Topics: Acetylcysteine; Animals; Antineoplastic Agents; Antioxidants; Breast Neoplasms; DNA Adducts; Estrogens; Female; Humans; Male; Neoplasms; Resveratrol; Stilbenes

2010
Resveratrol mobilizes endogenous copper in human peripheral lymphocytes leading to oxidative DNA breakage: a putative mechanism for chemoprevention of cancer.
    Pharmaceutical research, 2010, Volume: 27, Issue:6

    Plant polyphenols are important components of human diet, and a number of them are considered to possess chemopreventive and therapeutic properties against cancer. They are recognized as naturally occurring anti-oxidants but also act as pro-oxidants catalyzing DNA degradation in the presence of metal ions such as copper. The plant polyphenol resveratrol confers resistance to plants against fungal agents and has been implicated as a cancer chemopreventive agent. Of particular interest is the observation that resveratrol has been found to induce apoptosis in cancer cell lines but not in normal cells. Over the last few years, we have shown that resveratrol is capable of causing DNA breakage in cells such as human lymphocytes. Such cellular DNA breakage is inhibited by copper specific chelators but not by iron and zinc chelating agents. Similar results are obtained by using permeabilized cells or with isolated nuclei, indicating that chromatin-bound copper is mobilized in this reaction. It is well established that tissue, cellular and serum copper levels are considerably elevated in various malignancies. Therefore, cancer cells may be more subject to electron transfer between copper ions and resveratrol to generate reactive oxygen species responsible for DNA cleavage. The results are in support of our hypothesis that anti-cancer mechanism of plant polyphenols involves mobilization of endogenous copper and the consequent pro-oxidant action. Such a mechanism better explains the anti-cancer effects of resveratrol, as it accounts for the preferential cytotoxicity towards cancer cells.

    Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Chemoprevention; Copper; DNA Damage; Humans; Lymphocytes; Neoplasms; Resveratrol; Stilbenes

2010
Resveratrol and resveratrol analogues--structure-activity relationship.
    Pharmaceutical research, 2010, Volume: 27, Issue:6

    Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a compound found in wine and is held responsible for a number of beneficial effects of red wine. Besides the prevention of heart disease and significant anti-inflammatory effects, resveratrol might inhibit tumor cell growth and even play a role in the aging process. We here describe the structure-activity relationship of resveratrol and analogues of resveratrol regarding the free radical scavenging and antitumor effects of this exciting natural compound. In addition, we have synthesized a number of analogues of resveratrol with the aim to further improve the beneficial effects of resveratrol. Our studies were based on the analysis of structural properties, which were responsible for the most important effects of this compound. Striking in vivo effects can be observed with hexahydroxystilbene (M8), the most effective synthetic analogue of resveratrol. We could show that M8 inhibits tumor as well as metastasis growth of human melanoma in two different animal models, alone and in combination with dacarbacine.

    Topics: Animals; Antineoplastic Agents; Free Radical Scavengers; Humans; Neoplasms; Resveratrol; Stilbenes; Structure-Activity Relationship

2010
Modulation of apoptosis by natural products for cancer therapy.
    Planta medica, 2010, Volume: 76, Issue:11

    Natural products can exhibit many beneficial effects on human health. As far as cancer is concerned, naturally occurring compounds have been reported to prevent tumorigenesis and also to suppress the growth of established tumors. As cancer cells have evolved multiple mechanisms to resist the induction of programmed cell death (apoptosis), the modulation of apoptosis signaling pathways by natural compounds has been demonstrated to constitute a key event in these antitumor activities. This review presents some examples of how apoptosis pathways are targeted by selected naturally occurring agents and how these events can be exploited for cancer therapy.

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Betulinic Acid; Clinical Trials as Topic; Gossypol; Humans; Mitochondria; Neoplasms; Pentacyclic Triterpenes; Reactive Oxygen Species; Resveratrol; Signal Transduction; Stilbenes; Triterpenes; Vitamin E

2010
[Chemopreventive and chemotherapeutic effect of trans-resveratrol and its analogues in cancer].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2010, Volume: 28, Issue:168

    Trans-resveratrol (3,5,4'-trihydroxy-trans-stilbene), a naturalpolyphenol, displays diversified bioactivities that are crucial in chemoprevention of cancer and cardiovascular diseases. Equally promising action is exerted by resveratrol analogues, mainly pterostilbene (3,5-dimethoxy-4'-hydroxy-trans-stilbene) and piceatannol (3,5,3', 4'-tetrahydroxy-trans-stilbene). Although fruits and their products are the main natural source of resveratrol and their analogues, recently these polyphenols have been commercially available in numerous pharmaceutical preparations and diet supplements. The aim of this review is to present the status of clinical studies on chemopreventive/chemotherapeutic effect of resveratrol and its analogues.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Resveratrol; Stilbenes

2010
Resveratrol and derivatives for the prevention and treatment of cancer.
    Drug discovery today, 2010, Volume: 15, Issue:17-18

    Resveratrol, a naturally derived stilbene that exists in various foods and beverages, has attracted increasing attention over the past decade because of its multiple beneficial properties, including chemopreventive and antitumor activities. There are several other natural derivatives of resveratrol that are structurally similar to resveratrol and are also present in food. In addition, a series of resveratrol analogs have been synthesized by the addition of defined functional groups to increase the potency and/or enhance the activity of specific properties of resveratrol. Such resveratrol derivatives might provide promising tools as cancer chemopreventive agents, as well as cancer therapeutics in the prevention and treatment of cancer. This review provides an overview of key derivatives of resveratrol as cancer therapeutics.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Humans; Molecular Structure; Neoplasms; Resveratrol; Stilbenes

2010
Combretastatin A4 phosphate: a novel vascular disrupting agent.
    Future oncology (London, England), 2010, Volume: 6, Issue:8

    Combretastatin A4 phosphate (CA4P) is the lead compound of a relatively new class of agents termed vascular disrupting agents that target existing tumor blood vessels. Rapid tumor blood flow shutdown has been demonstrated in preclinical models and patients by various techniques such as dynamic contrast-enhanced MRI, perfusion computed tomography and PET scans following CA4P infusion. CA4P typically induces rapid tumor necrosis in the center of the tumor and leaves a rim of viable cells in the periphery. In oncology, CA4P does not appear to be that active by itself, but may be more efficacious when combined with chemotherapy, antiangiogenic therapy and radiation therapy. Studies are currently underway, which combine CA4P with antiangiogenic agents. Side effects have included hypertension, tumor pain and occasional cardiovascular toxicity, without any significant myelosuppression or disabling systemic symptoms. The utility of CA4P for conditions other than cancer, which involves neovascularization such as macular degeneration, is also being explored.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes

2010
Resveratrol. Monograph.
    Alternative medicine review : a journal of clinical therapeutic, 2010, Volume: 15, Issue:2

    Topics: Animals; Antioxidants; Cardiovascular Diseases; Evidence-Based Medicine; Humans; Inflammation; Metabolic Syndrome; Neoplasms; Phytotherapy; Protective Agents; Resveratrol; Stilbenes

2010
Pterostilbene. Monograph.
    Alternative medicine review : a journal of clinical therapeutic, 2010, Volume: 15, Issue:2

    Topics: Animals; Apoptosis; Evidence-Based Medicine; Humans; Inflammation; Neoplasms; Phytotherapy; Protective Agents; Stilbenes

2010
Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies.
    Molecules (Basel, Switzerland), 2010, Oct-12, Volume: 15, Issue:10

    Despite considerable improvements in the tolerance and efficacy of novel chemotherapeutic agents, the mortality of hematological malignancies is still high due to therapy relapse, which is associated with bad prognosis. Dietary polyphenolic compounds are of growing interest as an alternative approach, especially in cancer treatment, as they have been proven to be safe and display strong antioxidant properties. Here, we provide evidence that both resveratrol and curcumin possess huge potential for application as both chemopreventive agents and anticancer drugs and might represent promising candidates for future treatment of leukemia. Both polyphenols are currently being tested in clinical trials. We describe the underlying mechanisms, but also focus on possible limitations and how they might be overcome in future clinical use--either by chemically synthesized derivatives or special formulations that improve bioavailability and pharmacokinetics.

    Topics: Antioxidants; Apoptosis; Cell Cycle; Cell Proliferation; Clinical Trials as Topic; Curcumin; Diet; Hematologic Neoplasms; Humans; Molecular Structure; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Resveratrol; Stilbenes

2010
A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 1.
    Alternative medicine review : a journal of clinical therapeutic, 2010, Volume: 15, Issue:3

    The silent information regulator (SIR) genes (sirtuins) comprise a highly conserved family of proteins, with one or more sirtuins present in virtually all species from bacteria to mammals. In mammals seven sirtuin genes - SIRT1 to SIRT7 - have been identified. Emerging from research on the sirtuins is a growing appreciation that the sirtuins are a very complicated biological response system that influences many other regulator molecules and pathways in complex manners. Responses of this system to environmental factors, as well as its role in health and disease, are currently incompletely characterized and at most partially understood. This article reviews the mammalian sirtuin system, discusses the dietary, lifestyle, and environmental factors that influence sirtuin activity, and summarizes research on the importance of vitamin B3 in supporting sirtuin enzyme activity, as well as the role specifically of the amide form of this vitamin - nicotinamide - to inhibit sirtuin enzyme activity. Polyphenols, especially resveratrol, influence sirtuins. Existing evidence on these nutritional compounds, as they relate to the sirtuin system, is reviewed. In Part 2 of this review, clinical situations where sirtuins might play a significant role, including longevity, obesity, fatty liver disease, cardiovascular health, neurological disease, and cancer, are discussed.

    Topics: Aging; Biological Availability; Cardiovascular Diseases; Enzyme Activators; Humans; Learning; Longevity; Memory; Neoplasms; Nervous System Diseases; Obesity; Phenols; Resveratrol; Sirtuins; Stilbenes

2010
A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2.
    Alternative medicine review : a journal of clinical therapeutic, 2010, Volume: 15, Issue:4

    The silent information regulator (SIR) genes (sirtuins) comprise a highly conserved family of proteins, with one or more sirtuins present in virtually all species from bacteria to mammals. In mammals seven sirtuin genes - SIRT1 to SIRT7 - have been identified. Emerging from research on the sirtuins is a growing appreciation that they are a very complicated biological response system that influences many other regulator molecules and pathways in complex manners. Part 1 of this article provided an overview of the mammalian sirtuin system, discussed the dietary, lifestyle, and environmental factors that influence sirtuin activity, and summarized research on the importance of vitamin B3 in supporting sirtuin enzyme activity, as well as the role specifically of the amide form of this vitamin - nicotinamide - to inhibit sirtuin enzyme activity. In Part 2 of this review, clinical situations where sirtuins might play a significant role, including longevity, obesity, fatty liver disease, cardiovascular health, neurological disease, and cancer are discussed. Research on the ability of nutritional substances, especially resveratrol, to influence sirtuin expression and function, and hence alter the courses of some clinical situations, is also reviewed.

    Topics: Aging; Biological Availability; Cardiovascular Diseases; Enzyme Activators; Humans; Longevity; Neoplasms; Nervous System Diseases; Obesity; Phenols; Resveratrol; Sirtuins; Stilbenes

2010
[Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:3

    Vascular disrupting agents (VDAs) have presented a new kind of anti-cancer drug in recent years. VDAs take advantage of the weakness of established tumor endothelial cells and their supporting structures. In contrast to anti-angiogenic therapy, which inhibits the outgrowth of new blood vessels, vascular targeting treatments selectively attack the existing tumor vasculature. Here we summarized the anti-tumor activities, mechanisms and clinical applications of small molecule VDAs.

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Diphosphates; Endothelial Cells; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Serine; Stilbenes; Tubulin Modulators; Xanthones

2010
[Progress in the study of tubulin inhibitors].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:9

    Microtubule is one of the key components of the cytoskeleton and plays an important role in the maintenance of cell shape and the process of signal transduction and mitosis. Due to the extreme importance of microtubule in the process of mitosis, tubulin becomes one of the most important targets for development of new anticancer drugs and tubulin inhibitors are used for the treatment of cancer nowadays. These inhibitors have antitumor activity by inhibiting or promoting the assembly of tubulin to microtubules and interfering the process of cell mitosis. This review summarized the research progress of the tubulin inhibitors, especially the introduction of the tubulin inhibitors of pharmacological activities and the progress of clinical research. Also, the development trend of these inhibitors is discussed.

    Topics: Antineoplastic Agents; Humans; Microtubules; Mitosis; Molecular Structure; Neoplasms; Stilbenes; Structure-Activity Relationship; Tubulin; Tubulin Modulators

2010
Phytochemicals in cancer prevention and therapy: truth or dare?
    Toxins, 2010, Volume: 2, Issue:4

    A voluminous literature suggests that an increase in consumption of fruit and vegetables is a relatively easy and practical strategy to reduce significantly the incidence of cancer. The beneficial effect is mostly associated with the presence of phytochemicals in the diet. This review focuses on a group of them, namely isothiocyanate, curcumin, genistein, epigallocatechin gallate, lycopene and resveratrol, largely studied as chemopreventive agents and with potential clinical applications. Cellular and animal studies suggest that these molecules induce apoptosis and arrest cell growth by pleiotropic mechanisms. The anticancer efficacy of these compounds may result from their use in monotherapy or in association with chemotherapeutic drugs. This latter approach may represent a new pharmacological strategy against several types of cancers. However, despite the promising results from experimental studies, only a limited number of clinical trials are ongoing to assess the therapeutic efficacy of these molecules. Nevertheless, the preliminary results are promising and raise solid foundations for future investigations.

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Carotenoids; Catechin; Curcumin; Genistein; Humans; Isothiocyanates; Lycopene; Neoplasms; Resveratrol; Stilbenes

2010
Cancer chemoprevention and mitochondria: targeting apoptosis in transformed cells via the disruption of mitochondrial bioenergetics/redox state.
    Molecular nutrition & food research, 2009, Volume: 53, Issue:1

    Cancer chemoprevention employs agents that block, hinder, or reverse tumorigenesis to prevent malignancy. Several putative cancer chemopreventive agents promote apoptosis in transformed cells initiated in animal carcinogenesis models or identified in human subjects, and/or in tumor cells cultured in vitro. Consequently, apoptosis induction is increasingly valued as a biologically significant anticancer mechanism in the arena of chemoprevention. In vitro studies suggest that the permeabilization of mitochondrial membranes is an important mechanistic determinant associated with the apoptosis induced by these agents. Mitochondrial membrane permeabilization (MMP) may occur via the control of proapoptotic Bcl-2 family members, and/or by the induction of the mitochondrial permeability transition. Both of these cell death-inducing regulatory mechanisms are ultimately responsive to the bioenergetic status/redox state of mitochondria. Interestingly, in addition to inducing MMP, various chemopreventive agents can directly modulate mitochondrial bioenergetics and/or redox tone in transformed cells. This review will examine prospective mechanisms associated with the disruption of mitochondrial function by chemopreventive agents that affect MMP and apoptosis. In doing so, we will construct a paradigm supporting the notion that the bioenergetic and/or redox characteristics of the mitochondria in transformed cells are important targets in the chemoprevention of cancer.

    Topics: Animals; Apoptosis; Capsaicin; Catechin; Chemoprevention; Disease Models, Animal; Humans; Mitochondrial Membranes; Neoplasms; Permeability; Reactive Oxygen Species; Resveratrol; Stilbenes; Tea

2009
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:2

    Vascular-disrupting strategies impair a tumor's blood vessel network, which is essential for tumor progression and metastasis. Vascular-disrupting agents (VDAs) cause a rapid and selective vascular shutdown in tumors to produce extensive secondary neoplastic cell death due to ischemia. A lead agent in this therapeutic strategy is the tubulin depolymerizing agent combretastatin-A4 phosphate (CA4P). Used alone, CA4P induces extensive necrosis in a wide variety of preclinical cancer models and significant blood flow reductions in the patient tumors. Preclinical and clinical data further indicate that CA4P can effectively be combined with chemotherapy or radiotherapy. Finally, the potential of combining VDAs with antiangiogenic therapies has shown considerable promise in preclinical models and such combinations are now beginning to be evaluated in patients.

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Stilbenes

2009
Resveratrol and chemoprevention.
    Cancer letters, 2009, Oct-18, Volume: 284, Issue:1

    Resveratrol is a phytoalexin, highly abundant in skins of red grapes and moderately abundant in peanuts and blueberries. Originally a constituent of oriental medicines, it has lately been rediscovered for a plethora of beneficial properties such as anti-cancer, anti-aging, antiviral, cardiovascular and neuroprotective effects, thereby making it one of the most sought after phytochemicals for supplementing human diet. Studies done in various laboratories have shown its modulatory effects on multitudes of cell signaling and gene expression pathways. Although most of its effects have been observed in cultured cells, quite a few have also been validated in whole animals as well. It is thus necessary to have a comprehensive look at all those effects of resveratrol in an organismal context. The following review summarizes the effects of resveratrol in the context of chemoprevention.

    Topics: Animals; Anticarcinogenic Agents; Antioxidants; Cardiovascular Diseases; Drug Evaluation, Preclinical; Gene Expression Regulation; Humans; Neoplasms; Neoplasms, Hormone-Dependent; Phytoestrogens; Resveratrol; Signal Transduction; Stilbenes

2009
Cellular signaling perturbation by natural products.
    Cellular signalling, 2009, Volume: 21, Issue:11

    Cancer cells are known to have alterations in multiple cellular signaling pathways and because of the complexities in the communication between multiple signaling networks, the treatment and the cure for most human malignancies is still an open question. Perhaps, this is the reason why specific inhibitors that target only one pathway have been typically failed in cancer treatment. However, the in vitro and in vivo studies have demonstrated that some natural products such as isoflavones, indole-3-carbinol (I3C), 3,3'-diindolylmethane (DIM), curcumin, (-)-epigallocatechin-3-gallate (EGCG), resveratrol, lycopene, etc, have inhibitory effects on human and animal cancers through targeting multiple cellular signaling pathways and thus these "natural agents" could be classified as multi-targeted agents. This is also consistent with the epidemiological studies showing that the consumption of fruits, soybean and vegetables is associated with reduced risk of several types of cancers. By regulating multiple important cellular signaling pathways including NF-kappaB, Akt, MAPK, Wnt, Notch, p53, AR, ER, etc, these natural products are known to activate cell death signals and induce apoptosis in pre-cancerous or cancer cells without affecting normal cells. Therefore, non-toxic "natural agents" harvested from the bounties of nature could be useful either alone or in combination with conventional therapeutics for the prevention of tumor progression and/or treatment of human malignancies.

    Topics: Antineoplastic Agents; Carotenoids; Catechin; Curcumin; Humans; Indoles; Isoflavones; Lycopene; Neoplasms; Resveratrol; Signal Transduction; Stilbenes

2009
Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials.
    Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:5

    Resveratrol (3,4',5-trihydroxy-trans-stilbene) is a dietary polyphenol derived from grapes, berries, peanuts, and other plant sources. During the last decade, resveratrol has been shown to possess a fascinating spectrum of pharmacologic properties. Multiple biochemical and molecular actions seem to contribute to resveratrol effects against precancerous or cancer cells. Resveratrol affects all three discrete stages of carcinogenesis (initiation, promotion, and progression) by modulating signal transduction pathways that control cell division and growth, apoptosis, inflammation, angiogenesis, and metastasis. The anticancer property of resveratrol has been supported by its ability to inhibit proliferation of a wide variety of human tumor cells in vitro. These in vitro data have led to numerous preclinical animal studies to evaluate the potential of this drug for cancer chemoprevention and chemotherapy. This review provides concise, comprehensive data from preclinical in vivo studies in various rodent models of human cancers, highlighting the related mechanisms of action. Bioavailability, pharmacokinetic, and potential toxicity studies of resveratrol in humans and ongoing interventional clinical trials are also presented. The conclusion describes directions for future resveratrol research to establish its activity and utility as a human cancer preventive and therapeutic drug.

    Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Resveratrol; Stilbenes

2009
Anticancer strategies involving the vasculature.
    Nature reviews. Clinical oncology, 2009, Volume: 6, Issue:7

    The growth and metastasis of solid tumors critically depends on their ability to develop their own blood supply, a process known as tumor angiogenesis. Over the past decade much work has been performed to understand this process, and modifying this process provides a key point of therapeutic intervention in the fight against cancer. This Review explores the development of anti-VEGF-based antiangiogenic therapies, of which there are currently three licensed for clinical use worldwide. Although originally anticipated to inhibit the growth of tumor vessels, the induction of vascular normalization caused by these approved agents has provided a novel means of effective delivery of known chemotherapeutic agents. The development of small molecules that target VEGF receptors has resulted in the generation of inhibitors with not only vascular activity but antitumor activity in certain cancers. This Review will address the current status of vascular-disrupting strategies, such as therapies designed to induce tumor collapse by selectively destroying existing tumor vessels. These therapies can be broadly divided into small-molecular-weight vascular-disrupting agents and ligand-directed approaches. We discuss the current status of development, drug mechanisms of actions, combination with conventional chemotherapy and radiotherapy, and potential future targets for therapeutic intervention.

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Regional Blood Flow; Stilbenes; Vascular Endothelial Growth Factor A

2009
The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: convergence with the anti-apoptotic effect of thyroid hormone.
    Cell cycle (Georgetown, Tex.), 2009, Jun-15, Volume: 8, Issue:12

    Constitutively expressed cyclooxygenase-2 (COX-2) is a marker of tumor cell aggressiveness. Inducible COX-2 has also been described in cancer cells and localizes in the cancer cell nucleus, where formation of a complex of mitogen-activated protein kinase (MAPK) and COX-2 is antecedent to p53-dependent apoptosis. The stilbene resveratrol is a model pharmacologic activator of this pro-apoptotic mechanism. Physiological concentrations of thyroid hormone are anti-apoptotic in several types of tumor cells. A mechanism by which the hormone is anti-apoptotic is disruption of the nuclear MAPK-COX-2 complex. We review here the apoptosis-relevant effects of resveratrol and thyroid hormone and then speculate about the significance of convergence of these actions in cancer cells in the intact organism. Clinical activity of resveratrol may be modulated by normal tissue levels of endogenous thyroid hormone, and hypothyroidism in the cancer patient -- whether spontaneous or induced by chemotherapeutic agents -- may permit full expression of the apoptotic activity of the administered stilbene. Chronic pharmacologic inhibition of COX-2 may oppose the pro-apoptotic effect of resveratrol.

    Topics: Animals; Anticarcinogenic Agents; Apoptosis; Cell Proliferation; Cyclooxygenase 2; Cytokines; Enzyme Inhibitors; Humans; Neoplasms; Protein Kinases; Resveratrol; Signal Transduction; Stilbenes; Thyroid Hormones

2009
Wine, resveratrol and health: a review.
    Natural product communications, 2009, Volume: 4, Issue:5

    Several studies have cited the Mediterranean diet as an example of healthy eating. In fact, the Mediterranean diet has become the reference diet for the prevention of cardiovascular disease. Red wine seems to be an essential component of the diet, since moderate consumption of wine is associated with lower risk and mortality from cardiovascular disease. Evidence is also accumulating that wine helps prevent the development of certain cancers. Of all the many components of wine, resveratrol, which is a natural component specifically present in wine, has been identified as being mainly responsible for these health-promoting properties. Many valuable properties such as cardioprotective and anticarcinogenic activity have been attributed to resveratrol; however, its bioavailability is quite low. The bioactivity of metabolites derived from resveratrol, and the accumulation of resveratrol in vital organs are still under study, but there are high expectations of positive results. Other stilbene compounds are also considered in this review, despite being present in undetectable or very small quantities in wine. The present paper reviews all aspects of the health properties of wine, bioactive compounds found in wine, and their concentrations, bioavailability and possible synergistic effects.

    Topics: Anticoagulants; Antineoplastic Agents, Phytogenic; Biological Availability; Cardiovascular Agents; Diet, Mediterranean; Humans; Lipid Metabolism; Neoplasms; Protective Agents; Resveratrol; Stilbenes; Vitis; Wine

2009
Multiple molecular targets of resveratrol: Anti-carcinogenic mechanisms.
    Archives of biochemistry and biophysics, 2009, Jun-15, Volume: 486, Issue:2

    Plant-derived polyphenolic compounds, such as the stilbene resveratrol (trans-3,4',5-trihydroxystilbene), have been identified as potent anti-cancer agents. Extensive in vitro studies revealed multiple intracellular targets of resveratrol, which affect cell growth, inflammation, apoptosis, angiogenesis, and invasion and metastasis. These include tumor suppressors p53 and Rb; cell cycle regulators, cyclins, CDKs, p21WAF1, p27KIP and INK and the checkpoint kinases ATM/ATR; transcription factors NF-kappaB, AP-1, c-Jun, and c-Fos; angiogenic and metastatic factors, VEGF and matrix metalloprotease 2/9; cyclooxygenases for inflammation; and apoptotic and survival regulators, Bax, Bak, PUMA, Noxa, TRAIL, APAF, survivin, Akt, Bcl2 and Bcl-X(L). In addition to its well-documented anti-oxidant properties, there is increasing evidence that resveratrol exhibits pro-oxidant activity under certain experimental conditions, causing oxidative DNA damage that may lead to cell cycle arrest or apoptosis. This review summarizes in vitro mechanistic data available for resveratrol and discusses new potential anti-cancer targets and the antiproliferative mechanisms of resveratrol.

    Topics: Anticarcinogenic Agents; Breast Neoplasms; Cathepsins; Cell Cycle; Cell Division; Female; Humans; Inflammation; Leukemia; Lymphoma; Male; Neoplasms; Prostatic Neoplasms; Resveratrol; Safety; Stilbenes; Transcription Factors

2009
AVE8062: a new combretastatin derivative vascular disrupting agent.
    Expert opinion on investigational drugs, 2009, Volume: 18, Issue:10

    Angiogenesis has an essential role in promoting and supporting tumor growth and it is an important therapeutic target. The tumor vascular network is the result of pro-angiogenic and inhibitory factors as well as of the interaction between endothelial cells and extracellular matrix. Different antiangiogenic therapeutics have been developed to improve tumor control through vascular-targeting agents (VTA). VTAs can be divided into two groups: antiangiogenic agents and vascular-disrupting agents (VDAs). VTAs inhibit specific factors required to induce and direct the angiogenic process, with major activity against small tumor masses and at the tumor periphery, encompassing monoclonal antibodies and small molecules inhibitors of the tyrosine kinase domain of the VEGF receptor. VDAs specifically target and destroy well-established tumor vessels with ischemia and destruction of large masses with central hemorrhagic necrosis and survival of a thin peripheral tumor layer. VDAs can be divided into biologics, such as ligand-based, and small-molecule agents; this second group includes small-molecule VDAs like flavonoids, such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA), and microtubule-destabilizing agents. In this review we will discuss the mechanism of action, as well as the preclinical and clinical results, of one of the most promising antitubulin agents: the combretastatin A4-phosphate derivative, AVE8062A.

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Neoplasms; Neovascularization, Pathologic; Serine; Stilbenes; Tubulin

2009
[Contemporary view of plant antioxidants role in prevention of civilization diseases].
    Roczniki Panstwowego Zakladu Higieny, 2009, Volume: 60, Issue:3

    The role of plant antioxidants as factors of civilization diseases prevention was described. The free-radical theory as a mechanism of action of antioxidants was mentioned. The main substances e.g. polyphenols including flavonoids, ascorbic acid, carotenoids and tocoferols were presented. Resveratrol of wine, as an example of possible health beneficial agent was stressed. On the other handsome doubts of beneficial effects of antioxidants e.g. beta-carotene, as supplement of diet, were mentioned. It is possible, that supplementation with flavonoids might create some health risk. But there was highlighted, that vegetables as a source of natural antioxidants are beneficial for health.

    Topics: Antioxidants; Ascorbic Acid; beta Carotene; Chronic Disease; Dietary Supplements; Flavonoids; Health Promotion; Humans; Neoplasms; Phenols; Phytotherapy; Plant Extracts; Polyphenols; Resveratrol; Stilbenes

2009
Fighting cancer with red wine? Molecular mechanisms of resveratrol.
    Critical reviews in food science and nutrition, 2009, Volume: 49, Issue:9

    Resveratrol, a red wine constituent, has been known for its cardioprotective effects. Recent data give ample evidence that resveratrol can act as a chemopreventive agent as well. Tumor initation, promotion, and progression are affected by resveratrol via multiple pathways, which are discussed in this review. Resveratrol has anti-inflammatory effects by counteracting NF-kappa B and AP-1 transcription and can prevent bioactivation of procarcinogens by interacting with drug metabolizing enzymes. Furthermore, resveratrol exerts antioxidant activities, hence contributing to the prevention of tumor initiation. Growing or metastasizing carcinomas are inhibited by resveratrol through prevention of angiogenesis by inhibiting VEGF and matrix metalloproteases. Induction of apoptosis and cell cycle arrest, important mechanisms for cancer therapy, are stimulated by resveratrol through different mechanisms, e.g., activation of p53 and modulation of cell cycle proteins. Although there has been remarkable evidence for resveratrol as a potent chemopreventive agent in vitro, it seems that the low bioavailability of resveratrol in humans could interfere with a successful in vivo treatment. Nevertheless, resveratrol offers two major advantages over conventional chemotherapy. The cytotoxic effects of resveratrol on healthy cells can be neglected, and, as several pathways leading to chemotherapeutic effects are activated by resveratrol, chemoresistance-inducing mutations in cancer cells can be overcome.

    Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Biological Availability; Humans; Neoplasms; Resveratrol; Stilbenes; Wine

2009
Molecular mechanism of apoptosis induction by resveratrol, a natural cancer chemopreventive agent.
    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition, 2008, Volume: 78, Issue:1

    In efforts to identify naturally occurring compounds that act as protective agents, resveratrol, a phytoalexin existing in wine, has attracted much interest because of its diverse pharmacological characteristics. Considering that apoptosis induction is the most potent defense approach for cancer treatment, we have tried to summarize our present understanding of apoptosis induction by resveratrol based on the two major apoptosis pathways.

    Topics: Anticarcinogenic Agents; Apoptosis; Biological Products; Chemoprevention; Humans; Neoplasms; Resveratrol; Signal Transduction; Stilbenes

2008
Tumour vascular disrupting agents: combating treatment resistance.
    The British journal of radiology, 2008, Volume: 81 Spec No 1

    A large group of tubulin-binding microtubule-depolymerizing agents act as tumour vascular disrupting agents (VDAs). Several members of this group are now in clinical trials in combination with conventional anticancer drugs and radiotherapy. Here we briefly update on the development of tubulin-binding combretastatins as VDAs, summarize what is known of their mechanisms of action and address issues relating to treatment resistance, using disodium combretastatin A-4 3-O-phosphate (CA-4-P) as an example. Characteristically, VDAs cause a rapid shutdown of blood flow to tumour tissue with much less effect in normal tissues. However, the tumour rim is relatively resistant to treatment. Hypoxia (or hypoxia reoxygenation) induces upregulation of genes associated with angiogenesis and drug resistance. It may be possible to take advantage of treatment-induced hypoxia by combining with drugs that are activated under hypoxic conditions. In summary, VDAs provide a novel approach to cancer treatment, which should effectively complement standard treatments, if treatment resistance is addressed by judicious combination treatment strategies.

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Blood Vessels; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Mice; Microtubules; Neoplasms; Rats; Stilbenes; Tubulin Modulators

2008
Cell cycle control as a basis for cancer chemoprevention through dietary agents.
    Frontiers in bioscience : a journal and virtual library, 2008, Jan-01, Volume: 13

    The development of cancer is associated with disorders in the regulation of the cell cycle. The purpose of this review is to briefly summarize the known sequence of events that regulate cell cycle progression with an emphasis on the checkpoints and the mechanisms cell employ to insure DNA stability in the face of genotoxic stress. Key transitions in the cell cycle are regulated by the activities of various protein kinase complexes composed of cyclin and cyclin-dependent kinases (CDK) molecules. The cyclins are CDK binding partners which are required for kinase activity and their protein levels are intimately linked to the cell cycle stage. CDK activity can be regulated by other mechanisms, such as phosphorylation events, that may contribute to deregulation of cell cycle and the development of cancer. While fruits and vegetables are recommended for prevention of cancer, their active ingredients and mechanisms of action are less well understood. Here, we briefly present evidence that dietary agents identified from fruits and vegetables can act to modulate the effects of deregulated cell cycle checkpoints, and that this may contribute to the prevention of cancer. The agents include apigenin (celery, parsley), curcumin (turmeric), (-)-epigallocatechin-3-gallate (green tea), resveratrol (red grape, peanuts and berries), genistein (soybean), and silymarin (milk thistle). The teachings of Hippocrates are still true "let food be thy medicine and medicine be thy food".

    Topics: Animals; Anticarcinogenic Agents; Apigenin; Catechin; Cell Cycle; Cell Proliferation; Curcumin; Cyclin-Dependent Kinases; Diet; Genistein; Humans; Neoplasms; Resveratrol; Silymarin; Stilbenes; Tea

2008
Cancer chemoprevention through dietary antioxidants: progress and promise.
    Antioxidants & redox signaling, 2008, Volume: 10, Issue:3

    It is estimated that nearly one-third of all cancer deaths in the United States could be prevented through appropriate dietary modification. Various dietary antioxidants have shown considerable promise as effective agents for cancer prevention by reducing oxidative stress which has been implicated in the development of many diseases, including cancer. Therefore, for reducing the incidence of cancer, modifications in dietary habits, especially by increasing consumption of fruits and vegetables rich in antioxidants, are increasingly advocated. Accumulating research evidence suggests that many dietary factors may be used alone or in combination with traditional chemotherapeutic agents to prevent the occurrence of cancer, their metastatic spread, or even to treat cancer. The reduced cancer risk and lack of toxicity associated with high intake of fruits and vegetables suggest that specific concentrations of antioxidant agents from these dietary sources may produce cancer chemopreventive effects without causing significant levels of toxicity. This review presents an extensive analysis of the key findings from studies on the effects of dietary antioxidants such as tea polyphenols, curcumin, genistein, resveratrol, lycopene, pomegranate, and lupeol against cancers of the skin, prostate, breast, lung, and liver. This research is also leading to the identification of novel cancer drug targets.

    Topics: Animals; Anticarcinogenic Agents; Antioxidants; Carotenoids; Curcumin; Dietary Supplements; Fruit; Genistein; Humans; Lycopene; Neoplasms; Oxidative Stress; Pentacyclic Triterpenes; Resveratrol; Stilbenes; Triterpenes

2008
Berry fruits for cancer prevention: current status and future prospects.
    Journal of agricultural and food chemistry, 2008, Feb-13, Volume: 56, Issue:3

    Overwhelming evidence suggests that edible small and soft-fleshed berry fruits may have beneficial effects against several types of human cancers. The anticancer potential of berries has been related, at least in part, to a multitude of bioactive phytochemicals that these colorful fruits contain, including polyphenols (flavonoids, proanthocyanidins, ellagitannins, gallotannins, phenolic acids), stilbenoids, lignans, and triterpenoids. Studies show that the anticancer effects of berry bioactives are partially mediated through their abilities to counteract, reduce, and also repair damage resulting from oxidative stress and inflammation. In addition, berry bioactives also regulate carcinogen and xenobiotic metabolizing enzymes, various transcription and growth factors, inflammatory cytokines, and subcellular signaling pathways of cancer cell proliferation, apoptosis, and tumor angiogenesis. Berry phytochemicals may also potentially sensitize tumor cells to chemotherapeutic agents by inhibiting pathways that lead to treatment resistance, and berry fruit consumption may provide protection from therapy-associated toxicities. Although a wide variety of berry fruits are consumed worldwide, this paper focuses on those commonly consumed in North America, namely, blackberries, black raspberries, blueberries, cranberries, red raspberries, and strawberries. In addition, a large body of studies on singly purified berry bioactives is available, but this paper focuses on studies of "whole berries" per se, that is, as berry extracts and purified fractions, juices, and freeze-dried powders. Potential mechanisms of anticancer action and bioavailability of berry phenolics, as well as gaps in knowledge and recommendations for future berry research, are also briefly discussed.

    Topics: Animals; Anticarcinogenic Agents; Biological Availability; Cell Line, Tumor; Diet; Female; Flavonoids; Fruit; Humans; Lignans; Male; Neoplasms; Phenols; Polyphenols; Stilbenes; Triterpenes

2008
Phytochemical composition of nuts.
    Asia Pacific journal of clinical nutrition, 2008, Volume: 17 Suppl 1

    Observational studies suggest nut consumption is inversely associated with the incidence of cardiovascular disease and cancer. In addition to being rich in several vitamins and minerals, unsaturated fatty acids, and fiber, tree nuts and peanuts contain numerous phytochemicals that may contribute to promoting health and reducing the risk of chronic disease. While many of these bioactive constituents remain to be fully identified and characterized, broad classes include carotenoids, phenols, and phytosterols. Phytosterols in nuts range from 95-280 mg/100 g. alpha- and beta-Carotene, beta-cryptoxanthin, lutein, and zeaxanthin are found in microg/100 g amounts in some nuts but at 1-3 mg/100 g in pistachios and none at all in Brazils, macadamias, and peanuts. Phenols, including phenolic acids, flavonoids, and stilbenes, are present in nuts. Walnuts are particularly rich in total phenols with 1625 mg gallic acid equivalents/100 g. The stilbene resveratrol is found in peanuts and pistachios at 84 and 115 microg/100 g, respectively. The flavonoid content of nuts as provided in USDA Database for the Flavonoid Content of Selected Foods, lists totals in pecans at 34, almonds at 15, and pistachios and hazelnuts at 12 mg/100 g. Proanthocyanidins are found in almonds, cashews, hazelnuts, pecans, pistachios, peanuts, and walnuts, with concentrations varying from 9-494 mg/100 g. Nut phytochemicals have been associated with numerous bioactivities known to affect the initiation and progression of several pathogenic processes. However, as complete phytochemical profiles are lacking for most nuts, information is limited regarding their bioavailability and metabolism, so further research on this topic is warranted.

    Topics: Antioxidants; Cardiovascular Diseases; Flavonoids; Food, Organic; Humans; Neoplasms; Nuts; Phenols; Seeds; Stilbenes

2008
Resveratrol: a multitargeted agent for age-associated chronic diseases.
    Cell cycle (Georgetown, Tex.), 2008, Apr-15, Volume: 7, Issue:8

    Extensive research within the last decade has revealed that most chronic illnesses such as cancer, cardiovascular and pulmonary diseases, neurological diseases, diabetes, and autoimmune diseases exhibit dysregulation of multiple cell signaling pathways that have been linked to inflammation. Thus mono-targeted therapies developed for the last two decades for these diseases have proven to be unsafe, ineffective and expensive. Although fruits and vegetables are regarded to have therapeutic potential against chronic illnesses, neither their active component nor the mechanism of action is well understood. Resveratrol (trans-3, 5, 4'-trihydroxystilbene), a component of grapes, berries, peanuts and other traditional medicines, is one such polyphenol that has been shown to mediate its effects through modulation of many different pathways. This stilbene has been shown to bind to numerous cell-signaling molecules such as multi drug resistance protein, topoisomerase II, aromatase, DNA polymerase, estrogen receptors, tubulin and F1-ATPase. Resveratrol has also been shown to activate various transcription factor (e.g; NFkappaB, STAT3, HIF-1alpha, beta-catenin and PPAR-gamma), suppress the expression of antiapoptotic gene products (e.g; Bcl-2, Bcl-X(L), XIAP and survivin), inhibit protein kinases (e.g; src, PI3K, JNK, and AKT), induce antioxidant enzymes (e,g; catalase, superoxide dismutase and hemoxygenase-1), suppress the expression of inflammatory biomarkers (e.g., TNF, COX-2, iNOS, and CRP), inhibit the expression of angiogenic and metastatic gene products (e.g., MMPs, VEGF, cathepsin D, and ICAM-1), and modulate cell cycle regulatory genes (e.g., p53, Rb, PTEN, cyclins and CDKs). Numerous animal studies have demonstrated that this polyphenol holds promise against numerous age-associated diseases including cancer, diabetes, Alzheimer, cardiovascular and pulmonary diseases. In view of these studies, resveratrol's prospects for use in the clinics are rapidly accelerating. Efforts are also underway to improve its activity in vivo through structural modification and reformulation. Our review describes various targets of resveratrol and their therapeutic potential.

    Topics: Aging; Cardiotonic Agents; Gene Expression Regulation; Gene Regulatory Networks; Inflammation; Intracellular Signaling Peptides and Proteins; Neoplasms; Platelet Aggregation; Resveratrol; Stilbenes; Transcription Factors

2008
Resveratrol: a review of preclinical studies for human cancer prevention.
    Toxicology and applied pharmacology, 2007, Nov-01, Volume: 224, Issue:3

    The search for novel and effective cancer chemopreventive agents has led to the identification of various naturally occurring compounds one of which is resveratrol (trans-3,4',5-trihydroxystilbene), a phytoalexin derived from the skin of grapes and other fruits. Resveratrol is known to have potent anti-inflammatory and antioxidant effects and to inhibit platelet aggregation and the growth of a variety of cancer cells. Its potential chemopreventive and chemotherapeutic activities have been demonstrated in all three stages of carcinogenesis (initiation, promotion, and progression), in both chemically and UVB-induced skin carcinogenesis in mice, as well as in various murine models of human cancers. Evidence from numerous in vitro and in vivo studies has confirmed its ability to modulate various targets and signaling pathways. This review discusses the current preclinical and mechanistic data available and assesses resveratrol's anticancer effects to support its potential as an anticancer agent in human populations.

    Topics: Animals; Anticarcinogenic Agents; Drug Screening Assays, Antitumor; Humans; Neoplasms; Resveratrol; Stilbenes

2007
Vascular disrupting agents in clinical development.
    British journal of cancer, 2007, Apr-23, Volume: 96, Issue:8

    Growth of human tumours depends on the supply of oxygen and nutrients via the surrounding vasculature. Therefore tumour vasculature is an attractive target for anticancer therapy. Apart from angiogenesis inhibitors that compromise the formation of new blood vessels, a second class of specific anticancer drugs has been developed. These so-called vascular disrupting agents (VDAs) target the established tumour vasculature and cause an acute and pronounced shutdown of blood vessels resulting in an almost complete stop of blood flow, ultimately leading to selective tumour necrosis. As a number of VDAs are now being tested in clinical studies, we will discuss their mechanism of action and the results obtained in preclinical studies. Also data from clinical studies will be reviewed and some considerations with regard to the future development are given.

    Topics: Animals; Antineoplastic Agents; Blood Vessels; Humans; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Organophosphorus Compounds; Regional Blood Flow; Stilbenes; Tubulin Modulators; Xanthones

2007
Cranberry and blueberry: evidence for protective effects against cancer and vascular diseases.
    Molecular nutrition & food research, 2007, Volume: 51, Issue:6

    Growing evidence from tissue culture, animal, and clinical models suggests that the flavonoid-rich fruits of the North American cranberry and blueberry (Vaccinium spp.) have the potential ability to limit the development and severity of certain cancers and vascular diseases including atherosclerosis, ischemic stroke, and neurodegenerative diseases of aging. The fruits contain a variety of phytochemicals that could contribute to these protective effects, including flavonoids such as anthocyanins, flavonols, and proanthocyanidins; substituted cinnamic acids and stilbenes; and triterpenoids such as ursolic acid and its esters. Cranberry and blueberry constituents are likely to act by mechanisms that counteract oxidative stress, decrease inflammation, and modulate macromolecular interactions and expression of genes associated with disease processes. The evidence suggests a potential role for dietary cranberry and blueberry in the prevention of cancer and vascular diseases, justifying further research to determine how the bioavailability and metabolism of berry phytonutrients influence their activity in vivo.

    Topics: Animals; Anthocyanins; Anticarcinogenic Agents; Antioxidants; Atherosclerosis; Blueberry Plants; Flavonoids; Humans; Neoplasms; Phytotherapy; Proanthocyanidins; Stilbenes; Stroke; Triterpenes; Vaccinium macrocarpon; Vascular Diseases

2007
Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential.
    Frontiers in bioscience : a journal and virtual library, 2007, Sep-01, Volume: 12

    Resveratrol, a polyphenol found in numerous plant species, including mulberries, peanuts and grapes, has shown to possess chemopreventive properties against several cancers, and cardiovascular diseases. Recently, resveratrol has been shown to have positive effects on age longevity, lipid levels and a preventative quality against certain cancers and viral infections. Resveratrol induces apoptosis by up-regulating the expression of Bax, Bak, PUMA, Noxa, Bim, p53, TRAIL, TRAIL-R1/DR4 and TRAIL-R2/DR5 and simultaneously down-regulating the expression of Bcl-2, Bcl-XL, Mcl-1 and survivin. Resveratrol causes growth arrest at G1 and G1/S phases of cell cycle by inducing the expression of CDK inhibitors p21/WAF1/CIP1 and p27/KIP1. Resveratrol has also been shown to reduce inflammation via inhibition of prostaglandin production, cyclooxygenase-2 activity, and nuclear factor-kappaB activity. Modulation of cell signaling pathway by resveratrol explains its diverse bioactivities related with human health. Resveratrol also potentiates the apoptotic effects of cytokines, chemotherapeutic agents and gamma-radiation. Pharmacokinetic and pharmacodynamic studies demonstrated that the main target organs of resveratrol are liver and kidney, and it is metabolized by hydroxylation, glucuronidation, sulfation and hydrogenation. As a chemoprevention agent, resveratrol has been shown to inhibit tumor initiation, promotion, and progression. There is growing evidence that resveratrol can prevent or delay the onset of various cancers, heart diseases, ischemic and chemically induced injuries, pathological inflammation and viral infections. This review summarizes the molecular mechanisms of resveratrol and its clinical benefits for human diseases.

    Topics: Cardiovascular Diseases; Cell Cycle; Chemoprevention; Chemotherapy, Adjuvant; Diabetes Mellitus; Gene Expression Regulation; Humans; Inflammation; Neoplasms; Neovascularization, Pathologic; Resveratrol; Signal Transduction; Stilbenes

2007
Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals.
    Acta pharmacologica Sinica, 2007, Volume: 28, Issue:9

    There is growing interest in the ability of phytochemicals to prevent chronic diseases, such as cancer and heart disease. However, some of these agents have poor bioavailability and many of the in-depth studies into their mechanisms of action have been carried out in vitro using doses which are unachievable in humans. In order to optimize the design of chemopreventive treatment, it is important to determine which of the many reported mechanisms of action are clinically relevant. In this review we consider the physiologically achievable doses for a few of the best studied agents (indole-3-carbinol, diindolylmethane, curcumin, epigallocatechin-3-gallate and resveratrol) and summarize the data derived from studies using these low concentrations in cell culture. We then cite examples of in vitro effects which have been observed in vivo. Finally, the ability of agent combinations to act synergistically or antagonistically is considered. We conclude that each of the compounds shows an encouraging range of activities in vitro at concentrations which are likely to be physiologically relevant. There are also many examples of in vivo studies which validate in vitro observations. An important consideration is that combinations of agents can result in significant activity at concentrations where any single agent is inactive. Thus, for each of the compounds reviewed here, in vitro studies have provided useful insights into their mechanisms of action in humans. However, data are lacking on the full range of activities at low doses in vitro and the benefits or otherwise of combinations in vivo.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Catechin; Curcumin; Humans; Indoles; Neoplasms; Resveratrol; Stilbenes

2007
Tumour targeting by microtubule-depolymerizing vascular disrupting agents.
    Expert opinion on therapeutic targets, 2007, Volume: 11, Issue:11

    Low molecular weight vascular disrupting agents of the microtubule depolymerizing family cause marked and selective disruption of the established tumour blood vessel network, resulting in tumour cell necrosis. The combretastatins are members of this family and these, together with several other related compounds, have undergone extensive preclinical testing and are now in clinical trials for cancer. Potentially, vascular disrupting agents can also interfere with angiogenesis and constitute a very promising group of novel cancer drugs. In vitro analysis of their signalling activities points to the endothelial cytoskeleton as being their major target and a key player in the events that culminate in vascular collapse. As more of these agents progress into the clinical setting, more research in this area is warranted in order to decipher exact mechanisms responsible for vascular disruption and to understand the reasons for drug selectivity for the tumour vasculature. This information is essential in order to identify new targets within the tumour vasculature and to improve present therapies.

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Microtubules; Neoplasms; Neovascularization, Pathologic; Stilbenes

2007
New enlightenment of French Paradox: resveratrol's potential for cancer chemoprevention and anti-cancer therapy.
    Cancer biology & therapy, 2007, Volume: 6, Issue:12

    Resveratrol is a phytoalexin produced by many plants, and the skin of red grapes is particularly rich in resveratrol which accounts for the "French Paradox". Besides its protection of the cardiovascular system, it can affect the processes underlying all three stages of carcinogenesis, involving tumor initiation, promotion and progression. It has also been shown to suppress angiogenesis and metastasis. The anti-carcinogenic effects of resveratrol appear to be closely associated with its capacity to interact with multiple molecular targets involved in cancer development, while minimizing toxicity in normal tissues as tested. By reviewing many in vitro and in vivo studies, also considering both the supporting and challenging evidences, we are provided with a theory in support of the use of resveratrol in human cancer chemoprevention, in combination with either chemotherapeutic drugs or cytotoxic factors for the highly efficient treatment of drug refractory tumor cells. Anti-carcinogenic potential for cancer chemoprevention and anticancer therapy, which is one of the pleiotropic effects of resveratrol, is so called a new enlightenment of French Paradox.

    Topics: Animals; Anticarcinogenic Agents; Antioxidants; Cardiovascular Diseases; Cell Line, Tumor; Cell Transformation, Neoplastic; Clinical Trials as Topic; Diet; Europe; France; Gene Expression Regulation, Neoplastic; Humans; Incidence; Mice; Mice, Inbred A; Neoplasms; Resveratrol; Stilbenes; Wine

2007
Radiation combined with antiangiogenic and antivascular agents.
    Seminars in radiation oncology, 2006, Volume: 16, Issue:1

    Angiogenesis is critical for a number of physiologic and pathophysiologic processes, and angiogenesis inhibitors are now being used in the treatment of cancer. Although antiangiogenic agents offer great therapeutic potential, preclinical and clinical trial results suggest that these agents will have a delayed onset of activity and may only induce disease stabilization for patients with advanced malignancy. The use of radiation therapy for cancer is also associated with therapeutic challenges that are distinct from those that might be expected with antiangiogenic agents. Thus, the use of angiogenesis inhibitors in combination with radiation therapy should help to overcome the limitations of each leading to enhanced efficacy and diminished toxicity. The goal of this review is to provide an overview and discussion of the combination of angiogenesis inhibitors with radiation therapy.

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Humans; Neoplasms; Organophosphorus Compounds; Stilbenes; Vascular Endothelial Growth Factor A

2006
A review of the effects and mechanisms of polyphenolics in cancer.
    Critical reviews in food science and nutrition, 2006, Volume: 46, Issue:2

    This paper is a comprehensive review of the effects of bioactive polyphenolic compounds commonly found in many fruits and vegetables on cancer. These include the pheniolic acids, anthocyanins, catechins, stilbenes and several other flavonoids. We have attempted to compile information from most of the major studies in this area into one source. The review encompasses the occurrence and bioavailability of the polyphenolics, the in vitro and in vivo evidence for their effects on cancer, both positive and negative, and the various mechanisms by which the chemicals may exert their effects. Although most of the work done to date indicates a chemopreventative activity of these compounds, there are some studies that show cancer-inducing or no effects. There are several common mechanisms by which these chemicals exert their effects that could be conducive to additive, synergistic, or antagonistic interactions. These include effects on cellular differentiation, proliferation, and apoptosis, effects on proteins and enzymes that are involved in these processes at a molecular level, and other various effects through altered immune function and chemical metabolism.

    Topics: Animals; Anthocyanins; Biological Availability; Catechin; Cell Line, Tumor; Chemoprevention; Flavonoids; Flavonols; Fruit; Humans; Neoplasms; Phenols; Polyphenols; Stilbenes; Vegetables

2006
Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer.
    Current drug targets, 2006, Volume: 7, Issue:4

    Resveratrol (3,4',5 tri-hydroxystilbene) is a phytoalexin produced in hudge amount in grapevine skin in response to infection by Bothrytis cinerea. This production of resveratrol blocks the proliferation of the pathogen, thereby acting as a natural antibiotic. Numerous studies have reported interesting properties of trans-resveratrol as a preventive agent against important pathologies i.e. vascular diseases, cancers, viral infection or neurodegenerative processes. Moreover, several epidemiological studies have revealed that resveratrol is probably one of the main microcomponents of wine responsible for its health benefits such as prevention of vaso-coronary diseases and cancer. Resveratrol acts on the process of carcinogenesis by affecting the three phases: tumor initiation, promotion and progression phases and suppresses the final steps of carcinogenesis, i.e. angiogenesis and metastasis. It is also able to activate apoptosis, to arrest the cell cycle or to inhibit kinase pathways. Interestingly, resveratrol does not present any cytotoxicity in animal models. Moreover, concentrations of resveratrol in blood seem to be sufficient for anti-invasive activity. The enterohepatic recirculation may contribute to a delayed elimination of the drug from the body and bring about a prolonged effect. By its binding to plasmatic proteins, resveratrol also exhibits a prolonged effect. Interestingly, low doses of resveratrol can sensitize to low doses of cytotoxic drugs and so provide an innovative strategy to enhance the efficacy of anticancer therapy in various human cancers. By these properties, resveratrol appears to be a good candidate in chemopreventive or chemotherapeutic strategies and is believed to be a novel weapon for new therapeutic strategies.

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Cell Cycle; Humans; Neoplasms; Radiation-Sensitizing Agents; Resveratrol; Stilbenes

2006
Therapeutic potential of resveratrol: the in vivo evidence.
    Nature reviews. Drug discovery, 2006, Volume: 5, Issue:6

    Resveratrol, a constituent of red wine, has long been suspected to have cardioprotective effects. Interest in this compound has been renewed in recent years, first from its identification as a chemopreventive agent for skin cancer, and subsequently from reports that it activates sirtuin deacetylases and extends the lifespans of lower organisms. Despite scepticism concerning its bioavailability, a growing body of in vivo evidence indicates that resveratrol has protective effects in rodent models of stress and disease. Here, we provide a comprehensive and critical review of the in vivo data on resveratrol, and consider its potential as a therapeutic for humans.

    Topics: Aging; Animals; Heart Diseases; Humans; Inflammation; Myocardial Infarction; Neoplasms; Protective Agents; Resveratrol; Stilbenes; Stroke

2006
[Resveratrol--evaluation of anticancer activity].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2006, Volume: 20, Issue:117

    Resveratrol (3, 4',5-trihydroxystilbene) is a natural polyphenol isolated from many plants widely used in human diet e.g. in grapes and red wine. Many experimental studies have revealed the resveratrol ability to interfere with all the stages of carcinogenesis to suppress growth of many chemical-induced and spontaneous tumors in normal and transgenic rodents. Furthermore, the substance inhibited local growth and dissemination of some transplantable tumors in laboratory animals. Due to its valuable biological properties and lack of significant side effects after long-term administration it seems that resveratrol is one of the most promising agent which could be applied in the feature in cancer prevention and therapy in humans.

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Evaluation Studies as Topic; Humans; Neoplasm Transplantation; Neoplasms; Plant Extracts; Resveratrol; Stilbenes; Wine

2006
Current development status of small-molecule vascular disrupting agents.
    Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:6

    There is increasing interest in small-molecule drugs that can selectively disrupt the abnormal vasculature associated with disease processes such as cancer and macular degeneration. These agents are distinct from anti-angiogenic strategies, which do not target existing vessels but prevent additional vessel growth, althouglh they may potentially be complimentary with these antiangiogenic strategies. Several vascular disrupting agents (VDAs) are now undergoing clinical evaluation. The main focus of research has been on two drug classes: the first is comprised of agents that bind reversibly with tubulin and prevent microtubule assembly; the second are the flavanoids, which can induce intratumor cytokine release. Data from phase I studies have established that these agents can selectively reduce tumor blood flow at well-tolerated doses. Preclinical data indicate that VDAs can improve the tumor response to cytotoxic chemotherapy, radiation and antiangiogenic treatments. This activity has been attributed to the ability of these agents to selectively destroy the central regions of tumors, areas widely believed to contain cell populations resistant to cytotoxic therapies. The VDA compounds combretastatin A4 phosphate (CA4P) and 5,6-dimethylxantlenone-4-acetic acid (DMXAA) are being evaluated in phase II clinical trials in combination with conventional cytotoxic therapies for the potential treatment of cancer. This review discusses the small-molecule VDAs in clinical development. In addition, the potential for combination therapy with VDAs and traditional anticancer therapies, such as radiation, chemotherapy and anti-angiogenics is described.

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; Drug Therapy, Combination; Humans; Neoplasms; Neovascularization, Pathologic; Regional Blood Flow; Stilbenes; Tubulin Modulators; Xanthones

2006
The roles of polyphenols in cancer chemoprevention.
    BioFactors (Oxford, England), 2006, Volume: 26, Issue:2

    Oxidative stress imposed by reactive oxygen species (ROS) plays a crucial role in the pathophysiology associated with neoplasia, atherosclerosis, and neurodegenerative diseases. The ROS-induced development of cancer involves malignant transformation due to altered gene expression through epigenetic mechanisms as well as DNA mutations. Considerable attention has been focused on identifying naturally occurring antioxidative phenolic phytochemicals that are able to decrease ROS levels, but the efficacies of antioxidant therapies have been equivocal at best. Several studies have shown that some antioxidants exhibit prooxidant activity under certain conditions and potential carcinogenicity under others, and that dietary supplementation with large amounts of a single antioxidant may be deleterious to human health. This article reviews the intracellular signaling pathways that respond to oxidative stress and how they are modulated by naturally occurring polyphenols. The possible toxicity and carcinogenicity of polyphenols is also discussed.

    Topics: Animals; Anticarcinogenic Agents; Antioxidants; Carcinogens; Catechin; Cell Communication; Cyclooxygenase Inhibitors; Diet; Flavonoids; Gap Junctions; Genistein; Humans; Matrix Metalloproteinases; Neoplasms; Oxidative Stress; Phenols; Polyphenols; Prostaglandin-Endoperoxide Synthases; Quercetin; Reactive Oxygen Species; Resveratrol; Signal Transduction; Stilbenes

2006
Resveratrol modulation of signal transduction in apoptosis and cell survival: a mini-review.
    Cancer detection and prevention, 2006, Volume: 30, Issue:3

    There is mounting evidence in the literature that resveratrol is a promising natural compound for prevention and treatment of a variety of human cancers. This overview summarizes recent studies of the major apoptosis and survival pathways regulated by resveratrol.. Apoptosis or programmed cell death is a key regulator of tissue homeostasis during normal development and also in adult organism under various conditions including adaptive responses to cellular stress. For example, tissue homeostasis is maintained by tight control of signaling events regulating cell death and survival. Thus, uncontrolled proliferation or failure to undergo cell death is involved in pathogenesis and progression of many human diseases, for example in tumorigenesis or in cardiovascular disorders. Moreover, current cancer therapies primarily act by triggering apoptosis programs in cancer cells.. Natural products such as resveratrol have gained considerable attention as cancer chemopreventive or cardioprotective agents and also because of their antitumor properties. Among its wide range of biological activities, resveratrol has been reported to interfere with many intracellular signaling pathways, which regulate cell survival or apoptosis.. Further insights into the signaling network and interaction points modulated by resveratrol may provide the basis for novel drug discovery programs to exploit resveratrol for the prevention and treatment of human diseases.

    Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Cell Survival; Humans; Inhibitor of Apoptosis Proteins; MAP Kinase Signaling System; Microtubule-Associated Proteins; Mitochondria; Models, Biological; Neoplasm Proteins; Neoplasms; NF-kappa B; Protein-Tyrosine Kinases; Resveratrol; Signal Transduction; Stilbenes; Survivin

2006
Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs.
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:9

    Anthracyclines are a well-known cause of cardiotoxicity, but a number of other drugs used to treat cancer can also result in cardiac and cardiovascular adverse effects. Cardiotoxicity can result in the alteration of cardiac rhythm, changes in blood pressure and ischemia, and can also alter the ability of the heart to contract and/or relax. The clinical spectrum of these toxicities can range from subclinical abnormalities to catastrophic life-threatening, and sometimes fatal, sequelae. These events may occur acutely or may only become apparent months or years following completion of oncological treatment. Ischemia and rhythm abnormalities are treated symptomatically in most cases. Knowledge of these toxicities can aid clinicians to choose the optimal and least toxic regimen suitable for an individual patient.

    Topics: Anthracyclines; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cardiovascular Diseases; Heart Diseases; Humans; Interferons; Interleukin-2; Neoplasms; Oxides; Stilbenes; Tretinoin

2006
The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2006, Volume: 9, Issue:6

    A major challenge in cancer therapy is tumor drug resistance. To overcome it, it is essential to understand the mechanisms and identify the molecules involved, so that they can be specifically targeted in combination therapies. The proteasome is such a validated target: it plays a key role in cancer cell proliferation, inhibition of chemotherapy-induced apoptosis and drug resistance development. Bortezomib (Velcade, PS-341) was the first proteasome inhibitor to receive regulatory approval from the US Food and Drug Administration for the treatment of multiple myeloma. Clinical combination trials have demonstrated a chemo-sensitizing effect of bortezomib on conventional agents in hematological malignancies and some solid tumors such as androgen-independent prostate and ovarian cancer. Although generally well-tolerated, bortezomib still generates toxicity which underscores the need for less toxic proteasome inhibitors. Several naturally occurring products, such as green tea polyphenols and the antibiotic lactacystin, have been shown to be potent proteasome inhibitors. Significantly, green tea polyphenols, as well as several flavonoids such as genistein, curcumin and resveratrol, have also been shown to have chemo-sensitizing properties in prostate, breast, hepatic, and lung tumors. Further studies on natural proteasome inhibitors as chemo-sensitizers could lead to identification of more potent and less toxic compounds that could be used in combination therapies for drug-resistant tumors.

    Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Catechin; Clinical Trials as Topic; Curcumin; Drug Resistance, Neoplasm; Drug Therapy, Combination; Genistein; Humans; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Radiation-Sensitizing Agents; Resveratrol; Stilbenes; Structure-Activity Relationship; Ubiquitin

2006
Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy.
    Advanced drug delivery reviews, 2005, Jan-02, Volume: 57, Issue:1

    The blood supply of solid tumours affects the outcome of treatment via its influence on the microenvironment of tumour cells and drug delivery. In addition, tumour blood vessels are an important target for cancer therapy. Intravital microscopy of tumours growing in 'window chambers' in animal models provides a means of directly investigating tumour angiogenesis and vascular response to treatment, in terms of both the morphology of blood vessel networks and the function of individual vessels. These techniques allow repeated measurements of the same tumour. Recently, multi-photon fluorescence microscopy techniques have been applied to these model systems to obtain 3D images of the tumour vasculature, whilst simultaneously avoiding some of the problems associated with the use of conventional fluorescence microscopy in living tissues. Here, we review the current status of this work and provide some examples of its use for studying the dynamics of tumour angiogenesis and vascular function.

    Topics: Animals; Anisoles; Drug Delivery Systems; Humans; Microcirculation; Microscopy, Fluorescence, Multiphoton; Neoplasms; Stilbenes; Technology, Pharmaceutical

2005
Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds.
    Current oncology reports, 2005, Volume: 7, Issue:2

    Novel anticancer compounds are being developed that attempt to exploit the unique properties of the vascular endothelium, which supplies rapidly dividing neoplasms. The goal of these vascular targeting agents (VTAs) or endothelial disrupting agents is to cause rapid shutdown of tumor blood supply with subsequent tumor death from hypoxia and nutrient deprivation. VTAs are classified into two broad categories: biologic therapies or small molecule compounds. A variety of VTAs are in early clinical development. These agents have demonstrated clinical activity in phase I trials and are being evaluated with cytotoxic chemotherapy and radiotherapy.

    Topics: Antineoplastic Agents, Phytogenic; Clinical Trials, Phase I as Topic; Endothelium, Vascular; Humans; Neoplasms; Organophosphorus Compounds; Stilbenes; Xanthones

2005
Nutraceuticals as anti-angiogenic agents: hopes and reality.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2005, Volume: 56 Suppl 1

    Angiogenesis, the formation of new blood vessels from preexisting vascular network is a driving force of organ development in ontogeny, is necessary for ovulation and hair growth, and is prerequisite for proper wound healing. It is also a critical mechanism of numerous diseases, the most important of which are cancer and atherosclerosis. Therefore, modulation of angiogenesis is considered as therapeutic strategies of great importance for human health. Numerous bioactive plant compounds, often referred to as nutraceuticals are recently tested for the potential clinical applications. Among the most frequently studied are resveratrol, a polyphenol present in red-wine and grape-seed, epigallocatechin-3-gallate (EGCG) from green tea and curcumin from Curcuma longa. It is also possible that components of other plants, including the constituents of local food diet may find application for modulation of angiogenesis, provided that their effectiveness will be confirmed in controlled, scientifically validated trials.

    Topics: Angiogenesis Inhibitors; Animals; Atherosclerosis; Catechin; Curcumin; Dietary Supplements; Flavonoids; Humans; Neoplasms; Neovascularization, Pathologic; Phenols; Polyphenols; Resveratrol; Stilbenes; Vascular Endothelial Growth Factor A

2005
Disrupting tumour blood vessels.
    Nature reviews. Cancer, 2005, Volume: 5, Issue:6

    Low-molecular-weight vascular-disrupting agents (VDAs) cause a pronounced shutdown in blood flow to solid tumours, resulting in extensive tumour-cell necrosis, while they leave the blood flow in normal tissues relatively intact. The largest group of VDAs is the tubulin-binding combretastatins, several of which are now being tested in clinical trials. DMXAA (5,6-dimethylxanthenone-4-acetic acid) - one of a structurally distinct group of drugs - is also being tested in clinical trials. A full understanding of the action of these and other VDAs will provide insights into mechanisms that control tumour blood flow and will be the basis for the development of new therapeutic drugs for targeting the established tumour vasculature for therapy.

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Capillary Permeability; Clinical Trials as Topic; Endothelial Cells; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes; Xanthones

2005
Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700).
    Chemotherapy, 2005, Volume: 51, Issue:6

    Despite extensive research efforts, effective therapies for refractive cancers have not yet been established, and development of successful treatment strategies remains the most important task in the field of oncology. We recently showed that AVE8062 (formerly AC7700), a derivative of combretastatin A-4, achieved irreversible stasis of tumor blood flow (TBF), thereby causing necrosis of tumor tissue by halting the supply of nutrients. Such effects were unrelated to cancer type. In this review, we summarize our experiments on antivascular and antitumor effects by AVE8062. We maintain that such starvation tactics against solid tumors constitute a new therapeutic strategy for all solid tumors, including refractory cancers.

    Topics: Animals; Antineoplastic Agents; Microcirculation; Neoplasms; Rats; Regional Blood Flow; Serine; Stilbenes

2005
Vascular targeting agents as cancer therapeutics.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-15, Volume: 10, Issue:2

    Vascular targeting agents (VTAs) for the treatment of cancer are designed to cause a rapid and selective shutdown of the blood vessels of tumors. Unlike antiangiogenic drugs that inhibit the formation of new vessels, VTAs occlude the pre-existing blood vessels of tumors to cause tumor cell death from ischemia and extensive hemorrhagic necrosis. Tumor selectivity is conferred by differences in the pathophysiology of tumor versus normal tissue vessels (e.g., increased proliferation and fragility, and up-regulated proteins). VTAs can kill indirectly the tumor cells that are resistant to conventional antiproliferative cancer therapies, i.e., cells in areas distant from blood vessels where drug penetration is poor, and hypoxia can lead to radiation and drug resistance. VTAs are expected to show the greatest therapeutic benefit as part of combined modality regimens. Preclinical studies have shown VTA-induced enhancement of the effects of conventional chemotherapeutic agents, radiation, hyperthermia, radioimmunotherapy, and antiangiogenic agents. There are broadly two types of VTAs, small molecules and ligand-based, which are grouped together, because they both cause acute vascular shutdown in tumors leading to massive necrosis. The small molecules include the microtubulin destabilizing drugs, combretastatin A-4 disodium phosphate, ZD6126, AVE8062, and Oxi 4503, and the flavonoid, DMXAA. Ligand-based VTAs use antibodies, peptides, or growth factors that bind selectively to tumor versus normal vessels to target tumors with agents that occlude blood vessels. The ligand-based VTAs include fusion proteins (e.g., vascular endothelial growth factor linked to the plant toxin gelonin), immunotoxins (e.g., monoclonal antibodies to endoglin conjugated to ricin A), antibodies linked to cytokines, liposomally encapsulated drugs, and gene therapy approaches. Combretastatin A-4 disodium phosphate, ZD6126, AVE8062, and DMXAA are undergoing clinical evaluation. Phase I monotherapy studies have shown that the agents are tolerated with some demonstration of single agent efficacy. Because efficacy is expected when the agents are used with conventional chemotherapeutic drugs or radiation, the results of Phase II combination studies are eagerly awaited.

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Cell Division; Clinical Trials as Topic; Diphosphates; Genetic Therapy; Humans; Hypoxia; Immunotoxins; Ligands; Models, Biological; Necrosis; Neoplasms; Organophosphorus Compounds; Peptides; Radioimmunotherapy; Stilbenes; Time Factors; Up-Regulation; Xanthones

2004
Combretastatin A4 phosphate.
    Anti-cancer drugs, 2004, Volume: 15, Issue:3

    Combretastatin A4 phosphate (CA4P) is a water-soluble prodrug of combretastatin A4 (CA4). The vascular targeting agent CA4 is a microtubule depolymerizing agent. The mechanism of action of the drug is thought to involve the binding of CA4 to tubulin leading to cytoskeletal and then morphological changes in endothelial cells. These changes increase vascular permeability and disrupt tumor blood flow. In experimental tumors, anti-vascular effects are seen within minutes of drug administration and rapidly lead to extensive ischemic necrosis in areas that are often resistant to conventional anti-cancer treatments. Following single-dose administration a viable tumor rim typically remains from which tumor regrowth occurs. When given in combination with therapies targeted at the proliferating viable rim, enhanced tumor responses are seen and in some cases cures. Results from the first clinical trials have shown that CA4P monotherapy is safe and reduces tumor blood flow. There has been some promising demonstration of efficacy. CA4P in combination with cisplatin is also safe. Functional imaging studies have been used to aid the selection of doses for phase II trials. Both dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and positron emission tomography can measure the anti-vascular effects of CA4P in humans. This review describes the background to the development of CA4P, its proposed mechanism of action, the results from the first clinical trials with CA4P and the role of imaging techniques in its clinical development.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes; Technology, Pharmaceutical

2004
Combretastatin A4 phosphate: background and current clinical status.
    Expert opinion on investigational drugs, 2004, Volume: 13, Issue:9

    Combretastatin A4 phosphate (CA4P) represents the lead compound in a group of novel tubulin depolymerising agents being developed as vascular targeting agents (VTAs). VTAs are drugs that induce rapid and selective vascular dysfunction in tumours. CA4P is a water-soluble prodrug of the cis-stilbene CA4 originally isolated from the tree Combretum caffrum. Preclinical studies have shown that CA4P induces blood flow reductions and subsequent tumour cell death in a variety of preclinical models. Moreover, this activity has been linked to its ability to rapidly alter the morphology of immature endothelial cells by disrupting their tubulin cytoskeleton. Phase I clinical trials have established a maximum tolerated dose in the range 60-68 mg/m2 and in addition have established that significant changes to tumour perfusion can be achieved across a wide range of doses. The dose-limiting toxicities include tumour pain, ataxia and cardiovascular changes. The maximum tolerated dose was independent of schedule, indicating the absence of cumulative toxicity. Although unexpected from preclinical studies, some evidence of clinical response was seen using CA4P as a single modality. Based on the Phase I data, combination studies of CA4P with established therapies are in progress and should determine whether the exciting preclinical data obtained when VTAs are used in combination with cytotoxic chemotherapy, radiation, radioimmunotherapy and even antiangiogenic agents, can be translated into man.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes

2004
Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets.
    Mutation research, 2004, Nov-02, Volume: 555, Issue:1-2

    Recently, chemoprevention by the use of naturally occurring substances is considered as a priority to reduce the ever-increasing incidence of cancer. The intervention of multistage carcinogenesis by modulating intracellular signaling pathways may provide molecular basis of chemoprevention with a wide variety of dietary phytochemicals. Resveratrol, a red wine polyphenol, has been studied extensively for the chemopreventive activity in the context of its ability to interfere with the multistage carcinogenesis. Numerous intracellular signaling cascades converge with the activation of nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1), which act independently or coordinately to regulate expression of target genes. These ubiquitous eukaryotic transcription factors mediate pleiotropic effects on cellular transformation and tumor promotion. This review aims to update the molecular mechanisms underlying chemoprevention by resveratrol with special focus on its effect on cellular signaling cascades mediated by NF-kappaB and AP-1.

    Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Chemoprevention; Humans; Neoplasms; NF-kappa B; Resveratrol; Signal Transduction; Stilbenes; Transcription Factor AP-1

2004
Chemotherapeutic potential of the chemopreventive phytoalexin resveratrol.
    Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2004, Volume: 7, Issue:6

    The last couple of decades have seen a tremendous increase in interest in the biological properties of natural products as a means to identify novel small compounds that could have potential in clinical medicine. To that end, flavonoids- and flavonoid-like compounds percolate to the top due to their presence in diet constituents and reported beneficial effects on diverse biological processes and disease conditions. As such, the plant polyphenolic antibiotic resveratrol, found in grapes, nuts and wines, has been the focus of many studies aimed at understanding its full range of health beneficial effects. The interest in this compound stems from the earlier observations describing the therapeutic benefits of roots of the oriental medicinal plant from which resveratrol was first isolated. Being a constituent of grapes and wines, the initial work was focused on linking resveratrol to the beneficial cardiovascular effects of moderate wine intake, however, since its reported cancer chemopreventive activity in a murine model of carcinogenesis, there has been a heightened interest in understanding the anti-cancer activity of resveratrol. As a result, a substantial amount of data strongly suggests that resveratrol could affect the process of carcinogenesis through a variety of different mechanisms in different tumor cell types. However, a couple of recent reports provide evidence to the contrary. This critical review attempts to summarize some of these findings and discuss the clinical potential of this compound or its derivatives in the light of the recent conflicting reports.

    Topics: Animals; Anticarcinogenic Agents; Apoptosis; Biological Availability; Cell Line, Tumor; Humans; Neoplasms; Phytoalexins; Plant Extracts; Resveratrol; Sesquiterpenes; Stilbenes; Terpenes

2004
Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities.
    Current medicinal chemistry. Anti-cancer agents, 2003, Volume: 3, Issue:2

    The polyphenolic compound Resveratrol is a naturally occurring phytochemical and can be found in many plant species, including grapes, peanuts and various herbs. Several studies have established that Resveratrol can exert anti-oxidant and anti-inflammatory activities. It also has activity in the regulation of multiple cellular events associated with carcinogenesis. This review describes the general properties of Resveratrol including its relationship to estrogen, its effect on lipid metabolism, its cardiovascular effects, and its role on gene expression. Resveratrol has also been examined in several model systems for its potential effect against cancer. Its anti-cancer effects include its role as a chemopreventive agent, its ability to inhibit cell proliferation, its direct effect in cytotoxicity by induction of apoptosis and on its potential therapeutic effect in pre-clinical studies. In addition, Resveratrol has been shown to exert sensitization effects on cancer cells that will result in a synergistic cytotoxic activity when Resveratrol is used in combination with cytotoxic drugs in drug-resistant tumor cells. Clearly, the studies with Resveratrol provide support for the use of Resveratrol in human cancer chemoprevention and combination with chemotherapeutic drugs or cytotoxic factors in the treatment of drug refractory tumor cells.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Humans; Neoplasms; Resveratrol; Stilbenes

2003
Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review).
    International journal of oncology, 2003, Volume: 23, Issue:1

    Cancer, next only to heart diseases, is the second leading cause of deaths in the United States of America and many other nations in the world. The prognosis for a patient with metastatic carcinoma of the lung, colon, breast, or prostate (four of the most common and lethal forms of cancer, which together account for more than half of all deaths from cancer in the USA), remains dismal. Conventional therapeutic and surgical approaches have not been able to control the incidence of most of the cancer types. Therefore, there is an urgent need to develop mechanism-based approaches for the management of cancer. Chemoprevention via non-toxic agents could be one such approach. Many naturally occurring agents have shown cancer chemopreventive potential in a variety of bioassay systems and animal models, having relevance to human disease. It is appreciated that an effective and acceptable chemopreventive agent should have certain properties: (a), little or no toxic effects in normal and healthy cells; (b), high efficacy against multiple sites; (c), capability of oral consumption; (d), known mechanism of action; (e), low cost; and (f), acceptance by human population. Resveratrol is one such agent. A naturally occurring polyphenolic antioxidant compound present in grapes, berries, peanuts and red wine. In some bioassay systems resveratrol has been shown to afford protection against several cancer types. The mechanisms of resveratrol's broad cancer chemopreventive effects are not completely understood. In this review, we present the cancer chemopreventive effects of resveratrol in an organ-specific manner. The mechanisms of the antiproliferative/cancer chemopreventive effects of resveratrol are also presented. We believe that continued efforts are needed, especially well-designed pre-clinical studies in the animal models that closely mimic/represent human disease, to establish the usefulness of resveratrol as cancer chemopreventive agent. This should be followed by human clinical trials in appropriate cancer types in suitable populations.

    Topics: Animals; Anticarcinogenic Agents; Cell Line, Tumor; Diet; Humans; In Vitro Techniques; Models, Chemical; Neoplasms; Resveratrol; Stilbenes

2003
From sandwiches to center stage. Peanuts pack a powerful nutritional punch.
    Advance for nurse practitioners, 2003, Volume: 11, Issue:7

    Topics: Arachis; Coronary Disease; Fatty Acids, Monounsaturated; Health Promotion; Humans; Menu Planning; Neoplasms; Phytosterols; Resveratrol; Stilbenes; Stroke

2003
Pleiotropic effects of resveratrol.
    Drug news & perspectives, 2003, Volume: 16, Issue:5

    Resveratrol, a phytoalexin found in red wine, has several pharmacological properties which include inhibition of arachidonate metabolism in leukocytes and platelets, modulation of lipid metabolism, inhibition of platelet aggregation and lipid peroxidation, reduction of expression and activity of cyclooxygenase-2. Resveratrol induces cell cycle arrest at S/G(2) phase transition and a pro-apoptotic cell death in several types of cancer cells. All these biological activities help to explain the vasorelaxing, anticancer and antiinflammatory activity of resveratrol. This article summarizes the wide range of biological activities of resveratrol in three disease states: cancer, coronary heart disease and pain. In addition, the mechanisms underlying these promising properties of resveratrol are also reviewed.

    Topics: Antineoplastic Agents, Phytogenic; Coronary Disease; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Gene Expression; Isoenzymes; Neoplasms; Pain; Prostaglandin-Endoperoxide Synthases; Resveratrol; Stilbenes

2003
Wine and resveratrol: mechanisms of cancer prevention?
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2003, Volume: 12, Issue:5

    Low alcohol consumption seems to decrease total mortality and to have beneficial properties on cardiovascular disease; data for cancer are still inconclusive. There is evidence that wine consumption decreases the risk of cancer at several sites, including cancer of upper digestive tract, lung, colon, basal cell carcinoma, and non-Hodgkin lymphoma. The presence of resveratrol, a polyphenol specifically present in red wine, may contribute to these cancer preventive effects. Resveratrol in fact inhibits the metabolic activation of carcinogens, has antioxidant and anti-inflammatory properties, decreases cell proliferation and induces apoptosis. Data on the availability of resveratrol in vivo are however still lacking. Although regular consumption of one or two glasses of wine seems reasonably safe from the health point of view, a recommendation to the general population for low wine consumption is not justified.

    Topics: Alcohol Drinking; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Chemoprevention; Humans; Mortality; Neoplasms; Resveratrol; Risk Factors; Stilbenes; Wine

2003
Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2003, Volume: 12, Issue:10

    Topics: Angiogenesis Inhibitors; Animals; Anticarcinogenic Agents; Biological Availability; Humans; Neoplasms; Palliative Care; Phenols; Resveratrol; Ribonucleotide Reductases; Rodentia; Stilbenes; Vasodilator Agents

2003
Recent advances in the field of tubulin polymerization inhibitors.
    Expert review of anticancer therapy, 2002, Volume: 2, Issue:6

    In recent years, enormous progress has been made in the field of tubulin targeting agents. Several companies and academic laboratories have entered this field and competition has become very strong. Nevertheless, clinically promising compounds often face substantial limitations, such as high systemic toxicity, poor water solubility and bioavailability, as well as complex synthesis and isolation procedures. As a drawback of established drugs, like paclitaxel or the vinca alkaloids, the outcome of cancer chemotherapy is often affected by the emergence of the multidrug resistance phenotype. Among the recently disclosed tubulin polymerization inhibitors, there are several interesting low molecular weight compounds with improved oral bioavailability and demonstrated activity against multi-drug resistance positive phenotypes. As documented by the imidazole-based combretastatin analogs, to name just one example, chemical optimization of a lead structure resulted in compounds with potent in vitro and in vivo activity along with appropriate pharmacodynamic and pharmacokinetic requirements for a potential therapeutic candidate. Currently, several compounds are undergoing Phase I or Phase II clinical trials, among them orally bioavailable sulfonamides or dolastatin 10. Several other compounds are close to entering Phase I trials. The purpose of this review is to focus on the most recent advances in tubulin polymerization inhibitors from a survey of the published patent literature and related publications between late 1999 and April 2002. However, biological data, especially for the inhibition of tubulin polymerization, obtained from different laboratories cannot easily be compared.

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Biological Factors; Drug Design; Humans; Neoplasms; Protein Binding; Stilbenes; Tubulin; Tubulin Modulators

2002
Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer.
    The American journal of medicine, 2002, Dec-30, Volume: 113 Suppl 9B

    "Bioactive compounds" are extranutritional constituents that typically occur in small quantities in foods. They are being intensively studied to evaluate their effects on health. The impetus sparking this scientific inquiry was the result of many epidemiologic studies that have shown protective effects of plant-based diets on cardiovascular disease (CVD) and cancer. Many bioactive compounds have been discovered. These compounds vary widely in chemical structure and function and are grouped accordingly. Phenolic compounds, including their subcategory, flavonoids, are present in all plants and have been studied extensively in cereals, legumes, nuts, olive oil, vegetables, fruits, tea, and red wine. Many phenolic compounds have antioxidant properties, and some studies have demonstrated favorable effects on thrombosis and tumorogenesis and promotion. Although some epidemiologic studies have reported protective associations between flavonoids or other phenolics and CVD and cancer, other studies have not found these associations. Various phytoestrogens are present in soy, but also in flaxseed oil, whole grains, fruits, and vegetables. They have antioxidant properties, and some studies demonstrated favorable effects on other CVD risk factors, and in animal and cell culture models of cancer. However, because phytoestrogens act both as partial estrogen agonists and antagonists, their effects on cancer are likely complex. Hydroxytyrosol, one of many phenolics in olives and olive oil, is a potent antioxidant. Resveratrol, found in nuts and red wine, has antioxidant, antithrombotic, and anti-inflammatory properties, and inhibits carcinogenesis. Lycopene, a potent antioxidant carotenoid in tomatoes and other fruits, is thought to protect against prostate and other cancers, and inhibits tumor cell growth in animals. Organosulfur compounds in garlic and onions, isothiocyanates in cruciferous vegetables, and monoterpenes in citrus fruits, cherries, and herbs have anticarcinogenic actions in experimental models, as well as cardioprotective effects. In summary, numerous bioactive compounds appear to have beneficial health effects. Much scientific research needs to be conducted before we can begin to make science-based dietary recommendations. Despite this, there is sufficient evidence to recommend consuming food sources rich in bioactive compounds. From a practical perspective, this translates to recommending a diet rich in a variety of fruits, vegetables, whole grains, le

    Topics: Antioxidants; Cardiovascular Diseases; Carotenoids; Chronic Disease; Dietary Fiber; Estrogens, Non-Steroidal; Food; Humans; Isoflavones; Isothiocyanates; Lycopene; Monoterpenes; Neoplasms; Olive Oil; Phenols; Phytoestrogens; Phytosterols; Plant Oils; Plant Preparations; Resveratrol; Stilbenes; Tea

2002
Structural concepts in cancer prevention.
    European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2002, Volume: 11 Suppl 2

    The notion of developing cancer preventative strategies is attractive both from a public health and from a health economic viewpoint. However, as currently visualized, this may involve dietary supplementation of publicly available foods or the ingestion of specific supplements for prolonged periods of time. In view of the fact that the outcome of such preventative strategies may as yet not be known, it is essential that the strategy is devoid of risks. Structure-activity relationship (SAR) concepts can be of use in identifying possible health hazards associated with chemoprevention. Overall, SAR can be used (1) to predict the chemopreventative potential of a chemical and to understand its mechanism of action, (2) to evaluate the toxicological liabilities of such agents and (3) to design molecules with enhanced chemopreventative potency and decreased (or abolished) toxicity. While SAR techniques currently available are appropriate to achieve these aims, the primary block to their widespread deployment is lack of sufficient experimental data of acceptable quality to perform SAR modeling. The present report analyzes the current applicability of SAR methods to cancer chemoprevention.

    Topics: Anticarcinogenic Agents; Chemoprevention; Clinical Trials as Topic; Female; Humans; Male; Mass Screening; Neoplasms; Prognosis; Resveratrol; Risk Assessment; Sensitivity and Specificity; Stilbenes; Structure-Activity Relationship

2002
The basis for the chemopreventive action of resveratrol.
    Drugs of today (Barcelona, Spain : 1998), 2002, Volume: 38, Issue:8

    The polyphenolic phytoalexin resveratrol (3,5,4'- trihydroxy-trans-stilbene) is produced, perhaps primarily, as a natural fungicide by more than 70 plant species, and can be found in high to moderate quantities in various foods including grapes, peanuts and wine. Recent in vitro and a limited number of in vivo studies have documented that physiological concentrations of resveratrol can modulate multiple molecular pathways thought to be associated with the development and progression of cardiovascular disease and cancer, among them phase II drug metabolizing, cyclooxygenase, lipid metabolizing, nitric oxide, DNA-synthesis, inflammation, cell survival, cell death and cell division cycle pathways. Work on the mechanisms underlying the cytostatic activities, which appear to affect all dividing tissues, and the cytotoxic activities of the compound, which seem to preferentially target tumor cells, has produced some controversial and, at times, seemingly conflicting results. The present review attempts to integrate some of the established biochemical activities of resveratrol into a common framework of function in an attempt to understand precisely how the compound affects cell proliferation and survival.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cardiovascular Diseases; Humans; Neoplasms; Resveratrol; Stilbenes

2002
Resveratrol and cancer: a review.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2002, Volume: 56, Issue:2

    The various properties of the stilbene phytoalexin Resveratrol provide interesting new avenues of research in the field of chemoprevention and chemotherapy. A particular emphasis is given on xenobiotic-related carcinogenesis.

    Topics: Antineoplastic Agents, Phytogenic; Estrogens; Humans; Neoplasms; Polygonum; Receptors, Estrogen; Resveratrol; Stilbenes; Xenobiotics

2002
The biology of the combretastatins as tumour vascular targeting agents.
    International journal of experimental pathology, 2002, Volume: 83, Issue:1

    The tumour vasculature is an attractive target for therapy. Combretastatin A-4 (CA-4) and A-1 (CA-1) are tubulin binding agents, structurally related to colchicine, which induce vascular-mediated tumour necrosis in animal models. CA-1 and CA-4 were isolated from the African bush willow, Combretum caffrum, and several synthetic analogues are also now available, such as the Aventis Pharma compound, AVE8062. More soluble, phosphated, forms of CA-4 (CA-4-P) and CA-1 (CA-1-P) are commonly used for in vitro and in vivo studies. These are cleaved to the natural forms by endogenous phosphatases and are taken up into cells. The lead compound, CA-4-P, is currently in clinical trial as a tumour vascular targeting agent. In animal models, CA-4-P causes a prolonged and extensive shut-down of blood flow in established tumour blood vessels, with much less effect in normal tissues. This paper reviews the current understanding of the mechanism of action of the combretastatins and their therapeutic potential.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Endothelium, Vascular; Humans; Neoplasms; Neovascularization, Pathologic; Stilbenes

2002
Cancer chemopreventive activity of resveratrol.
    Annals of the New York Academy of Sciences, 2002, Volume: 957

    Cancer chemopreventive agents are designed to reduce the incidence of tumorigenesis by intervening at one or more stages of carcinogenesis. Recently, resveratrol, a natural product found in the diet of humans, has been shown to function as a cancer chemopreventive agent. Resveratrol was first shown to act as an antioxidant and antimutagenic agent, thus acting as an anti-initiation agent. Further evidence indicated that resveratrol selectively suppresses the transcriptional activation of cytochrome P-450 1A1 and inhibits the formation of carcinogen-induced preneoplastic lesions in a mouse mammary organ culture model. Resveratrol also inhibits the formation of 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted mouse skin tumors in the two-stage model. The enzymatic activities of COX-1 and -2 are inhibited by resveratrol in cell-free models, and COX-2 mRNA and TPA-induced activation of protein kinase C and AP-1-mediated gene expression are suppressed by resveratrol in mammary epithelial cells. In addition, resveratrol strongly inhibits nitric oxide generation and inducible nitric oxide synthase protein expression. NF kappa B is strongly linked to inflammatory and immune responses and is associated with oncogenesis in certain models of cancer, and resveratrol suppresses the induction of this transcription factor by a number of agents. The mechanism may involve decreasing the phosphorylation and degradation of I kappa B alpha. At the cellular level, resveratrol also induces apoptosis, cell cycle delay or a block in the G(1) --> S transition phase in a number of cell lines. Thus, resveratrol holds great promise for future development as a chemopreventive agent that may be useful for several disorders. Preclinical toxicity studies are underway that should be followed by human clinical trials.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Antioxidants; Humans; Neoplasms; Resveratrol; Stilbenes

2002
[Combretastatin A4 phosphate].
    Bulletin du cancer, 2001, Volume: 88, Issue:3

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Quantitative Structure-Activity Relationship; Rats; Stilbenes; Transplantation, Heterologous

2001
[Biological activity of resveratrol].
    Postepy higieny i medycyny doswiadczalnej, 2001, Volume: 55, Issue:1

    Resveratrol is a phytoalexin found in many plants, mainly in grapes. It has been shown to prevent coronary heart diseases and to exert a variety of anti-cancer and anti-inflammatory effects.

    Topics: Animals; Anticarcinogenic Agents; Antioxidants; Cardiovascular Diseases; Humans; Inflammation; Neoplasms; Resveratrol; Ribonucleotide Reductases; Stilbenes

2001
Resveratrol--from the bottle to the bedside?
    Leukemia & lymphoma, 2001, Volume: 40, Issue:5-6

    Resveratrol, a naturally occurring plant antibiotic has been the focus of a number of studies investigating its biological attributes, which include anti-oxidant activity, anti-platelet aggregation effect, anti-atherogenic property, estrogen-like growth promoting effect, growth inhibiting activity, immunomodulation, and chemoprevention. More recently, since the first report on the apoptosis inducing activity of resveratrol in human cancer cells, the interest in this molecule as a potential chemotherapy agent has significantly intensified. Not only has its role as an anti-cancer agent been corroborated, but the precise mechanism(s) of the anti-cancer activity of resveratrol is/are being elucidated. Our group has been active in studying the cross talk between the caspase family of proteases and mitochondria, in drug-induced apoptosis. In this regard, we have shown that the cancer preventive activity of resveratrol could be attributed to its ability to trigger apoptosis in human leukemia and breast carcinoma cells. The cytotoxicity of resveratrol is restricted against these transformed cell types due to its ability to selectively upregulate CD95-CD95L interaction on the tumor cell surface, unlike normal peripheral blood cells. Despite the involvement of the CD95 signaling pathway, apoptosis induced by resveratrol is not accompanied by robust caspase 8 activation, but involves mitochondrial release of cytochrome C and downstream activation of caspases 9 and 3. We also extrapolate these in vitro findings in a murine model of carcinogensis, and demonstrate in vivo induction of apoptosis in mouse skin papillomas. These findings highlight the chemotherapeutic potential of this polyphenolic compound.

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Fas Ligand Protein; fas Receptor; Humans; Membrane Glycoproteins; Neoplasms; Resveratrol; Stilbenes

2001
A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol.
    Carcinogenesis, 2001, Volume: 22, Issue:8

    Resveratrol, a phytoalexin found in grapes and wines, has been reported to exhibit a wide range of pharmacological properties and is believed to play a role in the prevention of human cardiovascular disease (the so-called 'French paradox'). This molecule may also play a major role in both cancer prevention and therapy. In this review article we summarize the recent advances that have provided new insights into the molecular mechanisms underlying the promising properties of resveratrol. These include cyclooxygenase, nitric oxide synthase and cytochrome P450 inhibition, as well as cell cycle effects, apoptosis modulation and hormonal activity.

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Cell Transformation, Neoplastic; Humans; Neoplasms; Resveratrol; Stilbenes

2001
The world of resveratrol.
    Advances in experimental medicine and biology, 2001, Volume: 492

    Topics: Animals; Anticarcinogenic Agents; Antioxidants; Arteriosclerosis; Biological Availability; Cell Division; Gene Transfer, Horizontal; Humans; Inflammation; Intestinal Absorption; Neoplasms; Resveratrol; Stilbenes; Vitis

2001
The effects of resveratrol on CYP1A1 expression and aryl hydrocarbon receptor function in vitro.
    Advances in experimental medicine and biology, 2001, Volume: 492

    Topics: Anticarcinogenic Agents; Cytochrome P-450 CYP1A1; Humans; Neoplasms; Receptors, Aryl Hydrocarbon; Resveratrol; Stilbenes; Tumor Cells, Cultured

2001
Targeting tumour vasculature: the development of combretastatin A4.
    The Lancet. Oncology, 2001, Volume: 2, Issue:2

    The requirement for neovascularisation to permit the development of solid tumours beyond a threshold size, has focused attention on the therapeutic potential of agents that prevent angiogenesis. The multistep nature of angiogenesis presents several targets for intervention, including the inhibition of the endothelial-cell migration or proliferation normally associated with developing vessels. Compounds that damage established tumour vasculature are also of potential clinical use. We review the development of one such antivascular drug, combretastatin A4. This tubulin-binding agent was originally isolated from an African shrub, Combretum caffrum. The disodium combretastatin A4 phosphate prodrug is currently undergoing phase I clinical trials in the UK and USA. This review assesses the in vitro and in vivo data for combretastatin and the prodrug, and the preliminary data that have emerged from the phase I clinical trials.

    Topics: Antineoplastic Agents, Phytogenic; Cells, Cultured; Clinical Trials as Topic; Humans; Neoplasms; Stilbenes

2001
Molecular targets for nutrients involved with cancer prevention.
    Nutrition and cancer, 2001, Volume: 41, Issue:1-2

    Dietary nutrients can influence cancer risk by inhibiting or enhancing carcinogenesis through diverse mechanisms of action. The identification and elucidation of their sites of action have been a focus of nutrition and cancer research for more than four decades. Transforming nutrition and cancer research from a predominantly observational to a molecular approach offers exciting opportunities for truly identifying those who will and will not benefit from dietary intervention strategies. The emerging field of nutritional genomics, defined here as the study of any genetic or epigenetic interaction with a nutrient, will be key to this evolution. Unraveling which genetic upregulation or downregulation leads to subsequent phenotype changes will not be easy. There is evidence that genetic polymorphisms can influence the dynamics between nutrients and molecular targets and, thus, contribute to variation in response among individuals. Because many molecular targets will likely be identified, it may be necessary to credential nutrients, that is, to determine which specific nutrient-related genetic and epigenetic changes bring about phenotypic changes, to establish which interactions are the most important and under what circumstances. Vitamin D, calcium, folate, selenium, genistein, and resveratrol are highlighted, because they represent specific classes of nutrients and illustrate the need to credential various nutrients to understand their physiological significance in cancer prevention. As the science of nutrition unfolds, a clearer understanding will emerge about how nutrients can modulate cancer risk through molecular interactions and how foods might be changed by agronomic approaches and/or biotechnology. Undeniably, embracing new genomic technologies offers exciting opportunities for advances in the broad area of nutrition, especially those related to cancer prevention.

    Topics: Anticarcinogenic Agents; Calcium; Diet; Folic Acid; Food Technology; Genistein; Humans; Neoplasms; Nutritional Physiological Phenomena; Polymorphism, Genetic; Resveratrol; Selenium; Stilbenes; Vitamin D

2001
New agents in cancer clinical trials.
    Oncogene, 2000, Dec-27, Volume: 19, Issue:56

    Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dioxoles; Enzyme Inhibitors; Humans; Hydroxamic Acids; Imatinib Mesylate; Isoquinolines; Lactams, Macrocyclic; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Rifabutin; Stilbenes; Tetrahydrofolates; Tetrahydroisoquinolines; Trabectedin; Vorinostat

2000
Chemoprevention of cancer and cardiovascular disease by resveratrol.
    Proceedings of the National Science Council, Republic of China. Part B, Life sciences, 1999, Volume: 23, Issue:3

    Resveratrol (trans-3,4',5-trihydroxystibene) is a phytopolyphenol isolated from the seeds and skins of grapes. Recent studies indicate that resveratrol can block the process of multistep carcinogenesis, namely, tumor initiation, promotion and progression. Resveratrol can also reduce the risk of cardiovascular disease in man. The molecular mechanisms of resveratrol in chemoprevention of cancer and cardiovascular disease are interesting and under intensive investigation. Resveratrol was found to strongly inhibit nitric oxide (NO) generation in activated macrophages, as measured by the amount of nitrite released into the culture medium, and resveratrol strongly reduced the amount of cytosolic inducible nitric oxide synthase (iNOS) protein. The activation of nuclear factor kappa B (NF kappa B) induced by lipopolysaccharide (LPS) was inhibited by resveratrol. The phosphorylation and degradation of nuclear factor inhibitor kappa B alpha (I kappa B alpha) were inhibited by resveratrol simultaneously. Reactive oxygen species (ROS) are regarded as having carcinogenic potential and have been associated with tumor promotion. Resveratrol may act as a reactive oxygen species scavenger to suppress tumor development. In addition, resveratrol may block multistep carcinogenesis through mitotic signal transduction blockade. Reactive oxygen species are pivotal factors in the genesis of heart disease. Meanwhile, efficient endogenous antioxidants, including superoxide dismutase (SOD), glutathione peroxidase (GSHPx), and catalase, are present in tissues. A fine balance between reactive oxygen species and endogenous antioxidants is believed to exist. Any disturbance of this balance in favor of reactive oxygen species causes an increase in oxidative stress and initiates subcellular changes, leading to cardiomyopathy and heart failure. The experimental results indicate that exogenous antioxidant resveratrol is of value in chemopreventing the development of heart disease. It is urgent that more efforts be made to investigate newer therapies employing antioxidants for the chemoprevention of cardiovascular disease and cancer.

    Topics: Anticarcinogenic Agents; Carcinogens; Cardiovascular Diseases; Cell Cycle; Cyclin D1; Enzyme Inhibitors; Gene Expression Regulation; Growth Substances; Humans; Lipid Peroxidation; Neoplasms; NF-kappa B; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxidative Stress; Phosphorylation; Protein Processing, Post-Translational; Reactive Oxygen Species; Receptor Protein-Tyrosine Kinases; Resveratrol; Risk Factors; Rosales; Signal Transduction; Stilbenes; Transcription, Genetic; Wine

1999
Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances.
    Mutation research, 1999, Jul-16, Volume: 428, Issue:1-2

    Recently, considerable attention has been focused on identifying naturally occurring chemopreventive substances capable of inhibiting, retarding, or reversing the multi-stage carcinogenesis. A wide array of phenolic substances, particularly those present in dietary and medicinal plants, have been reported to possess substantial anticarcinogenic and antimutagenic activities. The majority of these naturally occurring phenolics retain antioxidative and anti-inflammatory properties which appear to contribute to their chemopreventive or chemoprotective activity. Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide), a pungent ingredient of hot chili pepper, protects against experimentally-induced mutagenesis and tumorigenesis. It also induces apoptosis in various immortalized or malignant cell lines. Plants of ginger family (Zingiberaceae) have been frequently and widely used as spices and also, in traditional oriental medicine. Curcumin, a yellow ingredient from turmeric (Curcuma longa L., Zingiberaceae), has been extensively investigated for its cancer chemopreventive potential. Yakuchinone A [1-(4'-hydroxy-3'-methoxyphenyl)-7-phenyl-3-heptanone] and yakuchinone B [1-(4'-hydroxy-3'-methoxyphenyl)-7-phenylhept-1-en-3-one] present in Alpinia oxyphylla Miquel (Zingiberaceae) have inhibitory effects on phorbol ester-induced inflammation and skin carcinogenesis in mice, and oxidative stress in vitro. These diarylheptanoids suppress phorbol ester-induced activation of ornithine decarboxylase and production of tumor necrosis factor-alpha or interleukin-1alpha and their mRNA expression. They also nullified the phorbol ester-stimulated induction of activator protein 1 (AP-1) in cultured human promyelocytic leukemia (HL-60) cells. In addition, both yakuchinone A and B induced apoptotic death in HL-60 cells. Ginger (Zingiber officinale Roscoe, Zingiberaceae) contains such pungent ingredients as [6]-gingerol and [6]-paradol, which also have anti-tumor promotional and antiproliferative effects. Resveratrol (3, 5,4'-trihydroxy-trans-stilbene), a phytoalexin found in grapes and other dietary and medicinal plants, and (-)-epigallocatechin gallate, a major antioxidative green tea polyphenol, exert striking inhibitory effects on diverse cellular events associated with multi-stage carcinogenesis. In addition, these compounds have ability to suppress proliferation of human cancer cells via induction of apoptosis.

    Topics: Animals; Capsaicin; Catechin; Catechols; Curcumin; Diet; Fatty Alcohols; Humans; Mice; Neoplasms; Neoplasms, Experimental; Phenols; Plants, Edible; Plants, Medicinal; Resveratrol; Stilbenes

1999
Stilbenes and bibenzyls with potential anticancer or chemopreventive activity.
    Advances in experimental medicine and biology, 1999, Volume: 472

    Topics: Anticarcinogenic Agents; Bibenzyls; Humans; Neoplasms; Plants, Edible; Stilbenes

1999
[Causal genesis of malignant tumors].
    Archiv fur klinische und experimentelle Ohren- Nasen- und Kehlkopfheilkunde, 1973, Volume: 205, Issue:1

    Topics: Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Carcinogens; Carcinoma, Squamous Cell; Child; Ear Neoplasms; Ependymoma; Female; Humans; Immunosuppressive Agents; Isoniazid; Maternal-Fetal Exchange; Mice; Mycotoxins; Neoplasms; Nitrosourea Compounds; Occupational Diseases; Oligodendroglioma; Otorhinolaryngologic Diseases; Pregnancy; Rats; Stilbenes

1973
Food additives and chemical carcinogens: on the concept of zero tolerance.
    Food and cosmetics toxicology, 1968, Volume: 6, Issue:2

    Topics: Animals; Anthracenes; Carbon Tetrachloride; Carcinogens; Fluorine; Food Additives; Methylcholanthrene; Mice; Neoplasms; Neoplasms, Experimental; Nitrogen Mustard Compounds; p-Dimethylaminoazobenzene; Rats; Stilbenes

1968

Trials

18 trial(s) available for stilbenes and Neoplasms

ArticleYear
    American journal of obstetrics & gynecology MFM, 2021, Volume: 3, Issue:1

    Obstetrical complications affect more than a third of women globally, but are underrepresented in clinical research. Little is known about the comprehensive obstetrical clinical trial landscape, how it compares with other fields, or factors associated with the successful completion of obstetrical trials.. This study aimed to characterize obstetrical clinical trials registered on ClinicalTrials.gov with the primary objective of identifying features associated with early discontinuation and results reporting.. This is a cross-sectional study with descriptive, logistic regression and Cox regression analyses of clinical trials registered on ClinicalTrials.gov. Our primary exposure variables were trial focus (obstetrical or nonobstetrical) and trial funding (industry, United States government, or academic). We conducted additional exploratory analyses of other trial features including design, enrollment, and therapeutic focus. We examined the associations of exposure variables and other trial features with 2 primary outcomes: early discontinuation and results reporting.. Obstetrical trials represent only 1.9% of all clinical trials in ClinicalTrials.gov and have comparatively poor completion. All stakeholders should commit to increasing the number of obstetrical trials and improving their completion and dissemination to ensure clinical research reflects the obstetrical burden of disease and advances maternal health.

    Topics: Adipose Tissue, White; Adult; Aged; Air Pollutants; Animals; Anti-Inflammatory Agents; Arginine; bcl-2-Associated X Protein; Biofuels; Biological Products; Blood Glucose; Breast Neoplasms; Caspases; CD36 Antigens; Cell Communication; Cell Proliferation; Cell Survival; Cooking; Cross-Sectional Studies; Databases, Factual; Diabetes Mellitus, Type 2; Diphtheria Toxin; Double-Blind Method; Exenatide; Extracellular Polymeric Substance Matrix; Feasibility Studies; Female; Filgrastim; Fruit; Galactose; Gene Deletion; Gene Knockdown Techniques; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Secreting Cells; Glucose; Glycated Hemoglobin; Hematopoietic Stem Cell Mobilization; Household Articles; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islets of Langerhans; Lung; Lymphoma; Male; Metals, Heavy; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Nanoparticles; Neoplasms; Obesity; Obstetrics; Odds Ratio; Oxygen; Peripheral Blood Stem Cell Transplantation; Photochemotherapy; Plant Extracts; Polyethylene Glycols; Polyglutamic Acid; Porosity; Postprandial Period; Prospective Studies; Quality of Life; Receptors, Glucagon; Receptors, LDL; Receptors, Somatostatin; Registries; Rhodophyta; Rhodotorula; Risk Factors; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Signal Transduction; Somatostatin; Stilbenes; Terminalia; Treatment Outcome; United States; Venoms

2021
A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections.
    Anti-cancer drugs, 2014, Volume: 25, Issue:4

    Combretastatin A4 phosphate (CA4P) is a prodrug that selectively destroys tumor blood vessels, and has shown efficacy as a targeted anticancer drug in both animal models and clinical trials. The aims of this single-center, open label, phase I clinical trial were to investigate the safety and tolerability of CA4P administered intravenously to patients aged 18-65 years with advanced solid tumors. Using a dose-escalation protocol, patients were assigned to five groups that received injections with 20 (n=3), 33 (n=3), 50 (n=11), 65 (n=6), or 85 (n=2) mg/m² CA4P. Patients in the 20 and 85 mg/m² groups received a single dose and the other groups received multiple doses. Adverse events (AE), cardiovascular parameters, and biochemical investigations were studied, and the maximum tolerated dose was determined. Of twenty-five patients enrolled, eight were withdrawn/excluded (not because of AE). There were no deaths. A total of 394 AE occurred in the 25 patients, with 89.3% considered related/possibly related to the drug. AE included headache and dizziness (19.8%), tumor-induced pain (14.2%), vascular vagal excitation (10.7%), and vomiting (9.4%). Ninety-five percent of AE were mild (grades 0-II), with only 5% being grade III-IV. Drug administration was associated with biphasic changes in heart rate and blood pressure, and only limited abnormalities in the laboratory investigations performed. The maximum tolerated dose was 65 mg/m². We conclude that CA4P is generally well tolerated, with the vast majority of AE that occurred being of mild severity. Further studies will establish the role of CA4P in cancer therapy.

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Female; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prodrugs; Stilbenes; Treatment Outcome; Young Adult

2014
Resveratrol levels and all-cause mortality in older community-dwelling adults.
    JAMA internal medicine, 2014, Volume: 174, Issue:7

    Resveratrol, a polyphenol found in grapes, red wine, chocolate, and certain berries and roots, is considered to have antioxidant, anti-inflammatory, and anticancer effects in humans and is related to longevity in some lower organisms.. To determine whether resveratrol levels achieved with diet are associated with inflammation, cancer, cardiovascular disease, and mortality in humans.. Prospective cohort study, the Invecchiare in Chianti (InCHIANTI) Study ("Aging in the Chianti Region"), 1998 to 2009 conducted in 2 villages in the Chianti area in a population-based sample of 783 community-dwelling men and women 65 years or older.. Twenty-four-hour urinary resveratrol metabolites.. Primary outcome measure was all-cause mortality. Secondary outcomes were markers of inflammation (serum C-reactive protein [CRP], interleukin [IL]-6, IL-1β, and tumor necrosis factor [TNF]) and prevalent and incident cancer and cardiovascular disease.. Mean (95% CI) log total urinary resveratrol metabolite concentrations were 7.08 (6.69-7.48) nmol/g of creatinine. During 9 years of follow-up, 268 (34.3%) of the participants died. From the lowest to the highest quartile of baseline total urinary resveratrol metabolites, the proportion of participants who died from all causes was 34.4%, 31.6%, 33.5%, and 37.4%, respectively (P = .67). Participants in the lowest quartile had a hazards ratio for mortality of 0.80 (95% CI, 0.54-1.17) compared with those in the highest quartile of total urinary resveratrol in a multivariable Cox proportional hazards model that adjusted for potential confounders. Resveratrol levels were not significantly associated with serum CRP, IL-6, IL-1β, TNF, prevalent or incident cardiovascular disease, or cancer.. In older community-dwelling adults, total urinary resveratrol metabolite concentration was not associated with inflammatory markers, cardiovascular disease, or cancer or predictive of all-cause mortality. Resveratrol levels achieved with a Western diet did not have a substantial influence on health status and mortality risk of the population in this study.

    Topics: Aged; Cardiovascular Diseases; Cohort Studies; Female; Humans; Incidence; Inflammation; Italy; Male; Mortality; Neoplasms; Prevalence; Prospective Studies; Resveratrol; Stilbenes

2014
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Mar-01, Volume: 18, Issue:5

    Preclinical studies show that OXi4503 (combretastatin A1 diphosphate, CA1P) is more potent than other clinically evaluated vascular-disrupting agents.. Escalating doses of OXi4503 were given intravenously over 10 minutes on days 1, 8, and 15 every 28 days to patients with advanced solid tumors.. Doses were escalated in single-patient cohorts from 0.06 to 1.92 mg/m(2), then expanded cohorts to 15.4 mg/m(2) in 43 patients. Common adverse drug reactions were hypertension, tumor pain, anemia, lymphopenia, and easily controllable nausea/vomiting and fatigue. Five patients experienced different drug-related dose-limiting toxicities, atrial fibrillation, increased troponin, blurred vision, diplopia, and tumor lysis. Prophylactic amlodipine failed to prevent adverse events. Pharmacokinetics showed dose-dependent linear increases in peak plasma concentrations and area under the curve value of OXi4503. One partial response was seen in a heavily pretreated patient with ovarian cancer. Dynamic contrast-enhanced MRI confirmed a dose effect and showed significant antivascular effects in 10 of 13 patients treated at doses of 11 mg/m(2) or higher.. The maximum tolerated dose was 8.5 mg/m(2) but escalation to 14 mg/m(2) was possible with only temporary reversible cerebrovascular toxicity by excluding hypertensive patients. As a tumor response was seen at 14 mg/m(2) and maximum tumor perfusion reductions were seen at doses of 11 mg/m(2) or higher, the recommended phase II dose is from 11 to 14 mg/m(2).

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Diphosphates; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Stilbenes; Treatment Outcome; Young Adult

2012
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
    British journal of cancer, 2012, May-22, Volume: 106, Issue:11

    OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical studies demonstrated early drug-induced apoptosis in tumour endothelial cells at 1-3 h and secondary tumour cell necrosis between 6 and 72 h.. To capture both possible outcomes of OXi4503 treatment on cell death, plasma samples for analysis by M30 and M65 ELISAs, which measure different circulating forms of cytokeratin 18 as biomarkers of apoptosis and necrosis, respectively, were collected from patients entered into the trial at early (4/6 h) and later time points (24h, day 8 and day 15).. OXi4503 induced a selective dose-dependent elevation in M30 antigen levels (apoptosis) at 4/6 h and a similar elevation in M65 antigen levels at 24 h (necrosis) consistent with its preclinical cell death profile. For the purposes of investigating potential biomarker relationships to patient characteristics, the trial population was divided into three groups based on radiological and clinical response: (a) early progression, (b) progressive disease and (c) stable disease (SD)/partial response. A significant increase in antigen concentrations was measured by M65 at 24 h in the SD group compared with the two other groups (P=0.015, mean increase 30.9%).. These results provide pharmacodynamic evidence of drug mechanism of action in cancer patients and highlight the M65 ELISA as a potentially useful biomarker assay of response to OXi4503.

    Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Diphosphates; Enzyme-Linked Immunosorbent Assay; Humans; Keratin-18; Neoplasms; Neovascularization, Pathologic; Peptide Fragments; Stilbenes

2012
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jun-15, Volume: 18, Issue:12

    The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent. Preclinical models have shown that the addition of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly increases antitumor activity.. Patients with advanced solid malignancies received CA4P at 45, 54, or 63 mg/m(2) on day 1, day 8, and then every 14 days. Bevacizumab 10 mg/kg was given on day 8 and at subsequent cycles four hours after CA4P. Functional imaging with dynamic contrast enhanced-MRI (DCE-MRI) was conducted at baseline, after CA4P alone, and after cycle 1 CA4P + bevacizumab.. A total of 63 mg/m(2) CA4P + 10 mg/kg bevacizumab q14 is the recommended phase II dose. A total of 15 patients were enrolled. Dose-limiting toxicities were grade III asymptomatic atrial fibrillation and grade IV liver hemorrhage in a patient with a history of hemorrhage. Most common toxicities were hypertension, headache, lymphopenia, pruritus, and pyrexia. Asymptomatic electrocardiographic changes were seen in five patients. Nine of 14 patients experienced disease stabilization. A patient with ovarian cancer had a CA125 response lasting for more than a year. DCE-MRI showed statistically significant reductions in tumor perfusion/vascular permeability, which reversed after CA4P alone but which were sustained following bevacizumab. Circulating CD34(+) and CD133(+) bone marrow progenitors increased following CA4P as did VEGF and granulocyte colony-stimulating factor levels.. CA4P in combination with bevacizumab appears safe and well tolerated in this dosing schedule. CA4P induced profound vascular changes, which were maintained by the presence of bevacizumab.

    Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Stilbenes

2012
A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours.
    British journal of clinical pharmacology, 2011, Volume: 71, Issue:6

    • Three pharmacokinetic and safety studies for combretastatin A4 phosphate (CA4P), the first vascular disrupting agent, have been conducted in Western countries. • The maximum tolerated dose (MTD) was approximately 60-68 mg m(-2). • CA4P-related grade 3 or 4 adverse events were tumour pain, dyspnoea, hypoxia and syncope in patients who received doses ≥ 50 mg m(-2).. • This is the first pharmacokinetic and safety study conducted in East Asian patients. • There appeared to be a trend that Chinese patients metabolized CA4 more rapidly and had greater neurotoxicity than patients in Western countries. • We observed favourable clinical responses in patients with refractory nasopharyngeal carcinoma. • CA4P-induced acute renal failure was seen in one dehydrated Chinese patient.. This trial was conducted to evaluate the safety and pharmacokinetics of combretastatin A4 phosphate (CA4P) given intravenously as a single dose to Chinese patients with refractory solid tumours. METHODS Twenty-five patients were treated with single doses of CA4P according to a dose escalation scheme: 5, 10, 20, 33, 50, 65 and 85 mg m(-2) infused intravenously over 30 min.. CA4P was generally well tolerated at ≤ 65 mg m(-2). Transient, moderate increases in the heart rate-corrected QT interval occurred at all doses. CA4P produced a transient dose-dependent increase in neural and gastrointestinal toxicities. Acute renal failure occurred in one dehydrated patient who had also taken paracetamol. There were seven episodes of dose-limiting toxicity at doses ≥65 mg m(-2), including two episodes of reversible ataxia at 85 mg m(-2).For CA4, at 50 mg m(-2),mean (SD) peak plasma concentration (C(max) was 0.99 (0.33) mM, area under the curve from time zero to time of last quantifiable concentration (AUC(0,t)) was 1.42 (0.30) mM h and terminal elimination half-life (t(1/2)was 1.81 (0.61) h. At 65 mg m-2,C(max) was 1.73 (0.62) mM,AUC(0,t) was 3.19 (1.47) mM h and t (1/2) was 1.90 (0.61) h [corrected]One patient with nasopharyngeal carcinoma had an obvious clinical response with central necrosis in the metastatic lung mass. CONCLUSION Doses ≤ 65 mg m(-2) given as 30 min infusions define the maximum tolerated dose in East Asian patients, and doses in the range of 50-65 mg m(-2) have been selected for further studies.

    Topics: Adult; Antineoplastic Agents, Phytogenic; Asian People; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Stilbenes; Treatment Outcome

2011
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
    British journal of cancer, 2010, Apr-27, Volume: 102, Issue:9

    The vascular disrupting agent combretastatin A4 phosphate (CA4P) causes major regression of animal tumours when given as combination therapy.. Patients with advanced cancer refractory to standard therapy were treated with CA4P as a 10-min infusion, 20 h before carboplatin, paclitaxel, or paclitaxel, followed by carboplatin.. Combretastatin A4 phosphate was escalated from 36 to 54 mg m(-2) with the carboplatin area under the concentration curve (AUC) 4-5, from 27 to 54 mg m(-2) with paclitaxel 135-175 mg m(-2), and from 54 to 72 mg m(-2) with carboplatin AUC 5 and paclitaxel 175 mg m(-2). Grade 3 or 4 neutropenia was seen in 17%, and thrombocytopenia only in 4% of 46 patients. Grade 1-3 hypertension (26% of patients) and grade 1-3 tumour pain (65% of patients) were the most typical non-haematological toxicities. Dose-limiting toxicity of grade 3 hypertension or grade 3 ataxia was seen in two patients at 72 mg m(-2). Responses were seen in 10 of 46 (22%) patients with ovarian, oesophageal, small-cell lung cancer, and melanoma.. The combination of CA4P with carboplatin and paclitaxel was well tolerated in the majority of patients with adequate premedication and had antitumour activity in patients who were heavily pretreated.

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Carboplatin; Carcinoma, Small Cell; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Life Expectancy; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Paclitaxel; Patient Selection; Stilbenes

2010
Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial.
    European radiology, 2009, Volume: 19, Issue:11

    The purpose was to determine the reproducibility of apparent diffusion coefficient (ADC) measurements in a two-centre phase I clinical trial; and to track ADC changes in response to the sequential administration of the vascular disrupting agent, combretastatin A4 phosphate (CA4P), and the anti-angiogenic drug, bevacizumab. Sixteen patients with solid tumours received CA4P and bevacizumab treatment. Echo-planar diffusion-weighted MRI was performed using six b values (b = 0-750 s/mm(2)) before (x2), and at 3 and 72 h after a first dose of CA4P. Bevacizumab was given 4 h after a second dose of CA4P, and imaging performed 3 h post CA4P and 72 h after bevacizumab treatment. The coefficient of repeatability (r) of ADC total (all b values), ADC high (b = 100-750) and ADC low (b = 0-100) was calculated by Bland-Altman analysis. The ADC total and ADC high showed good measurement reproducibility (r% = 13.3, 14.1). There was poor reproducibility of the perfusion-sensitive ADC low (r% = 62.5). Significant increases in the median ADC total and ADC high occurred at 3 h after the second dose of CA4P (p < 0.05). ADC measurements were highly reproducible in a two-centre clinical trial setting and appear promising for evaluating the effects of drugs that target tumour vasculature.

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Diffusion Magnetic Resonance Imaging; Dose-Response Relationship, Drug; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Phantoms, Imaging; Reproducibility of Results; Stilbenes; Time Factors

2009
Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents.
    Cancer research, 2009, Oct-01, Volume: 69, Issue:19

    Vascular disrupting agents (VDA) cause acute shutdown of abnormal established tumor vasculature, followed by massive intratumoral hypoxia and necrosis. However, a viable rim of tumor tissue invariably remains from which tumor regrowth rapidly resumes. We have recently shown that an acute systemic mobilization and homing of bone marrow-derived circulating endothelial precursor (CEP) cells could promote tumor regrowth following treatment with either a VDA or certain chemotherapy drugs. The molecular mediators of this systemic reactive host process are unknown. Here, we show that following treatment of mice with OXi-4503, a second-generation potent prodrug derivative of combretastatin-A4 phosphate, rapid increases in circulating plasma vascular endothelial growth factor, stromal derived factor-1 (SDF-1), and granulocyte colony-stimulating factor (G-CSF) levels are detected. With the aim of determining whether G-CSF is involved in VDA-induced CEP mobilization, mutant G-CSF-R(-/-) mice were treated with OXi-4503. We found that as opposed to wild-type controls, G-CSF-R(-/-) mice failed to mobilize CEPs or show induction of SDF-1 plasma levels. Furthermore, Lewis lung carcinomas grown in such mice treated with OXi-4503 showed greater levels of necrosis compared with tumors treated in wild-type mice. Evidence for rapid elevations in circulating plasma G-CSF, vascular endothelial growth factor, and SDF-1 were also observed in patients with VDA (combretastatin-A4 phosphate)-treated cancer. These results highlight the possible effect of drug-induced G-CSF on tumor regrowth following certain cytotoxic drug therapies, in this case using a VDA, and hence G-CSF as a possible therapeutic target.

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemokine CXCL12; Diphosphates; Endothelial Cells; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Melanoma; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Neoplasms; Prodrugs; Stem Cells; Stilbenes; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2009
Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent.
    Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2007, Volume: 16, Issue:6

    The red grape constituent resveratrol possesses cancer chemopreventive properties in rodents. The hypothesis was tested that, in healthy humans, p.o. administration of resveratrol is safe and results in measurable plasma levels of resveratrol. A phase I study of oral resveratrol (single doses of 0.5, 1, 2.5, or 5 g) was conducted in 10 healthy volunteers per dose level. Resveratrol and its metabolites were identified in plasma and urine by high-performance liquid chromatography-tandem mass spectrometry and quantitated by high-performance liquid chromatography-UV. Consumption of resveratrol did not cause serious adverse events. Resveratrol and six metabolites were recovered from plasma and urine. Peak plasma levels of resveratrol at the highest dose were 539 +/- 384 ng/mL (2.4 micromol/L, mean +/- SD; n = 10), which occurred 1.5 h post-dose. Peak levels of two monoglucuronides and resveratrol-3-sulfate were 3- to 8-fold higher. The area under the plasma concentration curve (AUC) values for resveratrol-3-sulfate and resveratrol monoglucuronides were up to 23 times greater than those of resveratrol. Urinary excretion of resveratrol and its metabolites was rapid, with 77% of all urinary agent-derived species excreted within 4 h after the lowest dose. Cancer chemopreventive effects of resveratrol in cells in vitro require levels of at least 5 micromol/L. The results presented here intimate that consumption of high-dose resveratrol might be insufficient to elicit systemic levels commensurate with cancer chemopreventive efficacy. However, the high systemic levels of resveratrol conjugate metabolites suggest that their cancer chemopreventive properties warrant investigation.

    Topics: Adult; Anticarcinogenic Agents; Area Under Curve; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Resveratrol; Stilbenes; Tandem Mass Spectrometry

2007
A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Sep-01, Volume: 12, Issue:17

    HMN-214 is an oral prodrug of HMN-176, a stilbene derivative that interferes with the subcellular spatial location of polo-like kinase-1, a serine/threonine kinase that regulates critical mitotic events. We conducted a dose escalation study of HMN-214 in patients with advanced cancer to assess the safety profile and pharmacokinetics of HMN-214 and to establish the maximum tolerated dose.. Thirty-three patients were enrolled onto four dosing cohorts of HMN-214 from 3 to 9.9 mg/m2/d using a continuous 21-day dosing schedule every 28 days, with pharmacokinetic sampling during cycle 1.. A severe myalgia/bone pain syndrome and hyperglycemia were dose-limiting toxicities at 9.9 mg/m2/d. A dose reduction and separate enrollment by pretreatment status (lightly versus heavily pretreated) was undertaken, with one dose-limiting toxicity (grade 3 bone pain) at 8 mg/m2/d. The maximum tolerated dose was defined as 8 mg/m2/d for both treatment cohorts. Dose-proportional increases were observed in AUC but not Cmax. There was no accumulation of HMN-176, the metabolite of HMN-214, with repeated dosing. Seven of 29 patients had stable disease as best tumor response, including 6-month stable disease in a heavily pretreated breast cancer patient. A transient decline in carcinoembryonic antigen in a patient with colorectal cancer was noted.. The maximum tolerated dose and recommended phase II dose of HMN-214 when administered on this schedule was 8 mg/m2/d regardless of pretreatment status. Further development of HMN-214 will focus on patient populations for which high expression of polo-like kinase-1 is seen (i.e., prostate and pancreatic cancer patients).

    Topics: Administration, Oral; Adult; Aged; Benzylidene Compounds; Cell Cycle Proteins; Cohort Studies; Cyclic N-Oxides; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Molecular Structure; Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyridines; Stilbenes; Structure-Activity Relationship; Sulfonamides; Treatment Outcome

2006
Phase I trial of combretastatin a-4 phosphate with carboplatin.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Feb-15, Volume: 11, Issue:4

    Preclinical evidence of synergy led to a phase I trial employing combretastatin A-4 phosphate (CA4P), a novel tubulin-binding antivascular drug, in combination with carboplatin.. Based on preclinical scheduling studies, patients were treated on day 1 of a 21-day cycle. Carboplatin was given as a 30-minute i.v. infusion and CA4P was given 60 minutes later as a 10-minute infusion.. Sixteen patients with solid tumors received 40 cycles of therapy at CA4P doses of 27 and 36 mg/m(2) together with carboplatin at area under the concentration-time curve (AUC) values of 4 and 5 mg min/mL. The dose-limiting toxicity of thrombocytopenia halted the dose escalation phase of the study. Four patients were treated at an amended dose level of CA4P of 36 mg/m(2) and carboplatin AUC of 4 mg min/mL although grade 3 neutropenia and thrombocytopenia were still observed. Three lines of evidence are adduced to suggest that a pharmacokinetic interaction between the drugs results in greater thrombocytopenia than anticipated: the carboplatin exposure (as AUC) was greater than predicted; the platelet nadirs were lower than predicted; and the deviation of the carboplatin exposure from predicted was proportional to the AUC of CA4, the active metabolite of CA4P. Patient benefit included six patients with stable disease lasting at least four cycles.. This study of CA4P and carboplatin given in combination showed dose-limiting thrombocytopenia. Pharmacokinetic/pharmacodynamic modeling permitted the inference that altered carboplatin pharmacokinetics caused the increment in platelet toxicity.

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Stilbenes; Thrombocytopenia; Treatment Outcome; Vomiting

2005
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jan-01, Volume: 10, Issue:1 Pt 1

    The purpose of our study was to review and determine the cardiovascular safety profile of combretastatin A4 phosphate (CA4P) in a Phase I study in 25 patients with advanced solid tumors.. CA4P was administered in a dose-escalating fashion starting at 18 mg/m(2) i.v. every 21 days, and the maximal dosage was 90 mg/m(2). Continuous evaluation included bedside blood pressure and pulse monitoring, 12-lead electrocardiogram (ECG) at fixed time points for measured QT interval determination, determination of the corrected QT interval (QTc) using Bazett's formula QTc = QT/(R-R interval)(1/2), and chart review. Pharmacodynamic correlations of CA4P dose, CA4P/CA4 area under the curve, and C(max) versus heart rate (HR), blood pressure, QT, and QTc intervals, over the first 4 h postdosing were analyzed.. After CA4P administration, there were significant increases in QTc interval at the 3-h and 4-h time points [27.2 ms (P < 0.0001) and 30.8 ms (P < 0.0001), respectively] and HR at the 3- and 4-h time points [13.2 beats per minute (bpm; P < 0.01) and 15.1 bpm (P < 0.001), respectively]. Three of 25 patients had prolonged QTc intervals at baseline, whereas 15 (60%) of 25 and 18 (75%) of 24 patients had prolonged QTc intervals at 3 and 4 h. The slope of HR and QTc increasing as a function of time during the first 4 h was correlated to dose (in milligrams) of CA4P (P = 0.01 and r = 0.49 for HR, P = 0.005 and r = 0.55 for QTc) and to CA4 area under the curve (P = 0.04 and r = 0.41 for HR, P = 0.02 and r = 0.44 for QTc); blood pressure and uncorrected QTc interval dose-response correlations were not significant. Two patients had ECG changes consistent with an acute coronary syndrome within 24 h of CA4P infusion.. CA4P prolongs the QTc interval. There was a temporal relationship with the CA4P infusion and with ECG changes consistent with an acute coronary syndrome in two patients. It is advisable that future trials with CA4P have eligibility guidelines limiting patients with known coronary artery disease or those with multiple coronary artery disease risk factors until more experience is gained regarding potential cardiovascular toxicity with this agent.

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Blood Pressure; Cardiovascular System; Coronary Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Electrocardiography; Female; Heart Rate; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Safety; Stilbenes

2004
Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15

    A phase I trial was performed with combretastatin A4 phosphate (CA4P), a novel tubulin-binding agent that has been shown to rapidly reduce blood flow in animal tumors.. The drug was delivered by a 10-minute weekly infusion for 3 weeks followed by a week gap, with intrapatient dose escalation. Dose escalation was accomplished by doubling until grade 2 toxicity was seen. The starting dose was 5 mg/m2.. Thirty-four patients received 167 infusions. CA4P was rapidly converted to the active combretastatin A4 (CA4), which was further metabolized to the glucuronide. CA4 area under the curve (AUC) increased from 0.169 at 5 mg/m2 to 3.29 micromol * h/L at 114 mg/m2. The mean CA4 AUC in eight patients at 68 mg/m2 was 2.33 micromol * h/L compared with 5.8 micromol * h/L at 25 mg/kg (the lowest effective dose) in the mouse. The only toxicity that possibly was related to the drug dose up to 40 mg/m2 was tumor pain. Dose-limiting toxicity was reversible ataxia at 114 mg/m2, vasovagal syncope and motor neuropathy at 88 mg/m2, and fatal ischemia in previously irradiated bowel at 52 mg/m2. Other drug-related grade 2 or higher toxicities seen in more than one patient were pain, lymphopenia, fatigue, anemia, diarrhea, hypertension, hypotension, vomiting, visual disturbance, and dyspnea. One patient at 68 mg/m2 had improvement in liver metastases of adrenocortical carcinoma.. CA4P was well tolerated in 14 of 16 patients at 52 or 68 mg/m2; these are doses at which tumor blood flow reduction has been recorded.

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Area Under Curve; Bibenzyls; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Humans; Infusion Pumps; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Statistics, Nonparametric; Stilbenes; Tomography, Emission-Computed; Treatment Outcome

2003
Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15

    Clinical evaluation of novel agents that target tumor blood vessels requires pharmacodynamic end points that measure vascular damage. Positron emission tomography (PET) was used to measure the effects of the vascular targeting agent combretastatin A4 phosphate (CA4P) on tumor and normal tissue perfusion and blood volume.. Patients with advanced solid tumors were enrolled onto part of a phase I, accelerated-titration, dose-escalation study. The effects of 5 to 114 mg/m2 CA4P on tumor, spleen, and kidney were investigated. Tissue perfusion was measured using oxygen-15 (15O)-labeled water and blood volume was measured using 15O-labeled carbon monoxide (C15O). Scans were performed immediately before, and 30 minutes and 24 hours after the first infusion of each dose level of CA4P. All statistical tests were two sided.. PET data were obtained for 13 patients with intrapatient dose escalation. Significant dose-dependent reductions were seen in tumor perfusion 30 minutes after CA4P administration (mean change, -49% at >or= 52 mg/m2; P =.0010). Significant reductions were also seen in tumor blood volume (mean change, -15% at >or= 52 mg/m2; P =.0070). Although by 24 hours there was tumor vascular recovery, for doses >or= 52 mg/m2 the reduction in perfusion remained significant (P =.013). Thirty minutes after CA4P administration borderline significant changes were seen in spleen perfusion (mean change, -35%; P =.018), spleen blood volume (mean change, -18%; P =.022), kidney perfusion (mean change, -6%; P =.026), and kidney blood volume (mean change, -6%; P =.014). No significant changes were seen at 24 hours in spleen or kidney.. CA4P produces rapid changes in the vasculature of human tumors that can be assessed using PET measurements of tumor perfusion.

    Topics: Adult; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Female; Humans; Image Processing, Computer-Assisted; Infusion Pumps; Kidney; Male; Middle Aged; Neoplasms; Spleen; Statistics, Nonparametric; Stilbenes; Tomography, Emission-Computed; Treatment Outcome

2003
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-01, Volume: 21, Issue:23

    Combretastatin A4 (CA4) phosphate (CA4P) inhibits microtubule polymerization and is toxic to proliferating endothelial cells in vitro. It causes reversible vascular shutdown in established tumors in vivo, consistent with an antivascular mechanism of action. The present study investigated escalating doses of CA4P administered intravenously to patients with advanced cancer.. Patients with solid malignancies and good performance status received CA4P as a 10-minute infusion daily for 5 days repeated every 3 weeks. Pharmacokinetic sampling was performed during cycle 1. Patients receiving >/= 52 mg/m2/d had serial dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies to measure changes in tumor perfusion with CA4P treatment.. Thirty-seven patients received 133 treatment cycles. CA4P dose levels ranged from 6 mg/m2 to 75 mg/m2 daily. Severe pain at sites of known tumor was dose limiting at 75 mg/m2. Dose-limiting cardiopulmonary toxicity (syncope and dyspnea or hypoxia) was noted as well in two patients treated at 75 mg/m2. Other toxicities included hypotension, ataxia, dyspnea, nausea or vomiting, headache, and transient sensory neuropathy. Plasma CA4P and CA4 area under the concentration-time curve and maximal concentration values increased linearly with dose. Tumor perfusion, as measured by the first-order rate constant of gadolinium plasma to tissue transfer during DCE-MRI studies, was found to decrease in eight of 10 patients. Relationships were also demonstrated between perfusion changes and pharmacokinetic indices. A partial response was observed in a patient with metastatic soft tissue sarcoma, and 14 patients exhibited disease stability for a minimum of two cycles.. Doses of CA4P on a daily times five schedule of 52 to 65 mg/m2 were reasonably well-tolerated. The 52 mg/m2 dose is recommended for further study based on cumulative phase I experience with CA4P. Antitumor efficacy was observed, and the use of DCE-MRI provided a valuable noninvasive measure of the vascular effects of CA4P treatment.

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Area Under Curve; Contrast Media; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Stilbenes; Tomography, Emission-Computed; Treatment Outcome

2003
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.
    Cancer research, 2002, Jun-15, Volume: 62, Issue:12

    Combretastatin A-4 phosphate (CA4P) is a novel antitumor vascular targeting agent, the first agent of this class of compounds to enter the clinic. We performed a Phase I trial to determine the maximum-tolerated dose, safety, and pharmacokinetic profile of CA4P on a single-dose i.v. schedule. We also obtained preliminary data on its effect on tumor blood flow using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) techniques and cell adhesion molecules at the higher-dose levels. Twenty-five assessable patients with advanced cancer received a total of 107 cycles over the following dose escalation schema: 18, 36, 60, 90 mg/m(2) as a 10-min infusion and 60 mg/m(2) as a 60-min infusion at 3-week intervals. There was no significant myelotoxicity, stomatitis, or alopecia. Tumor pain was a unique side effect, which occurred in 10% of cycles, and there were four episodes of dose-limiting toxicity at dosages > or =60 mg/m(2), including two episodes of acute coronary syndrome. Pharmacokinetics revealed rapid dephosphorylation of the parent compound (CA4P) to combretastatin A4 (CA4), with a short plasma half-life (approximately 30 min). A significant (P < 0.03) decline in gradient peak tumor blood flow by DCE-MRI in six of seven patients treated at 60 mg/m(2) was observed. A patient with anaplastic thyroid cancer had a complete response and is alive 30 months after treatment. The toxicity profile is consistent with a drug that is "vascularly active" and devoid of traditional "cytotoxic" side effects. Dosages < or =60 mg/m(2) as a 10-min infusion define the upper boundary of the maximum-tolerated dose.

    Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Cell Adhesion Molecules; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Magnetic Resonance Angiography; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Stilbenes

2002

Other Studies

206 other study(ies) available for stilbenes and Neoplasms

ArticleYear
Trans-gnetin H isolated from the seeds of Paeonia species induces autophagy via inhibiting mTORC1 signalling through AMPK activation.
    Cell proliferation, 2023, Volume: 56, Issue:3

    Paeonia is a well-known species of ornamental plants, traditional Chinese medicines, and emerging oilseed crops. Apart from nutritional unsaturated fatty acids, the seeds of peonies are rich in stilbenes characterized by their wide-ranging health-promoting properties. Although the typical stilbene resveratrol has been widely reported for its multiple bioactivities, it remains uncertain whether the trimer of resveratrol trans-gnetin H has properties that regulate cancer cell viability, let alone the underlying mechanism. Autophagy regulated by trans-gnetin H was detected by western blotting, immunofluorescence, and quantitative real-time PCR. The effects of trans-gnetin H on apoptosis and proliferation were examined by flow cytometry, colony formation and Cell Counting Kit-8 assays. Trans-gnetin H significantly inhibits cancer cell viability through autophagy by suppressing the phosphorylation of TFEB and promoting its nuclear transport. Mechanistically, trans-gnetin H inhibits the activation and lysosome translocation of mTORC1 by inhibiting the activation of AMPK, indicating that AMPK is a checkpoint for mTORC1 inactivation induced by trans-gnetin H. Moreover, the binding of TSC2 to Rheb was markedly increased in response to trans-gnetin H stimulation. Similarly, trans-gnetin H inhibited the interaction between Raptor and RagC in an AMPK-dependent manner. More importantly, trans-gnetin H-mediated autophagy highly depends on the AMPK-mTORC1 axis. We propose a regulatory mechanism by which trans-gnetin H inhibits the activation of the mTORC1 pathway to control cell autophagy.

    Topics: AMP-Activated Protein Kinases; Autophagy; Humans; Mechanistic Target of Rapamycin Complex 1; Neoplasms; Paeonia; Resveratrol; Seeds; Stilbenes

2023
Systematic Studies on Anti-Cancer Evaluation of Stilbene and Dibenzo[
    Molecules (Basel, Switzerland), 2023, Apr-18, Volume: 28, Issue:8

    Cancer is one of the most common causes of human death worldwide; thus, numerous therapies, including chemotherapy, have been and are being continuously developed. In cancer cells, an aberrant mitotic spindle-a microtubule-based structure necessary for the equal splitting of genetic material between daughter cells-leads to genetic instability, one of the hallmarks of cancer. Thus, the building block of microtubules, tubulin, which is a heterodimer formed from α- and β-tubulin proteins, is a useful target in anti-cancer research. The surface of tubulin forms several pockets, i.e., sites that can bind factors that affect microtubules' stability. Colchicine pockets accommodate agents that induce microtubule depolymerization and, in contrast to factors that bind to other tubulin pockets, overcome multi-drug resistance. Therefore, colchicine-pocket-binding agents are of interest as anti-cancer drugs. Among the various colchicine-site-binding compounds, stilbenoids and their derivatives have been extensively studied. Herein, we report systematic studies on the antiproliferative activity of selected stilbenes and oxepine derivatives against two cancer cell lines-HCT116 and MCF-7-and two normal cell lines-HEK293 and HDF-A. The results of molecular modeling, antiproliferative activity, and immunofluorescence analyses revealed that compounds

    Topics: Antineoplastic Agents; Binding Sites; Cell Proliferation; Colchicine; HEK293 Cells; Humans; Microtubules; Neoplasms; Oxepins; Stilbenes; Tubulin; Tubulin Modulators

2023
Emissive Nanoparticles from Co-assembly of Metallatetragon and Amphiphilic Tetraphenylethylene for Cancer Theranostics.
    Inorganic chemistry, 2023, Sep-18, Volume: 62, Issue:37

    Platinum(II)-based metallacycles/cages have obtained tremendous attention due to their fascinating topology and wide range of applications, such as fluorescent materials, cell imaging, and tumor treatment. In this work, a metallatetragon (

    Topics: Coloring Agents; Humans; Nanoparticles; Neoplasms; Precision Medicine; Stilbenes; Tumor Microenvironment

2023
An NIR Discrete Metallacycle Constructed from Perylene Bisimide and Tetraphenylethylene Fluorophores for Imaging-Guided Cancer Radio-Chemotherapy.
    Advanced materials (Deerfield Beach, Fla.), 2022, Volume: 34, Issue:7

    To promote the clinical theranostic performances of platinum-based anticancer drugs, imaging capability is urgently desired, and their chemotherapeutic efficacy needs to be upgraded. Herein, a theranostic metallacycle (M) is developed for imaging-guided cancer radio-chemotherapy using perylene bisimide fluorophore (PPy) and tetraphenylethylene-based di-Pt(II) organometallic precursor (TPE-Pt) as building blocks. The formation of this discrete supramolecular coordination complex facilitates the encapsulation of M by a glutathione (GSH)-responsive amphiphilic block copolymer to prepare M-loaded nanoparticles (MNPs). TPE-Pt acts as a chemotherapeutic drug and also an excellent radiosensitizer, thus incorporating radiotherapy into the nanomedicine to accelerate the therapeutic efficacy and overcome drug resistance. The NIR-emission of PPy is employed to detect the intracellular delivery and tissue distribution of MNPs in real time. In vitro and in vivo investigations demonstrate the excellent anticancer efficacy combining chemotherapy and radiotherapy; the administration of this nanomedicine effectively inhibits the tumor growth and greatly extends the survival rate of cisplatin-resistant A2780CIS-tumor-bearing mice. Guided by in vivo fluorescence imaging, radio-chemotherapy is precisely carried out, which facilitates boosting of the therapeutic outcomes and minimizing undesired side effects. The success of this theranostic system brings new hope to supramolecular nanomedicines for their potential clinical translations.

    Topics: Animals; Cell Line, Tumor; Fluorescent Dyes; Imides; Mice; Nanoparticles; Neoplasms; Perylene; Stilbenes; Theranostic Nanomedicine

2022
Kinome-Wide Profiling Identifies Human WNK3 as a Target of Cajanin Stilbene Acid from
    International journal of molecular sciences, 2022, Jan-28, Volume: 23, Issue:3

    Topics: Binding Sites; Cajanus; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Models, Molecular; Molecular Docking Simulation; Neoplasms; Protein Binding; Protein Conformation; Protein Kinases; Protein Serine-Threonine Kinases; Salicylates; Stilbenes; Survival Analysis

2022
Design, Synthesis and Cytotoxicity of Thiazole-Based Stilbene Analogs as Novel DNA Topoisomerase IB Inhibitors.
    Molecules (Basel, Switzerland), 2022, Feb-02, Volume: 27, Issue:3

    A series of new thiazole-based stilbene analogs were designed, synthesized and evaluated for DNA topoisomerase IB (Top1) inhibitory activity. Top1-mediated relaxation assays showed that the synthesized compounds possessed variable Top1 inhibitory activity. Among them, (

    Topics: Antineoplastic Agents; Drug Design; HCT116 Cells; Humans; MCF-7 Cells; Molecular Docking Simulation; Neoplasms; Stilbenes; Thiazoles; Topoisomerase Inhibitors

2022
Discovery of a Novel Stilbene Derivative as a Microtubule Targeting Agent Capable of Inducing Cell Ferroptosis.
    Journal of medicinal chemistry, 2022, 03-24, Volume: 65, Issue:6

    Microtubule targeting agents (MTAs) are used as clinically effective chemotherapies for cancer treatment but might be limited by the acquired or intrinsic resistance of cancer cells to apoptosis. The vulnerability of therapy-resistant cancers to ferroptosis provides an alternative way to overcome drug resistance. In this study, on the basis of the MTAs obtained in our previous studies, a series of MTAs were synthesized, and detailed structure-activity relationships were obtained through extensive molecular dynamics studies. Among them, a diphenylethene derivative, compound

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Ferroptosis; Humans; Microtubules; Neoplasms; Stilbenes

2022
Self-assembled Pt(II) metallacycles enable precise cancer combination chemotherapy.
    Proceedings of the National Academy of Sciences of the United States of America, 2022, 05-17, Volume: 119, Issue:20

    Combination chemotherapy, which involves the simultaneous use of multiple anticancer drugs in adequate combinations to disrupt multiple mechanisms associated with tumor growth, has shown advantages in enhanced therapeutic efficacy and lower systemic toxicity relative to monotherapy. Herein, we employed coordination-driven self-assembly to construct discrete Pt(II) metallacycles as monodisperse, modular platforms for combining camptothecin and combretastatin A4, two chemotherapy agents with a disparate mechanism of action, in precise arrangements for combination chemotherapy. Formulation of the drug-loaded metallacycles with folic acid–functionalized amphiphilic diblock copolymers furnished nanoparticles with good solubility and stability in physiological conditions. Folic acids on the surface of the nanoparticles promote their internalization into cancer cells. The intracellular reductive environment of cancer cells induces the release of the drug molecules at an exact 1:1 ratio, leading to a synergistic anticancer efficacy. In vivo studies on tumor-bearing mice demonstrated the favorable therapeutic outcome and minimal side effects of the combination chemotherapy approach based on a self-assembled metallacycle.

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Liberation; Drug Synergism; Folic Acid; Humans; Mice; Nanoparticles; Neoplasms; Platinum; Polymers; Stilbenes; Tumor Microenvironment

2022
Piceatannol, a Dietary Polyphenol, Alleviates Adipose Tissue Loss in Pre-Clinical Model of Cancer-Associated Cachexia via Lipolysis Inhibition.
    Nutrients, 2022, May-31, Volume: 14, Issue:11

    Cancer-associated cachexia (CAC) is the nutrition-independent loss of lean muscle and adipose tissues, and results in reduced chemotherapy effectiveness and increased mortality. Preventing adipose loss is considered a key target in the early stages of cachexia. Lipolysis is considered the central driver of adipose loss in CAC. We recently found that piceatannol, but not its analogue resveratrol, exhibits an inhibitory effect on lipolysis. The objective of this study was to investigate the role of piceatannol in cancer-associated lipolysis and cachexia-induced weight loss. Cancer cell-induced lipolysis in adipocytes was stimulated using cancer-conditioned media (CCM) or co-culture with human pancreatic cancer cells and the cachexia-associated cytokines TNF-α and interleukin-6 in 3T3-L1 adipocytes. C26 colon carcinoma-bearing mice were modeled using CAC

    Topics: Adipose Tissue; Animals; Cachexia; Colonic Neoplasms; Culture Media, Conditioned; Cytokines; Lipolysis; Mice; Neoplasms; Polyphenols; Stilbenes; Weight Loss

2022
Fabrication of a phototheranostic nanoplatform for single laser-triggered NIR-II fluorescence imaging-guided photothermal/chemo/antiangiogenic combination therapy.
    Acta biomaterialia, 2022, 10-01, Volume: 151

    Phototheranostics that integrates real-time optical imaging and light-controlled therapy has recently emerged as a promising paradigm for cancer theranostics. Herein, a new small molecule dye DPP-BT-TPA with strong emission above 1000 nm and a redox-responsive prodrug camptothecin-combretastatin A4 (CPT-CA4) were designed and successfully synthesized. A multifunctional phototheranostic nanoplatform was then fabricated by encapsulating them within an amphiphilic polymer. The presence of DPP-BT-TPA enabled high-resolution imaging in the second near-infrared window (NIR-II) and efficient photothermal therapy. The prodrug was cleaved by the overexpressed glutathione (GSH) in the tumor microenvironment to release the chemotherapeutic drug CPT and the angiogenesis inhibitor CA4. Because this process can be accelerated with elevated temperature, laser-induced hyperthermia was utilized to control the drug release and enhance the therapeutic effect. Tumors in living mice were observed through NIR-II imaging after intravenous injection of the obtained nanoparticles. Improved antitumor efficacy by photothermal/chemo/antiangiogenic combination therapy was achieved with a NIR laser both in vitro and in vivo. This work provides a promising strategy for developing tumor microenvironment responsive and light-controlled theranostic platforms. STATEMENT OF SIGNIFICANCE: Fluorescence imaging in the second near-infrared (NIR-II, 1000-1700 nm) window and near-infrared light-controlled drug release have been recognized as efficient strategies for cancer theranostics. Herein, we present a phototheranostic platform fabricated with a biocompatible NIR-II emissive dye DPP-BT-TPA and a redox-responsive prodrug camptothecin-combretastatin A4 (CPT-CA4). DPP-BT-TPA not only provides high-resolution NIR-II imaging in vivo but also enables efficient photothermal therapy. In addition, the photothermal effect largely accelerates the release of the chemotherapeutic drug CPT and the angiogenesis inhibitor CA4 in the glutathione-overexpressed tumor microenvironment. Thus, the designed phototheranostic platform can be used for NIR-II imaging-guided photothermal/chemo/antiangiogenic combination therapy for tumors with a single laser.

    Topics: Angiogenesis Inhibitors; Animals; Camptothecin; Cell Line, Tumor; Glutathione; Infrared Rays; Lasers; Mice; Nanoparticles; Neoplasms; Optical Imaging; Phototherapy; Photothermal Therapy; Polymers; Prodrugs; Stilbenes; Theranostic Nanomedicine

2022
Resveratrol Carbon Dots Disrupt Mitochondrial Function in Cancer Cells.
    Bioconjugate chemistry, 2022, 09-21, Volume: 33, Issue:9

    Resveratrol, a natural polyphenol, exhibits beneficial health properties and has been touted as a potential anti-tumor agent. Here, we demonstrate potent anti-cancer effects of carbon dots (C-dots) synthesized from resveratrol. The mild synthesis conditions retained resveratrol functional moieties upon the carbon dots' (C-dots) surface, an important requisite for achieving specificity toward cancer cells and biological activities. Indeed, the disruptive effects of the resveratrol-C-dot were more pronounced in several cancer cell types compared to normal cells, underscoring targeting capabilities of the C-dots, a pertinent issue for the development of cancer therapeutics. In particular, we observed impairment of mitochondrial functionalities, including intracellular calcium release, inhibition of cytochrome-C oxidase enzyme activity, and mitochondrial membrane perturbation. Furthermore, the resveratrol C-dots were more potent than either resveratrol molecules alone, known anti-cancer polyphenolic agents such as curcumin and triphenylphosphonium, or C-dots prepared from different carbonaceous precursors. This study suggests that resveratrol-synthesized C-dots may have promising therapeutic potential as anti-cancer agents.

    Topics: Antineoplastic Agents; Apoptosis; Calcium; Carbon; Curcumin; Electron Transport Complex IV; Mitochondria; Neoplasms; Polyphenols; Resveratrol; Stilbenes

2022
Resveratrol: A Vital Therapeutic Agent with Multiple Health Benefits.
    Drug research, 2022, Volume: 72, Issue:1

    Resveratrol (RSV), the most effective stilbene phytoalexin synthesized naturally or induced in plants as part of their defense mechanism, is a key component of natural phenolic compounds and is being considered as a treatment option for a variety of diseases. RSV was discovered in the skin of red grapes, mulberries, peanuts, pines, and

    Topics: Antioxidants; Humans; Neoplasms; Resveratrol; Stilbenes

2022
A Tumor-Targeting Near-Infrared Heptamethine Cyanine Photosensitizer with Twisted Molecular Structure for Enhanced Imaging-Guided Cancer Phototherapy.
    Journal of the American Chemical Society, 2021, 12-15, Volume: 143, Issue:49

    In recent years, cancer phototherapy has been extensively studied as noninvasive cancer treatment. To present efficient recognition toward cancer cells, most photosensitizers (PSs) are required to couple with tumor-targeted ligands. Interestingly, the heptamethine cyanine IR780 displays an intrinsic tumor-targeted feature even without modification. However, the photothermal efficacy and photostability of IR780 are not sufficient enough for clinical use. Herein, we involve a twisted structure of tetraphenylethene (TPE) between two molecules of IR780 to improve the photothermal conversion efficiency (PCE). The obtained molecule T780T shows strong near-infrared (NIR) fluorescence and improved PCE (38.5%) in the dispersed state. Also, the photothermal stability and ROS generation capability of T780T at the NIR range (808 nm) are both promoted. In the aqueous phase, the T780T was formulated into uniform nanoaggregates (∼200 nm) with extremely low fluorescence and PTT response, which would reduce in vivo imaging background and side effect of PTT response in normal tissues. After intravenous injection into tumor-bearing mice, the T780T nanoaggregates display high tumor accumulation and thus remarkably inhibit the tumor growth. Moreover, the enhanced photostability of the T780T allows for twice irradiation after one injection and leads to more significant tumor inhibition. In summary, our study presents a tumor-targeted small-molecule PS for efficient cancer therapy and brings a new design of heptamethine cyanine PS for potential clinical applications.

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Fluorescent Dyes; Humans; Indoles; Infrared Rays; Mice, Inbred BALB C; Neoplasms; Photochemotherapy; Photosensitizing Agents; Photothermal Therapy; Stilbenes

2021
Role of Resveratrol in Modulating microRNAs in Human Diseases: From Cancer to Inflammatory Disorder.
    Current medicinal chemistry, 2021, Volume: 28, Issue:2

    Cancer and inflammatory disorders are two important public health issues worldwide with significant socio.economic impacts. Despite several efforts, the current therapeutic platforms are associated with severe limitations. Therefore, developing new therapeutic strategies for the treatment of these diseases is a top priority. Besides current therapies, the utilization of natural compounds has emerged as a new horizon for the treatment of cancer and inflammatory disorders as well. Such natural compounds could be used either alone or in combination with the standard cancer therapeutic modalities such as chemotherapy, radiotherapy, and immunotherapy. Resveratrol is a polyphenolic compound that is found in grapes as well as other foods. It has been found that this medicinal agent displays a wide pharmacological spectrum, including anti-cancer, anti-inflammatory, anti-microbial, and antioxidant activities. Recently, clinical and pre-clinical studies have highlighted the anti-cancer and anti-inflammatory effects of resveratrol. Increasing evidence revealed that resveratrol exerts its therapeutic effects by targeting various cellular and molecular mechanisms. Among cellular and molecular targets that are modulated by resveratrol, microRNAs (miRNAs) have appeared as key targets. MiRNAs are short non-coding RNAs that act as epigenetic regulators. These molecules are involved in many processes that are involved in the initiation and progression of cancer and inflammatory disorders. Herein, we summarized various miRNAs that are directly/indirectly influenced by resveratrol in cancer and inflammatory disorders.

    Topics: Anti-Inflammatory Agents; Antioxidants; Humans; MicroRNAs; Neoplasms; Resveratrol; Stilbenes

2021
Cyclic bridged analogs of isoCA-4: Design, synthesis and biological evaluation.
    European journal of medicinal chemistry, 2021, Jan-01, Volume: 209

    In this work, a series of cyclic bridged analogs of isocombretastatin A-4 (isoCA-4) with phenyl or pyridine linkers were designed and synthesized. The synthesis of the desired analogs was performed by the formation of nitro-vinyl intermediates, followed by a Cadogan cyclization. Structure activity relationship (SAR) study demonstrates the critical role of the combination of quinaldine as ring A, pyridine as the linker, and indole as ring B in the same molecule, for the cytotoxic activity. Among all tested compounds, compound 42 showed the highest antiproliferative activity against a panel of cancer cell lines with average IC50 values of 5.6 nM. Also, compound 42 showed high antiproliferative activity against the MDR1-overexpressing K562R cell line; thus, it was 1.5- and 12-fold more active than the reference compounds, isoCA-4 and CA-4, respectively. Moreover, 42 displayed a strong antiproliferative activity against the colon-carcinoma cells (HT-29), which are resistant to combretastatin A-4 and isoCA-4, and it was found to be 8000-fold more active than natural CA-4. Compound 42 also effectively inhibited tubulin polymerization both in vitro and in cells, and induced cell cycle arrest in G2/M phase. Next, we demonstrated that compound 42 dose-dependently caused caspase-induced apoptosis of K562 cells through mitochondrial dysfunction. Finally, we evaluated the effect of compound 42 in human no cancer cells compared to the reference compound. We demonstrated that 42 was 73 times less cytotoxic than isoCA-4 in quiescent peripheral blood lymphocytes (PBLs). In summary, these results suggest that compound 42 represents a promising tubulin inhibitor worthy of further investigation.

    Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclization; Drug Design; Humans; Molecular Docking Simulation; Neoplasms; Stilbenes; Tubulin; Tubulin Modulators

2021
Combretastatin A4-derived payloads for antibody-drug conjugates.
    European journal of medicinal chemistry, 2021, Apr-15, Volume: 216

    We describe the use of natural product combretastatin A4 (CA4) as a versatile new payload for the construction of antibody-drug conjugates (ADCs). Cetuximab conjugates consisting of CA4 derivatives were site-specially prepared by disulfide re-bridging approach using cleavable and non-cleavable linkers. These ADCs retained antigen binding and internalization efficiency and exhibited high potencies against cancer cell lines in vitro. The conjugates also demonstrated significant antitumor activities in EGFR-positive xenograft models without observed toxicities. CA4 appears to be a viable payload option for ADCs research and development.

    Topics: Animals; Cell Line, Tumor; Cell Survival; Cetuximab; Disulfides; Drug Design; Humans; Immunoconjugates; Male; Mice; Mice, Inbred NOD; Neoplasms; Stilbenes; Transplantation, Heterologous

2021
Nanoparticles Composed of PEGylated Alternating Copolymer-Combretastatin A4 Conjugate for Cancer Therapy.
    Macromolecular bioscience, 2021, Volume: 21, Issue:8

    Chemotherapy using vascular targeting agents is an emerging new approach for cancer therapy. Combretastatin A4 (CA4) is a leading vascular-disrupting agent that targets the tumor blood vasculature for clinical tumor elimination. However, the extremely poor water solubility of CA4 hinders its biomedical applications. In this study, nanoparticles composed of novel PEGylated alternating copolymer-CA4 conjugates are designed to improve the therapeutic efficiency of CA4. First, an alternating copolymer with an alkene-pendant is synthesized by mPEG-OH-initiated ring-opening copolymerization. Then, side carboxyl groups are introduced by a thio-ene "click" chemical reaction, followed with CA4 conjugation through the Yamaguchi-reaction, resulting in the target copolymer, mPEG-b-P(PA-alt-GCA4). Interestingly, the polymer-drug conjugates can self-assemble into nanoparticles with an average diameter of 55.6 nm. The in vitro drug release and cytotoxicity of the obtained CA4-NPs toward 4T1 cells are investigated. Finally, the antitumor efficiency is evaluated in a 4T1-tumor bearing murine model. The in vivo test results demonstrate that CA4-NPs inhibited tumor growth much more efficiently at doses of 30 and 60 mg kg

    Topics: Animals; Cell Line, Tumor; Mice; Nanoparticles; Neoplasms; Polyethylene Glycols; Polymers; Stilbenes

2021
Targeting of VPS18 by the lysosomotropic agent RDN reverses TFE3-mediated drug resistance.
    Signal transduction and targeted therapy, 2021, 06-07, Volume: 6, Issue:1

    Topics: Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Neoplasms; PC-3 Cells; Phenyl Ethers; Stilbenes; Vesicular Transport Proteins

2021
Tumor regression and potentiation of polymeric vascular disrupting therapy through reprogramming of a hypoxia microenvironment with temsirolimus.
    Biomaterials science, 2020, Jan-01, Volume: 8, Issue:1

    Although the polymeric vascular disrupting agent (poly(l-glutamic acid)-graft-methoxy poly(ethylene glycol)/combretastatin A4) nanoparticles (CA4-NPs) has great potential to inhibit cancer growth, it is still a challenge to avert tumor recurrence and metastasis after treatment. It is mainly tightly associated with hypoxia induced by CA4-NPs, which can activate many downstream genes regulating tumor growth and metastasis. Herein, to relieve a tumor hypoxia microenvironment, the mTOR inhibitor temsirolimus was employed to modulate the tumor microenvironment when treated with CA4-NPs. In vitro MTT experiments strongly verified that the combination of temsirolimus with polymeric CA4-NPs exhibited an additive toxicity to 4T1 cells. An in vivo study with the 4T1 mammary adenocarcinoma model revealed that consistent with the proposed scenario, combination therapy with CA4-NPs plus temsirolimus suppressed tumor growth significantly more strongly compared to either CA4-NPs or temsirolimus monotherapy, and the inhibition rate to 4T1 tumor with a volume of 300 mm

    Topics: Animals; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Female; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Polyglutamic Acid; Polymers; Sirolimus; Stilbenes; Tumor Microenvironment

2020
Stiff-Stilbene Ligands Target G-Quadruplex DNA and Exhibit Selective Anticancer and Antiparasitic Activity.
    Chemistry (Weinheim an der Bergstrasse, Germany), 2020, May-15, Volume: 26, Issue:28

    G-quadruplex nucleic acid structures have long been studied as anticancer targets whilst their potential in antiparasitic therapy has only recently been recognized and barely explored. Herein, we report the synthesis, biophysical characterization, and in vitro screening of a series of stiff-stilbene G4 binding ligands featuring different electronics, side-chain chemistries, and molecular geometries. The ligands display selectivity for G4 DNA over duplex DNA and exhibit nanomolar toxicity against Trypasanoma brucei and HeLa cancer cells whilst remaining up to two orders of magnitude less toxic to non-tumoral mammalian cell line MRC-5. Our study demonstrates that stiff-stilbenes show exciting potential as the basis of selective anticancer and antiparasitic therapies. To achieve the most efficient G4 recognition the scaffold must possess the optimal electronics, substitution pattern and correct molecular configuration.

    Topics: Antineoplastic Agents; Antiparasitic Agents; Binding Sites; Circular Dichroism; DNA; Drug Design; G-Quadruplexes; Humans; Neoplasms; Stilbenes; Structure-Activity Relationship; Telomere

2020
Pyridinium-Substituted Tetraphenylethylenes Functionalized with Alkyl Chains as Autophagy Modulators for Cancer Therapy.
    Angewandte Chemie (International ed. in English), 2020, 06-15, Volume: 59, Issue:25

    Tuning autophagy in a controlled manner could facilitate cancer therapy but it remains challenging. Pyridinium-substituted tetraphenylethylene salts (PTPE 1-3), able to target mitochondria and disrupt autophagy after forming complexes with albumin, are reported. Mitochondrion affinity and autophagy-inducing activity are improved by prolonging the length of alkyl chains in PTPE 1-3. PTPE 1-3 demonstrate proautophagic activity and a mitophagy blockage effect. Failure of autophagosome-lysosome fusion in downstream autophagy flux results in cancer cell death. Moreover, fast formation of complexes of PTPE 1-3 with albumin in blood can facilitate biomimetic delivery and deep tumor penetration. Efficient tumor accumulation and effective tumor suppression are successfully demonstrated with in vitro and in vivo studies. PTPE 1-3 salts exhibit dual functionality: they target and image mitochondria because of aggregation-induced emission effects and they are promising for cancer therapy.

    Topics: Alkylation; Antineoplastic Agents; Autophagy; Cell Fusion; Cell Line, Tumor; Hep G2 Cells; Humans; Neoplasms; Pyridinium Compounds; Stilbenes

2020
AIEgens Conjugation Improves the Photothermal Efficacy and Near-Infrared Imaging of Heptamethine Cyanine IR-780.
    ACS applied materials & interfaces, 2020, Apr-08, Volume: 12, Issue:14

    Near-infrared (NIR) fluorescent probes can deeply penetrate through tissues with little damage. To facilitate image-guided theranostics, researchers usually apply a desired amount of photosensitizers to achieve effective photothermal responses. However, these probes could easily suffer from low photostability and aggregated-caused quenching effect in high concentrations. In this paper, the rational incorporation of an aggregated-induced emission (AIE) unit into the structure of heptamethine cyanine IR-780 is reported. Using tetraphenylethene (TPE) as an AIE core, we synthesize three TPE-modified IR-780 probes (IR-780 AIEgens) via different linkages. The IR-780 derivatives all show enhanced AIE features, in which the probe with an ether linkage (IR780-O-TPE) is superior in rapid cell uptake, high targeting capacity, and good photostability. Moreover, IR780-O-TPE exhibits the strongest cytotoxicity to HeLa cells (IC

    Topics: Animals; Antineoplastic Agents; Carbocyanines; Fluorescent Dyes; HeLa Cells; Humans; Indoles; Mice; Neoplasms; Optical Imaging; Photothermal Therapy; Spectroscopy, Near-Infrared; Stilbenes

2020
Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib.
    International journal of molecular sciences, 2020, Nov-25, Volume: 21, Issue:23

    In this study, we aimed at the application of the concept of photopharmacology to the approved vascular endothelial growth factor receptor (VEGFR)-2 kinase inhibitor axitinib. In a previous study, we found out that the photoisomerization of axitinib's stilbene-like double bond is unidirectional in aqueous solution due to a competing irreversible [2+2]-cycloaddition. Therefore, we next set out to azologize axitinib by means of incorporating azobenzenes as well as diazocine moieties as photoresponsive elements. Conceptually, diazocines (bridged azobenzenes) show favorable photoswitching properties compared to standard azobenzenes because the thermodynamically stable

    Topics: Axitinib; Azo Compounds; Carbon; Humans; Isomerism; Light; Neoplasms; Photochemical Processes; Stilbenes; Sulfur; Thermodynamics; Vascular Endothelial Growth Factor Receptor-1; Water

2020
Redox-responsive tetraphenylethylene-buried crosslinked vesicles for enhanced drug loading and efficient drug delivery monitoring.
    Journal of materials chemistry. B, 2019, 12-21, Volume: 7, Issue:47

    Liposomes have been applied extensively as nanocarriers in the clinic (e.g., to deliver anticancer drugs) due to their biocompatibility and internal cavity structures. However, their low drug-loading capacity (DLC; <10%) and uncontrolled release reduce their efficacy in cancer treatment. To improve the DLC and monitor release of drugs in cells in real-time, stimuli-responsive vesicles must be developed. We present various amphiphilic tetraphenylethylene (TPE)-containing compounds designed to self-assemble into liposome-like vesicles that can load both hydrophilic and hydrophobic drugs. The highest DLC for doxorubicin (DOX) was ≤26% for vesicles (diameter = 105 nm) that could encapsulate hydrophilic DOX in the interior water pool and hydrophobic DOX viaπ-π stacking interactions between DOX and the TPE moiety. The stable vesicles could respond rapidly to overexpressed glutathione in the tumor microenvironment to release loaded DOX for cancer therapy. Vesicles modified by active targeting groups showed more efficacious tumor treatment compared with unmodified vesicles and free DOX in vitro and in vivo. Simultaneously we observed, spatiotemporally, the subcellular location of the delivery system and release process of DOX. Our work provides a novel nano-engineering technology to integrate the desired properties for anticancer theranostics: high DLC, stability, stimuli-responsiveness to the cancer environment, drug-delivery monitoring, active targeting, and suppression of tumor growth. These novel vesicles could be employed as multifunctional drug-delivery systems for cancer therapy.

    Topics: Animals; Antibiotics, Antineoplastic; Cell Survival; Doxorubicin; Drug Liberation; Half-Life; Hep G2 Cells; Humans; Liposomes; Mice; Mice, Inbred BALB C; Neoplasms; Oxidation-Reduction; Particle Size; Stilbenes

2019
DHS (trans-4,4'-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2).
    Oncogene, 2019, Volume: 38, Issue:13

    DNA replication machinery is responsible for accurate and efficient duplication of the chromosome. Since inhibition of DNA replication can lead to replication fork stalling, resulting in DNA damage and apoptotic death, inhibitors of DNA replication are commonly used in cancer chemotherapy. Ribonucleotide reductase (RNR) is the rate-limiting enzyme in the biosynthesis of deoxyribonucleoside triphosphates (dNTPs) that are essential for DNA replication and DNA damage repair. Gemcitabine, a nucleotide analog that inhibits RNR, has been used to treat various cancers. However, patients often develop resistance to this drug during treatment. Thus, new drugs that inhibit RNR are needed to be developed. In this study, we identified a synthetic analog of resveratrol (3,5,4'-trihydroxy-trans-stilbene), termed DHS (trans-4,4'-dihydroxystilbene), that acts as a potent inhibitor of DNA replication. Molecular docking analysis identified the RRM2 (ribonucleotide reductase regulatory subunit M2) of RNR as a direct target of DHS. At the molecular level, DHS induced cyclin F-mediated down-regulation of RRM2 by the proteasome. Thus, treatment of cells with DHS reduced RNR activity and consequently decreased synthesis of dNTPs with concomitant inhibition of DNA replication, arrest of cells at S-phase, DNA damage, and finally apoptosis. In mouse models of tumor xenografts, DHS was efficacious against pancreatic, ovarian, and colorectal cancer cells. Moreover, DHS overcame both gemcitabine resistance in pancreatic cancer and cisplatin resistance in ovarian cancer. Thus, DHS is a novel anti-cancer agent that targets RRM2 with therapeutic potential either alone or in combination with other agents to arrest cancer development.

    Topics: Animals; Cell Line, Tumor; Cell Proliferation; DNA Replication; Enzyme Inhibitors; Female; HCT116 Cells; Humans; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Neoplasms; Protein Subunits; Ribonucleotide Reductases; Stilbenes; Xenograft Model Antitumor Assays

2019
Bio-orthogonal AIE Dots Based on Polyyne-Bridged Red-emissive AIEgen for Tumor Metabolic Labeling and Targeted Imaging.
    Chemistry, an Asian journal, 2019, Mar-15, Volume: 14, Issue:6

    In this work, we aim to develop cancer cell-targeting AIE dots based on a polyyne-bridged red-emissive AIEgen, 2TPE-4E, through the combination of metabolic engineering and bio-orthogonal reactions. Azide groups on a tumor were efficiently produced by intravenous injection of Ac4ManNAz and glycol-metabolic engineering. These bio-orthogonal azide groups could facilitate the specific targeting of DBCO-AIE dots to the tumor cells undergoing metal-free click reaction in vivo. The efficiency of this targeting strategy could be further improved with the development of new bio-orthogonal chemical groups with higher reactivity and a large amount of AIEgens could be delivered to the tumor for diagnosis.

    Topics: Animals; Azides; Click Chemistry; Female; Fluorescent Dyes; Hexosamines; Humans; MCF-7 Cells; Metabolic Engineering; Mice; Mice, Inbred BALB C; Microscopy, Confocal; Neoplasms; Polyynes; Quantum Dots; Spectrometry, Fluorescence; Stilbenes; Transplantation, Heterologous

2019
Amphiphilic Tetraphenylethene-Based Pyridinium Salt for Selective Cell-Membrane Imaging and Room-Light-Induced Special Reactive Oxygen Species Generation.
    ACS applied materials & interfaces, 2019, Mar-20, Volume: 11, Issue:11

    The cell membrane is the protecting frontier of cells, which is crucial for maintaining cell integrity, and has a close relationship with cell growth and death. There is a growing need for cell membrane imaging and monitoring in both living and dying cells. Herein, we report a new amphiphilic tetraphenylethene-based pyridinium salt (TPE-MEM) with aggregation-induced emission features for discriminatory cell membrane imaging. The fluorogenic probe with high yield was synthesized following asymmetric McMurry reaction, Williamson ether synthesis reaction, Suzuki coupling, and aldol condensation between a double-charged pyridinium salt and hexyloxytetraphenylethene benzaldehyde. TPE-MEM shows good water solubility, biocompatibility, and cell membrane specificity. Interestingly, a reactive oxygen species (ROS) is produced by the molecule (TPE-MEM) under room-light irradiation, which could destroy the integrity of the plasma membrane and cause cell necrosis. This enables a visible observation of cell necrosis and the phototherapeutic effect under a mild condition. Preliminary animal investigations also demonstrated the photodynamic therapy (PDT) effectiveness of TPE-MEM in tumor growth inhibition. We conclude that TPE-MEM is potentially a cell membrane-selective photosensitizer for PDT and it is worthy of further exploration of the phototherapeutic effect on animals systematically.

    Topics: Animals; Cell Membrane; Cell Survival; Fluorescent Dyes; HeLa Cells; Humans; Light; Mice; Mice, Nude; Microscopy, Confocal; Neoplasms; Photochemotherapy; Photosensitizing Agents; Pyridinium Compounds; Reactive Oxygen Species; Salts; Stilbenes; Transplantation, Heterologous

2019
A red mitochondria-targeted AIEgen for visualizing H
    The Analyst, 2019, May-21, Volume: 144, Issue:10

    Hydrogen sulfide (H

    Topics: Animals; Drug Stability; Fluorescent Dyes; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen Sulfide; Indoles; Light; MCF-7 Cells; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Mitochondria; Neoplasms; Stilbenes

2019
Design, Synthesis and Cancer Cell Growth Inhibition Evaluation of New Aminoquinone Hybrid Molecules.
    Molecules (Basel, Switzerland), 2019, Jun-14, Volume: 24, Issue:12

    Molecular hybridization has proven to be a successful multi-target strategy in the design and development of new antitumor agents. Based on this rational approach, we have planned hybrid molecules containing covalently linked pharmacophoric units, present individually in compounds acting as inhibitors of the cancer protein targets tubulin, human topoisomerase II and ROCK1. Seven new molecules, selected by docking calculation of the complexes with each of the proteins taken into consideration, have been efficiently synthesized starting from 2,3-dichloro-1,4-naphtoquinone or 6,7-dichloro-5,8-quinolinquinone. By screening the full National Cancer Institute (NCI) panel, including 60 human cancer cell lines, four molecules displayed good and sometimes better growth inhibition GI

    Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Naphthoquinones; Neoplasms; Podophyllotoxin; Pyridines; Quinolines; rho-Associated Kinases; Stilbenes; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tubulin; Tubulin Modulators

2019
Determination of the in vitro metabolic stability and metabolites of the anticancer derivative riccardin D-N in human and mouse hepatic S9 fractions using HPLC-Q-LIT-MS.
    Journal of pharmaceutical and biomedical analysis, 2019, Sep-10, Volume: 174

    Riccardin D-N (RD-N) is an aminomethylated derivative of the macrocyclic bisbibenzyl compound riccardin D (RD), which has shown stronger activity against cancer cells than RD. However, there has been no research on the metabolism of RD-N. The present study aimed to characterize the in vitro metabolism and metabolic stability of RD-N after incubation with mouse and human hepatic S9 fractions using high performance liquid chromatography-hybrid triple quadrupole/linear ion trap mass spectrometry (HPLC-Q-LIT-MS). Multiple ion monitoring (MIM) and multiple reaction monitoring (MRM)-information dependent acquisition-enhanced product ion (MIM/MRM-IDA-EPI) scans were used to identify the metabolites formed. MRM scans were also used to quantify the changes in the amount of RD-N and to semi-quantify the main metabolites. Twenty-eight metabolic products were detected and 25 structures were predicted. Hydroxylation, dehydrogenation, glucuronidation, and methylation were proposed to be the principle metabolic pathways in the in vitro incubation with human and mouse hepatic S9 fractions. There were differences in the number and abundance of RD-N metabolites between the human and mouse hepatic S9 fractions. RD-N was shown to have good metabolic stability. After 2 h of incubation, 44% of the original RD-N remained in the human hepatic S9 fraction compared with 22% in the mouse. The major metabolites of RD-N, M4, M8, M20 and M21, were monitored semi-quantitatively using the typical transitions. Finally, HPLC-Q-LIT-MS was used for the identification and quantitation of the metabolites of R D-N, which is a simple and efficient method to rapidly screen potential drug candidates.

    Topics: Animals; Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Humans; Hydrogen; Hydroxylation; Liver; Methylation; Mice; Microsomes, Liver; Neoplasms; Oxygen; Phenyl Ethers; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Stilbenes

2019
Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature.
    Biotechnology and bioengineering, 2018, Volume: 115, Issue:6

    Blood vessel development is critical for the continued growth and progression of solid tumors and, therefore, makes an attractive target for improving cancer therapy. Indeed, vascular-targeted therapies have been extensively explored but they have shown minimal efficacy as monotherapies. Combretastatin A4 (CA-4) is a tubulin-binding vascular disrupting agent that selectively targets the established tumor endothelium, causing rapid vascular beak down. Despite its potent anticancer potential, the drug has dose-limiting side effects, particularly in the form of cardiovascular toxicity. Furthermore, its poor aqueous solubility and the resulting limited bioavailability hinder its antitumor activity in the clinic. To improve the therapeutic efficacy of CA-4, we investigated its application as a combination therapy with doxorubicin (Dox) in a tumor vasculature targeted delivery vehicle: peptide-modified cross-linked multilamellar liposomal vesicles (cMLVs). In vitro cell culture studies showed that a tumor vasculature-targeting peptide, RIF7, could facilitate higher cellular uptake of drug-loaded cMLVs, and consequently enhance the antitumor efficacy in both drug resistant B16 mouse melanoma and human MDA-MB-231 breast cancer cells. In vivo, upon intravenous injection, targeted cMLVs could efficiently deliver both Dox and CA-4 to significantly slow tumor growth through the specific interaction of the targeting peptide with its receptor on the surface of tumor vasculature. This study demonstrates the potential of our novel targeted combination therapy delivery vehicle to improve the outcome of cancer treatment.

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Humans; Mice; Models, Biological; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Stilbenes

2018
Covalent functionalization of SWCNT with combretastatin A4 for cancer therapy.
    Nanotechnology, 2018, Jun-15, Volume: 29, Issue:24

    Single walled carbon nanotubes (SWCNT) are currently under intensive investigation by many labs all over the world for being promising candidates for cancer chemotherapy delivery. On the other hand, combretastatin A4 (CA4) is an anticancer drug that induces cell apoptosis by inhibiting tubulin polymerization. However, it has the disadvantage of low water solubility and the non-selective targeting. Therefore, we aim to create nano-drug from the functionalization of SWCNT covalently with CA4 through click reaction in the presence of tetraethylene glycol linker in order to improve its dispersibility. Scanning electron microscopy and transmission electron microscopy showed good dispersibility of the functionalized SWCNT with diameters of 5-15 nm. Moreover, thermogravometric analysis showed that the efficiency of SWCNT functionalization was around 45%. The in vitro release profile of CA4 at physiological conditions showed that approximately 90% of the loaded drug was released over 50 h. After that MTS test was used to determine the suitable concentration range for the in vitro investigation of the SWCNT-CA4. After that the cytotoxic activity of the SWCNT-CA4 was evaluated by flow cytometry using annexin V/propidium iodide (PI) test. In comparison with free CA4, SWCNT-CA4 treatment demonstrated a significant increase in necrotic cells (around 50%) at the expense of the proportion of the apoptotic cells. Moreover, cell cycle PI test demonstrated that free CA4 and SWCNT-CA4 caused G2/M arrest. However with CA4 treatment higher proportion of cells were in the S-phase while with SWCNT-CA4 treatment greater proportion of cells appeared to be in the G1-phase. Taken together, the provided data suggest that the novel SWCNT-CA4 has a significant anticancer activity that might be superior to that of free CA4.

    Topics: Apoptosis; Cell Cycle; Cell Survival; Click Chemistry; Drug Liberation; HeLa Cells; Humans; Nanotubes, Carbon; Neoplasms; Stilbenes; Thermogravimetry

2018
Inhibition of cancer progression by a novel trans-stilbene derivative through disruption of microtubule dynamics, driving G2/M arrest, and p53-dependent apoptosis.
    Cell death & disease, 2018, 05-01, Volume: 9, Issue:5

    Resveratrol, a trans-stilbene polyphenolic compound and its synthetic analogs are widely used bioactive molecules due to their remarkable chemo-preventive potential. Here, we have identified a novel synthetic trans-stilbene compound, Z-DAN-11 ((Z)-3-(3, 4-dimethoxyphenyl)-2-(3, 4, 5-trimethoxyphenyl) acrylonitrile) which shows remarkable efficacy in blocking tumor growth and progression both in vitro and in vivo. Z-DAN-11 inhibits proliferation of cancer cells in vitro through microtubule depolymerization that induced G2/M arrest and consequently leads to apoptotic cell death. More importantly, Z-DAN-11 shows limited cytotoxicity to normal cells as compared to cancer cells. Quite interestingly, we have found that Z-DAN-11-mediated ROS production helps in dramatic alteration in the mitochondrial redox status which critically contributes to the apoptosis. Mechanistic studies reveal that Z-DAN-11 induces the expression of pro-apoptotic proteins and decreases anti-apoptotic protein expression that decisively helps in the activation of caspase 8, caspase 9, and caspase 3, leading to cleavage of PARP1 and cell death via intrinsic and extrinsic pathways of apoptosis. Moreover, Z-DAN-11-mediated apoptosis of cancer cells is through a partial p53-dependent pathway, since both HCT116 p53

    Topics: A549 Cells; Animals; Apoptosis; Caspases; Female; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; M Phase Cell Cycle Checkpoints; MCF-7 Cells; Mice; Mice, Inbred BALB C; Microtubules; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Reactive Oxygen Species; Stilbenes; Tumor Suppressor Protein p53

2018
A new inhibitor of glucose-6-phosphate dehydrogenase blocks pentose phosphate pathway and suppresses malignant proliferation and metastasis in vivo.
    Cell death & disease, 2018, 05-01, Volume: 9, Issue:5

    Pentose phosphate pathway (PPP) is a major glucose metabolism pathway, which has a fundamental role in cancer growth and metastasis. Even though PPP blockade has been pointed out as a very promising strategy against cancer, effective anti-PPP agents are not still available in the clinical setting. Here we demonstrate that the natural molecule polydatin inhibits glucose-6-phosphate dehydrogenase (G6PD), the key enzyme of PPP. Polydatin blocks G6PD causing accumulation of reactive oxygen species and strong increase of endoplasmic reticulum stress. These effects are followed by cell cycle block in S phase, an about 50% of apoptosis, and 60% inhibition of invasion in vitro. Accordingly, in an orthotopic metastatic model of tongue cancer, 100 mg/kg polydatin induced an about 30% tumor size reduction with an about 80% inhibition of lymph node metastases and 50% reduction of lymph node size (p < 0.005). Polydatin is not toxic in animals up to a dose of 200 mg/kg and a phase II clinical trial shows that it is also well tolerated in humans (40 mg twice a day for 90 days). Thus, polydatin may be used as a reliable tool to limit human cancer growth and metastatic spread.

    Topics: Animals; Glucosephosphate Dehydrogenase; Glucosides; Humans; Male; MCF-7 Cells; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Pentose Phosphate Pathway; S Phase Cell Cycle Checkpoints; Stilbenes; Xenograft Model Antitumor Assays

2018
A single dose of intravenous combretastatin A4-phosphate is reasonably well tolerated and significantly reduces tumour vascularization in canine spontaneous cancers.
    Veterinary and comparative oncology, 2018, Volume: 16, Issue:4

    Combretastatin A4-phosphate (CA4P) is an anti-tumour vascular targeting agent which selectively blocks tumour blood flow. Research on CA4P in rodent tumour models is extensive; however, knowledge of its effect on spontaneous cancer is scarce. This study was conducted in canine patients with spontaneous solid tumours. The goal was to assess the toxicity and efficacy of CA4P in various spontaneous tumour types. Eight dogs with spontaneous tumours were enrolled and treated with a single dose of 75 mg m

    Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Cell Count; Dog Diseases; Dogs; Female; Injections, Intravenous; Male; Neoplasms; Neovascularization, Pathologic; Stilbenes; Ultrasonography, Doppler, Pulsed

2018
Rhaponticin decreases the metastatic and angiogenic abilities of cancer cells via suppression of the HIF‑1α pathway.
    International journal of oncology, 2018, Volume: 53, Issue:3

    Rhaponticin (RA; 3'5-dihydroxy-4'-methoxystilbene 3-O-β-D‑glucopyranoside) is a component isolated from various medicinal herbs including Rheum undulatum L. RA has been reported to be an effective treatment for allergy, diabetes, thrombosis, liver steatosis, lung fibrosis and colitis. In addition, RA effectively inhibits tumor growth and induces apoptosis; however, the effects of RA, at non-cytotoxic doses, on the metastasis and angiogenesis of malignant cancer cells have, to be the best of our knowledge, not been identified. In the present study, it was identified that RA suppressed the metastatic potential of MDA‑MB231 breast cancer cells, including colony formation, migration and invasion. Human umbilical vein endothelial cells (HUVECs) treated with RA exhibited a decreased ability to form tube-like networks and to migrate across a Transwell membrane, when compared with RA‑untreated HUVECs. Using the chick chorioallantoic membrane assay, RA treatment significantly suppressed spontaneous and vascular endothelial growth factor (VEGF)-induced angiogenesis. Furthermore, RA inhibited the production of pro-angiogenic factors, including matrix metalloproteinase (MMP)-9, pentraxin‑3, interleukin-8, VEGF and placental growth factor under normoxic and hypoxic conditions, and suppressed the phorbol 12-myristate 13-acetate-induced increase in the gelatinolytic MMP‑9 activity and MMP‑9 expression in HT1080 cells. RA also significantly inhibited the hypoxia-inducible factor (HIF)-1α pathway, leading to decreased HIF‑1α accumulation and HIF‑1α nuclear expression under hypoxia. These results indicated that RA exhibits potent anti‑metastatic and anti‑angiogenic activities with no cytotoxicity via suppression of the HIF‑1α signaling pathway. Thus, RA may control malignant cancer cells by inhibiting the spread from primary tumors and expansion to distant organs.

    Topics: Angiogenesis Inhibitors; Animals; Biological Assay; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Chick Embryo; Drug Screening Assays, Antitumor; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Neovascularization, Pathologic; Rheum; Signal Transduction; Stilbenes; Toxicity Tests; Vascular Endothelial Growth Factor A

2018
Synthesis and biological evaluation of cyclic derivatives of combretastatin A-4 containing group 14 elements.
    Organic & biomolecular chemistry, 2018, 08-15, Volume: 16, Issue:32

    Several tricyclic compounds inspired by the structure of combretastatin A-4 and bearing group 14 elements have been synthesized by homocoupling lithiated aryl fragments followed by ring-closing metathesis. These tricyclic compounds and their diolefin precursors were evaluated for their antiproliferative action on the tumor cell lines HT-29, MCF-7, HeLa and A-549 and on the non-tumor cell line HEK-293. In addition, their effects on the cell cycle were also measured. The tricyclic compounds show antiproliferative activity similar to that of combretastatin A-4, even though they are not so active in arresting the cell cycle. However, some diolefin precursors are able to cause accumulation of cells in the G2/M phase in a higher percentage than combretastatin A-4 itself. Inhibition of endothelial tube formation and VEGFR-2 phosphorylation of some selected compounds is comparable to that of combretastatin A-4, particularly those of tin-containing compounds 23c and 26c, whose actions exceed those of sorafenib, a clinically used VEGFR-2 inhibitor.

    Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Neoplasms; Stilbenes; Tubulin; Vascular Endothelial Growth Factor Receptor-2

2018
A turn-on fluorescence probe based on aggregation-induced emission for leucine aminopeptidase in living cells and tumor tissue.
    Analytica chimica acta, 2018, Nov-15, Volume: 1031

    Abnormally-expressed leucine aminopeptidase (LAP) is associated with diverse physiological and pathological disorders; hence developing a highly selective and sensitive detection system for LAP is of great significance. Herein, a fluorescent light-up system with aggregation-induced emission (AIE) characteristic, (DPA-TPE-Leu) has been developed for detecting LAP, in which the recognition unit l-leucine amide group also acts as the hydrophilic moiety. Upon LAP-triggered enzymatic reaction, l-leucine amide moiety is cleaved from the probe molecule, resulting in the formation and aggregation of the hydrophobic reaction product (DPE-TPE-OH) with AIE effect and thus giving out the turn-on green fluorescence. The system features excellent photostability, large Stokes shift (194 nm), good water solubility, high sensitivity with the detection limit of 0.16 U L

    Topics: Animals; Diphenylamine; Fluorescent Dyes; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Leucyl Aminopeptidase; Limit of Detection; Mice; Mice, Nude; Microscopy, Fluorescence; Nanostructures; Neoplasms; Optical Imaging; Spectrometry, Fluorescence; Stilbenes; Transplantation, Heterologous

2018
Red/NIR-Emissive Benzo[d]imidazole-Cored AIEgens: Facile Molecular Design for Wavelength Extending and In Vivo Tumor Metabolic Imaging.
    Advanced materials (Deerfield Beach, Fla.), 2018, Volume: 30, Issue:50

    Aggregation-induced emission (AIE) luminogens (AIEgens) with red/near-infrared (NIR) emissions are appealing for applications in optoelectronics and biomedical engineering owing to their intrinsic advantages of efficient solid-state emission, low background, and deep tissue penetration. In this context, an AIEgen with long-wavelength emission is synthesized by introducing tetraphenylethene (TPE) to the periphery of electron-deficient spiro-benzo[d]imidazole-2,1'-cyclohexane (BI). The resulting AIEgen, abbreviated as 2TPE-BI, adopts a donor-acceptor structure and shows bathochromic absorption and emission with a larger Stokes shift of 157 nm in acetonitrile than that based on benzo[c][1,2,5]thiadiazole. It also exhibits a high solid-state fluorescence quantum yield of 56.6%. By further insertion of thiophene to its molecular structure generates 2TPE-2T-BI with higher conjugation and NIR emission. 2TPE-2T-BI can be fabricated into AIE dots for in vivo metabolic labeling through bio-orthogonal click chemistry. These results open a new approach for facile construction of long-wavelength emissive AIEgens based on the BI core.

    Topics: Animals; Click Chemistry; Cyclooctanes; Fluorescent Dyes; Humans; Imidazoles; MCF-7 Cells; Mice; Mice, Nude; Microscopy, Confocal; Neoplasms; Optical Imaging; Quantum Theory; Spectrophotometry; Stilbenes; Transplantation, Heterologous

2018
Influence of charge transfer on the isomerisation of stilbene derivatives for application in cancer therapy.
    Physical chemistry chemical physics : PCCP, 2018, Nov-14, Volume: 20, Issue:44

    The photoisomerisation of non-toxic trans-combretastatin CA4 to its cytotoxic cis isomer demonstrates the high potential of this and similar compounds for localised cancer therapy. The introduction of intramolecular charge-transfer character by altering the substituents of combretastatin systems opens up possibilities to tailor these stilbene derivatives to the special demands of anticancer drugs. In this TDDFT study we explore how absorption wavelengths for both the trans and cis isomers can be red shifted to enable deeper light penetration into tissue and how the trans → cis and cis → trans isomerisations are affected by charge transfer effects to different degrees.

    Topics: Antineoplastic Agents; Bibenzyls; Humans; Isomerism; Light; Models, Molecular; Molecular Structure; Neoplasms; Photochemical Processes; Stilbenes; Structure-Activity Relationship; Thermodynamics

2018
Engineering of Electrochromic Materials as Activatable Probes for Molecular Imaging and Photodynamic Therapy.
    Journal of the American Chemical Society, 2018, 11-28, Volume: 140, Issue:47

    Electrochromic materials (EMs) are widely used color-switchable materials, but their applications as stimuli-responsive biomaterials to monitor and control biological processes remain unexplored. This study reports the engineering of an organic π-electron structure-based EM (dicationic 1,1,4,4-tetraarylbutadiene, 1

    Topics: Aniline Compounds; Animals; Cell Line, Tumor; Drug Design; Female; Fluorescent Dyes; HEK293 Cells; Humans; Hydrogen Sulfide; Infrared Rays; Liver; Mice; Mice, Inbred BALB C; Molecular Imaging; Nanoparticles; Neoplasms; Photochemotherapy; Photosensitizing Agents; Polymers; RAW 264.7 Cells; Singlet Oxygen; Stilbenes; Thiadiazoles; Vinyl Compounds; Xenograft Model Antitumor Assays

2018
Janus-faced Acrolein prevents allergy but accelerates tumor growth by promoting immunoregulatory Foxp3+ cells: Mouse model for passive respiratory exposure.
    Scientific reports, 2017, 03-23, Volume: 7

    Acrolein, a highly reactive unsaturated aldehyde, is generated in large amounts during smoking and is best known for its genotoxic capacity. Here, we aimed to assess whether acrolein at concentrations relevant for smokers may also exert immunomodulatory effects that could be relevant in allergy or cancer. In a BALB/c allergy model repeated nasal exposure to acrolein abrogated allergen-specific antibody and cytokine formation, and led to a relative accumulation of regulatory T cells in the lungs. Only the acrolein-treated mice were protected from bronchial hyperreactivity as well as from anaphylactic reactions upon challenge with the specific allergen. Moreover, grafted D2F2 tumor cells grew faster and intratumoral Foxp3+ cell accumulation was observed in these mice compared to sham-treated controls. Results from reporter cell lines suggested that acrolein acts via the aryl-hydrocarbon receptor which could be inhibited by resveratrol and 3'-methoxy-4'-nitroflavone Acrolein- stimulation of human PBMCs increased Foxp3+ expression by T cells which could be antagonized by resveratrol. Our mouse and human data thus revealed that acrolein exerts systemic immunosuppression by promoting Foxp3+ regulatory cells. This provides a novel explanation why smokers have a lower allergy, but higher cancer risk.

    Topics: Acrolein; Allergens; Animals; Antibody Formation; Cytokines; Disease Models, Animal; Forkhead Transcription Factors; Hypersensitivity; Immunologic Factors; Lung; Mice; Neoplasms; NF-kappa B; Receptors, Aryl Hydrocarbon; Resveratrol; Signal Transduction; Stilbenes; T-Lymphocytes, Regulatory

2017
Effects of combretastatin A-4 phosphate on canine normal and tumor tissue-derived endothelial cells.
    Research in veterinary science, 2017, Volume: 112

    Combretastatin A-4 phosphate (CA4P) selectively blocks tumor blood flow. However, the detailed mechanisms through which CA4P specifically affects tumor blood vessels are not well understood. Recent reports revealed that tumor tissue-derived endothelial cells (TECs) have various specific features in comparison with normal tissue-derived endothelial cells (NECs). Thus, abnormalities in TECs may be involved in the selective vascular blockade mechanism of CA4P. In this study, we evaluated the effects of CA4P on canine NECs and TECs using confocal microscopy. NECs exhibited different susceptibilities at subconfluence and at 100% confluence. In addition, inhibition of vascular endothelial cadherin (VE-cadherin) in NECs increased the sensitivity of the cells to CA4P. TECs seemed to be more susceptible to CA4P than NECs. The expression pattern of VE-cadherin in TECs was abnormal compared with that of NECs, suggesting that VE-cadherin may have functional abnormalities in these cells. Taken together, these results indicate that the tumor-vascular selectivity of CA4P may be related to VE-cadherin dysfunction in TECs.

    Topics: Animals; Bibenzyls; Cells, Cultured; Dogs; Endothelial Cells; Endothelium, Vascular; Humans; Neoplasms; Neovascularization, Pathologic; Phosphates; Stilbenes

2017
Water-Soluble Combretastatin A4 Phosphate Orally Delivered via Composite Nanoparticles With Improved Inhibition Effect Toward S180 Tumors.
    Journal of pharmaceutical sciences, 2017, Volume: 106, Issue:10

    Combretastatin A4 phosphate (CA4P) is a novel vascular disrupting agent for cancer therapy. However, frequent dosing and negative patient compliance have been encountered over CA4P by injection administration due to its quite short-term action and acute side effects. Therefore, it is significant to develop an oral formulation of CA4P. We established a novel method to prepare CA4P-loaded nanoparticles (CA4P-NPs) for oral administration by combining methoxy poly(ethylene glycol)-b-polylactide (PELA) and poly(d,l-lactic-co-glycolic acid) (PLGA) polymers. Transport study in vitro was evaluated on Madin-Darby canine kidney cell models, and antitumor effect evaluation in vivo was performed on S180 subcutaneous xenotransplanted tumor models in mice. The highest entrapment efficiency of CA4P-NPs was achieved when the weight ratio of PELA to PLGA was optimized to 1:1. The apparent permeability coefficient of CA4P-NPs was found to be 2.08-fold higher than that of free CA4P in transport study. CA4P-NPs reached an absolute bioavailability of 77.6% with the tumor inhibition ratio of 41.2% that was significantly superior to free CA4P. These results suggest a promising application of this composite nanoparticle for the oral delivery of water-soluble drugs.

    Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Dogs; Drug Carriers; Lactic Acid; Madin Darby Canine Kidney Cells; Mice; Nanoparticles; Neoplasms; Permeability; Polyesters; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Stilbenes; Water

2017
Antitumor activity of resveratrol is independent of Cu(II) complex formation in MCF-7 cell line.
    Bioorganic & medicinal chemistry letters, 2017, 08-01, Volume: 27, Issue:15

    Resveratrol (Rsv) is widely reported to possess anticarcinogenic properties in a plethora of cellular and animal models having limited toxicity toward normal cells. In the molecular level, Rsv can act as a suppressive agent for several impaired signaling pathways on cancer cells. However, Fukuhara and Miyata have shown a non-proteic reaction of Rsv, which can act as a prooxidant agent in the presence of copper (Cu), causing cellular oxidative stress accompanied of DNA damage. After this discovery, the complex Rsv-Cu was broadly explored as an antitumor mechanism in multiples tumor cell lines. The aim of the study is to explore the anticarcinogenic behavior of resveratrol-Cu(II) complex in MCF-7 cell line. Selectivity of Rsv binding to Cu ions was analyzed by HPLC and UV-VIS. The cells were enriched with concentrations of 10 and 50µM CuSO

    Topics: Antineoplastic Agents; Apoptosis; Coordination Complexes; Copper; Humans; MCF-7 Cells; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Resveratrol; Stilbenes

2017
Nicotine Exposure Augments Renal Toxicity of 5-aza-cytidine Through p66shc: Prevention by Resveratrol.
    Anticancer research, 2017, Volume: 37, Issue:8

    We have shown that either chronic nicotine (NIC) exposure or 5-aza-cytidine (AZA) augments oxidative stress-dependent injury through stimulating p66shc in renal cells. Hence, NIC could exacerbate adverse effects of AZA while antioxidants such as resveratrol (RES) could prevent it.. Renal proximal tubule cells (NRK52E) were treated with 20 μM RES prior to 200 μM NIC plus 100 nM AZA and cell injury (LDH release) was determined. Reporter luciferase assays determined p66shc activation and RES-induced antioxidant responses. Genetic manipulations identified the mechanism of RES action.. NIC exacerbated AZA-dependent injury via augmenting p66shc transcription. While RES suppressed NIC+AZA-mediated injury, -surprisingly-it further enhanced activity of the p66shc promoter. RES protected cells via the cytoplasmic p66shc/Nrf2/heme oxygenase-1 (HO-1) axis.. RES can protect the kidney from adverse effects of NIC in patients undergoing anticancer therapy.

    Topics: Antioxidants; Azacitidine; Cell Line; Heme Oxygenase-1; Humans; Kidney Tubules, Proximal; Neoplasms; NF-E2-Related Factor 2; Nicotine; Oxidative Stress; Promoter Regions, Genetic; Resveratrol; Signal Transduction; Src Homology 2 Domain-Containing, Transforming Protein 1; Stilbenes

2017
Design, Synthesis, and Biological Evaluation of Novel Selenium-Containing Isocombretastatins and Phenstatins as Antitumor Agents.
    Journal of medicinal chemistry, 2017, 09-14, Volume: 60, Issue:17

    Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; G2 Phase; Humans; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Rats, Sprague-Dawley; Selenium; Stilbenes

2017
Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor.
    Nutrients, 2017, Oct-27, Volume: 9, Issue:11

    The chemopreventive and anticancer effects of resveratrol (RSV) are widely reported in the literature. Specifically, mechanisms involving epigenetic regulation are promising targets to regulate tumor development. Bromodomains act as epigenetic readers by recognizing lysine acetylation on histone tails and boosting gene expression in order to regulate tissue-specific transcription. In this work, we showed that RSV is a pan-BET inhibitor. Using Differential Scanning Fluorimetry (DSF), we showed that RSV at 100 µM increased the melting temperature (∆Tm) of BET bromodomains by around 2.0 °C. The micromolar dissociation constant (

    Topics: Acetylation; Antineoplastic Agents, Phytogenic; Cell Cycle Proteins; Diet; Epigenesis, Genetic; Gene Expression; Histones; Humans; Kinetics; Lysine; Molecular Docking Simulation; Neoplasms; Nuclear Proteins; Phytotherapy; Plant Extracts; Proteins; Resveratrol; Stilbenes; Transcription Factors

2017
The inhibition of indoleamine 2, 3-dioxygenase 1 by connexin 43.
    International journal of medical sciences, 2017, Volume: 14, Issue:12

    Upregulation of connexin 43 (Cx43) showed potential in enhancing immune surveillance that was suppressed in the tumor microenvironment. The expression of indoleamine 2, 3-dioxygenase (IDO) is one of the crucial factors contributing to tumor immune tolerance by depletion of tryptophan and IDO-mediated tryptophan metabolites. Here, we aim to investigate the role of Cx43 in IDO production in murine tumor by using Cx43 inducers. Resveratrol (trans-3, 5, 4 '-trihydroxystilbene) is a natural plant-derived polyphenol possessing positive effect against cancer.. All of which could be inhibited once the expression of Cx43 was blocked. Cx43 involved in IDO regulation might be useful in developing IDO-targeted cancer immune therapy.

    Topics: Animals; Cell Line, Tumor; Connexin 43; Gene Knockdown Techniques; Humans; Immune Tolerance; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Neoplasms; Resveratrol; RNA Interference; RNA, Small Interfering; Salmonella enterica; Signal Transduction; Stilbenes; T-Lymphocytes; Up-Regulation

2017
The resveratrol analogue trimethoxystilbene inhibits cancer cell growth by inducing multipolar cell mitosis.
    Molecular carcinogenesis, 2017, Volume: 56, Issue:3

    Natural compounds are extensively studied for their potential use in traditional and non-traditional medicine. Several natural and synthetic Resveratrol analogues have shown interesting biological activities in the field of cancer chemoprevention. In the present study, we have focused on the ability of Resveratrol and two methoxylated derivatives (Trimethoxystilbene and Pterostilbene) to inhibit human cancer cell growth particularly analyzing their ability to interfere with tubulin dynamics at mitosis. We show that Trimethoxystilbene, differently from Resveratrol and Pterostilbene, alters microtubule polymerization dynamics in HeLa cells specifically inducing multipolar spindles and mitotic arrest coupled to a reduction of cell growth and an increase in apoptotic death by mitotic catastrophe. This work demonstrates that the structural modification of Rsv causes substantial changes in the mechanism of action of the derivatives. The presence of three extra methyl groups renders Trimethoxy very efficient in impairing cell proliferation by inducing mitotic catastrophe in cancer cells. © 2016 Wiley Periodicals, Inc.

    Topics: Animals; Cell Cycle; Cell Proliferation; Cell Survival; CHO Cells; Cricetulus; HeLa Cells; Humans; Mitosis; Neoplasms; Resveratrol; Stilbenes; Tubulin

2017
Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy.
    Theranostics, 2017, Volume: 7, Issue:2

    Aggressive, desmoplastic tumors are notoriously difficult to treat because of their extensive stroma, high interstitial pressure, and resistant tumor microenvironment. We have developed a combination therapy that can significantly slow the growth of large, stroma-rich tumors by causing massive apoptosis in the tumor center while simultaneously increasing nanoparticle uptake through a treatment-induced increase in the accumulation and retention of nanoparticles in the tumor. The vascular disrupting agent Combretastatin A-4 Phosphate (CA4P) is able to increase the accumulation of radiation-containing nanoparticles for internal radiation therapy, and the retention of these delivered radioisotopes is maintained over several days. We use ultrasound to measure the effect of CA4P in live tumor-bearing mice, and we encapsulate the radio-theranostic isotope

    Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Drug Therapy, Combination; Lutetium; Mice; Nanoparticles; Neoplasms; Radioisotopes; Stilbenes; Treatment Outcome

2017
Direct arterial injection of hyperpolarized
    Magnetic resonance in medicine, 2017, Volume: 78, Issue:6

    A rat model was developed to enable direct administration of hyperpolarized. Rat P22 sarcomas were implanted into the right inguinal fat pad of BDIX rats such that the developing tumors received their principle blood supply directly from the right superior epigastric artery. Hyperpolarized. Intra-arterial infusion of hyperpolarized. The model maximizes tumor substrate/drug delivery and minimizes T

    Topics: Animals; Arteries; Carbon Isotopes; Drug Delivery Systems; Epigastric Arteries; Female; Femoral Vein; Gadolinium; Magnetic Resonance Spectroscopy; Male; Neoplasm Metastasis; Neoplasms; Optical Imaging; Perfusion; Phosphorylation; Pyruvic Acid; Rats; Spectrophotometry; Stilbenes

2017
Different effect of resveratrol to induction of apoptosis depending on the type of human cancer cells.
    International journal of oncology, 2017, Volume: 50, Issue:3

    The effect of resveratrol on various human cancer cells was investigated with special focus on apoptotic cell death, in an attempt to further characterize its mechanism of action. There were great differences in the anti-viability effect of resveratrol between different types of human cancer cells. While the inhibition of cell viability by resveratrol was marked in U937 and MOLT-4 leukemia cells, resveratrol moderately inhibited cell viability in MCF-7 breast, HepG2 liver, and A549 lung cancer cells, and the effect was slight on cell viability in Caco-2, HCT116, and SW480 colon cancer cells. Following resveratrol treatment, U937 and MOLT-4 markedly increased the population of late apoptotic cells but MCF-7 and HepG2 underwent apoptosis with an increased population of early apoptosis, and resveratrol-induced DNA fragmentation was observed only in leukemic cells. Activation of sirtuin 1 and adenosine-monophosphate-activated protein kinase was not responsible for resveratrol-induced cancer cell death. Instead, resveratrol significantly reduced Akt activation with the downregulation of H-Ras, resulting in facilitation of Bax translocation to mitochondria in leukemic cells. This study suggests that resveratrol can induce apoptotic cell death in human leukemic cells to a greater extent than in human solid tumor cells via reducing Akt activation due to Ras downregulation.

    Topics: A549 Cells; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Fragmentation; Enzyme Activation; HCT116 Cells; Hep G2 Cells; Humans; MCF-7 Cells; Mitochondria; Neoplasms; Proto-Oncogene Proteins c-akt; Resveratrol; Sirtuin 1; Stilbenes

2017
Resveratrol sequentially induces replication and oxidative stresses to drive p53-CXCR2 mediated cellular senescence in cancer cells.
    Scientific reports, 2017, 03-16, Volume: 7, Issue:1

    Resveratrol (RSV) acts either as an antioxidant or a pro-oxidant depending on contexts. RSV-treated cancer cells may experience replication stress that can lead to cellular senescence or apoptosis. While both oxidative and replication stresses may mediate the anti-proliferation effect of RSV, to what extent each contributes to the impaired proliferation in response to RSV remains uncharacterized. We here report the study of the roles of replication and oxidative stresses in mediating cellular senescence in cancer cells treated with RSV. RSV induced S-phase arrest and cellular senescence in a dose-dependent manner in U2OS and A549 cancer cells as well as in normal human fibroblasts. We observed that nucleosides significantly alleviated RSV-induced replication stress and DNA damage response, and consequently attenuating cellular senescence. While the elevation of reactive oxygen species (ROS) also mediated the pro-senescent effect of RSV, it occurred after S-phase arrest. However, the induction of ROS by RSV was independent of S-phase arrest and actually reinforced the latter. We also demonstrated a critical role of the p53-CXCR2 axis in mediating RSV-induced senescence. Interestingly, CXCR2 also functioned as a barrier to apoptosis. Together, our results provided more insights into the biology of RSV-induced stress and its cellular consequences.

    Topics: A549 Cells; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cellular Senescence; DNA Replication; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Oxidative Stress; Reactive Oxygen Species; Receptors, Interleukin-8B; Resveratrol; S Phase Cell Cycle Checkpoints; Stilbenes; Tumor Suppressor Protein p53

2017
Resveratrol: beneficial or not? Opposite effects of resveratrol on hypoxia-dependent PAI-1 expression in tumour and primary cells.
    Thrombosis and haemostasis, 2016, Volume: 115, Issue:2

    Topics: Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatocytes; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasms; Oxygen; Plasminogen Activator Inhibitor 1; Polyphenols; Resveratrol; RNA, Messenger; Stilbenes

2016
Tumor vascular-targeted co-delivery of anti-angiogenesis and chemotherapeutic agents by mesoporous silica nanoparticle-based drug delivery system for synergetic therapy of tumor.
    International journal of nanomedicine, 2016, Volume: 11

    To overcome the drawback of drug non-selectivity in traditional chemotherapy, the construction of multifunctional targeting drug delivery systems is one of the most effective and prevailing approaches. The intratumoral anti-angiogenesis and the tumor cell-killing are two basic approaches in fighting tumors. Herein we report a novel tumor vascular-targeting multidrug delivery system using mesoporous silica nanoparticles as carrier to co-load an antiangiogenic agent (combretastatin A4) and a chemotherapeutic drug (doxorubicin) and conjugate with targeting molecules (iRGD peptide) for combined anti-angiogenesis and chemotherapy. Such a dual-loaded drug delivery system is capable of delivering the two agents at tumor vasculature and then within tumors through a differentiated drug release strategy, which consequently results in greatly improved antitumor efficacy at a very low doxorubicin dose of 1.5 mg/kg. The fast release of the antiangiogenic agent at tumor vasculatures led to the disruption of vascular structure and had a synergetic effect with the chemotherapeutic drug slowly released in the following delivery of chemotherapeutic drug into tumors.

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Carriers; Drug Delivery Systems; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Nanoparticles; Neoplasms; Oligopeptides; Silicon Dioxide; Stilbenes; Tissue Distribution; Xenograft Model Antitumor Assays

2016
Design, Synthesis and Antitumor Activity of Novel link-bridge and B-Ring Modified Combretastatin A-4 (CA-4) Analogues as Potent Antitubulin Agents.
    Scientific reports, 2016, 05-03, Volume: 6

    A series of 12 novel acylhydrazone, chalcone and amide-bridged analogues of combretastatin A-4 were designed and synthesized toward tubulin. All these compounds were determined by elemental analysis, (1)H NMR, and MS. Among them, compound 7 with acylhydrazone-bridge, bearing a benzyl at the indole-N position, was identified as a potent antiproliferative agent against a panel of cancer cell lines with IC50 values ranging from 0.08 to 35.6 μM. In contrast, its cytotoxic effects on three normal human cells were minimal. Cellular studies have revealed that the induction of apoptosis by compound 7 was associated with a collapse of mitochondrial membrane potential, accumulation of reactive oxygen species, alterations in the expression of some cell cycle-related proteins (Cyclin B1, Cdc25c, Cdc2, P21) and some apoptosis-related proteins (Bax, PARP, Bcl-2, Caspase3). The docking mode showed the binding posture of CA-4 and compound 7 are similar in the colchicine-binding pocket of tubulin, as confirmed by colchicine-tubulin competitive binding assay, tubulin polymerization inhibitory activity, extracellular protein expression determination assay and confocal immunofluorescence microscopy. In vivo study, compound 7 effectively inhibited A549 xenograft tumor growth without causing significant loss of body weight suggesting that compound 7 is a promising new antimitotic agent with clinical potential.

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chalcone; Drug Screening Assays, Antitumor; Humans; Hydrazones; Mice; Neoplasms; Stilbenes; Structure-Activity Relationship; Tubulin; Tubulin Modulators; Xenograft Model Antitumor Assays

2016
Design and Synthesis of Potent in Vitro and in Vivo Anticancer Agents Based on 1-(3',4',5'-Trimethoxyphenyl)-2-Aryl-1H-Imidazole.
    Scientific reports, 2016, 05-24, Volume: 6

    A novel series of tubulin polymerization inhibitors, based on the 1-(3',4',5'-trimethoxyphenyl)-2-aryl-1H-imidazole scaffold and designed as cis-restricted combretastatin A-4 analogues, was synthesized with the goal of evaluating the effects of various patterns of substitution on the phenyl at the 2-position of the imidazole ring on biological activity. A chloro and ethoxy group at the meta- and para-positions, respectively, produced the most active compound in the series (4o), with IC50 values of 0.4-3.8 nM against a panel of seven cancer cell lines. Except in HL-60 cells, 4o had greater antiproliferative than CA-4, indicating that the 3'-chloro-4'-ethoxyphenyl moiety was a good surrogate for the CA-4 B-ring. Experiments carried out in a mouse syngenic model demonstrated high antitumor activity of 4o, which significantly reduced the tumor mass at a dose thirty times lower than that required for CA-4P, which was used as a reference compound. Altogether, our findings suggest that 4o is a promising anticancer drug candidate that warrants further preclinical evaluation.

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; HeLa Cells; HL-60 Cells; HT29 Cells; Humans; Jurkat Cells; MCF-7 Cells; Mice; Models, Molecular; Molecular Structure; Neoplasms; Stilbenes; Tubulin Modulators; Xenograft Model Antitumor Assays

2016
Evidence supporting the conceptual framework of cancer chemoprevention in canines.
    Scientific reports, 2016, 05-24, Volume: 6

    As with human beings, dogs suffer from the consequences of cancer. We investigated the potential of a formulation comprised of resveratrol, ellagic acid, genistein, curcumin and quercetin to modulate biomarkers indicative of disease prevention. Dog biscuits were evaluated for palatability and ability to deliver the chemopreventive agents. The extent of endogenous DNA damage in peripheral blood lymphocytes from dogs given the dietary supplement or placebo showed no change. However, H2O2-inducible DNA damage was significantly decreased after consumption of the supplement. The expression of 11 of 84 genes related to oxidative stress was altered. Hematological parameters remained in the reference range. The concept of chemoprevention for the explicit benefit of the canine is compelling since dogs are an important part of our culture. Our results establish a proof-of-principle and provide a framework for improving the health and well-being of "man's best friend".

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Curcumin; DNA Damage; Dog Diseases; Dogs; Ellagic Acid; Food, Formulated; Genistein; Hydrogen Peroxide; Neoplasms; Oxidative Stress; Quercetin; Resveratrol; Stilbenes; Treatment Outcome

2016
The Novel Antitubulin Agent TR-764 Strongly Reduces Tumor Vasculature and Inhibits HIF-1α Activation.
    Scientific reports, 2016, 06-13, Volume: 6

    Tubulin binding agents (TBAs) are commonly used in cancer therapy as antimitotics. It has been described that TBAs, like combretastatin A-4 (CA-4), present also antivascular activity and among its derivatives we identified TR-764 as a new inhibitor of tubulin polymerization, based on the 2-(alkoxycarbonyl)-3-(3',4',5'-trimethoxyanilino)benzo[b]thiophene molecular skeleton. The antiangiogenic activity of TR-764 (1-10 nM) was tested in vitro on human umbilical endothelial cells (HUVECs), and in vivo, on the chick embryo chorioallantoic membrane (CAM) and two murine tumor models. TR-764 binding to tubulin triggers cytoskeleton rearrangement without affecting cell cycle and viability. It leads to capillary tube disruption, increased cell permeability, and cell motility reduction. Moreover it disrupts adherens junctions and focal adhesions, through mechanisms involving VE-cadherin/β-catenin and FAK/Src. Importantly, TR-764 is active in hypoxic conditions significantly reducing HIF-1α. In vivo TR-764 (1-100 pmol/egg) remarkably blocks the bFGF proangiogenic activity on CAM and shows a stronger reduction of tumor mass and microvascular density both in murine syngeneic and xenograft tumor models, compared to the lead compound CA-4P. Altogether, our results indicate that TR-764 is a novel TBA with strong potential as both antivascular and antitumor molecule that could improve the common anticancer therapies, by overcoming hypoxia-induced resistance mechanisms.

    Topics: Actin Cytoskeleton; Aniline Compounds; Animals; Antigens, CD; beta Catenin; Cadherins; Cell Adhesion; Cell Membrane Permeability; Cell Movement; Chick Embryo; Chickens; Chorioallantoic Membrane; Fibroblast Growth Factors; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Inbred C57BL; Neoplasms; Neovascularization, Physiologic; Stilbenes; Thiophenes; Tubulin Modulators; Vascular Endothelial Growth Factor A

2016
Novel multifunctional pH-sensitive nanoparticles loaded into microbubbles as drug delivery vehicles for enhanced tumor targeting.
    Scientific reports, 2016, 07-05, Volume: 6

    This study fabricated novel multifunctional pH-sensitive nanoparticles loaded into microbubbles (PNP-MB) with the combined advantages of two excellent drug delivery vehicles, namely, pH-sensitive nanoparticles and microbubbles. As an antitumor drug, resveratrol (RES) was loaded into acetylated β-cyclodextrin nanoparticles (RES-PNP). The drug-loaded nanoparticles were then encapsulated into the internal space of the microbubbles. The characterization and morphology of this vehicle were investigated through dynamic light scattering and confocal laser scanning microscopy, respectively. In vitro drug release was performed to investigate the pH sensitivity of RES-PNP. The antitumor property of RES-loaded PNP-MB (RES-PNP-MB) was also analyzed in vivo to evaluate the antitumor effect of RES-PNP-MB. Results suggested that PNP exhibited pH sensitivity, and was successfully encapsulated into the microbubbles. RES-PNP-MB exhibit effective tumor growth suppressing in vivo. Therefore, such drug delivery vehicle should be of great attention in tumor therapy.

    Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Carriers; Hydrogen-Ion Concentration; Mice; Microbubbles; Molecular Targeted Therapy; Nanoparticles; Neoplasm Transplantation; Neoplasms; Resveratrol; Stilbenes; Treatment Outcome

2016
A Novel Resveratrol Based Tubulin Inhibitor Induces Mitotic Arrest and Activates Apoptosis in Cancer Cells.
    Scientific reports, 2016, 10-17, Volume: 6

    Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Benzene Derivatives; Cell Line, Tumor; Cells, Cultured; G2 Phase Cell Cycle Checkpoints; HEK293 Cells; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Mitosis; Neoplasms; Neoplasms, Experimental; Polymerization; Resveratrol; Stilbenes; Tubulin; Tubulin Modulators

2016
Resveratrol Induces Cancer Cell Apoptosis through MiR-326/PKM2-Mediated ER Stress and Mitochondrial Fission.
    Journal of agricultural and food chemistry, 2016, Dec-14, Volume: 64, Issue:49

    Topics: Apoptosis; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; MicroRNAs; Mitochondria; Mitochondrial Dynamics; Neoplasms; Resveratrol; Stilbenes; Thyroid Hormone-Binding Proteins; Thyroid Hormones

2016
Further studies on anti-invasive chemotypes: An excursion from chalcones to curcuminoids.
    Bioorganic & medicinal chemistry letters, 2015, Mar-01, Volume: 25, Issue:5

    In our ongoing search for new anti-invasive chemotypes, we have made an excursion from previously reported potent 1,3-diarylpropenones (chalcones) to congeners bearing longer linkers between the aromatic moieties. Nine 1,ω-diarylalkenones, including curcumin and bisdemethoxycurcumin, were evaluated in the chick heart invasion assay. Unfortunately, these compounds proved less potent and more toxic than earlier evaluated chemotypes. In the 1,3-diarylpenta-2,4-dien-1-one series, fluoro and/or trimethoxy substitution caused an increase in potency. This agrees with observations made earlier for the chalcone class.

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chalcones; Chickens; Curcumin; Halogenation; Heart; Humans; Neoplasm Invasiveness; Neoplasms; Structure-Activity Relationship

2015
Resveratrol-loaded polymeric nanoparticles suppress glucose metabolism and tumor growth in vitro and in vivo.
    International journal of pharmaceutics, 2015, Jan-15, Volume: 478, Issue:1

    Resveratrol (RSV) is a natural phenol with promising anti-tumor activities, but its use for in vivo cancer treatment is limited by low aqueous solubility and poor stability. In this study, we prepared RSV-loaded polyethylene glycol-polylactic acid (PEG-PLA; M.W. 5000-5000) polymer nanoparticles (NPs) for improved stability and controlled delivery, and investigated its metabolic and anti-tumor effect in vitro and in vivo. CT26 colon cancer cells displayed significantly reduced cell number to 5.6% and colony forming capacity to 6.3% of controls by 72 h treatment with 40 and 20 μM of RSV-NP, respectively. Flow cytometry and western blots demonstrated increased apoptotic cell death, and (18)F FDG uptake and reactive oxygen species was significantly reduced by RSV-NP. All of these effects were comparable to or greater in potency compared to free RSV. When RSV-NP was intravenously administered to CT26 tumor bearing mice, there was a reduction of (18)F FDG uptake on PET/CT by day 4. Longer treatment led to retardation of tumor growth accompanied by an improvement in survival compared to empty NP-injected controls. These results demonstrate that the in vitro and in vivo metabolic and anti-tumor effects of RSV is preserved by PEG-PLA NP loading, and provide an encouraging outlook on the potential of polymeric NPs as an effective method to deliver RSV for cancer therapy.

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Liberation; Glucose; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Poly(ADP-ribose) Polymerases; Polyethylene Glycols; Reactive Oxygen Species; Resveratrol; Stilbenes; Tumor Burden

2015
Quantum chemistry calculation-aided structural optimization of combretastatin A-4-like tubulin polymerization inhibitors: improved stability and biological activity.
    Journal of medicinal chemistry, 2015, Mar-12, Volume: 58, Issue:5

    A potent combretastatin A-4 (CA-4) like tubulin polymerization inhibitor 22b was found with strong antitumor activity previously. However, it easily undergoes cis-trans isomerization under natural light, and the resulting decrease in activity limits its further applications. In this study, we used quantum chemistry calculations to explore the molecular basis of its instability. Aided by the calculations, two rounds of structural optimization of 22b were conducted. Accelerated quantitative light stability testing confirmed that the stability of these designed compounds was significantly improved as predicted. Among them, compounds 1 and 3b displayed more potent inhibitory activity on tumor cell growth than 22b. In addition, the potent in vivo antitumor activity of compound 1 was confirmed. Quantum chemistry calculations were used in the optimization of stilbene-like molecules, providing new insight into stilbenoid optimization and important implications for the future development of novel CA-4-like tubulin polymerization inhibitors.

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cell Proliferation; Female; Humans; Mice; Mice, Inbred BALB C; Models, Molecular; Molecular Structure; Neoplasms; Quantum Theory; Stilbenes; Structure-Activity Relationship; Tubulin; Tubulin Modulators; Xenograft Model Antitumor Assays

2015
3,4',5-trans-Trimethoxystilbene; a natural analogue of resveratrol with enhanced anticancer potency.
    Investigational new drugs, 2015, Volume: 33, Issue:3

    Resveratrol is a phytoalexin produced by many plant species as a defence mechanism. Over the last decade, this polyphenol has been reported to be active against multiple targets associated with chronic disorders. However, its poor pharmacokinetic profile, as well as multiple discrepancies related to its in vitro and in vivo profile, has resulted not only on the study of suitable delivery systems, but the use of resveratrol derivatives. In this regard, the 3,4',5-trans-trimethoxystilbene (TMS), a natural analogue of resveratrol, has emerged as a strong candidate. TMS has an enhanced anticancer profile compared to resveratrol, exhibiting higher potency than resveratrol, as shown by multiple reports describing an improved cancer cell proliferation inhibition, induction of cell cycle arrest, decreased metastasis, reduced angiogenesis, and increased apoptosis. In this review, we provide a concise summary of results reported in the literature, related to the similarities and differences between resveratrol and TMS, and we submit to the scientific community that TMS is a promising and (still) understudied natural agent candidate, with potential applications in cancer research. Nevertheless, based on the available evidence, we also submit to the scientific community that TMS may also find a niche in any other research area in which resveratrol has been used.

    Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Cell Line, Tumor; Cell Proliferation; Free Radical Scavengers; Humans; Inhibitory Concentration 50; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Resveratrol; Stilbenes; Xenograft Model Antitumor Assays

2015
Nanopotentiated combination cancer therapy: Chemotherapeutic and chemosensitizer (2C approach).
    Medical hypotheses, 2015, Volume: 84, Issue:6

    An insight into the complex cancer pathophysiology reveals that a dependable amelioration of the disease could only be envisaged with a multipronged treatment approach. It is highly evident that singular chemotherapeutic agents used in clinical practice have shown limitations like severe side effects, MDR and are often associated with poor QOL while combinations of drugs have yielded better therapeutic outcomes. The current hypothesis takes it a step forward wherein a chemotherapeutic agent is combined with a natural chemosensitizer, both loaded into a nanopotentiated particulate system, which would eventually deliver the drug cargo at the target site with certitude. The encapsulated natural bioactive would then favorably act on the tumor milieu through multiple portals and chemosensibilize the cells towards cytotoxic action of the synthetic drug moiety. This 2C (chemotherapeutic and chemosensitizer) approach along with nanosystem's attributes like high payload, prolonged action and diminished side effects would proffer a more dependable treatment modality. In conclusion, the proposed system would be a value addition to the currently available armamentarium of cancer treatment tools.

    Topics: Antineoplastic Agents, Phytogenic; Curcumin; Drug Delivery Systems; Drug Therapy, Combination; Flavonoids; Fluorouracil; Humans; Models, Biological; Nanoparticles; Neoplasms; Resveratrol; Stilbenes

2015
Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.
    European journal of medicinal chemistry, 2015, May-05, Volume: 95

    To identify novel multi-target-directed drug candidates for the treatment of cancer, a series of benzoselenazole-stilbene hybrids were synthesised by combining the pharmacophores of resveratrol and ebselen. The biological assay indicated that all of the hybrids exhibited antiproliferative activities against four human cancer cell lines and demonstrated good TrxR inhibitory activities. The mechanism of cell apoptosis was investigated in G2/M cell cycle arrest induced by compound 6e and the apoptosis of the human liver carcinoma Bel-7402 cell line. The significant increase in intracellular ROS confirmed that compound 6e was capable of causing oxidative stress-induced apoptosis in cancer cells. Our results support the potential of compound 6e as a candidate for further studies examining the development of novel drugs for cancer treatment.

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Drug Design; Flow Cytometry; Humans; Neoplasms; Organoselenium Compounds; Stilbenes; Thioredoxin Reductase 1; Tumor Cells, Cultured

2015
Therapeutic potential of using the vascular disrupting agent OXi4503 to enhance mild temperature thermoradiation.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2015, Volume: 31, Issue:5

    The response of tissues to radiation with mild temperature hyperthermia is dependent on the interval between the two modalities. This study investigated the effect that the vascular disrupting agent OXi4503 had on this time-interval interaction.. The normal right rear foot of female CDF1 mice or foot-implanted C3H mammary carcinomas were locally irradiated (230 kV X-rays) and heated (41.5 °C for 60 min) by foot immersion in a water bath. OXi4503 (50 mg/kg) was injected intraperitoneally 1.5 h before irradiating. Irradiation was performed either in the middle of the heating period (simultaneous treatment) or at 1 or 4 h prior to starting the heating (sequential treatments). Response was the percentage of mice showing local tumour control at 90 days or skin moist desquamation between days 11-23. From the radiation dose response curves the dose producing tumour control (TCD(50)) or moist desquamation (MDD50) in 50% of mice was calculated.. The TCD(50) and MDD50 values for radiation alone were 54 Gy and 29 Gy, respectively. Simultaneously heating the tissues enhanced radiation response, the respective TCD(50) and MDD50 values being significantly (chi-square test, p < 0.05) reduced to 33 Gy and 14 Gy. A smaller enhancement was obtained with a sequential treatment in both tissues. OXi4503 enhanced the radiation response of tumour and skin. Combined with radiation and heat, the only effect was in tumours where OXi4503 prevented the decrease in sensitisation seen with the sequential treatment.. Combining OXi4503 with a sequential radiation and heat treatment resulted in a 1.4-fold therapeutic gain.

    Topics: Animals; Diphosphates; Female; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Neoplasms; Radiation, Ionizing; Stilbenes

2015
Coadministration of Vascular Disrupting Agents and Nanomedicines to Eradicate Tumors from Peripheral and Central Regions.
    Small (Weinheim an der Bergstrasse, Germany), 2015, Volume: 11, Issue:31

    A strategy for enhancing the treatment efficacy of nanomedicines within the central region of solid tumors is developed by combining nanomedicines and free small-molecule vascular disrupting agents (VDAs). The nanomedicines (cis-diamminedichloroplatinum-loaded nanoparticles) primarily target cells at the tumor periphery whereas the free small-molecule VDA (combretastatin A4 disodium phosphate) efficiently kills the cancer cells within the central regions of the tumor.

    Topics: Acoustics; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Drug Therapy, Combination; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasms; Stilbenes

2015
Site-Specific Drug-Releasing Polypeptide Nanocarriers Based on Dual-pH Response for Enhanced Therapeutic Efficacy against Drug-Resistant Tumors.
    Theranostics, 2015, Volume: 5, Issue:8

    To enhance effective drug accumulation in drug-resistant tumors, a site-specific drug-releasing polypeptide system (PEG-Phis/Pasp-DOX/CA4) was exploited in response to tumor extracellular and intracellular pH. This system could firstly release the embedded tumor vascular inhibitor (CA4) to transiently 'normalize' vasculature and facilitate drug internalization to tumors efficiently, and then initiate the secondary pH-response to set the conjugated active anticancer drug (DOX) free in tumor cells. The encapsulated system (PEG-Phis/DOX/CA4), both CA4 and DOX embedding in the nanoparticles, was used as a control. Comparing with PEG-Phis/DOX/CA4, PEG-Phis/Pasp-DOX/CA4 exhibited enhanced cytotoxicity against DOX-sensitive and DOX-resistant cells (MCF-7 and MCF-7/ADR). Moreover, PEG-Phis/Pasp-DOX/CA4 resulted in enhanced therapeutic efficacy in drug-resistant tumors with reduced toxicity. These results suggested that this site-specific drug-releasing system could be exploited as a promising treatment for cancers with repeated administration.

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Resistance; Female; Humans; Hydrogen-Ion Concentration; Mice, Inbred BALB C; Mice, Inbred ICR; Molecular Medicine; Neoplasms; Peptides; Stilbenes

2015
Acidosis and Formaldehyde Secretion as a Possible Pathway of Cancer Pain and Options for Improved Cancer Pain Control.
    Journal of pain & palliative care pharmacotherapy, 2015, Volume: 29, Issue:3

    The prevalence of cancer pain in patients with cancer is high. The majority of efforts are spent on research in cancer treatment, but only a small fraction focuses on cancer pain. Pain in cancer patients, viewed predominantly as a secondary issue, is considered to be due to the destruction of tissues, compression of the nerves, inflammation, and secretion of biological mediators from the necrotic tumor mass. As a result, opioid drugs have remained as the primary pharmacological therapy for cancer pain for the past hundred years. This report reviews evidence that cancer pain may be produced by the metabolic effects of two byproducts of cancer-high acidity in the cancer microenvironment and the secretion of formaldehyde and its metabolites. We propose the research and development of therapeutic approaches for preemptive, short- and long-term management of cancer pain using available drugs or nutraceutical agents that can suppress or neutralize lactic acid production in combination with formaldehyde scavengers. We believe this approach may not only improve cancer pain control but may also enhance the quality of life for patients.

    Topics: Acidosis; Aldehyde Dehydrogenase; Dichloroacetic Acid; Formaldehyde; Glutathione; Humans; Hydrogen-Ion Concentration; Lactic Acid; Neoplasms; Pain; Pain Management; Quality of Life; Resveratrol; Sodium Bicarbonate; Stilbenes

2015
Isothiocyanatostilbenes as novel c-Met inhibitors.
    Oncotarget, 2015, Dec-01, Volume: 6, Issue:38

    The hepatocyte growth factor receptor (HGFR or c-Met) is a driver of multiple cancer subtypes. While there are several c-Met inhibitors in development, few have been approved for clinical use, warranting the need for continued research and development of c-Met targeting therapeutic modalities. The research presented here demonstrates a particular class of compounds known as isothiocyanatostilbenes can act as c-Met inhibitors in multiple cancer cell lines. Specifically, we found that 4,4'-Diisothiocyanatostilbene-2,2'-disulfonic acid (DIDS) and 4,4'-Diisothiocyanatodihydrostilbene-2,2'-disulfonic acid (H2DIDS) had c-Met inhibitory effective doses in the low micromolar range while 4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid (SITS) and 4,4'-dinitrostilbene-2, 2'-disulfonic acid (DNDS) exhibited IC50s 100 to 1000 fold higher. These compounds displayed much greater selectivity for inhibiting c-Met activation compared to similar receptor tyrosine kinases. In addition, DIDS and H2DIDS reduced hepatocyte growth factor (HGF)-induced, but not epidermal growth factor (EGF)-induced, cell scattering, wound healing, and 3-dimensional (3D) proliferation of tumor cell spheroids. In-cell and cell-free assays suggested that DIDS and H2DIDS can inhibit and reverse c-Met phosphorylation, similar to SU11274. Additional data demonstrated that DIDS is tolerable in vivo. These data provide preliminary support for future studies examining DIDS, H2DIDS, and derivatives as potential c-Met therapeutics.

    Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Animals; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Female; Hepatocyte Growth Factor; Humans; Mice, Nude; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Stilbenes; Time Factors; Xenograft Model Antitumor Assays

2015
Synthesis and bio-evaluation of novel quinolino-stilbene derivatives as potential anticancer agents.
    Bioorganic & medicinal chemistry, 2015, Dec-15, Volume: 23, Issue:24

    A series of 25 novel quinolino-stilbene derivatives were designed, synthesized and evaluated for their potential as anticancer agents. Three of them not only displayed quite potent antiproliferative activity with IC50 values<4μM but also showed approximately twofold selectivity against cancer cells, compared to non-cancerous cells. Three other compounds exhibited comparatively good activity with IC50 values in the range of 4-10μM, and the rest was moderately active or inactive. One of these viz. 3-[E-(4-fluorostyryl)]-2-chloroquinoline (compound 7B) caused substantial DNA damage and arrested cell cycle in S phase. Interestingly, 7B was very active against MDA-MB468 (IC50=0.12μM), but not against other cell lines examined. Compound 3-[Z-(3-(trifluoromethyl)styryl)]-2-chloroquinoline (12A), the most effective against all cancer cell lines examined, caused prolonged cell cycle arrest at mitosis and eventually apoptosis. Data from an in vitro study showed that compound 12A inhibited microtubule polymerization in a similar fashion to nocodazole. Further study using in silico molecular modeling revealed that 12A causes the impediment of microtubule polymerization by binding to tubulin at the same cavity where podophyllotoxin binds.

    Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Neoplasms; Quinolines; Stilbenes; Tubulin; Tubulin Modulators

2015
Pharmacologic Activities of 3'-Hydroxypterostilbene: Cytotoxic, Anti-Oxidant, Anti-Adipogenic, Anti-Inflammatory, Histone Deacetylase and Sirtuin 1 Inhibitory Activity.
    Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 2015, Volume: 18, Issue:4

    Delineate the selected pharmacodynamics of a naturally occurring stilbene 3'-Hydroxypterostilbene.. Characterize for the first time the pharmacodynamics bioactivity in several in-vitro assays with relevant roles in heart disease, inflammation, cancer, and diabetes etiology and pathophysiology.. 3'-Hydroxypterostilbene was studied in in-vitro assays to identify possible bioactivity.. 3'-Hydroxypterostilbene demonstrated anti-oxidant, anti-inflammatory, cytotoxic, anti-adipogenic, histone deacetylase, and sirtuin-1 inhibitory activity.. The importance of understanding individual stilbene pharmacologic activities were delineated. Small changes in chemical structure of stilbene compounds result in significant pharmacodynamic differences. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

    Topics: 3T3-L1 Cells; Adipogenesis; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Histone Deacetylases; Humans; Mice; Neoplasms; Sirtuin 1; Stilbenes

2015
Can resveratrol in wine protect against the carcinogenicity of ethanol? A probabilistic dose-response assessment.
    International journal of cancer, 2014, Jan-01, Volume: 134, Issue:1

    Resveratrol, which may occur in wine, was suggested to act as a chemopreventive agent against the carcinogenic effects of ethanol. The assumption was based on data from experimental animals, which have shown that resveratrol above certain thresholds may reduce the incidence of tumours in several of the alcohol-related cancer sites (colon, liver and female breast). Using a probabilistic Monte Carlo type methodology, we estimated daily intake based on chemical analysis of resveratrol (n = 672) and ethanol (n = 867). Benchmark dose (BMD)-response modelling was conducted for resveratrol based on eight animal experiments, whereas BMD data for ethanol were taken from the literature. The margin of exposure (MOE) was calculated for both substances as an indicator if the intake may reach effective dosages. For intake of one 100-mL glass of wine, the average MOE was found to be 4.1 for ethanol and 459,937 for resveratrol. In the best-case scenario for resveratrol (e.g., very high contents and assuming a low effective dosage), the minimum MOE would be 111, which means that 111 glasses of wine need to be consumed daily to reach the BMD. The MOE ratio between resveratrol and ethanol is 166,128 on average, meaning that per glass of wine, ethanol is more than 100,000 times more potent than resveratrol. As resveratrol intake may not optimally reach the effective dosage, our study excludes a preventive effect of this substance on alcohol-related cancer. Commercial information about cancer-preventive or -protective effects of resveratrol in wine is misleading and must be prohibited.

    Topics: Animals; Antioxidants; Carcinogens; Ethanol; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Monte Carlo Method; Neoplasms; Rats; Rats, Sprague-Dawley; Resveratrol; Stilbenes; Wine

2014
Synthesis and cytotoxic activity of a new group of heterocyclic analogues of the combretastatins.
    Molecules (Basel, Switzerland), 2014, Jun-11, Volume: 19, Issue:6

    A series of new analogs of combretastatin A-4 (CA-4, 1) with the A or B-ring replaced by a 3-oxo-2,3-dihydrofurocoumarin or a furocoumarin residue have been designed and synthesized by employing a cross-coupling approach. All the compounds were evaluated for their cytotoxic activity with respect to model cancer cell lines (CEM-13, MT-4, U-937) using conventional MTT assays. Structure-activity relationship analysis reveals that compounds 2, 3, 6-8 in which the (Z)-styryl substituent was connected to the 2-position of the 3-oxo-2,3-dihydrofurocoumarin core, demonstrated increased potency compared to 3-(Z)-styrylfurocoumarins 4, 5, 9-11. The methoxy-, hydroxyl- and formyl- substitution on the aromatic ring of the (Z)-styryl moiety seems to play an important role in this class of compounds. Compounds 2 and 3 showed the best potency against the CEM-13 cell lines, with CTD50 values ranging from 4.9 to 5.1 μM. In comparison with CA-4, all synthesized compounds presented moderate cytotoxic activity to the T-cellular human leucosis cells MT-4 and lymphoblastoid leukemia cells CEM-13, but most of them were active in the human monocyte cell lines U-937.

    Topics: Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Line, Tumor; Coumarins; Drug Screening Assays, Antitumor; Ficusin; Furocoumarins; Humans; Molecular Structure; Neoplasms; Stilbenes; Structure-Activity Relationship; Tubulin Modulators

2014
Interferon gamma induced by resveratrol analog, HS-1793, reverses the properties of tumor associated macrophages.
    International immunopharmacology, 2014, Volume: 22, Issue:2

    Macrophages are capable of both inhibiting and promoting the growth and spread of cancers, depending on their activation state. Tumor-associated macrophages (TAM) are a kind of alternatively activated M2 macrophage, which may contribute to tumor progression. Following our previous study to evaluate the anti-tumor effect of a synthetic resveratrol analog HS-1793, the current study demonstrated that HS-1793 treatment significantly increased IFN-γ secreting cells in splenocytes and decreased CD206+ macrophage infiltration compared to CD68+ cells in the tumor site with a higher expression of IFN-γ. As these results suggested that IFN-γ increased locally at the tumor sites could modulate the status of TAM, we designed an in vitro model to study macrophage morphology and functions in relation to the tumor microenvironment. Human monocytic cell line THP-1 cells stimulated with phorbol-12-myristate-13-acetate (PMA) differentiated to macrophages with M2-like phenotypes. TAM-like properties of CD206(high), CD204(high), IL-10(high), TGF-β(high), IL-6(low), IL-12(low), VEGF(high), and MMP-9(high) and promotion of tumor cell invasion were more pronounced in M-2-polarized THP-1 macrophages generated by differentiating THP-1 cells with PMA and subsequently polarizing them with Th2 cytokines (IL-4/IL-13). Upon IFN-γ exposure, THP-1-derived TAM changed their phenotypes to the M-1-like morphology and intracellular granular pattern with an expression of an increased level of proinflammatory and immunostimulatory cytokines and a reduced level of immunosuppressive and tumor progressive mediators. These results explain the underlying mechanism of the anti-tumor activity of HS-1793. The elevated level of IFN-γ production after HS-1793 treatment evoked reprogramming of M-2 phenotype TAM, which efficiently countered the immunosuppressive and tumor progressive influences of TAM.

    Topics: Animals; Cell Line, Tumor; Cell Movement; Female; Interferon-gamma; Macrophages; Mice; Mice, Inbred C3H; Naphthols; Neoplasm Invasiveness; Neoplasms; Resorcinols; Resveratrol; Stilbenes

2014
Immunomodulatory effects of high-protein diet with resveratrol supplementation on radiation-induced acute-phase inflammation in rats.
    Journal of medicinal food, 2014, Volume: 17, Issue:9

    We hypothesized that a high-protein diet and/or resveratrol supplementation will improve acute inflammatory responses in rats after receiving experimental abdominal radiation treatment (ART). Based on our previous study, the period of 10 days after ART was used as an acute inflammation model. Rats were exposed to a radiation dose of 17.5 Gy and were supplied with a control (C), 30% high-protein diet (HP), resveratrol supplementation (RES), or HP with RES diet ([HP+RES]). At day 10 after ART, we measured profiles of lipids, proteins, and immune cells in blood. The levels of clusters of differentiating 4(+) (CD4(+)) cells and regulatory T cells, serum proinflammatory cytokines, and 8-hydroxy-2'-deoxyguanosine (8-OHdG) in urine were also measured. ART caused significant disturbances of lipid profiles by increasing triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C), and decreasing high-density lipoprotein cholesterol. The proinflammatroy cytokine levels were also increased by ART. All the experimental diets (HP, RES, and [HP+RES]) significantly decreased levels of TG, monocytes, proinflammatory cytokines, and 8-OHdG, whereas the platelet counts were increased. In addition, the HP and [HP+RES] diets decreased the concentrations of plasma LDL-C and total cholesterol. Also, the HP and RES diets decreased regulatory T cells compared with those of the control diet in ART group. Further, the HP diet led to a significant recovery of white blood cell counts, as well as increased percentages of lymphocyte and decreased percentages of neutrophils. In summary, RES appeared to be significantly effective in minimizing radiation-induced damage to lipid metabolism and immune responses. Our study also demonstrated the importance of dietary protein intake in recovering from acute inflammation by radiation.

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cytokines; Deoxyguanosine; Diet; Dietary Proteins; Dietary Supplements; Female; Immune System; Inflammation; Leukocyte Count; Lipid Metabolism; Lipids; Neoplasms; Phytotherapy; Plant Extracts; Platelet Count; Radiation Injuries, Experimental; Rats, Wistar; Resveratrol; Stilbenes

2014
Synthesis and biological evaluation of novel 3,4-diaryl-1,2,5-selenadiazol analogues of combretastatin A-4.
    European journal of medicinal chemistry, 2014, Nov-24, Volume: 87

    A set of novel selenium-containing heterocyclic analogues of combretastatin A-4 (CA-4) have been designed and synthesised using a rigid 1,2,5-selenadiazole as a linker to fix the cis-orientation of ring-A and ring-B. All of the target compounds were evaluated for their in vitro anti-proliferative activities. Among these compounds, compounds 3a, 3i, 3n and 3q exhibited superior potency against different tumour cell lines with IC50 values at the nanomolar level. Moreover, compound 3n significantly induced cell cycle arrest in the G2/M phase, inhibited tubulin polymerisation into microtubules and caused microtubule destabilisation. A molecular modelling study of compound 3n was performed to elucidate its binding mode at the colchicine site in the tubulin dimer and to provide a basis for the further structure-guided design of novel CA-4 analogues.

    Topics: Antineoplastic Agents, Phytogenic; Bibenzyls; Cell Cycle; Cell Proliferation; Drug Screening Assays, Antitumor; Flow Cytometry; Fluorescent Antibody Technique; Heterocyclic Compounds; Humans; Models, Molecular; Molecular Structure; Neoplasms; Selenium; Stilbenes; Structure-Activity Relationship; Tumor Cells, Cultured

2014
Production of anti-cancer agent using microbial biotransformation.
    Molecules (Basel, Switzerland), 2014, Oct-16, Volume: 19, Issue:10

    Microbial biotransformation is a great model system to produce drugs and biologically active compounds. In this study, we elucidated the fermentation and production of an anti-cancer agent from a microbial process for regiospecific hydroxylation of resveratrol. Among the strains examined, a potent strain showed high regiospecific hydroxylation activity to produce piceatannol. In a 5 L (w/v 3 L) jar fermentation, this wild type Streptomyces sp. in the batch system produced 205 mg of piceatannol (i.e., 60% yields) from 342 mg of resveratrol in 20 h. Using the product, an in vitro anti-cancer study was performed against a human cancer cell line (HeLa). It showed that the biotransformed piceatannol possessed a significant anticancer activity. This result demonstrates that a biotransformation screening method might be of therapeutic interest with respect to the identification of anti-cancer drugs.

    Topics: Antineoplastic Agents; Biotransformation; Fermentation; Gas Chromatography-Mass Spectrometry; HeLa Cells; Humans; Hydroxylation; Neoplasms; Resveratrol; Stilbenes; Streptomyces

2014
Resveratrol enhances palmitate-induced ER stress and apoptosis in cancer cells.
    PloS one, 2014, Volume: 9, Issue:12

    Palmitate, a saturated fatty acid (FA), is known to induce toxicity and cell death in various types of cells. Resveratrol (RSV) is able to prevent pathogenesis and/or decelerate the progression of a variety of diseases. Several in vitro and in vivo studies have also shown a protective effect of RSV on fat accumulation induced by FAs. Additionally, endoplasmic reticulum (ER) stress has recently been linked to cellular adipogenic responses. To address the hypothesis that the RSV effect on excessive fat accumulation promoted by elevated saturated FAs could be partially mediated by a reduction of ER stress, we studied the RSV action on experimentally induced ER stress using palmitate in several cancer cell lines.. We show that, unexpectedly, RSV promotes an amplification of palmitate toxicity and cell death and that this mechanism is likely due to a perturbation of palmitate accumulation in the triglyceride form and to a less important membrane fluidity variation. Additionally, RSV decreases radical oxygen species (ROS) generation in palmitate-treated cells but leads to enhanced X-box binding protein-1 (XBP1) splicing and C/EBP homologous protein (CHOP) expression. These molecular effects are induced simultaneously to caspase-3 cleavage, suggesting that RSV promotes palmitate lipoapoptosis primarily through an ER stress-dependent mechanism. Moreover, the lipotoxicity reversion induced by eicosapentaenoic acid (EPA) or by a liver X receptor (LXR) agonist reinforces the hypothesis that RSV-mediated inhibition of palmitate channeling into triglyceride pools could be a key factor in the aggravation of palmitate-induced cytotoxicity.. Our results suggest that RSV exerts its cytotoxic role in cancer cells exposed to a saturated FA context primarily by triglyceride accumulation inhibition, probably leading to an intracellular palmitate accumulation that triggers a lipid-mediated cell death. Additionally, this cell death is promoted by ER stress through a CHOP-mediated apoptotic process and may represent a potential anticancer strategy.

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; DNA-Binding Proteins; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Neoplasms; Palmitates; Reactive Oxygen Species; Regulatory Factor X Transcription Factors; Resveratrol; Stearoyl-CoA Desaturase; Stilbenes; Transcription Factor CHOP; Transcription Factors; Triglycerides; X-Box Binding Protein 1

2014
Pterostilbene and its emerging antineoplastic effects: a prospective treatment option for systemic malignancies.
    American journal of surgery, 2013, Volume: 205, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Proliferation; Humans; Neoplasms; Stilbenes

2013
Synthesis and antiproliferative effects of 5,6-disubstituted Pyridazin-3(2H)-ones designed as conformationally constrained combretastatin A-4 Analogues.
    Anti-cancer agents in medicinal chemistry, 2013, Volume: 13, Issue:7

    Novel 5,6-disubstituted pyridazin-3(2H)-one derivatives were designed and synthesized as combretastatin A-4 analogues. Our objective was to overcome the spontaneous cis to trans isomerization of the compound. We therefore replaced the cis-double bond with a pyridazine ring. The antiproliferative activity of the novel analogues was evaluated against four human cancer cell lines (HL-60, MDAMB- 435, SF-295 and HCT-8). We found that the analogues had little activity either against selected cell lines or against purified tubulin. Molecular modeling studies may account for their inactivity.

    Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Conformation; Neoplasms; Pyridazines; Stilbenes; Tubulin

2013
Design, synthesis, and anti-tumor activities of novel triphenylethylene-coumarin hybrids, and their interactions with Ct-DNA.
    Bioorganic & medicinal chemistry letters, 2013, Sep-01, Volume: 23, Issue:17

    Novel triphenylethylene-coumarin hybrid derivatives containing different amounts of amino side chains were designed and synthesized in good yields under microwave radiation. The derivatives 5b-d which possessed two amino side chains (except morpholinyl) showed a broad-spectrum and good anti-proliferative activity against five tumor cells and low cytotoxicity in osteoblast. UV-vis, fluorescence, and circular dichroism (CD) spectroscopies and thermal denaturation exhibited that compounds 10 c, 5c, and 13c bearing amino side chain (except morpholinyl) on 4-phenyl had significant interactions with Ct-DNA by the intercalative mode of binding. Structure-activity relationships (SARs) analysis suggested that the amino alkyl chain would play an important role both in the compounds against tumor cells proliferation and their interactions with DNA.

    Topics: Animals; Antineoplastic Agents; Cattle; Cell Line, Tumor; Cell Proliferation; Coumarins; DNA; Drug Design; Drug Screening Assays, Antitumor; Humans; Intercalating Agents; Neoplasms; Stilbenes

2013
Antitumor effects of naturally occurring oligomeric resveratrol derivatives.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2013, Volume: 27, Issue:11

    This study was designed to evaluate and characterize the molecular basis of antitumor activity of naturally occurring resveratrol (RES; 3,5,4'-trihydroxy-trans-stilbene) derivatives. The compounds were isolated from plants in previous studies and characterized spectroscopically. The antitumor activities of 31 RES derivatives, including dimers, trimers, and tetramers of RES, were evaluated using cell-based assays and validated on a murine model. Several trimeric and a tetrameric stilbenoids induced tumor cell apoptosis or growth arrest of several tumor cell lines with IC50 values (2.8-19.7 μM), significantly lower than that of RES (IC50>70 μM). Using pauciflorol B (PauB) as an example, we showed that the compound induced apoptosis p53 dependently, inducing p53 accumulation and p53-modulated gene expression in cells with wild-type p53, but not in those with nonfunctional p53. Reexpression of p53 in p53-null cells rescued cell death response. In parallel, the MAPK/p38 was activated and critical for PauB-induced killing. Interestingly, activation of p38 in p53 deficient cells was sufficient to drive cells into senescence via the p16-pRb pathway. Finally, PauB dose-dependently inhibited tumor growth on nude mice. Naturally occurring trimeric and tetrameric stilbenoids are potent antitumor agents. Those compounds exert antitumor effect through p53-dependent induction of apoptosis or senescence.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; Genes, p16; HeLa Cells; Humans; MCF-7 Cells; Mice; Mice, Nude; Neoplasms; p38 Mitogen-Activated Protein Kinases; Polymers; Resveratrol; Stilbenes; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2013
Experimental and computational studies on newly synthesized resveratrol derivative: a new method for cancer chemoprevention and therapeutics?
    Omics : a journal of integrative biology, 2013, Volume: 17, Issue:11

    Nature has been a provenance of medicinal agents for thousands of years. Resveratrol (RESL) is a naturally occurring polyphenolic compound in food stuffs such as peanuts, seeds, berries, grapes, and beverages (red wine). RESL has received significant attention due to a plethora of in vitro and in vivo reports on its cancer chemopreventive and therapeutic properties. In the present study, diacetate RESL derivative (RESL43) was synthesized. The RESL43 displayed potent cytotoxicity and triggered apoptosis in U937 cells as evidenced by poly (ADP-ribose) polymerase (PARP) cleavage, DNA fragmentation, morphological changes, and activation of FasR and FasL genes. The electrophoretic mobility shift assay revealed the suppression NFkB activity in U937 cells after treatment with RESL43 in corroboration with the deactivation of NFkB dependent genes such as IL-8, TNFR, and TNFα. Furthermore, molecular docking and dynamics studies have shown that RESL and RESL43 might exert their inhibitory activity on NFkB by altering the intramolecular binding abilities between DNA and NFkB. Taken together, RESL43 can have greater putative activity than parental RESL in a context of cancer chemoprevention and therapeutics. We suggest that the diacetate resveratrol derivative RESL43 warrants further evaluation in preclinical and clinical bridging studies in the near future.

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Binding Sites; Cell Line, Tumor; DNA; DNA Fragmentation; Fas Ligand Protein; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Molecular Docking Simulation; Neoplasms; NF-kappa B; Poly(ADP-ribose) Polymerases; Protein Binding; Receptors, Tumor Necrosis Factor; Resveratrol; Stereoisomerism; Stilbenes; Tumor Necrosis Factor-alpha

2013
Synthesis and biological evaluation of a folate-targeted rhaponticin conjugate.
    Bioorganic & medicinal chemistry, 2013, Jan-01, Volume: 21, Issue:1

    To improve the therapeutic effect of rhaponticin (RHA), a folate receptor (FR) targeted RHA conjugate was synthesized by utilizing a hydrophilic peptide spacer linked to folic acid (FA) via a releasable disulfide linker. This water-soluble conjugate was found to retain high affinity for FR-positive cells, and it produced specific, dose-responsive activity in vitro. Treatment of FRHA with a reducing agent indicated that the amino-reactive derivative of RHA would be released spontaneously following disulfide bond reduction within the endosomes. FRHA also proved to be active predominantly specific against FR-positive syngeneic and xenograft models in vivo, and possible curative activity resulted with minimal to moderate toxicity. The FRHA conjugate greatly enhanced the therapeutic effects and reduced the toxicity of RHA. In conclusion, FRHA represents a folate-targeted chemotherapeutic that can produce potent activity against established sc tumors. Hence, this report has a great significance in pharmacology and clinical medicine as well as methodology.

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Folate Receptors, GPI-Anchored; Folic Acid; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Stilbenes

2013
Resveratrol suppresses tumor progression via the regulation of indoleamine 2,3-dioxygenase.
    Biochemical and biophysical research communications, 2013, Feb-08, Volume: 431, Issue:2

    This study showed the potential of resveratrol to inhibit the expression and activity of interferon-γ (IFN-γ)-induced indoleamine 2,3-dioxygenase (IDO) in bone marrow-derived dendritic cells (BMDCs). The mechanism of suppression was associated with the activity of Janus kinase/signal transducers and activators of transcription (JAK/STAT) and protein kinase Cδ (PKCδ). In addition, resveratrol-mediated IDO suppression in IFN-γ-stimulated BMDCs appears to play a pivotal role in anti-tumor activity through the regulation of CD8(+) T cell polarization and cytotoxic T lymphocyte (CTL) activity. Systemic administration of resveratrol suppressed tumor growth in EG7 thymoma-bearing mice in an IDO-dependent manner. Taken together, resveratrol not only regulates immune response through the regulation of IDO in a JAK/STAT1- and PKCδ-dependent manner, but also modulates the IDO-mediated immune tolerance in EG7 thymoma.

    Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Indoleamine-Pyrrole 2,3,-Dioxygenase; Janus Kinases; Male; Mice; Mice, Inbred C57BL; Neoplasms; Proto-Oncogene Proteins c-akt; Resveratrol; STAT1 Transcription Factor; Stilbenes; Tumor Escape

2013
Isolation of apoptosis-inducing stilbenoids from four members of the Orchidaceae family.
    Planta medica, 2012, Volume: 78, Issue:2

    High-throughput natural product research produced a suite of anticancer hits among several species of the Orchidaceae family (Oncidium microchilum, O. isthmi, and Myrmecophila humboldtii). A commercial Oncidium sp. was also examined as a convenient source of additional material. Isolation and structure elucidation led to the identification of fifteen stilbenoids including a new phenanthraquinone and two new dihydrostilbenes. NMR data for structure elucidation and dereplication were acquired utilizing a Bruker BioSpin TCI 1.7-mm MicroCryoProbe or a 5-μL CapNMR capillary microcoil. Several compounds inhibited proliferation of NCI-H460 and M14 cancer cell lines. All compounds were also examined for their ability to induce apoptosis. Apoptosis induction was determined by measuring caspase 3/7 activation and LDH release in a NCI-H460 cell line. Based on these results, a portion of the extract from a commercially available Oncidium sp. was chemically modified in an attempt to obtain additional phenanthraquinones.

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Humans; Molecular Structure; Neoplasms; Orchidaceae; Phytotherapy; Plant Extracts; Stilbenes

2012
Optimizing thiadiazole analogues of resveratrol versus three chemopreventive targets.
    Bioorganic & medicinal chemistry, 2012, Jan-01, Volume: 20, Issue:1

    Chemoprevention is an approach to decrease cancer morbidity and mortality through inhibition of carcinogenesis and prevention of disease progression. Although the trans stilbene derivative resveratrol has chemopreventive properties, its action is compromised by weak non-specific effects on many biological targets. Replacement of the stilbene ethylenic bridge of resveratrol with a 1,2,4-thiadiazole heterocycle and modification of the substituents on the two aromatic rings afforded potential chemopreventive agents with enhanced potencies and selectivities when evaluated as inhibitors of aromatase and NF-κB and inducers of quinone reductase 1 (QR1).

    Topics: Antineoplastic Agents; Aromatase; Binding Sites; Catalytic Domain; Chemoprevention; Computer Simulation; Enzyme Activation; Humans; NAD(P)H Dehydrogenase (Quinone); Neoplasms; NF-kappa B; Resveratrol; Stilbenes; Structure-Activity Relationship; Thiadiazoles

2012
Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival.
    British journal of pharmacology, 2012, Volume: 166, Issue:5

    Sphingosine kinase 1 catalyses formation of the bioactive lipid, sphingosine 1-phosphate, which protects cancer cells from apoptosis. Therefore, sphingosine kinase 1 is a novel target for intervention with anti-cancer agents. We have assessed the effect of the anti-cancer agent, resveratrol and its dimers (ampelopsin A and balanocarpol) on sphingosine kinase 1 activity and on survival of MCF-7 breast cancer cells.. Ampelopsin A and balanocarpol were purified from Hopea dryobalanoides and their effect on sphingosine kinase 1 activity and expression, [(3)H] thymidine incorporation, ERK-1/2 phosphorylation and PARP activity assessed in MCF-7 cells.. Resveratrol, ampelopsin A and balanocarpol were novel inhibitors of sphingosine kinase 1 activity. Balanocarpol was a mixed inhibitor (with sphingosine) of sphingosine kinase 1 with a K(ic) = 90 ± 10 µM and a K(iu) of ∼500 µM. Balanocarpol and ampelopsin A also induced down-regulation of sphingosine kinase 1 expression and reduced DNA synthesis, while balanocarpol stimulated PARP cleavage in MCF-7 breast cancer cells. Resveratrol was a competitive inhibitor (with sphingosine) of sphingosine kinase 1 with a K(ic) = 160 ± 40 µM, reduced sphingosine kinase 1 expression and induced PARP cleavage in MCF-7 cells.. Each molecule of balanocarpol may bind at least two sphingosine kinase 1 catalytic molecules to reduce the activity of each simultaneously. These findings suggest that resveratrol, ampelopsin A and balanocarpol could perturb sphingosine kinase 1-mediated signalling and this might explain their activity against MCF-7 breast cancer cells.

    Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Humans; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Resveratrol; Stilbenes

2012
Comment on 'Resveratrol in human cancer chemoprevention--choosing the 'right' dose'.
    Molecular nutrition & food research, 2012, Volume: 56, Issue:4

    Topics: Animals; Antineoplastic Agents, Phytogenic; Humans; Neoplasms; Stilbenes

2012
In this issue of the International Reviews of Immunology.
    International reviews of immunology, 2012, Volume: 31, Issue:3

    This issue hosts diverse topics, from myeloid derived suppressor cells (MDSC) with their mechanism and role in cancer, the interplay between diet and emerging allergies studied in a genetically closed population, the pleiotropic anti-inflammatory effects of resveratrol, to the quest to achieve more reliable immune correlates of protection against the hepatitis C virus (HCV).

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Hepatitis C; Humans; Hypersensitivity; Immune System; Models, Immunological; Myeloid Cells; Neoplasms; Resveratrol; Stilbenes; Viral Hepatitis Vaccines

2012
High-sensitivity in vivo imaging for tumors using a spectral up-conversion nanoparticle NaYF4: Yb3+, Er3+ in cooperation with a microtubulin inhibitor.
    Nanoscale, 2012, Jul-07, Volume: 4, Issue:13

    Fluorescein has been used for in vivo imaging to identify tumors. However, this technique presents several limitations, mainly due to its limited targeting efficiency, tissue autofluorescence and poor light penetration in tissue. In the present study, an alternative fluorescence imaging technique to localize tumors has been developed by using up-conversion nanoparticles (UCNs) and enhanced targeting approaches. A folic acid molecule is conjoined with UCNs (NaYF(4): Yb(3+), Er(3+)) to improve the tumor-specificity; the UCN is also loaded with the microtubule inhibitor CA4P, to further improve the local delivery of particles in the tumor. The proposed imaging technique combines several well-established individual concepts into one novel integrated procedure and significantly improves its tumor-imaging capability: the near-infrared excitation for UCNs minimizes tissue autofluorescence and allows imaging into deeper tissue; the improvement in the signal to noise ratio (SNR) is at least a magnitude better than that of a conventional fluorescence imaging technique, and the modification of UCNs with folic acid significantly improves the tumor targeting efficiency by utilizing its affinity for the folic acid receptor that is often over expressed in tumors. The loading of CA4P further helps UCNs to cross blood vessel walls to reach tumor cells by depolymerizing the microtubules of endothelial cells. The integrated nanoparticle possesses the near-infrared-identical optical properties of UCNs alone, thus achieving a highly effective fluorescence imaging probe. The results demonstrated that the proposed method provides an excellent alternative for tumor localization and a potential traceable vehicle for highly efficient drug delivery.

    Topics: Animals; Diagnostic Imaging; Erbium; Fluorescent Dyes; Fluorides; Folic Acid; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Nude; Microtubules; Nanoparticles; Neoplasms; Signal-To-Noise Ratio; Stilbenes; Tubulin Modulators; Ytterbium; Yttrium

2012
Synthesis, biological evaluation, and structure-activity relationships of novel substituted N-phenyl ureidobenzenesulfonate derivatives blocking cell cycle progression in S-phase and inducing DNA double-strand breaks.
    Journal of medicinal chemistry, 2012, Jul-12, Volume: 55, Issue:13

    Twenty-eight new substituted N-phenyl ureidobenzenesulfonate (PUB-SO) and 18 N-phenylureidobenzenesulfonamide (PUB-SA) derivatives were prepared. Several PUB-SOs exhibited antiproliferative activity at the micromolar level against the HT-29, M21, and MCF-7 cell lines and blocked cell cycle progression in S-phase similarly to cisplatin. In addition, PUB-SOs induced histone H2AX (γH2AX) phosphorylation, indicating that these molecules induce DNA double-strand breaks. In contrast, PUB-SAs were less active than PUB-SOs and did not block cell cycle progression in S-phase. Finally, PUB-SOs 4 and 46 exhibited potent antitumor activity in HT-1080 fibrosarcoma cells grafted onto chick chorioallantoic membranes, which was similar to cisplatin and combretastatin A-4 and without significant toxicity toward chick embryos. These new compounds are members of a promising new class of anticancer agents.

    Topics: Animals; Anticarcinogenic Agents; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Cisplatin; DNA Breaks, Double-Stranded; Histones; HT29 Cells; Humans; Imidazolidines; Jurkat Cells; Neoplasms; Phenylurea Compounds; Phosphorylation; S Phase; Stilbenes; Structure-Activity Relationship

2012
The effects of polyphenols on oxidative stress and the arachidonic acid cascade. Implications for the prevention/treatment of high prevalence diseases.
    Biochemical pharmacology, 2012, Nov-01, Volume: 84, Issue:9

    Redox state unbalance and the activation of the arachidonic acid (AA) cascade, contribute to the pathogenesis of cardiovascular disease (CVD) and cancer. Inflammatory cells that infiltrate the atheroma plaque or tumor are a major source of reactive oxygen species and eicosanoids. The human antioxidant defense network is complex and interlocking and there is controversy surrounding the beneficial effects of diet-derived antioxidants in vivo. However, epidemiological studies indicate that populations that consume high levels of plant-derived foods containing phenolic compounds have low rates of CVD and cancer. The molecular mechanisms for these effects are multi-faceted. They include the regulation of transcription factors and consequently the modulation of genes (cytokines, growth factors and adhesion molecules), and growth factor-receptor interactions and cell signaling cascades, which determine the expression of genes involved in cell cycle, cell survival and apoptosis, as well as adhesiveness/invasiveness and angiogenesis. The present paper also focuses on the effects of phenolic compounds on AA cascade enzymes (cyclooxygenases and lipoxygenases) and the subsequent synthesis of eicosanoids, which are involved in CVD and cancer. A better understanding of these processes could explain the beneficial effects of polyphenols on the most prevalent diseases in Western societies. This commentary shows that antioxidants under evaluation include structural modifications of low-molecular-mass polyphenols, which could lead to a valuable strategy for modulating the generation of inflammatory mediators involved in these chronic diseases.

    Topics: Acetylation; Animals; Anthocyanins; Antioxidants; Arachidonic Acid; Biological Availability; Cardiovascular Diseases; Chemoprevention; Dietary Supplements; Flavones; Food; Histones; Humans; Neoplasms; Nitric Oxide; Oxidative Stress; Polyphenols; Prevalence; Signal Transduction; Stilbenes

2012
Pterostilbene-induced tumor cytotoxicity: a lysosomal membrane permeabilization-dependent mechanism.
    PloS one, 2012, Volume: 7, Issue:9

    The phenolic phytoalexin resveratrol is well known for its health-promoting and anticancer properties. Its potential benefits are, however, limited due to its low bioavailability. Pterostilbene, a natural dimethoxylated analog of resveratrol, presents higher anticancer activity than resveratrol. The mechanisms by which this polyphenol acts against cancer cells are, however, unclear. Here, we show that pterostilbene effectively inhibits cancer cell growth and stimulates apoptosis and autophagosome accumulation in cancer cells of various origins. However, these mechanisms are not determinant in cell demise. Pterostilbene promotes cancer cell death via a mechanism involving lysosomal membrane permeabilization. Different grades of susceptibility were observed among the different cancer cells depending on their lysosomal heat shock protein 70 (HSP70) content, a known stabilizer of lysosomal membranes. A375 melanoma and A549 lung cancer cells with low levels of HSP70 showed high susceptibility to pterostilbene, whereas HT29 colon and MCF7 breast cancer cells with higher levels of HSP70 were more resistant. Inhibition of HSP70 expression increased susceptibility of HT29 colon and MCF7 breast cancer cells to pterostilbene. Our data indicate that lysosomal membrane permeabilization is the main cell death pathway triggered by pterostilbene.

    Topics: Antineoplastic Agents; Apoptosis; Autophagy; Caspases; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Flow Cytometry; HSP70 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; L-Lactate Dehydrogenase; Lysosomes; Microscopy, Confocal; Necrosis; Neoplasms; Permeability; Phagosomes; Resveratrol; Stilbenes

2012
Inhibition of DNA topoisomerases I and II of compounds from Reynoutria japonica.
    Archives of pharmacal research, 2012, Volume: 35, Issue:9

    Three anthraquinones (1, 2 and 4), three stilbenes (5, 6 and 7) and 3,5-dihydroxybenzyl alcohol (3) were isolated from Reynoutria japonica. Their structures were identified as emodin (1), emodin-8-O-β-D-glucoside (2), 3,5-dihydroxybenzyl alcohol (3), citreorosein (4), cis-resveratrol (5), trans-resveratrol (6) and trans-resveratrol-5-O-β-D-glucopyranoside (7) by comparing their physicochemical and spectral data with published data. Compound 3 was isolated for the first time from the Polygonaceae family. Among the purified compounds, 3 showed more potent inhibitory activity against topoisomerase I (IC₅₀: 4 μM) than camptothecin, as the positive control (IC₅₀: 18 μM). Compounds 3, 4, 5, 6 and 7 showed stronger inhibitory activities toward DNA topoisomerase II (IC₅₀: 0.54, 14, 15, 0.77 and 3 μM, respectively) than the positive control, etoposide (IC₅₀: 44 μM). Compounds 1 and 4 displayed weak cytotoxicities against human lung cancer (A549), ovarian cancer (SK-OV-3), human liver hepatoblastoma (HepG2) and colon adenocarcinoma (HT-29) cell lines.

    Topics: Animals; Anthraquinones; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Benzyl Alcohols; Cattle; Cell Line, Tumor; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Discovery; Fallopia japonica; Glucosides; Humans; Inhibitory Concentration 50; Medicine, Korean Traditional; Neoplasms; Plant Extracts; Plant Roots; Republic of Korea; Resorcinols; Stilbenes; Topoisomerase I Inhibitors; Transition Temperature

2012
Combretastatin A-4 phosphate affects tumor vessel volume and size distribution as assessed using MRI-based vessel size imaging.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Dec-01, Volume: 18, Issue:23

    Combretastatin A-4 disodium phosphate (CA4P) is a promising vascular disrupting agent (VDA) in clinical trials. As CA4P acts on dividing endothelial cells, we hypothesize that CA4P affects vessels of certain sizes. The aim of this study was to evaluate the effect of CA4P by the MRI-based vessel size imaging (VSI).. C3H mammary carcinomas were grown to 200 mm(3) in the right rear foot of female CDF(1) mice. A control group of mice received no treatment, and a treatment group had CA4P administered intraperitoneally at a dose of 250 mg/kg. VSI was conducted on a 3 Tesla MR scanner to estimate the tumor blood volume (ζ(0)) and mean vessel radius (R). Vascularization was also estimated histologically by endothelial and Hoechst 33342 staining.. ζ(0) and R showed different spatial heterogeneity. Tumor median and quartile values of ζ(0) were all significantly reduced by about 35% in the CA4P-treated group as compared with the control group, and the median and upper quartile of R were significantly increased. Histograms of ζ(0) and R showed a general decrease in ζ(0) following treatment, and values of R in a certain range (≈20-30 μm) were decreased in the treatment group. The drug-induced change in ζ(0) was in agreement with histology and our previous dynamic contrast enhanced MRI (DCE-MRI) data.. Tumor blood volume and mean vessel radius showed a clear response following treatment with CA4P. VSI may prove valuable in estimation of tumor angiogenesis and prediction of response to VDAs.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Blood Vessels; Disease Models, Animal; Female; Magnetic Resonance Imaging; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Stilbenes

2012
Interventions: Live long and prosper.
    Nature, 2012, Dec-06, Volume: 492, Issue:7427

    Topics: Age of Onset; Aging; Animal Diseases; Animals; Biomedical Research; Caloric Restriction; Cardiovascular Diseases; Female; Gene Expression Profiling; Geriatrics; Humans; Longevity; Macaca mulatta; Male; Mice; Models, Animal; Neoplasms; Oligonucleotide Array Sequence Analysis; Reproducibility of Results; Resveratrol; Sirolimus; Sirtuins; Somatomedins; Stilbenes; TOR Serine-Threonine Kinases

2012
Nutraceutical inhibition of muscle proteolysis: a role of diallyl sulphide in the treatment of muscle wasting.
    Clinical nutrition (Edinburgh, Scotland), 2011, Volume: 30, Issue:1

    The abnormalities associated with cancer cachexia include anorexia, weight loss, muscle loss and atrophy, anaemia and alterations in carbohydrate, lipid and protein metabolism. The aim of the present investigation was to examine the anti-wasting effects of some nutraceuticals such as genistein, resveratrol, epigallocatechin gallate and diallyl sulphide (DAS).. The in vitro effects of these nutraceuticals on proteolysis were examined in muscle cell cultures submitted to hyperthermia. The in vivo effects of DAS were also tested in cachectic tumour-bearing rats (Yoshida AH-130 ascites hepatoma).. Although all the nutraceuticals tested inhibited muscle proteolysis, the most promising effects were related with DAS. In vivo administration of DAS only leads to a small improvement in tibialis muscle and heart weights; however, administration of DAS to healthy animals increased all muscle weights, this being associated with a decreased gene expression of proteolytic systems components.. It may be suggested that DAS could be used to improve muscle mass during healthy conditions.

    Topics: Allyl Compounds; Animals; Anorexia; Cachexia; Catechin; Cells, Cultured; Dietary Supplements; Genistein; Male; Muscle, Skeletal; Muscular Atrophy; Neoplasms; Rats; Rats, Wistar; Resveratrol; Stilbenes; Sulfides; Weight Loss

2011
Microflow of fluorescently labelled red blood cells in tumours expressing single isoforms of VEGF and their response to vascular targeting agents.
    Medical engineering & physics, 2011, Volume: 33, Issue:7

    In this work we studied the functional differences between the microcirculation of murine tumours that express only single isoforms of vascular endothelial growth factor-A (VEGF), namely VEGF120 and VEGF188, and the effect of VEGF receptor tyrosine kinase (VEGF-R TK) inhibition on their functional response to the vascular disrupting agent, combretastatin A-4 phosphate (CA-4-P), using measurement of red blood cell (RBC) velocity by a 'keyhole' tracking algorithm. RBC velocities in VEGF188 tumours were unaffected by chronic treatment with a VEGF-R tyrosine kinase inhibitor, SU5416, whereas RBC velocities in VEGF120 tumours were significantly increased compared to control VEGF120 tumours. This effect was accompanied by a reduced tumour vascularisation. Pre-treatment of VEGF120 tumours with SU5416 made them much more resistant to CA-4-P treatment, with a RBC velocity response that was very similar to that of the more mature vasculature of the VEGF188 tumours. This study shows that vascular normalisation following anti-angiogenic treatment with a VEGF-R tyrosine kinase inhibitor reduced the response of a previously sensitive tumour line to CA-4-P.

    Topics: Animals; Antineoplastic Agents; Blood Vessels; Erythrocytes; Fluorescent Dyes; Gene Expression Regulation, Neoplastic; Hemodynamics; Male; Mice; Neoplasms; Protein Isoforms; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Stilbenes; Vascular Endothelial Growth Factor A

2011
Resveratrol interacts with estrogen receptor-β to inhibit cell replicative growth and enhance stress resistance by upregulating mitochondrial superoxide dismutase.
    Free radical biology & medicine, 2011, Apr-01, Volume: 50, Issue:7

    trans-Resveratrol (RES) is one of a number of dietary polyphenols that have been reported to beneficially affect human physiology. Although numerous studies have attributed this to direct interactions between RES and histone deacetylases, recently the reliability of these results has been questioned. We have shown that the mitochondrial superoxide dismutase (MnSOD) is substantially upregulated in RES-treated cells. Here we explore the mechanisms underlying this, showing that two of RES's more interesting effects, inhibition of replication and enhancement of stress resistance, are mediated by MnSOD upregulation in three cell lines: MRC5 human lung fibroblasts, C2C12 mouse myoblasts, and SHSY5Y human neuroblastoma cells. When small interfering RNA was used to prevent induction of MnSOD expression, the effects of RES on population doubling time of cells in culture, and resistance to cell death after exposure to hydrogen peroxide or paraquat, were abolished. Interestingly, the RES-induced upregulation of MnSOD levels could be prevented by the estrogen receptor antagonist ICI 182780. RES's effects also could be reproduced using estradiol or the estrogen receptor-β agonist diarylpropionitrile, but not using the estrogen receptor-α agonist propylpyrazole triol. Thus, we suggest that RES interacts with estrogen receptor-β to induce the upregulation of MnSOD, which affects cell cycle progression and stress resistance. These results have important implications for our understanding of RES's biological activities and potential applications to human health.

    Topics: Animals; Antioxidants; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Fulvestrant; Gene Expression; Humans; Hydrogen Peroxide; Mice; Mitochondria; Neoplasms; Nitriles; Phenols; Propionates; Pyrazoles; Resveratrol; Stilbenes; Stress, Physiological; Superoxide Dismutase; Up-Regulation

2011
A new dimeric resveratrol from the roots of Shorea roxburghii.
    Fitoterapia, 2011, Volume: 82, Issue:3

    A new resveratrol dimer, roxburghiol A (1) together with eleven known compounds were isolated from the roots of Shorea roxburghii. Their structures were identified on the basis of spectroscopic evidence and physicochemical properties. All isolated compounds were evaluated for their cytotoxicity (KB and HeLa cells). Compounds 8 and 9 showed potent cytotoxicity against both KB and HeLa cell lines with IC(50) values of 6.5, 8.5 and 8.7, 10.1 μg/mL, respectively.

    Topics: Antineoplastic Agents, Phytogenic; Dipterocarpaceae; HeLa Cells; Humans; Inhibitory Concentration 50; KB Cells; Molecular Structure; Neoplasms; Phytotherapy; Plant Extracts; Plant Roots; Stilbenes

2011
Quantum-chemical study of interactions of trans-resveratrol with guanine-thymine dinucleotide and DNA-nucleobases.
    Journal of molecular modeling, 2011, Volume: 17, Issue:12

    Trans-resveratrol, a natural phytoalexin present in red wine and grapes, has gained considerable attention because of its antiproliferative, chemopreventive and proapoptotic activity against human cancer cells. The accurate quantum-chemical computations based on the density functional theory (DFT) and ab initio second-order Møller-Plesset perturbation method (MP2) have been performed for the first time to study interactions of trans-resveratrol with guanine-thymine dinucleotide and DNA-derived nitrogenous bases: adenine, guanine, cytosine and thymine in vacuum and water medium. This compound is found to show high affinity to nitrogenous bases and guanine-thymine dinucleotide. The electrostatic interactions from intermolecular hydrogen bonding increase the stability of complexes studied. In particular, significantly strong hydrogen bonds between 4'-H atom of trans-resveratrol and imidazole nitrogen as well as carbonyl oxygen atoms of nucleobases studied stabilize these systems. The stabilization energies computed reveal that the negatively charged trans-resveratrol-dinucleotide complex is more energetically stable in water medium than in vacuum. MP2 method gives more reliable and significantly high values of stabilization energy of trans-resveratrol-dinucleotide, trans-resveratrol-guanine and trans-resveratrol-thymine complexes than B3LYP exchange-correlation functional because it takes into account London dispersion energy. According to the results, in the presence of trans-resveratrol the 3'-5' phosphodiester bond in dinucleotide can be cleaved and the proton from 4'-OH group of trans-resveratrol migrates to the 3'-O atom of dinucleotide. It is concluded that trans-resveratrol is able to break the DNA strand. Hence, the findings obtained help understand antiproliferative and anticancer properties of this polyphenol.

    Topics: Adenine; Antineoplastic Agents, Phytogenic; Cytosine; DNA; DNA Breaks; Guanine; Humans; Hydrogen Bonding; Models, Molecular; Neoplasms; Nucleic Acid Conformation; Quantum Theory; Resveratrol; Static Electricity; Stilbenes; Thermodynamics; Thymine; Vacuum; Water

2011
Food: The omnivore's labyrinth.
    Nature, 2011, Mar-24, Volume: 471, Issue:7339

    Topics: Animals; Brassica; Breeding; Cooking; Curcumin; Diet; Fruit; Genetic Variation; Genistein; Genome, Human; Humans; Isothiocyanates; Metagenome; Mice; Neoplasms; Phytotherapy; Rats; Reproducibility of Results; Resveratrol; Risk Management; Stilbenes; Sulfoxides; Thiocyanates; Time Factors; Vegetables

2011
Computational modeling of tumor response to vascular-targeting therapies--part I: validation.
    Computational and mathematical methods in medicine, 2011, Volume: 2011

    Mathematical modeling techniques have been widely employed to understand how cancer grows, and, more recently, such approaches have been used to understand how cancer can be controlled. In this manuscript, a previously validated hybrid cellular automaton model of tumor growth in a vascularized environment is used to study the antitumor activity of several vascular-targeting compounds of known efficacy. In particular, this model is used to test the antitumor activity of a clinically used angiogenesis inhibitor (both in isolation, and with a cytotoxic chemotherapeutic) and a vascular disrupting agent currently undergoing clinical trial testing. I demonstrate that the mathematical model can make predictions in agreement with preclinical/clinical data and can also be used to gain more insight into these treatment protocols. The results presented herein suggest that vascular-targeting agents, as currently administered, cannot lead to cancer eradication, although a highly efficacious agent may lead to long-term cancer control.

    Topics: Algorithms; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Vessels; Computer Simulation; Cytotoxins; Dacarbazine; Glioblastoma; Humans; Models, Biological; Neoplasms; Stilbenes; Temozolomide; Treatment Outcome

2011
Rhapontigenin inhibited hypoxia inducible factor 1 alpha accumulation and angiogenesis in hypoxic PC-3 prostate cancer cells.
    Biological & pharmaceutical bulletin, 2011, Volume: 34, Issue:6

    Hypoxia inducible factor 1 alpha (HIF-1α) is frequently over-expressed in the numerous types of cancer and plays an important role in angiogenesis. In the present study, the inhibitory mechanism of rhapontigenin isolated from Vitis coignetiae was investigated on HIF-1α stability and angiogenesis in human prostate cancer PC-3 cells. Rhapontigenin significantly suppressed HIF-1α accumulation at protein level but not at mRNA level in PC-3 cells under hypoxia. Also, rhapontigenin suppressed hypoxia-induced HIF-1α activation in various cancer cells, such as colorectal adenocarcinoma (SW620), breast adenocarcinoma (MCF-7), fibrosarcoma (HT-1080) and prostate carcinoma (LNCaP). Interestingly, rhapontigenin had more potency in inhibition of hypoxia-induced HIF-1α expression than that of resveratrol, a known HIF-1α inhibitor. In addition, rhapontigenin promoted hypoxia-induced HIF-1α degradation and cycloheximide (CHX) blocked protein synthesis. A prolyl hydroxylase (PHD) inhibitor dimethyloxalylglycine (DMOG) is usually utilized to examine whether prolyl hydroxylation is involved in inhibition of HIF-1α accumulation. Here, DMOG recovered HIF-1α accumulation inhibited by rhapontigenin. Immunoprecipitation assay also revealed that rhapotigenin enhanced the binding of hydroxylated HIF-1α to von Hippel-Lindau (VHL) tumor suppressor protein. Furthermore, rhapontigenin reduced vascular endothelial growth factor (VEGF) secretion in hypoxic PC-3 cells as well as suppressed tube formation in human umbilical vein endothelial cells (HUVECs) treated by the conditioned media of hypoxic PC-3 cells. However, anti-angiogenic effect of rhapontigenin in hypoxic PC-3 cells was reversed by DMOG. Taken together, these findings suggest that rhapontigenin inhibits HIF-1α accumulation and angiogenesis in PC-3 prostate cancer cells.

    Topics: Amino Acids, Dicarboxylic; Angiogenesis Inhibitors; Carcinoma; Cell Hypoxia; Cell Line; Cell Line, Tumor; Culture Media, Conditioned; Endothelium, Vascular; Enzyme Inhibitors; Female; Humans; Hydroxylation; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Neoplasms; Neovascularization, Pathologic; Procollagen-Proline Dioxygenase; Prostatic Neoplasms; Protein Processing, Post-Translational; Stilbenes; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein

2011
Pleiotropic effects of a schweinfurthin on isoprenoid homeostasis.
    Lipids, 2011, Volume: 46, Issue:10

    The schweinfurthins, a family of natural products derived from the isoprenoid biosynthetic pathway (IBP), have marked growth inhibitory activity. However, the biochemical basis for the schweinfurthins cellular effects has remained ill-defined. Here, the effects of the synthetic schweinfurthin, 3-deoxyschweinfurthin (3dSB) on multiple aspects of isoprenoid homeostasis are explored. Cytotoxicity assays demonstrate a synergistic interaction between 3dSB and the HMG-CoA reductase inhibitor lovastatin but not with other IBP inhibitors in a variety of human cancer cell lines. The cytotoxic effects of 3dSB were enhanced in cells incubated in lipid-depleted serum. 3dSB was found to enhance the lovastatin-induced decrease in protein prenylation. In addition, 3dSB decreases intracellular farnesyl pyrophosphate and geranylgeranyl pyrophosphate levels in both established cell lines and primary cells. To determine whether 3dSB alters the regulation of expression of genes involved in isoprenoid homeostasis, real-time PCR studies were performed in human cell lines cultured in either lipid-replete or -deplete conditions. These studies demonstrate that 3dSB abrogates lovastatin-induced upregulation of sterol regulatory element-containing genes and lovastatin-induced downregulation of ABCA1. In aggregate, these studies are the first to demonstrate that a schweinfurthin exerts pleiotropic effects on isoprenoid homeostasis.

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Humans; Lovastatin; Neoplasms; Polyisoprenyl Phosphates; Prenylation; Sesquiterpenes; Stilbenes; Terpenes

2011
Design, synthesis, and cytotoxicity of novel 3-arylidenones derived from alicyclic ketones.
    Chemical biology & drug design, 2011, Volume: 78, Issue:4

    Forty-four novel chalcone-inspired analogs having a 3-aryl-2-propenoyl moiety derived from alicyclic ketones were designed, synthesized, and investigated for cytotoxicity against murine B16 and L1210 cancer cell lines. The analogs belong to four structurally divergent series, three of which (series g, h, and i) contain differently substituted cyclopentanone units and the fourth (series j) contains a 3,3-dimethyl-4-piperidinone moiety. Of these, the analogs in series j showed potential cytotoxic activity against murine B16 (melanoma) and L1210 (lymphoma) cells. The most active compounds 5j, 11j, 15j, and 12h produced IC(50) values from 4.4 to 15 μm against both cell lines. A single-crystal X-ray structure analysis and molecular modeling studies confirmed that these chalcones have an E-geometry about the alkene bond and possess a slightly 'twisted' conformation similar to that of combretastatin A-4. At a concentration of 30 μm, compounds 5j, 11j, and 15j did not cause microtubule depolymerization in cells, suggesting that they have a different mechanism of action.

    Topics: Animals; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Cell Survival; Chalcones; Drug Design; Humans; Ketones; Mice; Models, Molecular; Neoplasms; Stilbenes; Structure-Activity Relationship; Tubulin Modulators

2011
Natural products reveal cancer cell dependence on oxysterol-binding proteins.
    Nature chemical biology, 2011, Aug-07, Volume: 7, Issue:9

    Cephalostatin 1, OSW-1, ritterazine B and schweinfurthin A are natural products that potently, and in some cases selectively, inhibit the growth of cultured human cancer cell lines. The cellular targets of these small molecules have yet to be identified. We have discovered that these molecules target oxysterol binding protein (OSBP) and its closest paralog, OSBP-related protein 4L (ORP4L)--proteins not known to be involved in cancer cell survival. OSBP and the ORPs constitute an evolutionarily conserved protein superfamily, members of which have been implicated in signal transduction, lipid transport and lipid metabolism. The functions of OSBP and the ORPs, however, remain largely enigmatic. Based on our findings, we have named the aforementioned natural products ORPphilins. Here we used ORPphilins to reveal new cellular activities of OSBP. The ORPphilins are powerful probes of OSBP and ORP4L that will be useful in uncovering their cellular functions and their roles in human diseases.

    Topics: Biological Products; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Cholestenones; Humans; Hydroxycholesterols; Lipid Metabolism; Neoplasms; Phenazines; Receptors, Steroid; Saponins; Signal Transduction; Sphingomyelins; Spiro Compounds; Steroids; Stilbenes

2011
Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.
    International immunopharmacology, 2011, Volume: 11, Issue:11

    We evaluated the anti-tumor effect of Resveratrol (RV) on M21 and NXS2 tumor cell lines and its immunosuppressive activity on human and murine immune cells to determine the potential for combining RV and immunotherapy. In vitro, concentrations of RV≥25 mcM, inhibited cell proliferation, blocked DNA synthesis and induced G1 phase arrest in tumor and immune cells. RV at 12-50 mcM inhibited antibody dependent cell mediated cytotoxicity (ADCC) of tumor cells facilitated by the hu14.18-IL2 immunocytokine (IC). The in vivo anti-tumor and immunomodulating activity of RV given systemically were assessed in mice. Results showed that this RV regimen inhibited the growth of NXS2 tumors in vivo but did not appear to interfere with blood cell count, splenocyte or macrophage function. Thus, RV may be a candidate for combining with immunotherapy.

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Female; Flow Cytometry; Humans; Immunotherapy; Leukocytes, Mononuclear; Mice; Mice, Nude; Neoplasms; Resveratrol; Spleen; Stilbenes

2011
Relevance of the C-5 position to schweinfurthin induced cytotoxicity.
    Bioorganic & medicinal chemistry, 2011, Dec-15, Volume: 19, Issue:24

    The schweinfurthins are an intriguing group of anti-proliferative agents that display low nanomolar activities against several cell types, including the human-derived glioblastoma cell line SF-295, but have little impact on other cell lines even at micromolar concentrations. This activity has inspired the synthesis of seven of the natural schweinfurthins, all with the correct absolute stereochemistry, and a variety of analogues designed to probe different facets of the pharmacophore. Reported herein is the synthesis of several new schweinfurthin analogues varied at the C-5 position along with data on their biological activity in the NCI 60 cell-line assay.

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Euphorbiaceae; Humans; Molecular Structure; Neoplasms; Stilbenes

2011
Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation.
    Journal of agricultural and food chemistry, 2010, Feb-10, Volume: 58, Issue:3

    Resveratrol functions as an agonist for estrogen receptor (ER)-mediated transcription. However, other researchers have reported that resveratrol decreases proliferation of breast cancer cells that are either ER-positive or ER-negative, which suggests that the interaction of resveratrol with the ER may not fully explain its inhibitory effect on proliferation. Similar to those effects associated with caloric restriction (CR), resveratrol has multiple beneficial activities, such as increased life span and delay in the onset of diseases associated with aging. One key enzyme thought to be activated during CR is the AMP-activated kinase (AMPK), a sensor of cellular energy levels. The suppression of nonessential energy expenditure by activated AMPK along with the CR mimetic and antiproliferative properties of resveratrol has led us to hypothesize that resveratrol activity might have an important role in the activation of AMPK. Here, we show that resveratrol activated AMPK in both ER-positive and ER-negative breast cancer cells. Once activated, AMPK inhibited 4E-BP1 signaling and mRNA translation via mammalian target of rapamycin (mTOR). Moreover, we also found that AMPK activity mediated by resveratrol in cancer cells was due to inducing the expression of Sirtuin type 1 (SIRT1) via elevation in the cellular NAD(+)/NADH in ER-positive cells. To our knowledge, we demonstrate here for the first time that resveratrol induces the expression of SIRT1 protein in human cancer cells. These observations raise the possibility that SIRT1 functions as a novel upstream regulator for AMPK signaling and may additionally modulate tumor cell proliferation. Targeting SIRT1/AMPK signaling by resveratrol may have potential therapeutic implications for cancer and age-related diseases.

    Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Female; Gene Expression; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Protein Biosynthesis; Resveratrol; Signal Transduction; Sirtuin 1; Stilbenes

2010
Phenolic compounds as selective antineoplasic agents against multidrug-resistant human cancer cells.
    Planta medica, 2010, Volume: 76, Issue:10

    Twelve phenolic compounds, including three stilbenes, two flavonoids, two coumarins, one neolignan, and four lignans, isolated from Euphorbia and Pycnanthus species or obtained by derivatization, were assayed for their potential antineoplastic efficacy in three human cancer cell lines: gastric (EPG85-257), pancreatic (EPP85-181), and colon (HT-29) carcinomas as well as derived multidrug-resistant sublines. In each case, two different multidrug-resistant variants, i.e., cell lines with classical and atypical MDR phenotype, were used. The majority of the MDR cancer sublines showed increased sensitivities to the studied compounds when compared to the parental sublines. The most active compound was the flavonoid naringenin, found to be 15-fold more effective against the atypical MDR subline of gastric carcinoma than in parental drug-sensitive cells. Furthermore, the stilbene trans-3,5,3',4'-tetramethoxypiceatannol and the lignans 4'-hydroxy-3,3',4-trimethoxylignan and heliobuphthalmin also exhibited high antineoplasic activities against the classical MDR subline derived from gastric carcinoma. The results of this study suggest that some phenolic compounds might be valuable for the treatment of multidrug-resistant cancer cells.

    Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Multiple; Euphorbia; Flavanones; Humans; Lignans; Magnoliopsida; Myristicaceae; Neoplasms; Pancreatic Neoplasms; Phenols; Phytotherapy; Plant Extracts; Stilbenes; Stomach Neoplasms

2010
Design and in vitro evaluation of branched peptide conjugates: turning nonspecific cytotoxic drugs into tumor-selective agents.
    ChemMedChem, 2010, Apr-06, Volume: 5, Issue:4

    The use of peptide receptors as targets for tumor-selective therapies was envisaged years ago with the findings that receptors for different endogenous regulatory peptides are overexpressed in several primary and metastatic human tumors, and can be used as tumor antigens. Branched peptides can retain or even increase, through multivalent binding, the biological activity of a peptide and are very resistant to proteolysis, thus having a markedly higher in vivo activity compared with the corresponding monomeric peptides. Oligo-branched peptides, containing the human regulatory peptide neurotensin (NT) sequence, have been used as tumor-specific targeting agents. These peptides are able to selectively and specifically deliver effector units, for cell imaging or killing, to tumor cells that overexpress NT receptors. Results obtained with branched NT conjugated to different functional units for tumor imaging and therapy indicate that branched peptides are promising novel multifunctional targeting molecules. This study is focused on the role of the releasing pattern of drug-conjugated branched NT peptides. We present results obtained with oligo-branched neurotensin peptides conjugated to 6-mercaptopurin (6-MP), combretastain A-4 (CA4) and monastrol (MON). Drugs were conjugated to oligo-branched neurotensin through different linkers, and the mode-of-release, together with cytotoxicity, was studied in different human cancer cell lines. The results show that branched peptides are very promising pharmacodelivery options. Among our drug-armed branched peptides, NT4-CA4 was identified as a candidate for further development and evaluation in preclinical pharmacokinetic and pharmacodynamic studies. This peptide-drug exhibits significant activity against pancreas and prostate human cancer cells. Consequently, this derivative is of considerable interest due to the high mortality rates of pancreas neuroendocrine tumors and the high incidence of prostate cancer.

    Topics: Antineoplastic Agents; Drug Design; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Mercaptopurine; Neoplasms; Neurotensin; Peptides; Pyrimidines; Receptors, Neurotensin; Stilbenes; Thiones

2010
Bcl-2 modulates resveratrol-induced ROS production by regulating mitochondrial respiration in tumor cells.
    Antioxidants & redox signaling, 2010, Sep-15, Volume: 13, Issue:6

    Resveratrol is a naturally occurring flavanoid with potent apoptosis-inducing activity against human tumor cells. We investigated the effect of resveratrol on human leukemia cell lines, in particular its ability to induce intracellular reactive oxygen species production and the effect of Bcl-2 overexpression on this model. Exposure of CEM cells to increasing concentrations of resveratrol (0-50 microM) resulted in an increase in mitochondrial superoxide production, decrease in transmembrane potential, and a concomitant decrease in cell viability. Whereas overexpression of Bcl-2 increased mitochondrial oxygen consumption and complex IV activity, CEM/Bcl-2 cells responded to the increased mitochondrial oxidative stress induced by resveratrol by significantly reducing mitochondrial respiration, complex IV activity, and O(2)(-) production, and promoted cell survival. The inhibitory effect of Bcl-2 on resveratrol-induced mitochondrial O(2)(-) production is further corroborated by the neutralization of this regulatory effect upon siRNA-mediated gene silencing of Bcl-2. These data provide evidence implicating mitochondrial metabolism in the anticancer activity of resveratrol, and underscore a novel regulatory role of Bcl-2 against exogenous oxidative stress through its ability to fine tune mitochondrial respiration, and by doing so maintaining mitochondrial O(2)(-) at a level optimal for survival.

    Topics: Apoptosis; Cell Line, Tumor; Humans; Mitochondria; Neoplasms; Oxidative Stress; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Resveratrol; RNA, Small Interfering; Stilbenes

2010
Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.
    Bioorganic & medicinal chemistry, 2010, Jul-15, Volume: 18, Issue:14

    A series of new resveratrol analogues were designed and synthesized and their inhibitory activities against aromatase were evaluated. The crystal structure of human aromatase (PDB 3eqm) was used to rationalize the mechanism of action of the aromatase inhibitor 32 (IC50 0.59 microM) through docking, molecular mechanics energy minimization, and computer graphics molecular modeling, and the information was utilized to design several very potent inhibitors, including compounds 82 (IC50 70 nM) and 84 (IC50 36 nM). The aromatase inhibitory activities of these compounds are much more potent than that for the lead compound resveratrol, which has an IC50 of 80 microM. In addition to aromatase inhibitory activity, compounds 32 and 44 also displayed potent QR2 inhibitory activity (IC50 1.7 microM and 0.27 microM, respectively) and the high-resolution X-ray structures of QR2 in complex with these two compounds provide insight into their mechanism of QR2 inhibition. The aromatase and quinone reductase inhibitors resulting from these studies have potential value in the treatment and prevention of cancer.

    Topics: Anticarcinogenic Agents; Aromatase; Aromatase Inhibitors; Chemoprevention; Crystallography, X-Ray; Humans; Models, Molecular; Neoplasms; Quinone Reductases; Resveratrol; Stilbenes; Veratrum

2010
Growth-stimulatory effect of resveratrol in human cancer cells.
    Molecular carcinogenesis, 2010, Volume: 49, Issue:8

    Earlier studies have shown that resveratrol could induce death in several human cancer cell lines in culture. Here we report our observation that resveratrol can also promote the growth of certain human cancer cells when they are grown either in culture or in athymic nude mice as xenografts. At relatively low concentrations (

    Topics: Animals; Female; Humans; Mice; Mice, Nude; Neoplasms; Nervous System Neoplasms; NF-kappa B; Nitriles; Phenols; Proto-Oncogene Proteins c-akt; Resveratrol; Signal Transduction; Stilbenes; Sulfones

2010
[Research on the virtues of resveratrol].
    Revue medicale suisse, 2010, Sep-22, Volume: 6, Issue:263

    Topics: Antioxidants; Humans; Neoplasms; Resveratrol; Stilbenes; Wine

2010
Detection of tumor response to a vascular disrupting agent by hyperpolarized 13C magnetic resonance spectroscopy.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:12

    Nuclear spin hyperpolarization can dramatically increase the sensitivity of the (13)C magnetic resonance experiment, allowing dynamic measurements of the metabolism of hyperpolarized (13)C-labeled substrates in vivo. Here, we report a preclinical study of the response of lymphoma tumors to the vascular disrupting agent (VDA), combretastatin-A4-phosphate (CA4P), as detected by measuring changes in tumor metabolism of hyperpolarized [1-(13)C]pyruvate and [1,4-(13)C(2)]fumarate. These measurements were compared with dynamic contrast agent-enhanced magnetic resonance imaging (DCE-MRI) measurements of tumor vascular function and diffusion-weighted MRI (DW-MRI) measurements of the tumor cell necrosis that resulted from subsequent loss of tumor perfusion. The rate constant describing flux of hyperpolarized (13)C label between [1-(13)C]pyruvate and lactate was decreased by 34% within 6 hours of CA4P treatment and remained at this lower level at 24 hours. The rate constant describing production of labeled malate from hyperpolarized [1,4-(13)C(2)]fumarate increased 1.6-fold and 2.5-fold at 6 and 24 hours after treatment, respectively, and correlated with the degree of necrosis detected in histologic sections. Although DCE-MRI measurements showed a substantial reduction in perfusion at 6 hours after treatment, which had recovered by 24 hours, DW-MRI showed no change in the apparent diffusion coefficient of tumor water at 6 hours after treatment, although there was a 32% increase at 24 hours (P < 0.02) when regions of extensive necrosis were observed by histology. Measurements of hyperpolarized [1-(13)C]pyruvate and [1,4-(13)C(2)]fumarate metabolism may provide, therefore, a more sustained and sensitive indicator of response to a VDA than DCE-MRI or DW-MRI, respectively.

    Topics: Angiogenesis Inhibitors; Animals; Carbon Isotopes; Contrast Media; Diffusion Magnetic Resonance Imaging; Fumarates; Injections, Intravenous; Magnetic Resonance Spectroscopy; Mice; Neoplasms; Neovascularization, Pathologic; Pyruvic Acid; Stilbenes; Time Factors

2010
The phytochemical piceatannol induces the loss of CBL and CBL-associated proteins.
    Molecular cancer therapeutics, 2009, Volume: 8, Issue:3

    Piceatannol is a naturally occurring bioactive stilbene with documented antileukemic properties. It has been extensively used as a Syk-selective protein tyrosine kinase inhibitor for the study of various signaling pathways. Herein, we show that the hydroxystilbene, piceatannol, and related catechol ring-containing compounds are able to induce the loss of the Cbl family of proteins. Normal cellular Cbl-regulatory mechanisms were not involved in this process. Screening of a small library of piceatannol-like compounds indicated that aromaticity and a catechol ring were required for the induction of Cbl loss. Further examination of these two chemical properties showed that the oxidative conversion of the catechol ring of piceatannol into a highly reactive O-benzoquinone was the cause of piceatannol-induced Cbl loss. Characterization of the Cbl selectivity of piceatannol-induced protein loss revealed that this compound was also able to induce the functional loss of specific Cbl-associated proteins involved in signaling pathways commonly associated with cancer. This work uncovers a new, piceatannol-dependent effect and shows a novel way in which this phenomenon can be exploited to inhibit disease-associated signaling pathways.

    Topics: 3T3 Cells; Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents, Phytogenic; Cells, Cultured; Humans; K562 Cells; Mice; Models, Biological; Neoplasms; Oxidation-Reduction; Protein Binding; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-cbl; Signal Transduction; Stilbenes

2009
Resveratrol and cancer prevention.
    Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:3

    Topics: Anticarcinogenic Agents; Humans; Neoplasms; Resveratrol; Stilbenes

2009
Synthesis, structural characterisation and biological evaluation of fluorinated analogues of resveratrol.
    Bioorganic & medicinal chemistry, 2009, Jul-01, Volume: 17, Issue:13

    Resveratrol is a potential chemopreventive agent and can be isolated from grape skins and other dietary sources. The Wittig reaction and the decarbonylative Heck reaction were employed to synthesise analogues of this stilbene. Fluorinated derivatives of this stilbene were synthesised maintaining the 3,4',5-substitution pattern. The hydroxyl groups were also replaced by amino groups and the biological activity evaluated. The compounds were assayed on a variety of cell lines, primarily the non-small lung carcinoma cell line DLKP-A. Analogues were evaluated alone and in combination with a known chemotherapeutic agent epirubicin.

    Topics: Antibiotics, Antineoplastic; Anticarcinogenic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Epirubicin; Halogenation; Humans; Molecular Structure; Neoplasms; Resveratrol; Stilbenes; Structure-Activity Relationship

2009
Regulation of autophagy by a beclin 1-targeted microRNA, miR-30a, in cancer cells.
    Autophagy, 2009, Volume: 5, Issue:6

    beclin 1, the mammalian homologue of the yeast Atg6, is a key autophagy-promoting gene that plays a critical role in the regulation of cell death and survival of various types of cells. However, recent studies have observed that the expression of beclin 1 is altered in certain diseases including cancers. The causes underlying the aberrant expression of beclin 1 remain largely unknown. We report here that microRNAs (miRNAs), a class of endogenous, 22-24 nucleotide noncoding RNA molecules able to affect stability and translation of mRNA, may represent a previously unrecognized mechanism for regulating beclin 1 expression and autophagy. We demonstrated that beclin 1 is a potential target for miRNA miR-30a, and this miRNA could negatively regulate beclin 1 expression resulting in decreased autophagic activity. Treatment of tumor cells with the miR-30a mimic decreased, and with the antagomir increased, the expression of beclin 1 mRNA and protein. Dual luciferase reporter assay confirmed that the miR-30a binding sequences in the 3'-UTR of beclin 1 contribute to the modulation of beclin 1 expression by miR-30a. Furthermore, inhibition of beclin 1 expression by the miR-30a mimic blunted activation of autophagy induced by rapamycin. Our study of the role of miR-30a in regulating beclin 1 expression and autophagy reveals a novel function for miRNA in a critical cellular event with significant impacts in cancer development, progression and treatment, and in other diseases.

    Topics: Apoptosis Regulatory Proteins; Autophagy; Base Sequence; Beclin-1; Cell Line, Tumor; Consensus Sequence; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; MicroRNAs; Molecular Sequence Data; Neoplasms; Oligonucleotide Array Sequence Analysis; Resveratrol; Sirolimus; Stilbenes; Vacuoles

2009
Identification and bioactivities of resveratrol oligomers and flavonoids from Carex folliculata seeds.
    Journal of agricultural and food chemistry, 2009, Aug-26, Volume: 57, Issue:16

    Plants of the Carex genus (Family: Cyperaceae) have attracted recent attention as potential food additives because they contain high levels of bioactive polyphenols commonly found in plant foods. Seven compounds, which included two resveratrol oligomers and five flavonoids, were isolated from seeds of Carex folliculata L. (northern long sedge), a forage prevalent in the northern United States. The compounds were identified by (1)H and (13)C nuclear magnetic resonance and mass spectrometry data. The resveratrol oligomers were pallidol (1), a resveratrol dimer reported to be present in levels equivalent to those of resveratrol in red wine, and kobophenol A (2), a resveratrol tetramer with a unique 2,3,4,5-tetraaryltetrahydrofuran skeleton. The flavonoids were isoorientin (3), luteolin (4), quercetin (5), 3-O-methylquercetin (6), and rutin (7). Compounds were evaluated for antioxidant activity in the diphenylpicrylhydrazyl (DPPH) radical scavenging assay; cytotoxicity activity against human colon (HCT116, HT29) and breast (MCF7, MDA-MB-231) tumor cell lines; and antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). The antioxidant activities of the flavonoids (3-7; IC(50) values ranging from 50 to 200 microM) were comparable to that of ascorbic acid (IC(50) = 60 microM) and superior to those of the resveratrol derivatives (1 and 2; IC(50) > 1000 microM) and butylated hydroxytoluene (BHT; IC(50) = 1500 microM), a commercial antioxidant. In the cytotoxicity and antibacterial bioassays, compounds 4 (IC(50) for HCT116 = 45 microM) and 6 (IC(50) for MRSA = 6.4 microM) were the most active, respectively. Therefore, given the wide availability and underutilization of C. folliculata, this forage may provide a source of bioactive compounds useful for nutraceutical purposes. Also, this is the first reported phytochemical investigation of C. folliculata.

    Topics: Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Carex Plant; Cell Line, Tumor; Cell Proliferation; Flavonoids; Humans; Methicillin-Resistant Staphylococcus aureus; Neoplasms; Plant Extracts; Resveratrol; Seeds; Stilbenes

2009
C3 halogen and c8'' substituents on stilbene arotinoids modulate retinoic Acid receptor subtype function.
    ChemMedChem, 2009, Volume: 4, Issue:10

    The synthesis and biological evaluation of the entire series of C3-halogenated derivatives and bulkier substituents at the C8'' position of the parent stilbene-based RARbeta-selective agonist BMS641 4 c was undertaken. The synthesis uses an E-selective Horner-Wadsworth-Emmons (HWE) condensation of C8-substituted C5-dimethyl dihydronaphthaldehyde and the benzylic phosphonates derived from the C3-halogenated benzoates to construct the stilbene skeleton. Transactivation studies revealed the synergistic effect of small halogen atoms at C3 (F, Cl) and the moderately bulky phenyl group at C8'' (in 4 b and 4 c) to achieve RARbeta selectivity. Our results, supported by computational studies, provide a structural rationale for the mixed agonist-antagonist activities of these arotinoids, which are potent agonists of the RARbeta subtype and antagonists of the RARalpha paralogue. Moreover, transitions from partial agonists to inverse agonists and antagonists can be accomplished with the incorporation of the same halogen atoms into the structures of known modulators BMS701 (5 a) and BMS493 (6 a), which have bulkier substituents than phenyl (p-tolyl and phenylethynyl, respectively) at C8''. Conversely, incorporation of halogen atoms in 6 a converted the ligand from an RARbeta inverse agonist (6 b) to an antagonist (6 c) or an agonist (6 d). Amazingly, 6 a-c commonly acted as inverse agonists for RARalpha, while 6 d and 6 e acted as regular RARalpha antagonists, not affecting co-repressor interaction. In the case of the mixed agonist/antagonist 5 a, C3-halogenation yields inverse RARalpha and RARbeta agonists (5 b-d) with the exception of iodinated 5 e, which is a regular antagonist for both these receptors. Because RARbeta gene expression is frequently deleted or epigenetically silenced in several tumor cells, the novel repertoire of receptor and function-selective RAR agonists, mixed agonist/antagonists, regular antagonists, and inverse agonists will be useful in the elucidation of the mechanism of tumor suppression by retinoids.

    Topics: Halogens; HeLa Cells; Humans; Neoplasms; Protein Conformation; Receptors, Retinoic Acid; Retinoids; Stilbenes; Structure-Activity Relationship; Transcriptional Activation

2009
cis-3, 4', 5-Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:2

    Targeting tumor vasculature by colchicine site microtubule inhibitors is a new approach in cancer therapy. Here we investigate cis-3, 4', 5-trimethoxy-3'-aminostilbene (stilbene 5c) in its effect on tumor vascular perfusion, pharmacokinetics, toxicity and therapeutic efficacy in a mouse xenograft model.. Tumor xenograft model was established with subcutaneous injection of UCI-101 ovarian cancer cells into nude mice. Tumor blood perfusion was investigated by dynamic contrast-enhanced (DCE) MRI studies. Pharmacokinetic studies were performed by LC/MS/MS to quantify the concentrations of stilbene 5c in plasma. Tumor size was measured by the long and short axes of tumor to calculate tumor volume. Mouse cardiac function study was determined by Doppler echocardiography using the Vevo770TM imaging system. Microvascular density was determined by CD34 staining of tissue sections.. Stilbene 5c selectively suppresses tumor perfusion without damaging normal organ perfusion in DCE-MRI studies. Histological sections of normal organs treated with stilbene 5c do not reveal any major toxicity in H&E staining. Microvascular density determined by CD34 staining is unchanged in normal organs, but significantly decreased in tumor after stilbene 5c treatment. Biodistribution study shows that stilbene 5c is not detectable in heart and lung, rapidly decreased in brain, liver, and kidney, but remains high in tumor for more than 3 h after IV injection of stilbene 5c, suggesting preferential accumulation in tumor. Mice treated with 5 days of stilbene 5c had negligible cardiac toxicity based on their normal left ventricular ejection fraction. In vivo efficacy study of stilbene 5c showed that it only suppresses tumor growth by 40% if used alone, but combination with bevacizumab is significantly better.. Stilbene 5c is a useful vascular disrupting agent and combination with bevacizumab could be a promising therapy for cancer.

    Topics: Angiogenesis Inhibitors; Animals; Antigens, CD34; Apoptosis; Cell Line, Tumor; Endothelial Cells; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Neoplasms; Organ Specificity; Regional Blood Flow; Stilbenes; Tissue Distribution; Ultrasonography, Doppler; Umbilical Veins; Xenograft Model Antitumor Assays

2009
Relationship between human tumour angiogenic profile and combretastatin-induced vascular shutdown: an exploratory study.
    British journal of cancer, 2008, Jul-22, Volume: 99, Issue:2

    Combretastatin-A4-phosphate (CA4P) acts most effectively against immature tumour vasculature. We investigated whether histological angiogenic profile can explain the differential sensitivity of human tumours to CA4P, by correlating the kinetic changes demonstrated by dynamic MRI (DCE-MRI) in response to CA4P, with tumour immunohistochemical angiogenic markers. Tissue was received from 24 patients (mean age 59, range 32-73, 18 women, 6 men). An angiogenic profile was performed using standard immunohistochemical techniques. Dynamic MRI data were obtained for the same patients before and 4 h after CA4P. Three patients showed a statistically significant fall in K(trans) following CA4P, and one a statistically significant fall in IAUGC(60). No statistically significant correlations were seen between the continuous or categorical variables and the DCE-MRI kinetic parameters other than between ang-2 and K(trans) (P=0.044). In conclusion, we found no strong relationships between changes in DCE-MRI kinetic variables following CA4P and the immunohistochemical angiogenic profile.

    Topics: Actins; Adult; Aged; Angiogenic Proteins; Antigens, CD; Antineoplastic Agents, Phytogenic; Endoglin; Endothelium, Vascular; Female; Gadolinium DTPA; Humans; Immunohistochemistry; Integrin beta3; Magnetic Resonance Angiography; Male; Middle Aged; Neoplasms; Neovascularization, Pathologic; Receptors, Cell Surface; Stilbenes

2008
Methoxylation enhances stilbene bioactivity in Caenorhabditis elegans.
    BMC pharmacology, 2008, Aug-13, Volume: 8

    Stilbenes are 1,2-diphenylethylene congeners produced by plants in response to stress. Many stilbenes also exhibit xenobiotic activities in animal cells, such as inhibition of cancer cell growth, neuroprotection, and immune modulation. In vivo, hydroxylated stilbenes are metabolized by glucuronidation to facilitate excretion. Methoxylated stilbenes are metabolized more slowly, which may have a positive effect on in vivo bioactivity. Here, we have directly compared in vivo bioactivities of methoxylated and hydroxylated stilbenes in a whole organism using the roundworm Caenorhabditis elegans, an advantageous experimental system for such studies due to its rapid lifecycle, genetic amenability and relatively low-cost.. Toxicity towards C. elegans adults was observed for trimethoxylated and dimethoxylated stilbenes, as well as the monomethoxylated stilbene desoxyrhapontigenin. Toxicity was not observed for the monomethoxylated stilbene, pinostilbene, nor for hydroxylated stilbenes. The methoxylated stilbenes that exhibited toxicity also showed stronger inhibitory effects than the hydroxylated stilbenes on germline tumor growth in gld-1(q485) adults. However, steady-state levels of three inhibitory methoxylated stilbenes did not directly correlate to their relative bioactivities.. These findings demonstrate that, for the group of stilbenes investigated, methoxylation generally increased bioactivity in vivo in a whole organism, with the exception of pinostilbene. Differences in bioactivity in C. elegans adults did not appear to correlate with differential uptake. Rather, we speculate that methoxylated stilbenes may have increased interactions with biological targets in vivo or may interact with specific targets unaffected by hydroxylated stilbenes. The potent activities of methoxylated stilbenes provide a basis for further investigations to identify in vivo targets for these compounds.

    Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Caenorhabditis elegans; Germ-Line Mutation; Hydroxylation; Neoplasms; Stilbenes; Tumor Burden

2008
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.
    Cancer cell, 2008, Oct-07, Volume: 14, Issue:4

    In lower eukaryotes, Sir2 serves as a histone deacetylase and is implicated in chromatin silencing, longevity, and genome stability. Here we mutated the Sirt1 gene, a homolog of yeast Sir2, in mice to study its function. We show that a majority of SIRT1 null embryos die between E9.5 and E14.5, displaying altered histone modification, impaired DNA damage response, and reduced ability to repair DNA damage. We demonstrate that Sirt1(+/-);p53(+/-) mice develop tumors in multiple tissues, whereas activation of SIRT1 by resveratrol treatment reduces tumorigenesis. Finally, we show that many human cancers exhibit reduced levels of SIRT1 compared to normal controls. Thus, SIRT1 may act as a tumor suppressor through its role in DNA damage response and genome integrity.

    Topics: Animals; Anticarcinogenic Agents; Cell Cycle; Cell Transformation, Neoplastic; Cells, Cultured; Chromosomal Instability; DNA Damage; DNA Repair; Down-Regulation; Embryo, Mammalian; Female; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Genomic Instability; Gestational Age; Heterochromatin; Histones; Humans; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitosis; Mutation; Neoplasms; Resveratrol; Sirtuin 1; Sirtuins; Stilbenes; Time Factors; Tumor Suppressor Proteins

2008
Non-canonical autophagy: an exception or an underestimated form of autophagy?
    Autophagy, 2008, Volume: 4, Issue:8

    Macroautophagy (hereafter called autophagy) is a dynamic and evolutionarily conserved process used to sequester and degrade cytoplasm and entire organelles in a sequestering vesicle with a double membrane, known as the autophagosome, which ultimately fuses with a lysosome to degrade its autophagic cargo. Recently, we have unraveled two distinct forms of autophagy in cancer cells, which we term canonical and non-canonical autophagy. In contrast to classical or canonical autophagy, non-canonical autophagy is a process that does not require the entire set of autophagy-related (Atg) proteins in particular Beclin 1, to form the autophagosome. Non-canonical autophagy is therefore not blocked by the knockdown of Beclin 1 or of its binding partner hVps34. Moreover overexpression of Bcl-2, which is known to block canonical starvation-induced autophagy by binding to Beclin 1, is unable to reverse the non-canonical autophagy triggered by the polyphenol resveratrol in the breast cancer MCF-7 cell line. In MCF-7 cells, at least, non-canonical autophagy is involved in the caspase-independent cell death induced by resveratrol.

    Topics: Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Humans; Membrane Proteins; Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-bcl-2; Resveratrol; Stilbenes

2008
Take a break--resveratrol in action on DNA.
    Carcinogenesis, 2008, Volume: 29, Issue:2

    The phytochemical resveratrol (RV) has become a focus of intense research owing to its roles in promoting longevity and in cancer prevention. As an anticancer agent, RV has primarily been linked to growth and death regulatory pathways. There is now growing evidence that, under physiological conditions, RV additionally contributes to the maintenance of genome stability. Thus, at the stage of DNA damage formation, RV protects the genome as an antioxidant via inhibition of inflammation, suppression of metabolic carcinogen activation, de novo expression of genes that encode detoxifying proteins and possibly even via radical scavenging properties. However, results demonstrating RV-dependent DNA breakage in the presence of Cu(II) ions and inhibition of DNA polymerases alpha and delta produced some controversy regarding RV's role as a caretaker compound. Significantly, recent studies have revealed that activation of ataxia telangiectasia mutated and ataxia telangiectasia Rad3 related could be a central effect of RV that underlies cell-cycle regulation and the newly described activation of fidelity control mechanisms in DNA double-strand break repair involving Nbs1 and p53. In this review, we discuss the existing data on RV's direct and indirect effects on genome integrity, in the light of future chemopreventive and chemotherapeutic protocols involving RV or related compounds.

    Topics: Animals; Antioxidants; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA Damage; DNA Repair; DNA-Binding Proteins; Enzyme Inhibitors; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genome; Humans; Models, Biological; Neoplasms; Protein Serine-Threonine Kinases; Resveratrol; Signal Transduction; Stilbenes; Tumor Suppressor Proteins

2008
Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents.
    Journal of natural products, 2008, Volume: 71, Issue:3

    Several stilbenoid compounds having structural similarity to the combretastatin group of natural products and characterized by the incorporation of two nitrogen-bearing groups (amine, nitro, serinamide) have been prepared by chemical synthesis and evaluated in terms of biochemical and biological activity. The 2',3'-diamino B-ring analogue 17 demonstrated remarkable cytotoxicity against selected human cancer cell lines in vitro (average GI 50 = 13.9 nM) and also showed good activity in regard to inhibition of tubulin assembly (IC 50 = 2.8 microM). In addition, a single dose (10 mg/kg) of compound 17 caused a 40% tumor-selective blood flow shutdown in tumor-bearing SCID mice at 24 h, thus suggesting the potential value of this compound and its corresponding salt formulations as new vascular-disrupting agents.

    Topics: Animals; Antineoplastic Agents; Bibenzyls; Disease Models, Animal; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Leukemia P388; Mice; Molecular Structure; Neoplasms; Regional Blood Flow; Stilbenes; Tubulin

2008
Isolation and identification of cytotoxic compounds from the wood of Pinus resinosa.
    Phytotherapy research : PTR, 2008, Volume: 22, Issue:7

    Methanol extracts of wood from Pinus resinosa were found to be selectively cytotoxic against human lung carcinoma cells, A549 (IC50 41 +/- 6 microg/mL), human colorectal adenocarcinoma cells, DLD-1 (IC50 47 +/- 4 microg/mL) in comparison with healthy cells, WS1 (IC50 130 +/- 11 microg/mL). Five known compounds were isolated and identified by 1H, 13C NMRspectroscopy and HR-ESI-MS mass spectrometry as, pinosylvin monomethyl ether (1), pinosylvin (2), pinosylvin dimethyl ether (3), pinobanksin (4) and (-)-norachelogenin (5). Compound 4 was isolated for the first time in P. resinosa. The cytotoxicity of compounds 1-5 was evaluated against A549, DLD-1 and WS1. Compound 1 exhibited the strongest cytotoxicity against both tumor cell lines and the healthy cell line with an IC50 of 25 +/- 4 microm for A549, 20 +/- 1 microm for DLD-1 and 34 +/- 3 microm for WS1.

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fibroblasts; Flavanones; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Methanol; Neoplasms; Pinus; Plant Extracts; Skin; Spectrometry, Mass, Electrospray Ionization; Stilbenes; Wood

2008
New Agents in Clinical Oncology. 24 November 2006, London, UK.
    IDrugs : the investigational drugs journal, 2007, Volume: 10, Issue:2

    Topics: 3-Iodobenzylguanidine; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Combined Modality Therapy; Enzyme Inhibitors; Humans; Medical Oncology; Neoplasms; Norepinephrine Plasma Membrane Transport Proteins; Poly(ADP-ribose) Polymerase Inhibitors; Proteomics; Stilbenes; Thioredoxins; Topotecan

2007
Chronic treatment with resveratrol induces redox stress- and ataxia telangiectasia-mutated (ATM)-dependent senescence in p53-positive cancer cells.
    The Journal of biological chemistry, 2007, Sep-14, Volume: 282, Issue:37

    The induction of senescence, an irreversible growth arrest, in cancer cells is regarded as a mean to halt tumor progression. The phytoalexin resveratrol (RV) is known to possess a variety of cancer-preventive, -therapeutic, and -chemosensitizing properties. We report here that chronic treatment with RV in a subapoptotic concentration induces senescence-like growth arrest in tumor cells. In contrast to the widely accepted antioxidant property of RV, we demonstrate that one causative stimulus for senescence induction by chronic RV is an increased level of reactive oxygen species (ROS). The ROS formed upon RV exposure include hydrogen peroxide and superoxide and originate largely from mitochondria. Consistently, co-incubation with the antioxidant N-acetyl cysteine interfered with RV-mediated reactivation of the senescence program. Molecular mediators on the way from increased ROS levels to the observed growth arrest include p38 MAPK, p53, and p21. Moreover, we provide evidence that RV-initiated replication stress, apparent by activation of the ataxia telangiectasia-mutated kinase pathway, is associated with increased ROS levels and senescence induction. This is the first report linking cell cycle effects with a pro-oxidant and pro-senescent effect of RV in cancer cells.

    Topics: Anticarcinogenic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; HCT116 Cells; Humans; Mitochondria; Neoplasms; Oxidation-Reduction; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Resveratrol; Stilbenes; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2007
Combretastatin-chalcone hybrids: synthesis and cytotoxicity.
    Medicinal chemistry (Shariqah (United Arab Emirates)), 2007, Volume: 3, Issue:4

    A series of all-trans-1-aryl-4-aryl-5-aryl-2,4-pentanediene-1-one (3), a hybridized form of chalcone and combretastatin, was synthesized and evaluated against a panel of cancer cell lines, including B16, murine melanoma; HCT116, colon cancer; A431, human epidermoid carcinoma; and human umbilical venous endothelial cells (HUVEC). Structure-activity relationships analysis of this series revealed that a 2,5-dihydroxyphenyl at position 1 of the 2,4-pentanediene-1-one was essential for cytotoxicity. all-trans-1-(2,5-Dihydroxyphenyl)-5-(4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-2,4-pentanediene-1-one (3a) was the most potent compound from this series.

    Topics: Bibenzyls; Cell Line; Cell Survival; Chalcone; Humans; Molecular Structure; Neoplasms; Stilbenes; Structure-Activity Relationship

2007
Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
    International journal of radiation oncology, biology, physics, 2007, Nov-15, Volume: 69, Issue:4

    To investigate the use of the transverse magnetic resonance imaging (MRI) relaxation rate R(2)(*) (s(-1)) as a biomarker of tumor vascular response to monitor vascular disrupting agent (VDA) therapy.. Multigradient echo MRI was used to quantify R(2)(*) in rat GH3 prolactinomas. R(2)(*) is a sensitive index of deoxyhemoglobin in the blood and can therefore be used to give an index of tissue oxygenation. Tumor R(2)(*) was measured before and up to 35 min after treatment, and 24 h after treatment with either 350 mg/kg 5,6-dimethylxanthenone-4-acetic acid (DMXAA) or 100 mg/kg combretastatin-A4-phosphate (CA4P). After acquisition of the MRI data, functional tumor blood vessels remaining after VDA treatment were quantified using fluorescence microscopy of the perfusion marker Hoechst 33342.. DMXAA induced a transient, significant (p < 0.05) increase in tumor R(2)(*) 7 min after treatment, whereas CA4P induced no significant changes in tumor R(2)(*) over the first 35 min. Twenty-four hours after treatment, some DMXAA-treated tumors demonstrated a decrease in R(2)(*), but overall, reduction in R(2)(*) was not significant for this cohort. Tumors treated with CA4P showed a significant (p < 0.05) reduction in R(2)(*) 24 h after treatment. The degree of Hoechst 33342 uptake was associated with the degree of R(2)(*) reduction at 24 h for both agents.. The reduction in tumor R(2)(*) or deoxyhemoglobin levels 24 h after VDA treatment was a result of reduced blood volume caused by prolonged vascular collapse. Our results suggest that DMXAA was less effective than CA4P in this rat tumor model.

    Topics: Angiogenesis Inhibitors; Animals; Biomarkers, Tumor; Female; Hemoglobins; Magnetic Resonance Imaging; Neoplasms; Neovascularization, Pathologic; Rats; Rats, Inbred WF; Stilbenes; Xanthones

2007
NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent.
    Anti-cancer drugs, 2006, Volume: 17, Issue:1

    The diketopiperazine NPI-2358 is a synthetic analog of NPI-2350, a natural product isolated from Aspergillus sp., which depolymerizes microtubules in A549 human lung carcinoma cells. Although structurally different from the colchicine-binding site agents reported to date, NPI-2358 binds to the colchicine-binding site of tubulin. NPI-2358 has potent in-vitro anti-tumor activity against various human tumor cell lines and maintains activity against tumor cell lines with various multidrug-resistant (MDR) profiles. In addition, when evaluated in proliferating human umbilical vein endothelial cells (HUVECs), concentrations as low as 10 nmol/l NPI-2358 induced tubulin depolymerization within 30 min. Furthermore, NPI-2358 dose dependently increases HUVEC monolayer permeability--an in-vitro model of tumor vascular collapse. NPI-2358 was compared with three tubulin-depolymerizing agents with vascular-disrupting activity: colchicine, vincristine and combretastatin A-4 (CA4). Results showed that the activity of NPI-2358 in HUVECs was more potent than either colchicine or vincristine; the profile of CA4 approached that of NPI-2358. Altogether, our data show that NPI-2358 is a potent anti-tumor agent which is active in MDR tumor cell lines, and is able to rapidly induce tubulin depolymerization and monolayer permeability in HUVECs. These data warrant further evaluation of NPI-2358 as a vascular-disrupting agent in vivo. Currently, NPI-2358 is in preclinical development for the treatment of cancer.

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Membrane Permeability; Cell Survival; Colchicine; Dextrans; Diketopiperazines; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endothelial Cells; Endothelium, Vascular; Fluorescein-5-isothiocyanate; HL-60 Cells; HT29 Cells; Humans; Imidazoles; Inhibitory Concentration 50; Jurkat Cells; Microtubules; Neoplasms; Piperazines; Stilbenes; Time Factors; Tubulin; Vincristine

2006
Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents.
    Bioorganic & medicinal chemistry, 2006, May-01, Volume: 14, Issue:9

    A series of analogs with nitro or serinamide substituents at the C-2'-, C-5'-, or C-6'-position of the combretastatin A-4 (CA4) B-ring was synthesized and evaluated for cytotoxic effects against heart endothelioma cells, blood flow reduction to tumors in SCID mice, and as inhibitors of tubulin polymerization. The synthesis of these analogs typically featured a Wittig reaction between a suitably functionalized arylaldehyde and an arylphosphonium salt followed by separation of the resultant E- and Z-isomers. Several of these nitrogen-modified CA4 derivatives (both amino and nitro) demonstrate significant inhibition of tubulin assembly as well as cytotoxicity and in vivo blood flow reduction. 2'-Aminostilbenoid 7 and 2'-amino-3'-hydroxystilbenoid 29 proved to be the most active in this series. Both compounds, 7 and 29, have the potential for further pro-drug modification and development as vascular disrupting agents for treatment of solid tumor cancers and certain ophthalmological diseases.

    Topics: Animals; Benzaldehydes; Bibenzyls; Cattle; Cell Proliferation; Drug Design; Isomerism; Mice; Molecular Structure; Neoplasms; Regional Blood Flow; Stilbenes; Structure-Activity Relationship; Tubulin; Xenograft Model Antitumor Assays

2006
Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein.
    Molecular cancer therapeutics, 2006, Volume: 5, Issue:3

    Resveratrol is a naturally occurring phytoalexin with antioxidant and antiinflammatory properties. Recent studies suggest that resveratrol possesses anticancer effects, although its mechanism of action is not well understood. We now show that resveratrol inhibits Src tyrosine kinase activity and thereby blocks constitutive signal transducer and activator of transcription 3 (Stat3) protein activation in malignant cells. Analyses of resveratrol-treated malignant cells harboring constitutively-active Stat3 reveal irreversible cell cycle arrest of v-Src-transformed mouse fibroblasts (NIH3T3/v-Src), human breast (MDA-MB-231), pancreatic (Panc-1), and prostate carcinoma (DU145) cell lines at the G0-G1 phase or at the S phase of human breast cancer (MDA-MB-468) and pancreatic cancer (Colo-357) cells, and loss of viability due to apoptosis. By contrast, cells treated with resveratrol, but lacking aberrant Stat3 activity, show reversible growth arrest and minimal loss of viability. Moreover, in malignant cells harboring constitutively-active Stat3, including human prostate cancer DU145 cells and v-Src-transformed mouse fibroblasts (NIH3T3/v-Src), resveratrol treatment represses Stat3-regulated cyclin D1 as well as Bcl-xL and Mcl-1 genes, suggesting that the antitumor cell activity of resveratrol is in part due to the blockade of Stat3-mediated dysregulation of growth and survival pathways. Our study is among the first to identify Src-Stat3 signaling as a target of resveratrol, further defining the mechanism of antitumor cell activity of resveratrol and raising its potential application in tumors with an activated Stat3 profile.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Female; Gene Expression; Humans; Male; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Resveratrol; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Stilbenes

2006
Synthesis of radiolabeled stilbene derivatives as new potential PET probes for aryl hydrocarbon receptor in cancers.
    Bioorganic & medicinal chemistry letters, 2006, Nov-15, Volume: 16, Issue:22

    New carbon-11 and fluorine-18 labeled stilbene derivatives, cis-3,5-dimethoxy-4'-[11C]methoxystilbene (4'-[11C]8a), cis-3,4',5-trimethoxy-3'-[11C]methoxystilbene (3'-[11C]8b), trans-3,5-dimethoxy-4'-[11C]methoxystilbene (4'-[11C]10a), trans-3,4',5-trimethoxy-3'-[11C]methoxystilbene (3'-[11C]10b), cis-3,5-dimethoxy-4'-[18F]fluorostilbene (4'-[18F]12a), and trans-3,5-dimethoxy-4'-[18F]fluorostilbene (4'-[18F]13a), were designed and synthesized as potential PET probes for aryl hydrocarbon receptor (AhR) in cancers.

    Topics: Animals; Carbon Radioisotopes; Fluorine Radioisotopes; Models, Chemical; Neoplasms; Radiopharmaceuticals; Rats; Receptors, Aryl Hydrocarbon; Stereoisomerism; Stilbenes; Tomography, Emission-Computed

2006
Resveratrol inhibits cell cycle progression in U937 cells.
    Oncology reports, 2005, Volume: 13, Issue:1

    Resveratrol, a naturally occurring stylbene present in grapes, is proposed to be responsible for the positive effects of red wine consumption on cardiovascular diseases (French paradox). In recent years this molecule has also been proposed as a cancer chemopreventive agent. The aim of the present study was to investigate the mechanisms by which resveratrol inhibits tumor growth. For this purpose, U937 cells were exposed to resveratrol at concentrations usually present in red wine, and the effects on proliferation, death and cell cycle machinery were assessed. The U937 cell growth was impaired due to reduced cell proliferation, without significant induction of apoptosis. This anti-proliferative effect is associated with modulations in the pattern of DNA distribution, with a reduction of G0/G1, particularly G2-M peaks and accumulation in the S phase of the cell cycle. This result was confirmed by the observation that the rate of [3H]-thymidine incorporation into DNA was significantly reduced in resveratrol-treated U937 cells. Consistent with this observation, in the same experimental conditions, the activity of ribonucleotide reductase, an enzyme critically involved in the process of DNA duplication, decreased. The altered progression in the cell cycle could depend on modulations in the activity of cyclin dependent kinases and their inhibitors. After exposure of U937 cultures to resveratrol, the expression of cyclins A and E, as well as that of CDK2 increased, while that of p21CIP was significantly reduced. The data shown in this report suggests that the prevention of cancer development exerted by resveratrol may result from modulations of molecules involved in the regulation of cell cycle progression, which block the cells at the S phase checkpoint.

    Topics: Anticarcinogenic Agents; CDC2-CDC28 Kinases; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cyclin A; Cyclin E; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Growth Inhibitors; Humans; Neoplasms; Resveratrol; Stilbenes; U937 Cells

2005
The cancer chemopreventive agent resveratrol induces tensin, a cell-matrix adhesion protein with signaling and antitumor activities.
    Oncogene, 2005, May-05, Volume: 24, Issue:20

    During a search to identify resveratrol (3,5,4'-trihydroxy-trans-stilbene, RV) target genes in the human erythroleukemic K562 cell line, we show here that the tensin gene and protein levels are remarkably induced by this dietary polyphenol. Tensin, a cell-matrix adhesion protein binding the integrins and cytoskeletal actin filaments also interacts with PI3-kinase and JNK signaling pathways. Tensin induction by RV is associated with increased K562 cell adhesion to fibronectin, cell spreading and actin polymerization. The same responses were observed in the tensin-deficient MCF7 human breast cancer cell line. In K562 and MCF7 cells treated by RV, tensin was found in punctate and intracytoplasmic areas. In MCF7 epithelial cells, induction of tensin is not exclusively associated with plasma membrane-bound vinculin, suggesting a dual localization of tensin in both focal and fibrillar adhesions. Pharmacological blockade of PI3-kinase and Rho GTPases/Rho-kinase resulted in selective depletion of focal adhesions, disorganization of tensin localization and disruption of stress fibers. RV increased cell motility and attachment to fibronectin in MCF7 cells submitted to mechanical laminar flow stress, and abrogated estrogen-induced MCF7 cancer cell invasion. Our data support the conclusion that induction of tensin by RV contributes to the chemopreventive and anti-invasive activity of this natural dietary compound in tensin-negative and -deficient leukemic cells or epithelioid cancers.

    Topics: Actins; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Movement; Cycloheximide; Cytoplasm; Cytoskeleton; DNA, Complementary; Dose-Response Relationship, Drug; Enzyme Inhibitors; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; K562 Cells; Microfilament Proteins; Neoplasm Invasiveness; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Synthesis Inhibitors; Resveratrol; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Stilbenes; Tensins; Time Factors

2005
Phosphorylations of DEAD box p68 RNA helicase are associated with cancer development and cell proliferation.
    Molecular cancer research : MCR, 2005, Volume: 3, Issue:6

    The nuclear p68 RNA helicase is essential for normal cell growth. The protein plays a very important role in early organ development and maturation. In our previous report, we showed that recombinant p68 RNA helicase was phosphorylated at serine/threonine and tyrosine residue(s). In the present study, we examined the phosphorylation status of p68 in six different cancer cell lines and compared the results with those in cells derived from the corresponding normal tissues. We showed here that p68 was phosphorylated at tyrosine residue(s) in all tested cancer cells but not in the corresponding normal cells/tissues. The tyrosyl phosphorylation of p68 also responded to platelet-derived growth factor. It is thus clear that p68 phosphorylation at tyrosine residue(s) is associated with abnormal cell proliferation and cancer development. The tyrosyl phosphorylation(s) was diminished if the cancer cells were treated with apoptosis agents, such as tumor necrosis factor-alpha, tumor necrosis factor-related apoptosis-inducer ligand, and STI-571. The tyrosyl phosphorylation of p68, however, was not affected by other anticancer drugs, such as piceatannol, etoposide, and taxol. The close correlation between p68 phosphorylations and cancer may provide a useful diagnostic marker and potential therapeutic target for cancer treatment.

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Benzamides; Blotting, Western; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Etoposide; HeLa Cells; Humans; Imatinib Mesylate; K562 Cells; Neoplasms; Paclitaxel; Phosphorus Radioisotopes; Phosphorylation; Piperazines; Precipitin Tests; Pyrimidines; RNA Helicases; RNA Interference; Stilbenes; Tumor Necrosis Factor-alpha

2005
Cancer: one step at a time.
    Nature, 2005, Jul-28, Volume: 436, Issue:7050

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Humans; Mice; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Stilbenes; Time Factors

2005
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system.
    Nature, 2005, Jul-28, Volume: 436, Issue:7050

    In the continuing search for effective treatments for cancer, the emerging model is the combination of traditional chemotherapy with anti-angiogenesis agents that inhibit blood vessel growth. However, the implementation of this strategy has faced two major obstacles. First, the long-term shutdown of tumour blood vessels by the anti-angiogenesis agent can prevent the tumour from receiving a therapeutic concentration of the chemotherapy agent. Second, inhibiting blood supply drives the intra-tumoural accumulation of hypoxia-inducible factor-1alpha (HIF1-alpha); overexpression of HIF1-alpha is correlated with increased tumour invasiveness and resistance to chemotherapy. Here we report the disease-driven engineering of a drug delivery system, a 'nanocell', which overcomes these barriers unique to solid tumours. The nanocell comprises a nuclear nanoparticle within an extranuclear pegylated-lipid envelope, and is preferentially taken up by the tumour. The nanocell enables a temporal release of two drugs: the outer envelope first releases an anti-angiogenesis agent, causing a vascular shutdown; the inner nanoparticle, which is trapped inside the tumour, then releases a chemotherapy agent. This focal release within a tumour results in improved therapeutic index with reduced toxicity. The technology can be extended to additional agents, so as to target multiple signalling pathways or distinct tumour compartments, enabling the model of an 'integrative' approach in cancer therapy.

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bibenzyls; Carcinoma, Lewis Lung; Coculture Techniques; Doxorubicin; Drug Delivery Systems; Drug Therapy, Combination; Endothelial Cells; Humans; Melanoma, Experimental; Mice; Nanotechnology; Neoplasms; Neovascularization, Pathologic; Stilbenes; Time Factors; Tissue Distribution

2005
Taking down tumors: vascular disrupting agents entering clinical trials.
    Journal of the National Cancer Institute, 2005, Sep-07, Volume: 97, Issue:17

    Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Drug Evaluation; Endothelial Cells; Europe; Humans; Ligands; Neoplasms; Neovascularization, Pathologic; Randomized Controlled Trials as Topic; Stilbenes

2005
An image worth a thousand lives?
    Nature biotechnology, 2004, Volume: 22, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzoquinones; Bibenzyls; Diagnostic Imaging; Down-Regulation; ErbB Receptors; Gefitinib; Heterocyclic Compounds, 1-Ring; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Magnetic Resonance Imaging; Molecular Probe Techniques; Mutation; Neoplasms; Phthalazines; Physiological Phenomena; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Rifabutin; Stilbenes; Tissue Distribution; Trastuzumab

2004
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2004, Volume: 18, Issue:13

    We have developed a simple yet sensitive dual color fluorescence-based technique for dissecting the tumor-neovascularization relationship and evaluated the susceptibility of each component to therapeutic interventions. Green fluorescent protein (GFP)-expressing melanoma cells were cocultured with endothelial cells on different three-dimensional (3-D) matrices and exposed to multiple growth factors and molecules with established anti-angiogenic or anticancer activities. Cells were fixed and stained with propidium iodide, imaged using a confocal microscope, and stereologically analyzed. Three-dimensionality of the system was tested by depth-coding and pseudocolor 3-D reconstruction in the z-axis. Selective ablation of the tumor cells was affected by the anthracycline antibiotic doxorubicin. Treatment with vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) promoted the neovascular responses on matrigel and collagen-1 matrices. VEGF-induced angiogenesis was inhibited after treatment with combretastatin and thalidomide. In contrast, HGF exerted a protective effect against these anti-angiogenics in a matrigel matrix. However, this effect was lost when the matrix was substituted with collagen, suggesting that the extracellular matrix impinges on cellular function, possibly through an Akt-mediated mechanism. The VEGF-receptor antagonist PTK787 also selectively ablated the VEGF-induced angiogenic effect without inhibiting the HGF-induced response, demonstrating the sensitivity of the system to detect modulation of distinct signal cascades. The current model encompasses the possibility of studying tumor-angiogenesis-matrix interaction on the same platform, expanding the rapid screening of novel molecules in a simulated clinicopathological setting.

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Extracellular Matrix; Fluorescence; Hepatocyte Growth Factor; Humans; Melanoma; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Stilbenes; Thalidomide; Vascular Endothelial Growth Factor A

2004
Consideration of QT/QTc interval data in a phase I study in patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17

    Topics: Antineoplastic Agents, Phytogenic; Cardiovascular System; Clinical Trials, Phase I as Topic; Coronary Disease; Electrocardiography; Heart Rate; Humans; Neoplasms; Safety; Stilbenes

2004
Inhibition of COX isoforms by nutraceuticals.
    Journal of herbal pharmacotherapy, 2004, Volume: 4, Issue:2

    Humans have two isoforms of Prostaglandin H Synthase or cyclooxygenase: COX-1 and COX-2. COX-1 is cytoprotective. COX-2 inhibitors reduce inflammation without the risk of ulceration and kidney damage. The ideal nutraceutical would inhibit COX-2 synthesis while preserving COX-1 synthesis. The hypothesis for this research was that COX inhibitors would fall primarily into three categories: COX-2 specific inhibition, non-specific inhibition (COX-1 and COX-2), and minimal inhibition. The human Cayman COX inhibitor screening assay was used to determine the inhibitory concentration 50 (IC50) of COX-1/ COX-2 activity of each nutraceutical. The assay was run, in duplicate, with three concentrations of a suspected inhibitor, a standard curve of eight concentrations, a non-specific binding sample, and a maximum binding sample. The inhibition and concentration of each sample was then put on a multiple regression best-fit line and the IC50 determined. For comparison, ibuprofen, rofecoxib, naproxen, and indomethacin were used. Positive results were seen for ipriflavone, resveratrol, MSV-60, amentoflavone, ruscus extract and notoginseng. Glucosamine, nexrutine, and berberine did not inhibit either isoform.

    Topics: Biflavonoids; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Humans; Inflammation; Isoenzymes; Isoflavones; Membrane Proteins; Neoplasms; Plant Extracts; Prostaglandin-Endoperoxide Synthases; Resveratrol; Ruscus; Stilbenes

2004
Resveratrol: a whiff that induces a biologically specific tsunami.
    Cancer biology & therapy, 2004, Volume: 3, Issue:9

    Topics: Angiogenesis Inhibitors; Antioxidants; Chemoprevention; Clinical Trials as Topic; Humans; Neoplasms; Phenols; Resveratrol; Ribonucleotide Reductases; Stilbenes; Vasodilator Agents

2004
Resveratrol may be a powerful cancer-fighting ally.
    Journal of the National Cancer Institute, 2004, Oct-20, Volume: 96, Issue:20

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Cell Line, Tumor; Histone Deacetylases; Humans; Neoplasms; NF-kappa B p50 Subunit; Resveratrol; Sirtuin 1; Sirtuins; Stilbenes; Transcription Factors; Tumor Necrosis Factor-alpha

2004
Drinking red wine may prevent cancer.
    Health news (Waltham, Mass.), 2004, Volume: 10, Issue:9

    Topics: Anticarcinogenic Agents; Antioxidants; Humans; Neoplasms; Resveratrol; Stilbenes; Wine

2004
Functional imaging in phase I studies: decorations or decision making?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15

    Topics: Animals; Antineoplastic Agents, Phytogenic; Bibenzyls; Clinical Trials, Phase I as Topic; Decision Making; Humans; Magnetic Resonance Imaging; Neoplasms; Rats; Stilbenes; Tomography, Emission-Computed

2003
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15

    Combretastatin A4 phosphate (CA4P) is a novel vascular targeting agent. Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) studies were performed to examine changes in parameters related to blood flow and vascular permeability in tumor and normal tissue after CA4P treatment.. Changes in kinetic DCE-MRI parameters (transfer constant [Ktrans] and area under contrast medium-time curve [AUC]) over 24 hours after treatment with CA4P were measured in 18 patients in a phase I trial and compared with those obtained in the rat P22 carcinosarcoma model, using the same imaging technique. Rats were treated with 30 mg/kg of CA4P; patients received escalating doses from 5 to 114 mg/m2.. A similar pattern and time course of change in tumor and normal tissue parameters was seen in rats and humans. Rat tumor Ktrans was reduced by 64% 6 hours after treatment with CA4P (30 mg/kg). No significant reductions in kidney or muscle parameters were seen. Significant reductions were seen in tumor Ktrans in six of 16 patients treated at >or= 52 mg/m2, with a significant group mean reduction of 37% and 29% at 4 and 24 hours, respectively, after treatment. The mean reduction in tumor initial area under the gadolinium-diethylenetriamine pentaacetic acid concentration-time curve (AUC) was 33% and 18%, respectively, at these times. No reduction was seen in muscle Ktrans or in kidney AUC in group analysis of the clinical data.. CA4P acutely reduces Ktrans in human as well as rat tumors at well-tolerated doses, with no significant changes in kidney or muscle, providing proof of principle that this drug has tumor antivascular activity in rats and humans.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Contrast Media; Disease Models, Animal; Gadolinium DTPA; Humans; Infusion Pumps; Magnetic Resonance Imaging; Male; Neoplasms; Neoplasms, Experimental; Rats; Stilbenes; Treatment Outcome

2003
Drug based approaches for targeting tumor vasculature: development of combretastatin A4 phosphate.
    Pathophysiology of haemostasis and thrombosis, 2003, Volume: 33 Suppl 1

    Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Humans; Neoplasms; Stilbenes; Treatment Outcome; Tubulin Modulators

2003
Anti-angiogenesis: the challenges ahead.
    MedGenMed : Medscape general medicine, 2003, Apr-30, Volume: 5, Issue:2

    Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Bevacizumab; Bibenzyls; Biological Availability; Biomarkers; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; Endostatins; Endothelial Growth Factors; Endothelium, Vascular; Growth Inhibitors; Humans; Kidney Neoplasms; Microtubules; Neoplasms; Neovascularization, Pathologic; Ontario; Receptors, Vascular Endothelial Growth Factor; Stilbenes

2003
Thrombosis and Hemostasis Issues in Cancer - Second International Conference. 19-21 September, 2003, Bergamo, Italy.
    IDrugs : the investigational drugs journal, 2003, Volume: 6, Issue:11

    Topics: Antineoplastic Agents; Azetidines; Benzylamines; Blood Coagulation Factors; Clinical Trials as Topic; Endothelium, Vascular; Fibrinolytic Agents; Fondaparinux; Hemostasis; Humans; Neoplasms; Neovascularization, Pathologic; Oligosaccharides; Polysaccharides; Stilbenes; Thrombosis

2003
Molecular analysis on the chemopreventive properties of resveratrol, a plant polyphenol microcomponent.
    International journal of molecular medicine, 2002, Volume: 10, Issue:6

    As a plant microcomponent, resveratrol is a polyphenolic compound produced by several species and found especially in Polygonum roots, peanuts seeds, berries and also grape and therefore can be present in human diet or beverages (red wine, for instance). Traditional chinese medicine and more recent epidemiological studies strongly suggested that resveratrol may act as a cancer chemopreventive compound. The biochemical mechanism by which resveratrol inhibits cell proliferation was provided by studies in numerous human cell lines including our work in hepatoblastoma HepG2 and colorectal tumor SW480 cells. The results show that resveratrol strongly inhibits cell proliferation at the micromolar range in a time- and dose-dependent manner. Resveratrol appears to block the cell cycle at the transition S to G2/M since there is no inhibition of [3H]-thymidine incorporation observed, while there is an increase of the cell number in S phase. On the other hand, in order to evaluate if the amount of resveratrol taken up during food or drink consumption is sufficient to ensure in the whole body the in vitro described beneficial effects, we evaluated the ratio between plasmatic level of resveratrol and its cell bioabsorption. Our study reports a higher uptake of resveratrol in the human hepatic derived HepG2 cells than in colorectal derived SW480 cells. In contrast, resveratrol is conjugated in these cells and derivatives are released in large amounts in the cell medium. Based on present knowledge, resveratrol appears to be a promising bioactive natural molecule with potential applications in phytotherapy, pharmacology or in nutriprotection (nutraceutic food) area.

    Topics: Antineoplastic Agents, Phytogenic; Cell Division; Colonic Neoplasms; Flow Cytometry; Genistein; Hepatoblastoma; Humans; In Vitro Techniques; Neoplasms; Resveratrol; S Phase; Stilbenes; Tumor Cells, Cultured

2002
Combination of vascular targeting agents with thermal or radiation therapy.
    International journal of radiation oncology, biology, physics, 2002, Dec-01, Volume: 54, Issue:5

    The most likely clinical application of vascular targeting agents (VTAs) is in combination with more conventional therapies. In this study, we report on preclinical studies in which VTAs were combined with hyperthermia and/or radiation.. A C3H mammary carcinoma grown in the right rear foot of female CDF1 mice was treated when at 200 mm3 in size. The VTAs were combretastatin A-4 disodium phosphate (CA4DP, 25 mg/kg), flavone acetic acid (FAA, 150 mg/kg), and 5,6-dimethylxanthenone-4-acetic acid (DMXAA, 20 mg/kg), and were all injected i.p. Hyperthermia and radiation were locally administered to tumors of restrained, nonanesthetized mice, and response was assessed using either a tumor growth or tumor control assay.. Heating tumors at 41.5 degrees C gave rise to a linear relationship between the heating time and tumor growth with a slope of 0.02. This slope was increased to 0.06, 0.09, and 0.08, respectively, by injecting the VTAs either 30 min (CA4DP), 3 h (FAA), or 6 h (DMXAA) before heating. The radiation dose (+/-95% confidence interval) that controls 50% of treated tumors (the TCD(50) value) was estimated to be 53 Gy (51-55 Gy) for radiation alone. This was decreased to 48 Gy (46-51 Gy), 45 Gy (41-49 Gy), and 42 Gy (39-45 Gy), respectively, by injecting CA4DP, DMXAA, or FAA 30-60 min after irradiating. These values were further decreased to around 28-33 Gy if the tumors of VTA-treated mice were also heated to 41.5 degrees C for 1 h, starting 4 h after irradiation, and this effect was much larger than the enhancement seen with either 41.5 degrees C or even 43 degrees C alone.. Our preclinical studies and those of others clearly demonstrate that VTAs can enhance tumor response to hyperthermia and/or radiation and support the concept that such combination studies should be undertaken clinically for the full potential of VTAs to be realized.

    Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Radiation; Flavonoids; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Stilbenes; Temperature; Time Factors; Tumor Cells, Cultured; X-Rays; Xanthenes; Xanthones

2002
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.
    NMR in biomedicine, 2002, Volume: 15, Issue:2

    The purpose of this study was to determine the reproducibility of dynamic contrast-enhanced (DCE)-MRI and compare quantitative kinetic parameters with semi-quantitative methods, and whole region-of-interest (ROI) with pixel analysis. Twenty-one patients with a range of tumour types underwent paired MRI examinations within a week, of which 16 pairs were evaluable. A proton density-weighted image was obtained prior to a dynamic series of 30 T(1)-weighted spoiled gradient echo images every 11.9 s with an intravenous bolus of gadopentetate dimeglumine given after the third baseline data point. Identical ROIs around the whole tumour and in skeletal muscle were drawn by the same observer on each pair of examinations and used for the reproducibility analysis. Semi-quantitative parameters, gradient, enhancement and AUC (area under the curve) were derived from tissue enhancement curves. Quantitative parameters (K(trans), k(ep), v(e)) were obtained by the application of the Tofts' model. Analysis was performed on data averaged across the whole ROI and on the median value from individual pixels within the ROI. No parameter showed a significant change between examinations. For all parameters except K(trans), the variability was not dependent on the parameter value, so the absolute values for the size of changes needed for significance should be used for future reference rather than percentages. The size of change needed for significance in a group of 16 in tumours for K(trans), k(ep) and v(e) was -14 to +16%, -0.20 ml/ml/min (15%) and -1.9[?]ml/ml (6%), respectively (pixel analysis), and -16 to +19%, -0.23 ml/ml/min (16%) and +/- 1.9[?]ml/ml (6%) (whole ROI analysis). For a single tumour, changes greater than -45 to +83%, +/- 0.78 ml/ml/min (60%) and +/- 7.6 ml/ml (24%), respectively, would be significant (pixel analysis). For gradient, enhancement and AUC the size of change needed for significance in tumours was -0.24 (17%), -0.05 (6%) and -0.06 (8%), respectively for a group of 16 (pixel analysis), and +/- 0.96 (68%), +/- 0.20 (25%) and +/- 0.22 (32%) for individuals. In muscle, the size of change needed for significance in a group of 16 for K(trans), k(ep) and v(e) was -30 to +44%, +/- 0.81 ml/ml/min (61%) and +/- 1.7 ml/ml (13%). For gradient, enhancement and AUC it was +/- 0.09 (20%), +/- 0.02 (8%) and +/- 0.03 (12%). v(e), enhancement and AUC are highly reproducible DCE-MRI parameters. K(trans), k(ep) and gradient have greater variability, with larger changes i

    Topics: Antineoplastic Agents; Bibenzyls; Contrast Media; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Muscle, Skeletal; Neoplasms; Reproducibility of Results; Stilbenes; Xanthenes; Xanthones

2002
The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1.
    British journal of cancer, 2002, Mar-04, Volume: 86, Issue:5

    Resveratrol is a cancer preventative agent that is found in red wine. Piceatannol is a closely related stilbene that has antileukaemic activity and is also a tyrosine kinase inhibitor. Piceatannol differs from resveratrol by having an additional aromatic hydroxy group. The enzyme CYP1B1 is overexpressed in a wide variety of human tumours and catalyses aromatic hydroxylation reactions. We report here that the cancer preventative agent resveratrol undergoes metabolism by the cytochrome P450 enzyme CYP1B1 to give a metabolite which has been identified as the known antileukaemic agent piceatannol. The metabolite was identified by high performance liquid chromatography analysis using fluorescence detection and the identity of the metabolite was further confirmed by derivatisation followed by gas chromatography-mass spectrometry studies using authentic piceatannol for comparison. This observation provides a novel explanation for the cancer preventative properties of resveratrol. It demonstrates that a natural dietary cancer preventative agent can be converted to a compound with known anticancer activity by an enzyme that is found in human tumours. Importantly this result gives insight into the functional role of CYP1B1 and provides evidence for the concept that CYP1B1 in tumours may be functioning as a growth suppressor enzyme.

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Chemoprevention; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme System; Gas Chromatography-Mass Spectrometry; Humans; Neoplasms; Resveratrol; Stilbenes; Tumor Cells, Cultured; Wine

2002
Antitumor agents. Part 3: synthesis and cytotoxicity of new trans-stilbene benzenesulfonamide derivatives.
    Bioorganic & medicinal chemistry letters, 2002, Apr-08, Volume: 12, Issue:7

    A new series of trans-stilbene benzenesulfonamide derivatives were designed and synthesized as potential antitumor agents. These new compounds were evaluated in the National Cancer Institute's 60 human tumor cell line in vitro screen. Compounds 9-13 were cytotoxic against several cell lines. Notably, two compounds, 9 and 12, demonstrated selective cytotoxic activity against BT-549 breast cancer (GI(50)=0.205 microM) and HT-29 colon cancer (GI(50)=0.554 microM), respectively.

    Topics: Antineoplastic Agents; Benzene; Cell Division; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Conformation; Molecular Structure; Neoplasms; Stilbenes; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured

2002
A culture of mistrust.
    The Lancet. Oncology, 2002, Volume: 3, Issue:5

    Topics: Antineoplastic Agents; Calcium; Carotenoids; Communication Barriers; Diet; Humans; Lycopene; Mass Media; Medical Oncology; Neoplasms; Resveratrol; Solanum lycopersicum; Stilbenes; Wine

2002
Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
    International journal of radiation biology, 2001, Volume: 77, Issue:2

    To compare the ability of combretastatin A-4 disodium phosphate (CA4DP) and 5,6-dimethylxanthenone-4-acetic acid (DMXAA) to change tissue blood perfusion.. The tissues were a C3H mouse mammary carcinoma and various murine normal tissues, with perfusion measured using the 86RbCl extraction technique.. CA4DP (250mg/kg; i.p.) reduced tumour perfusion to 34% of that seen in controls within 1 h of injection. It was maintained at this for at least 6 h, returning to control levels by 24 h. This decrease was dose-dependent. DMXAA (25mg/kg; i.p.) caused a 79% reduction in tumour perfusion 6h after injection; no recovery was observed even after 24 h. DMXAA showed no changes at doses below 10 mg/kg. Both CA4DP and DMXAA increased perfusion in the gut, kidney, bladder and lung, while decreasing splenic perfusion. CA4DP tended to decrease perfusion in muscle, while DMXAA increased liver perfusion. These changes in normal tissue perfusion were generally less than those changes seen in tumours. No significant changes were seen in skin.. CA4DP and DMXAA produced a selective and significant reduction in tumour perfusion, but the pattern of change was different. These results suggest how these vascular targeting drugs should be combined with more conventional therapies.

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood; Digestive System; Dose-Response Relationship, Drug; Female; Kidney; Liver; Lung; Mice; Mice, Inbred C3H; Muscles; Neoplasm Transplantation; Neoplasms; Perfusion; Skin; Spleen; Stilbenes; Time Factors; Tissue Distribution; Tumor Cells, Cultured; Urinary Bladder; Xanthenes; Xanthones

2001
Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, Volume: 15, Issue:10

    Topics: Allantois; Angiogenesis Inhibitors; Animals; Cell Division; Chick Embryo; Chorion; Cornea; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Fibroblast Growth Factor 2; Fibrosarcoma; Lymphokines; Mice; Mitogen-Activated Protein Kinases; Neoplasms; Neovascularization, Pathologic; Neovascularization, Physiologic; Resveratrol; Rosales; Stilbenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wine; Wound Healing

2001
Antiangiogenesis drugs target specific cancers, mechanisms.
    Journal of the National Cancer Institute, 2000, Apr-05, Volume: 92, Issue:7

    Topics: Angiostatins; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bibenzyls; Humans; Matrix Metalloproteinase Inhibitors; Neoplasms; Neovascularization, Pathologic; Peptide Fragments; Plasminogen; Stilbenes

2000
DNA breakage by resveratrol and Cu(II): reaction mechanism and bacteriophage inactivation.
    Cancer letters, 2000, Jun-01, Volume: 154, Issue:1

    Resveratrol (3,4',5-trihydroxy stilbene) is a phytoalexin and a polyphenolic compound present in human dietary material such as peanuts, mulberries, grapes and red wine. It is widely considered to possess cardiovascular protective properties and has also been shown to be chemopreventive against various stages of chemically induced carcinogenesis. It has recently been shown that resveratrol induces strand breakage in DNA in the presence of copper ions. In this paper, we have shown that resveratrol catalyzes the reduction of Cu(II) to Cu(I), which is accompanied by the formation of 'oxidized product(s)' of resveratrol, which in turn also appear to catalyze the reduction of Cu(II). Strand scission by the resveratrol-Cu(II) system was found to be biologically active as assayed by bacteriophage inactivation. The results are discussed in relation to the putative chemopreventive mechanism of resveratrol.

    Topics: Animals; Anticarcinogenic Agents; Bacteriophage lambda; Cattle; Copper; DNA; DNA Damage; Dose-Response Relationship, Drug; Endoribonucleases; Formazans; Free Radical Scavengers; Ions; Neoplasms; Phenanthrolines; Reactive Oxygen Species; Resveratrol; Spectrophotometry; Stilbenes; Thymus Gland; Time Factors; Ultraviolet Rays

2000
"Soybean" in a Haystack? pinpointing an anti-cancer effect.
    Journal of the National Cancer Institute, 1999, Oct-06, Volume: 91, Issue:19

    Topics: Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Colorectal Neoplasms; Garlic; Glycine max; Humans; Neoplasms; Phytotherapy; Plants, Medicinal; Resveratrol; Selenium; Stilbenes; Tea

1999
Benefits of the grape.
    Health news (Waltham, Mass.), 1999, Oct-25, Volume: 5, Issue:13

    Topics: Antioxidants; Heart Diseases; Humans; Male; Neoplasms; Resveratrol; Rosales; Stilbenes; Wine

1999
The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors.
    International journal of radiation oncology, biology, physics, 1998, Nov-01, Volume: 42, Issue:4

    To investigate the activity of combretastatin A-4 disodium phosphate in a transplanted C3H mouse mammary carcinoma and several murine spontaneous tumors.. The C3H mammary carcinoma was grown in the right rear foot of female CDF1 mice and treated when 200 mm3 in size. Spontaneous tumors (341-1437 mm3 in size) arose at different sites in female CDF1 mice that, 19-21 months earlier, had been irradiated. Oxygen partial pressure (pO2) distributions in the C3H tumors were measured with an Eppendorf oxygen electrode at various times after injecting combretastatin (100 mg/kg, i.p.) in restrained, nonanesthetized mice. Immediately after measurement, tumors were excised and necrotic fraction determined from histological sections. In the spontaneous tumors, pO2 was measured before and 3 h after giving combretastatin. The location of these spontaneous tumors required that measurements be made in anesthetised animals, achieved by injecting a mixture of hypnorm and diazepam.. In untreated C3H tumors, the mean (+/- 1 SE) percentage of pO2 values < or = 2.5 mmHg was 32% (+/- 11). This was significantly (Student's t-test; p < 0.05) increased to 74% (+/- 4) within 1 h after injecting combretastatin, and remained at this level for at least 6 h, although some recovery was seen at 12 and 24 h. The necrotic fraction in control tumors was 1.9% (+/- 0.4) and this was significantly increased to 16.1% (+/- 3.7) 24 h after drug administration. In spontaneous tumors, the pO2 measurements indicated that 5 of 6 showed some response to combretastatin, although the degree of change was variable.. Combretastatin increased tumor hypoxia and necrosis in the C3H mammary carcinoma, consistent with the induction of vascular damage. Drug-induced changes in pO2 were also found in spontaneous tumors, suggesting that the activity of this drug is not restricted to transplanted tumors alone.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Hypoxia; Drug Screening Assays, Antitumor; Female; Mammary Neoplasms, Experimental; Mice; Necrosis; Neoplasms; Oxygen Consumption; Partial Pressure; Stilbenes

1998
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature.
    Cancer research, 1997, May-15, Volume: 57, Issue:10

    Selective induction of vascular damage within tumors represents an emerging approach to cancer treatment. Histological studies have shown that several tubulin-binding agents can induce vascular damage within tumors but only at doses approximating the maximum tolerated dose, which has limited their clinical applicability. In this study, we show that the combretastatin A-4 prodrug induces vascular shutdown within tumors at doses less than one-tenth of the maximum tolerated dose. In vitro studies indicate that a short drug exposure results in profound long-term antiproliferative/cytotoxic effects against proliferating endothelial cells but not cells that are quiescent prior to and during drug exposure. Vascular shutdown, within experimental and human breast cancer models in vivo following systemic drug administration, was demonstrated with a reduction in functional vascular volume of 93% at 6 h following drug administration and persisted over the next 12 h, with corresponding histology consistent with hemorrhagic necrosis resulting from vascular damage. These actions against tumor vasculature and the broad therapeutic window demonstrate the clinical potential of these drugs and warrant further study to elucidate the mechanisms responsible for the antivascular effects of combretastatin A-4.

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Endothelium, Vascular; Hindlimb; Humans; Mice; Mice, Inbred CBA; Neoplasms; Neoplasms, Experimental; Neovascularization, Pathologic; Perfusion; Prodrugs; Rats; Stilbenes

1997
Combretastatin A-4 vascular damage to tumours.
    Molecular medicine today, 1997, Volume: 3, Issue:9

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Division; Endothelium, Vascular; Humans; Microtubules; Neoplasms; Phytotherapy; Plants; Protein Binding; Stilbenes; Tubulin

1997
Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor.
    Investigational new drugs, 1996, Volume: 14, Issue:2

    The tubulin-binding natural product combretastatin A-4 (CA-4) was tested for antitumor activity against fresh human tumors in vitro and 2 mouse tumors, both in vitro and in vivo. In colony forming assays using 10% fetal bovine serum, CA-4 was inhibitory in 27/40 human ovary cancers with a mean IC50 of 3.18 micrograms/mL for a 1-hour exposure (n = 35 specimens) and 0.27 microgramf1p4for a continuous exposure to CA-4 for 11-14 days (n = 5 specimens). Murine B-16 melanoma and P-388 leukemia were also highly sensitive to CA-4 in vitro with an identical IC50 value of 0.0007 micrograms/mL for continuous drug exposure for 8 days. Comparable in vitro cell culture studies performed in serum concentrations higher than 10%, revealed a significant loss of cytotoxic potency. Using the same reversed-phase HPLC technique as developed for paclitaxel, CA-4 was shown to bind to serum proteins (> or = 30,000 mw) > 99% and to albumin approximately 70%. CA-4 was only marginally active (25% increased lifespan) in DBA/2 mice bearing P-388 leukemia who were given doses of 100 mg/kg IP on either days, 1, 5 and 9 (p = 0.075 by Wilcoxon analysis) or on consecutive days 1-9 (p = 0.19 compared to control). A higher IP dose of 150 mg/kg on days 1, 5 and 9 did not delay subcutaneous B-16 melanoma tumor growth in C57/B1 mice. These findings demonstrate a substantial loss of antitumor efficacy for CA-4 in physiologic serum concentrations in vitro. No consistent antitumor activity was observed in two murine tumor models in vivo.

    Topics: Animals; Antineoplastic Agents, Phytogenic; Cattle; Cell Division; Chromatography, High Pressure Liquid; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Proteins; Neoplasms; Phosphates; Protein Binding; Stilbenes; Tubulin; Tubulin Modulators; Tumor Cells, Cultured

1996
[A new method of field marking in radiotherapy].
    Radiobiologia, radiotherapia, 1986, Volume: 27, Issue:4

    Topics: Fluorescent Dyes; Humans; Neoplasms; Radiotherapy; Stilbenes

1986
A quantum mechanical approach to the theory of cancer from polynuclear compounds. Metabolic activation and carcinogenicity of extended anilines and aminoazo compounds.
    Molecular pharmacology, 1985, Volume: 27, Issue:1

    Calculations have been carried out of the electronic structure and molecular properties in relation to metabolic activation and carcinogenic activities of polycyclic aromatic amines (PAAs). Quantum mechanical molecular orbital method MINDO/3 is employed in the calculations mainly on anilines, extended anilines, and aminoazo and other azo compounds. The calculations, in agreement with findings of Arcos and Argus, indicate that for the highest level of carcinogenic activity obtainable with the dicyclic aromatic amines, the amino substituent must be introduced at the terminal carbon atom of the longest conjugate chain. In the case of monocyclic compounds, in particular, charge distribution of the amino substitution aids in identifying the carcinogenic character of the PAAs. Our results demonstrate that ring hydroxylation leads to detoxification of the compounds. However, the major pathway leading to carcinogenic activity involves transformation to hydroxylamines and subsequently to electrophilic arylnitrenium ions (ANIs). These are in line with findings from experiments. Calculations of certain electronic parameters give expected relative carcinogenic potencies. In all cases the ANIs function as ambient electrophiles which can undergo both electrostatic and covalent binding with nucleophilic centers of proteins and DNA bases.

    Topics: Aniline Compounds; Animals; Azo Compounds; Biotransformation; Biphenyl Compounds; Carcinogens; Humans; Isomerism; Molecular Conformation; Neoplasms; Quantum Theory; Stilbenes; Structure-Activity Relationship

1985
A comparison of the expression of the DIDS-binding proteins from normal and tumorigenic human cells.
    British journal of cancer, 1984, Volume: 50, Issue:6

    A monoclonal antibody was prepared against DIDS, an inhibitor of anion transport, and used to compare the occurrence and distribution of DIDS-binding sites of tumorigenic and non-tumorigenic human somatic-cell hybrids. The monoclonal antibody (E8) was produced by the fusion of the mouse myeloma (NS-1) with mouse spleen cells and is of the IgG1 subclass. The apparent half-saturation of DIDS for HEp-2 cells is 16 microM and the reaction is rapid. The number of binding sites on tumorigenic and non-tumorigenic hybrid cells was the same. The DIDS-binding protein occurs homogeneously on all cells, a characteristic which distinguishes it from the possible tumour antigen recognised by the M/27 monoclonal antibody.

    Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid; Antibodies, Monoclonal; Antibody Specificity; Binding Sites; Carrier Proteins; Cell Line; Cell Membrane; Cells, Cultured; HeLa Cells; Humans; Kinetics; Neoplasms; Stilbenes

1984
Photocarcinogenesis: lack of enhancement by fluorescent white agents.
    Environmental quality and safety. Supplement, 1975, Volume: 4

    These studies were designed to determine whether fluorescent whitening agents (FWAs) could: (I) produce an augmented acute response of skin to a single ultraviolet light exposure (i.e., phototoxicity), or (II) increase the number or hasten the appearance of skin tumors after several ultraviolet light exposures (i.e., chemically enhanced photocarcinogenesis). Five substituted stilbene FWAs were screened for phototoxicity. The results of pretreatment with these agents were compared with pretreatment by a known photoxic agent, 8-methoxypsoralen (8-MOP) or the vehicle (methanol) using the skin of hairless mice, miniature pigs, and man. None of the FWAs was phototoxic. Photocarcinogenesis testing involved pretreating hairless mouse skin with FWAs, 8-MOP, or methanol only before each daily exposure to simulated solar ultraviolet light. In terms of tumor yield and tumor development time, photocarcinogenesis was enhanced by 8-MOP, but not by FWAs.

    Topics: Animals; Biphenyl Compounds; Coloring Agents; Humans; Light; Male; Mice; Mice, Nude; Neoplasms; Skin; Stilbenes; Swine; Triazoles; Ultraviolet Rays

1975
[The genetic effect of aromatic amines and their derivatives: induction of mytotic conversion in the yeast Saccharomyces cerevisiae].
    Zeitschrift fur Krebsforschung, 1970, Volume: 74, Issue:4

    Topics: Adenine; Amines; Carcinogens; Chemical Phenomena; Chemistry; Culture Media; Fluorenes; Genes; Genetics, Microbial; Mitosis; Mutation; Neoplasms; Nitroso Compounds; Recombination, Genetic; Saccharomyces; Stilbenes; Toluene; Tryptophan

1970
CORRELATION BETWEEN THE CHEMICAL INDUCTION OF HYPERPLASIA AND OF MALIGNANCY IN THE BLADDER EPITHELIUM.
    British journal of cancer, 1965, Volume: 19

    Topics: Animals; Azo Compounds; Carcinogens; Coloring Agents; Cricetinae; Dogs; Furans; Hydrocarbons; Hyperplasia; Mice; Neoplasms; Neoplasms, Experimental; Pharmacology; Rats; Research; Stilbenes; Urinary Bladder Diseases; Urinary Bladder Neoplasms

1965
N-HYDROXYLATION IN AMINOSTIBENE CARCINOGENESIS.
    British journal of cancer, 1965, Volume: 19

    Topics: Carcinogenesis; Carcinogens; Hydroxylamines; Hydroxylation; Liver; Metabolism; Neoplasms; Pharmacology; Rats; Research; Stilbenes; Urine

1965
CARCINOGENESIS AND INHIBITION OF THE WALKER 256 TUMOR IN THE RAT BY TRANS-4-ACETYLAMINOSTILBENE, ITS N-HYDROXY METABOLITE, AND RELATED COMPOUNDS.
    Cancer research, 1964, Volume: 24

    Topics: Amides; Animals; Carcinogenesis; Carcinogens; Carcinoma 256, Walker; Hydroxamic Acids; Metabolism; Neoplasms; Rats; Research; Stilbenes; Urine

1964
GYNECOLOGY AND OBSTETRICS.
    Surgery, gynecology & obstetrics, 1964, Volume: 118

    Topics: Congenital Abnormalities; Endometriosis; Female; Fetal Diseases; Gynecology; Humans; Maternal-Fetal Exchange; Metronidazole; Neoplasms; Obstetrics; Ovarian Neoplasms; Pregnancy; Stilbenes; Trichomonas Vaginitis; Uterine Cervical Neoplasms

1964
THE ACTION OF OESTRADIOL AND DIMETHYLSTILBOESTROL ON EARLY PREGNANCY AND DECIDUOMA FORMATION IN THE MOUSE.
    The Journal of endocrinology, 1964, Volume: 29

    Topics: Animals; Antimetabolites; Deciduoma; Estradiol; Estrogens; Female; Humans; Hydatidiform Mole, Invasive; Mice; Neoplasms; Neoplasms, Experimental; Pharmacology; Pregnancy; Pregnancy, Animal; Research; Stilbenes; Uterine Neoplasms

1964
CLOMIPHENE CITRATE (NSC-35770) IN DISSEMINATED MAMMARY CARCINOMA.
    Cancer chemotherapy reports, 1964, Volume: 43

    Topics: Biomedical Research; Breast; Breast Neoplasms; Clomiphene; Drug Therapy; Humans; Neoplasms; Stilbenes; Toxicology

1964
COMBINED EFFECT OF CARCINOGENS AND CO-CARCINOGENS ON METABOLIC PROCESS.
    Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20

    Topics: Carcinogens; Liver; Liver Neoplasms; Methylcholanthrene; Neoplasms; Neoplasms, Experimental; p-Dimethylaminoazobenzene; Pharmacology; Rats; Research; Skin Neoplasms; Stilbenes

1964
CARCINOGENIC ACTION OF N-HYDROXY-4-ACETYLAMINOSTILBENE.
    Nature, 1963, Aug-10, Volume: 199

    Topics: Antineoplastic Agents; Carcinogens; Carcinoma, Squamous Cell; Neoplasms; Neoplasms, Experimental; Rats; Research; Stilbenes; Toxicology

1963
[NON SURGICAL CANCER OF THE BREAST].
    Boletines y trabajos. Sociedad de Cirugia de Buenos Aires (1953), 1963, Sep-04, Volume: 47

    Topics: Breast; Breast Neoplasms; Humans; Lymphatic Metastasis; Neoplasms; Stilbenes

1963
[CONCERNING THE EFFECTS OF A NEW IMINO-STILBENE DERIVATIVE (INSIDON) IN CANCER IN THE COURSE OF RADIOTHERAPY TREATMENT].
    Minerva medica, 1963, Dec-19, Volume: 54

    Topics: Antidepressive Agents; Humans; Neoplasms; Opipramol; Psychology; Stilbenes

1963
Combine effect of carcinogens with different actions. II. Effect of pretreatment of painting with 20-methylcholanthrene or feeding of 4-dimethylaminostilbene upon carcinogenesis of 4-dimethylaminoazobenzene in the rat.
    Gan, 1962, Volume: 53

    Topics: Animals; Carcinogenesis; Carcinogens; Liver Neoplasms; Methylcholanthrene; Neoplasms; Neoplasms, Experimental; p-Dimethylaminoazobenzene; Paintings; Rats; Stilbenes

1962
[The effect of fatty acids on carcinogenesis. II. The effect of fatty acids on 4-dimethylaminostilbene-induced carcinogenesis in rats].
    Acta biologica et medica Germanica, 1961, Volume: 6

    Topics: Animals; Arachidonic Acid; Carcinogenesis; Ear, External; Fatty Acids; Neoplasms; Neoplasms, Experimental; Rats; Stilbenes

1961
[New treatments for cancer of the prostate].
    Vie medicale (Paris, France : 1920), 1959, Volume: 40, Issue:4

    Topics: Diethylstilbestrol; Humans; Male; Neoplasms; Prostatic Neoplasms; Stilbenes

1959
[Treatment of cancer of prostate & its metastases by chlorotrianisene (TACE)].
    Journal d'urologie medicale et chirurgicale, 1957, Volume: 63, Issue:6

    Topics: Chlorotrianisene; Humans; Male; Neoplasms; Neoplasms, Second Primary; Prostatic Neoplasms; Stilbenes

1957
[Quantitative experiments in producing cancer in rats with 4-dimethylamino-stilben].
    Experientia, 1956, May-15, Volume: 12, Issue:5

    Topics: Animals; Carcinogens; Neoplasms; Rats; Stilbenes

1956
Immunological properties of carcinogenprotein conjugates containing polycyclic aromatic hydrocarbons and substituted stilbenes.
    Cancer research, 1955, Volume: 15, Issue:11

    Topics: Antibodies; Antigens; Carcinogens; Neoplasms; Polycyclic Aromatic Hydrocarbons; Stilbenes

1955
[Modern trends in chemotherapy of tumors].
    Minerva medica, 1952, Dec-06, Volume: 43, Issue:98

    Topics: Colchicine; Ethers; Folic Acid Antagonists; Hormones; Humans; Mechlorethamine; Mitosis; Neoplasms; Nitrogen Mustard Compounds; Pentamidine; Podophyllin; Poisons; Steroids; Stilbenes; Urethane

1952
Determination of stilbamidine and 2-hydroxystilbamidine deposited in parenchymatous organs and tumors.
    Cancer, 1951, Volume: 4, Issue:6

    Topics: Neoplasms; Stilbamidines; Stilbenes

1951
Histopathologic study of the mode of inhibition of cellular proliferation; effect of 4-dimethylaminostilbene on the growth of Walker rat carcinoma 256.
    Cancer research, 1949, Volume: 9, Issue:11

    Topics: Animals; Carcinoma 256, Walker; Cell Proliferation; Neoplasms; Rats; Stilbenes

1949
Treatment of angiomas of the head and neck.
    America clinica, 1948, Volume: 13, Issue:2

    Topics: Anaphylaxis; Aniline Compounds; Head; Head and Neck Neoplasms; Hemangioma; Humans; Hypersensitivity; Neck; Neoplasms; Stilbenes

1948
Treatment of prostatic cancer with alpha-bromo-alpha beta. beta-triphenylethylene (Y59).
    Lancet (London, England), 1947, Aug-02, Volume: 2, Issue:6466

    Topics: Bromides; Bromine; Bromine Compounds; Humans; Male; Neoplasms; Prostatic Neoplasms; Stilbenes

1947
A note on the carcinogenic action of stilbene derivatives.
    British medical bulletin, 1946, Volume: 4, Issue:5-6

    Topics: Carcinogens; Humans; Neoplasms; Stilbenes

1946